{"11f7ded0830c7fb94e6918adf61b0cb22d80175a": [["IntroductionThe coronavirus disease 2019 (COVID-19) outbreak has currently affected more than 3.5 million people globally between the December 2019 and May 2020 period.", [["coronavirus disease", "DISEASE", 16, 35], ["COVID-19", "CHEMICAL", 42, 50], ["people", "ORGANISM", 106, 112], ["people", "SPECIES", 106, 112], ["coronavirus disease 2019 (COVID-19", "SPECIES", 16, 50], ["The coronavirus disease", "PROBLEM", 12, 35], ["COVID", "TEST", 42, 47], ["coronavirus disease", "OBSERVATION", 16, 35]]], ["Consequently, many countries around the world have implemented precautionary measures and quarantines to prevent the virus from spreading.IntroductionDuring the outbreak, the lack of any specific treatments or a vaccine, and factors like the hardships of lockdown (and social distancing) measures, not knowing when the measures will be loosened and bleak economic outlook have been determined to affect the mental health of individuals (Bao et al., 2020; Deng & Peng, 2020; Wang et al., 2020) .", [["precautionary measures", "TREATMENT", 63, 85], ["quarantines", "TREATMENT", 90, 101], ["the virus", "PROBLEM", 113, 122], ["a vaccine", "TREATMENT", 210, 219], ["virus", "OBSERVATION", 117, 122]]], ["A study conducted during the first severe acute respiratory syndrome (SARS) outbreak in fear of sickness), risky behavior (increasing alcohol or tobacco consumption) and psychiatric disorders (depression, somatization, post-traumatic stress disorder (PTSD), anxiety, etc.).IntroductionFrontline health care workers against COVID-19 are considered particularly susceptible to developing psychiatric disorders (Lai et al., 2020) .", [["acute respiratory syndrome", "DISEASE", 42, 68], ["SARS", "DISEASE", 70, 74], ["fear of sickness", "DISEASE", 88, 104], ["risky behavior", "DISEASE", 107, 121], ["alcohol", "CHEMICAL", 134, 141], ["psychiatric disorders", "DISEASE", 170, 191], ["depression", "DISEASE", 193, 203], ["somatization", "DISEASE", 205, 217], ["traumatic stress disorder", "DISEASE", 224, 249], ["PTSD", "DISEASE", 251, 255], ["anxiety", "DISEASE", 258, 265], ["psychiatric disorders", "DISEASE", 386, 407], ["alcohol", "CHEMICAL", 134, 141], ["tobacco", "ORGANISM_SUBDIVISION", 145, 152], ["tobacco", "SPECIES", 145, 152], ["A study", "TEST", 0, 7], ["the first severe acute respiratory syndrome", "PROBLEM", 25, 68], ["sickness", "PROBLEM", 96, 104], ["psychiatric disorders", "PROBLEM", 170, 191], ["depression", "PROBLEM", 193, 203], ["somatization", "PROBLEM", 205, 217], ["post-traumatic stress disorder (PTSD)", "PROBLEM", 219, 256], ["anxiety", "PROBLEM", 258, 265], ["developing psychiatric disorders", "PROBLEM", 375, 407], ["severe", "OBSERVATION_MODIFIER", 35, 41], ["acute", "OBSERVATION_MODIFIER", 42, 47], ["respiratory syndrome", "OBSERVATION", 48, 68]]], ["All health care workers, and particularly nurses in similar outbreaks, have suffered an increase in mental pressure due to the heavy workloads they have taken and lack of satisfactory personal protective equipment (PPE) and medication, as well as being exposed to a deathly virus for extended periods.", [["an increase in mental pressure", "PROBLEM", 85, 115], ["medication", "TREATMENT", 224, 234], ["a deathly virus", "TREATMENT", 264, 279], ["increase", "OBSERVATION_MODIFIER", 88, 96]]], ["In addition, having to stay away from their families has compounded this mental strain, as fear of infecting loved ones has posed another psychological burden to the health care workers (Lai et al., 2020; Xiang et al., 2020) .", [["this mental strain", "PROBLEM", 68, 86]]], ["During the 2003 SARS outbreak, health professionals suffered high levels of stress and anxiety and showed depression symptoms (Maunder et al., 2003) .", [["SARS", "DISEASE", 16, 20], ["anxiety", "DISEASE", 87, 94], ["depression", "DISEASE", 106, 116], ["high levels of stress", "PROBLEM", 61, 82], ["anxiety", "PROBLEM", 87, 94], ["depression symptoms", "PROBLEM", 106, 125]]], ["According to a study conducted on 1,830 frontline health care workers in China, approximately half of the respondents (50.4%) showed signs of depression, 44.6% of anxiety, 34% of insomnia and 71.5% have shown symptoms of increased stress (Lai et al., 2020) .", [["depression", "DISEASE", 142, 152], ["anxiety", "DISEASE", 163, 170], ["insomnia", "DISEASE", 179, 187], ["a study", "TEST", 13, 20], ["depression", "PROBLEM", 142, 152], ["anxiety", "PROBLEM", 163, 170], ["insomnia", "PROBLEM", 179, 187], ["symptoms", "PROBLEM", 209, 217], ["increased stress", "PROBLEM", 221, 237]]], ["Likewise, a study carried out in two hospitals caring for COVID-19 patients in Singapore found that 14.5% of the 470 health care workers had shown symptoms of anxiety, whereas 6.6% had shown symptoms of depression .", [["anxiety", "DISEASE", 159, 166], ["depression", "DISEASE", 203, 213], ["patients", "ORGANISM", 67, 75], ["patients", "SPECIES", 67, 75], ["a study", "TEST", 10, 17], ["COVID", "TEST", 58, 63], ["symptoms", "PROBLEM", 147, 155], ["anxiety", "PROBLEM", 159, 166], ["symptoms", "PROBLEM", 191, 199], ["depression", "PROBLEM", 203, 213], ["depression", "OBSERVATION", 203, 213]]], ["Lai et al. (2020) report has further confirmed that health professionals during the COVID-19 outbreak have reported higher levels of stress, sleep deprivation, depression and anxiety (Lai et al., 2020) .IntroductionMoreover, it has been known that COVID-19 patients who are cared for in hospitals in the intensive care unit or isolation units are likely to experience shortness of breath and fear of death.", [["sleep deprivation", "DISEASE", 141, 158], ["depression", "DISEASE", 160, 170], ["anxiety", "DISEASE", 175, 182], ["shortness of breath", "DISEASE", 368, 387], ["death", "DISEASE", 400, 405], ["patients", "ORGANISM", 257, 265], ["patients", "SPECIES", 257, 265], ["the COVID", "TEST", 80, 89], ["sleep deprivation", "PROBLEM", 141, 158], ["depression", "PROBLEM", 160, 170], ["anxiety", "PROBLEM", 175, 182], ["isolation units", "TREATMENT", 327, 342], ["shortness of breath", "PROBLEM", 368, 387], ["death", "PROBLEM", 400, 405]]], ["These experiences can make a traumatic effect on them (Horesh & Brown, 2020; Li et al., 2020) .", [["a traumatic effect", "PROBLEM", 27, 45]]], ["Professionals who work for extended amounts of time with patients with previous traumas are similarly prone to experiencing secondary trauma (Collins & Long, 2003) .", [["traumas", "DISEASE", 80, 87], ["trauma", "DISEASE", 134, 140], ["patients", "ORGANISM", 57, 65], ["patients", "SPECIES", 57, 65], ["previous traumas", "PROBLEM", 71, 87], ["secondary trauma", "PROBLEM", 124, 140]]], ["It has been documented that these instances of secondary trauma can cause loss of appetite, sleep deprivation, fatigue, anger, apathy and hopelessness in the affected individuals (Creighton et al., 2018) .IntroductionIn consideration of the lack of previous research into secondary trauma in health care professionals, this article aims to study the differences in secondary traumas experienced by the frontline workers, by the broader category of health care professionals and finally by the general public.", [["trauma", "DISEASE", 57, 63], ["loss of appetite", "DISEASE", 74, 90], ["fatigue", "DISEASE", 111, 118], ["anger", "DISEASE", 120, 125], ["apathy", "DISEASE", 127, 133], ["hopelessness", "DISEASE", 138, 150], ["trauma", "DISEASE", 282, 288], ["traumas", "DISEASE", 375, 382], ["secondary trauma", "PROBLEM", 47, 63], ["loss of appetite", "PROBLEM", 74, 90], ["sleep deprivation", "PROBLEM", 92, 109], ["fatigue", "PROBLEM", 111, 118], ["apathy", "PROBLEM", 127, 133], ["hopelessness", "PROBLEM", 138, 150], ["secondary trauma", "PROBLEM", 272, 288]]], ["Our results aim to help in the early recognition and remedying of secondary trauma in health care professionals, as well as identifying the important risk factors for future research.Study design and sampleThis study was fulfilled in a cross-sectional and descriptive design.", [["trauma", "DISEASE", 76, 82], ["secondary trauma", "PROBLEM", 66, 82], ["Study design", "TEST", 183, 195], ["sample", "TEST", 200, 206], ["This study", "TEST", 206, 216]]], ["We used an online survey to minimize face-to-face interactions with all participants and to facilitate participation of health care workers who work extensively during this emergency period.", [["participants", "SPECIES", 72, 84]]], ["A convenience sample of health care workers and the general population were contacted to participate in this study.", [["this study", "TEST", 104, 114]]], ["Participants also asked to share the survey with their colleagues and with the health care workers they know.", [["Participants", "SPECIES", 0, 12]]], ["After collecting the data of health care workers, we shared the survey form at various social network groups and asked participants to share the survey with their friends or family who is older than 18 years and a non-health care worker.", [["social network", "MULTI-TISSUE_STRUCTURE", 87, 101], ["participants", "SPECIES", 119, 131]]], ["The sample of the study was determined by using the snowball sampling method.", [["the study", "TEST", 14, 23], ["the snowball sampling method", "TEST", 48, 76]]], ["All the participants were from Turkey, and as we used snowball sampling and online surveys, we gathered subjects from several institutions.", [["participants", "ORGANISM", 8, 20], ["participants", "SPECIES", 8, 20]]], ["The Introductory Information Form, Secondary Traumatic Stress Scale (STSS) and Patient Health Questionnaire-4 (PHQ-4) were used as data collection tools.", [["Patient", "SPECIES", 79, 86], ["Secondary Traumatic Stress Scale", "PROBLEM", 35, 67], ["Patient Health Questionnaire", "TEST", 79, 107], ["PHQ", "TEST", 111, 114], ["data collection tools", "TEST", 131, 152]]], ["The data were collected online from 22 May to 30 May 2020.", [["The data", "TEST", 0, 8]]], ["Before collecting the data, all respondents were informed about the aim of the study, data privacy and only scientific intended use of the data.", [["the study", "TEST", 75, 84], ["the data", "TEST", 135, 143]]], ["To be able to carry out this study, approvals from Kent University clinical research ethics committee (28.05.2020/2020-04, 77083609-100/136) and Ministry of Health were received.Data collection toolsIntroductory Information Form.", [["this study", "TEST", 24, 34], ["Data collection tools", "TEST", 178, 199]]], ["This form, designed by the researchers, asks demographic questions such as gender, age, educational background, marital status and number of children.", [["children", "ORGANISM", 141, 149], ["children", "SPECIES", 141, 149]]], ["The medical worker respondents were asked if they are directly associated with the diagnosis, treatment or nursing services of the COVID-19-positive patients, and the respondents who answered this question affirmatively were accepted as frontline workers and the respondents who answered negatively were accepted as background workers.", [["patients", "ORGANISM", 149, 157], ["patients", "SPECIES", 149, 157]]], ["The form revealed if the respondents had any traumatic life experiences (after giving a detailed description of trauma).", [["trauma", "DISEASE", 112, 118], ["trauma", "PROBLEM", 112, 118]]], ["Also, the respondents were asked overall assessment questions such as if they have someone close to them who have a disease or passed away due to the pandemic, how much time they spent on social media during the pandemic and if they have any psychological or medical diseases, and the subjective changes in their anxiety levels.Data collection toolsSTSS.", [["anxiety", "DISEASE", 313, 320], ["a disease", "PROBLEM", 114, 123], ["any psychological or medical diseases", "PROBLEM", 238, 275], ["the subjective changes in their anxiety levels", "PROBLEM", 281, 327], ["Data collection toolsSTSS", "TEST", 328, 353]]], ["The STSS is a 17-item 5-point Likert-type selfreport scale designed by Bride and colleagues (2004) .", [["STSS", "DNA", 4, 8], ["The STSS", "TEST", 0, 8]]], ["The scale was developed to measure the secondary posttraumatic stress symptoms, and it evaluates individual's reactions in the last 7 days.", [["posttraumatic stress symptoms", "DISEASE", 49, 78], ["the secondary posttraumatic stress symptoms", "PROBLEM", 35, 78], ["individual's reactions", "PROBLEM", 97, 119], ["secondary", "OBSERVATION_MODIFIER", 39, 48], ["posttraumatic", "OBSERVATION_MODIFIER", 49, 62]]], ["The obtained points from the scale vary between 17 and 85, and higher points indicate a higher affection level.", [["the scale vary", "TEST", 25, 39], ["a higher affection level", "PROBLEM", 86, 110], ["higher", "OBSERVATION_MODIFIER", 88, 94], ["affection", "OBSERVATION", 95, 104]]], ["Turkish reliability and validity of the scale was performed by Y\u0131ld\u0131r\u0131m and colleagues (2017; Bride et al., 2004) .PHQ-4.This four-question scale was designed by Kroenke and colleagues (2009) , and it evaluates anxiety and depression symptoms.", [["anxiety", "DISEASE", 211, 218], ["depression", "DISEASE", 223, 233], ["PHQ", "TEST", 115, 118], ["anxiety", "PROBLEM", 211, 218], ["depression symptoms", "PROBLEM", 223, 242]]], ["The first two questions examine anxiety, and the other two questions examine depression complaints.", [["anxiety", "DISEASE", 32, 39], ["depression", "DISEASE", 77, 87], ["anxiety", "PROBLEM", 32, 39], ["depression complaints", "PROBLEM", 77, 98]]], ["Turkish adaptation of the scale was performed by Demirci and Eksi (2018; Kroenke et al., 2009 ).Statistical analysisStatistical analysis was performed by using the SPSS version 24.0 (IBM Corp., Armonk, NY, ABD) packaged software.", [["Statistical analysisStatistical analysis", "TEST", 96, 136], ["the SPSS version", "TEST", 160, 176], ["ABD", "ANATOMY", 206, 209]]], ["Significance levels of all outcomes were taken as \u03b1 = .05, and analyses were made two-way.", [["Significance levels", "TEST", 0, 19], ["analyses", "TEST", 63, 71]]], ["The normality assumption of the data was evaluated with normality tests (Kolmogorov-Smirnov vs Shapiro-Wilk), and it showed normal distribution with a 95% trust.", [["the data", "TEST", 28, 36], ["normality tests", "TEST", 56, 71], ["Kolmogorov", "TEST", 73, 83], ["normal", "OBSERVATION", 124, 130], ["distribution", "OBSERVATION_MODIFIER", 131, 143]]], ["The relation between the sociodemographic attributes and scale total and subdimension points was examined with the Pearson correlation analysis and oneway analysis of variance (ANOVA).", [["the Pearson correlation analysis", "TEST", 111, 143]]], ["The differences between the sociodemographic attributes and scale total and subdimension points were analyzed with a t test in independent groups.", [["a t test", "TEST", 115, 123]]], ["To specify the factors that affect the respondents' secondary traumatization level, multivariate logistic regression analysis was performed, and the relations and rates between risk factors and results were evaluated considering a 95% confidence interval.Demographic attributesFive hundred sixty-three participants, 212 (37.7%) men and 351 (62.3%) women aged between 20 and 61 years (M: 32 \u00b1 10.2), completed the research.", [["participants", "ORGANISM", 302, 314], ["men", "ORGANISM", 328, 331], ["women", "ORGANISM", 348, 353], ["participants", "SPECIES", 302, 314], ["men", "SPECIES", 328, 331], ["women", "SPECIES", 348, 353], ["traumatization level", "PROBLEM", 62, 82], ["multivariate logistic regression analysis", "TEST", 84, 125]]], ["Thirty-four (14%) of the health care workers were hospital personnel such as biochemistry technicians, physiotherapists and janitors.", [["janitors", "TREATMENT", 124, 132]]], ["One hundred nine (43.4%) of the health care workers were directly working with the COVID-19-positive patients and 142 (56.6%) were not in direct contact.", [["patients", "ORGANISM", 101, 109], ["patients", "SPECIES", 101, 109], ["the COVID", "TEST", 79, 88]]], ["Three hundred sixtytwo (64.3%) respondents lived with their spouses and children, 79 (14%) lived with their parents and 67 (11.9%) lived alone.", [["respondents", "ORGANISM", 31, 42], ["children", "ORGANISM", 72, 80], ["children", "SPECIES", 72, 80]]], ["The sociodemographic attributes of the respondents and their answers to the questions were represented in Table 1 .Severity of measurements and differences between the groupsThe demographic attributes of the respondents such as age, marital status, having a child and having other health care workers in the family were compared with their secondary traumatization scale points, and no significant difference was found (p < .05).", [["no", "UNCERTAINTY", 383, 385], ["significant", "OBSERVATION_MODIFIER", 386, 397]]], ["Also, there is no significant difference between the health care worker respondents' secondary traumatization scale total points and their institutions, conditions, occupational groups, units, weekly working hours and number of patients (p < .05).Severity of measurements and differences between the groupsThe difference between the secondary traumatization scale and PHQ total point average of the respondents who directly work with the COVID-19-positive patients and the respondents who do not directly work with the COVID-19-positive patients was compared with one-way ANOVA, and a statistically significant difference was found (p < .001).", [["patients", "ORGANISM", 228, 236], ["COVID-19", "GENE_OR_GENE_PRODUCT", 438, 446], ["patients", "ORGANISM", 456, 464], ["COVID-19", "GENE_OR_GENE_PRODUCT", 519, 527], ["patients", "ORGANISM", 537, 545], ["patients", "SPECIES", 228, 236], ["patients", "SPECIES", 456, 464], ["patients", "SPECIES", 537, 545], ["the secondary traumatization scale", "TEST", 329, 363], ["the COVID", "TEST", 515, 524], ["a statistically significant difference", "PROBLEM", 583, 621], ["no", "UNCERTAINTY", 15, 17], ["significant", "OBSERVATION_MODIFIER", 18, 29], ["difference", "OBSERVATION_MODIFIER", 30, 40]]], ["While the health care worker group who work with the COVID-19-positive patients got the highest score, the non-medical worker group got the lowest score (Table 2) .Severity of measurements and differences between the groupsBesides, being a woman, being in the first years of the work, living with a parent, having chronic diseases, having a trauma history in the past and increased use of social media were found related to scoring significantly higher points from the secondary traumatization scale (Table 2) .Risk factors of secondary traumatizationThe effects of the variables on the secondary traumatization were analyzed with simple linear regression, and the output values were represented in Table 3 .", [["chronic diseases", "DISEASE", 314, 330], ["trauma", "DISEASE", 341, 347], ["traumatization", "DISEASE", 537, 551], ["COVID-19", "ORGANISM", 53, 61], ["patients", "ORGANISM", 71, 79], ["woman", "ORGANISM", 240, 245], ["patients", "SPECIES", 71, 79], ["woman", "SPECIES", 240, 245], ["the COVID", "TEST", 49, 58], ["chronic diseases", "PROBLEM", 314, 330], ["social media", "TREATMENT", 389, 401], ["secondary traumatization", "PROBLEM", 527, 551], ["the secondary traumatization", "PROBLEM", 583, 611], ["simple linear regression", "PROBLEM", 631, 655], ["the output values", "TEST", 661, 678], ["chronic", "OBSERVATION_MODIFIER", 314, 321], ["diseases", "OBSERVATION", 322, 330], ["increased", "OBSERVATION_MODIFIER", 372, 381], ["secondary traumatization", "OBSERVATION", 527, 551], ["linear", "OBSERVATION_MODIFIER", 638, 644], ["regression", "OBSERVATION_MODIFIER", 645, 655]]], ["Analyses showed that gender, age, anxiety and depression levels, anxiety about the COVID-19 and past trauma history are independent risk factors for secondary traumatization (p < .05).DiscussionStudies state that the COVID-19 pandemic can cause many psychological effects, such as anxiety, fear, depression and stress on people, especially on health care workers (Ahmed et al., 2020; Bao et al., 2020; Deng & Peng, 2020; Jiao et al., 2020; Lai et al., 2020; Shigemura et al., 2020) .", [["anxiety", "DISEASE", 34, 41], ["depression", "DISEASE", 46, 56], ["anxiety", "DISEASE", 65, 72], ["trauma", "DISEASE", 101, 107], ["traumatization", "DISEASE", 159, 173], ["anxiety", "DISEASE", 281, 288], ["depression", "DISEASE", 296, 306], ["people", "ORGANISM", 321, 327], ["people", "SPECIES", 321, 327], ["Analyses", "TEST", 0, 8], ["anxiety", "PROBLEM", 34, 41], ["depression levels", "PROBLEM", 46, 63], ["anxiety", "PROBLEM", 65, 72], ["the COVID", "TEST", 79, 88], ["secondary traumatization", "PROBLEM", 149, 173], ["the COVID", "TREATMENT", 213, 222], ["anxiety", "PROBLEM", 281, 288], ["depression", "PROBLEM", 296, 306]]], ["This study aims to evaluate the anxiety and depression signs of the health care workers exposed to secondary traumatization during the pandemic.", [["anxiety", "DISEASE", 32, 39], ["depression", "DISEASE", 44, 54], ["traumatization", "DISEASE", 109, 123], ["This study", "TEST", 0, 10], ["the anxiety", "PROBLEM", 28, 39], ["depression signs", "PROBLEM", 44, 60], ["secondary traumatization", "PROBLEM", 99, 123], ["the pandemic", "PROBLEM", 131, 143]]], ["Five hundred sixty-three participants, 251 of whom are health care professionals, attended this cross-sectional study, and we found that health care workers who treat the COVID-19 patients experience higher secondary traumatization.", [["traumatization", "DISEASE", 217, 231], ["patients", "ORGANISM", 180, 188], ["participants", "SPECIES", 25, 37], ["patients", "SPECIES", 180, 188], ["this cross-sectional study", "TEST", 91, 117], ["the COVID", "TREATMENT", 167, 176], ["higher secondary traumatization", "PROBLEM", 200, 231]]], ["Our findings present a necessity for primary assessment of frontline health care workers' mental health.", [["primary assessment", "TEST", 37, 55]]], ["Fear of being infected and infecting their loved ones, heavy workload, limited material and decrease in social support are the factors related to the anxiety and depression signs (Chua et al., 2004; Lai et al., 2020; Wong et al., 2005) .", [["anxiety", "DISEASE", 150, 157], ["depression", "DISEASE", 162, 172], ["limited material", "PROBLEM", 71, 87], ["social support", "TREATMENT", 104, 118], ["the anxiety", "PROBLEM", 146, 157], ["depression signs", "PROBLEM", 162, 178], ["infected", "OBSERVATION", 14, 22], ["decrease", "OBSERVATION_MODIFIER", 92, 100]]], ["Also, the rapid spread of the COVID-19 from person to person, being constantly exposed to the virus, high morbidity and potential death risk can cause secondary traumatization by intensifying the danger perception (Chen et al., 2020; Lai et al., 2020; Wang et al., 2020) .DiscussionAlso, in our study, we found that being a woman, being in the first years of the work, living with a parent, having a chronic disease, trauma history and increased use of social media are associated with high secondary traumatization and patient health scale points.", [["death", "DISEASE", 130, 135], ["traumatization", "DISEASE", 161, 175], ["chronic disease", "DISEASE", 400, 415], ["trauma", "DISEASE", 417, 423], ["woman", "ORGANISM", 324, 329], ["patient", "ORGANISM", 520, 527], ["COVID-19", "DNA", 30, 38], ["person", "SPECIES", 44, 50], ["person", "SPECIES", 54, 60], ["woman", "SPECIES", 324, 329], ["patient", "SPECIES", 520, 527], ["the virus", "PROBLEM", 90, 99], ["high morbidity", "PROBLEM", 101, 115], ["secondary traumatization", "PROBLEM", 151, 175], ["a chronic disease", "PROBLEM", 398, 415], ["trauma history", "PROBLEM", 417, 431], ["social media", "TREATMENT", 453, 465], ["high secondary traumatization", "PROBLEM", 486, 515], ["rapid", "OBSERVATION_MODIFIER", 10, 15], ["spread", "OBSERVATION_MODIFIER", 16, 22], ["chronic", "OBSERVATION_MODIFIER", 400, 407], ["disease", "OBSERVATION", 408, 415], ["increased", "OBSERVATION_MODIFIER", 436, 445]]], ["Several studies suggest that female health care workers are affected by the pandemic more than others.", [["Several studies", "TEST", 0, 15]]], ["When considered many female health care workers who treat the COVID-19 patients are nurses, they can carry a higher risk for mental health due to the close and frequent contact with the patients and longer working hours than usual (Chan, 2003; Chen et al., 2020; Lai et al., 2020; Zhang & Ma, 2020) .", [["patients", "ORGANISM", 71, 79], ["patients", "ORGANISM", 186, 194], ["patients", "SPECIES", 71, 79], ["patients", "SPECIES", 186, 194]]], ["Considering our findings, one can see that health care workers with 10 years or less of work experience have higher secondary traumatization points.", [["higher secondary traumatization points", "PROBLEM", 109, 147]]], ["Our study findings showed the group who was working for 20 years or more as health care worker has the least traumatization, depression and anxiety.", [["traumatization", "DISEASE", 109, 123], ["depression", "DISEASE", 125, 135], ["anxiety", "DISEASE", 140, 147], ["Our study", "TEST", 0, 9], ["depression", "PROBLEM", 125, 135], ["anxiety", "PROBLEM", 140, 147]]], ["In parallel with our research, Fried and Fisher's study in 2016 asserted employees with less experience have a higher level of stress and burnout related to work.", [["burnout", "DISEASE", 138, 145], ["Fisher's study", "TEST", 41, 55]]], ["People who live with their parents have higher points of both secondary traumatization and anxiety, and it can be related to the severity and the fatality of COVID-19 disease among the elders.", [["traumatization", "DISEASE", 72, 86], ["anxiety", "DISEASE", 91, 98], ["COVID", "DISEASE", 158, 163], ["People", "ORGANISM", 0, 6], ["People", "SPECIES", 0, 6], ["secondary traumatization", "PROBLEM", 62, 86], ["anxiety", "PROBLEM", 91, 98], ["COVID-19 disease", "PROBLEM", 158, 174], ["secondary traumatization", "OBSERVATION", 62, 86]]], ["The health care workers with a traumatic history in their past have significantly high secondary traumatization points.", [["significantly high secondary traumatization points", "PROBLEM", 68, 118], ["secondary traumatization", "OBSERVATION", 87, 111]]], ["Related studies presented that past traumas are risky for the future PTSD.", [["traumas", "DISEASE", 36, 43], ["PTSD", "DISEASE", 69, 73], ["PTSD", "PROBLEM", 69, 73]]], ["During the pandemic, participants who used social media more than usual have significantly higher secondary traumatization points.", [["participants", "ORGANISM", 21, 33], ["participants", "SPECIES", 21, 33], ["social media", "TREATMENT", 43, 55], ["significantly higher secondary traumatization points", "PROBLEM", 77, 129]]], ["Unfounded information and speculative news on social media, being frequently exposed to the pandemic-related news, witnessing the ambiguity of the further pandemic process and keeping track of the death toll can be counted as the reasons for high secondary traumatization points.DiscussionThere are various limitations to this research.", [["pandemic", "DISEASE", 92, 100], ["death", "DISEASE", 197, 202], ["the further pandemic process", "PROBLEM", 143, 171], ["high secondary traumatization points", "PROBLEM", 242, 278]]], ["It was applied cross-sectional and could not be pursued longitudinally due to the long working hours and social isolation rules of the health care workers.", [["social isolation", "TREATMENT", 105, 121]]], ["Another limitation is that the data collected only through an online questionnaire and a structured or semistructured interview could not be actualized.", [["the data", "TEST", 27, 35]]], ["So, the study does not have a strong sampling frame; therefore, the results may not be generalizable (Pierce et al., 2020) .", [["the study", "TEST", 4, 13]]], ["But we decided to do the study with the idea that it is important to document these data about the secondary traumatization that health care workers and general population experience during the COVID process.ConclusionIn Turkey, frontline health care workers who work with the COVID-19 patients stated a high level of secondary traumatization.", [["traumatization", "DISEASE", 328, 342], ["patients", "ORGANISM", 286, 294], ["patients", "SPECIES", 286, 294], ["the study", "TEST", 21, 30], ["secondary traumatization", "PROBLEM", 318, 342], ["secondary traumatization", "OBSERVATION", 318, 342]]], ["High traumatization values were found related to being a woman, living with a parent, having less work experience, having a trauma history in the past and increased use of social media.", [["trauma", "DISEASE", 124, 130], ["woman", "ORGANISM", 57, 62], ["woman", "SPECIES", 57, 62], ["High traumatization values", "PROBLEM", 0, 26], ["social media", "TREATMENT", 172, 184]]], ["In this case, considering the risk factors, protecting the health care workers and taking precautions are very important (Greenberg et al., 2020) .Conflict of interestThe author(s) declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article.FundingThe author(s) received no financial support for the research, authorship and/or publication of this article.", [["financial support", "TREATMENT", 334, 351]]]], "PMC7416682": [["Medical history ::: Case #1A 68-year old female presented on 04/06/2020 with presyncope.", [["presyncope", "DISEASE", 77, 87], ["female", "ORGANISM", 41, 47], ["presyncope", "PROBLEM", 77, 87]]], ["A week ago, she developed right shoulder pain with radiation to her arm but did not seek medical attention due concerns for COVID-19 exposure.", [["right shoulder", "ANATOMY", 26, 40], ["right shoulder pain", "DISEASE", 26, 45], ["COVID-19", "CHEMICAL", 124, 132], ["COVID-19", "CHEMICAL", 124, 132], ["shoulder", "ORGANISM_SUBDIVISION", 32, 40], ["COVID-19", "SIMPLE_CHEMICAL", 124, 132], ["right shoulder pain", "PROBLEM", 26, 45], ["COVID", "TEST", 124, 129], ["right", "ANATOMY_MODIFIER", 26, 31], ["shoulder", "ANATOMY", 32, 40], ["pain", "OBSERVATION", 41, 45], ["radiation", "OBSERVATION", 51, 60], ["arm", "ANATOMY", 68, 71]]], ["Initial vital signs on presentations were blood pressure of 143/38 mmHg, heart rate 82 bpm and saturating 95% on 4 L nasal canula.Investigations ::: Case #1Electrocardiogram (EKG) was concerning for a posterior myocardial infarction (Fig. 1.1).", [["blood", "ANATOMY", 42, 47], ["heart", "ANATOMY", 73, 78], ["nasal", "ANATOMY", 117, 122], ["myocardial", "ANATOMY", 211, 221], ["myocardial infarction", "DISEASE", 211, 232], ["blood", "ORGANISM_SUBSTANCE", 42, 47], ["heart", "ORGAN", 73, 78], ["myocardial", "MULTI-TISSUE_STRUCTURE", 211, 221], ["Initial vital signs", "TEST", 0, 19], ["blood pressure", "TEST", 42, 56], ["heart rate", "TEST", 73, 83], ["saturating", "TEST", 95, 105], ["4 L nasal canula", "TREATMENT", 113, 129], ["1Electrocardiogram", "TEST", 155, 173], ["EKG", "TEST", 175, 178], ["a posterior myocardial infarction", "PROBLEM", 199, 232], ["heart", "ANATOMY", 73, 78], ["posterior", "ANATOMY_MODIFIER", 201, 210], ["myocardial", "ANATOMY", 211, 221], ["infarction", "OBSERVATION", 222, 232]]], ["Laboratory results showed troponin I of 4.42 ng/ml, serum lactic acid 8.4 mmol/L. COVID-19 PCR was negative.", [["serum", "ANATOMY", 52, 57], ["lactic acid", "CHEMICAL", 58, 69], ["lactic acid", "CHEMICAL", 58, 69], ["troponin I", "GENE_OR_GENE_PRODUCT", 26, 36], ["serum", "ORGANISM_SUBSTANCE", 52, 57], ["lactic acid", "SIMPLE_CHEMICAL", 58, 69], ["troponin I", "PROTEIN", 26, 36], ["troponin I", "TEST", 26, 36], ["serum lactic acid", "TEST", 52, 69], ["L. COVID", "TEST", 79, 87], ["PCR", "TEST", 91, 94]]], ["Bedside transthoracic echocardiogram showed a hyperdynamic left ventricle (LV), a large hemopericardium with signs of tamponade, and basal to mid posterior wall akinesis (Video 1).Management ::: Case #1She subsequently became hypotensive and was started on norepinephrine drip after 2 L saline infusion.", [["left ventricle", "ANATOMY", 59, 73], ["LV", "ANATOMY", 75, 77], ["hemopericardium", "ANATOMY", 88, 103], ["posterior wall", "ANATOMY", 146, 160], ["hemopericardium", "DISEASE", 88, 103], ["tamponade", "DISEASE", 118, 127], ["hypotensive", "DISEASE", 226, 237], ["norepinephrine", "CHEMICAL", 257, 271], ["norepinephrine", "CHEMICAL", 257, 271], ["left ventricle", "MULTI-TISSUE_STRUCTURE", 59, 73], ["LV", "MULTI-TISSUE_STRUCTURE", 75, 77], ["hemopericardium", "CANCER", 88, 103], ["She", "ORGANISM", 202, 205], ["norepinephrine", "SIMPLE_CHEMICAL", 257, 271], ["Bedside transthoracic echocardiogram", "TEST", 0, 36], ["a hyperdynamic left ventricle", "PROBLEM", 44, 73], ["a large hemopericardium", "PROBLEM", 80, 103], ["tamponade", "PROBLEM", 118, 127], ["basal to mid posterior wall akinesis", "PROBLEM", 133, 169], ["hypotensive", "PROBLEM", 226, 237], ["norepinephrine drip", "TREATMENT", 257, 276], ["2 L saline infusion", "TREATMENT", 283, 302], ["hyperdynamic", "OBSERVATION", 46, 58], ["left ventricle", "ANATOMY", 59, 73], ["LV", "ANATOMY", 75, 77], ["large", "OBSERVATION_MODIFIER", 82, 87], ["hemopericardium", "OBSERVATION", 88, 103], ["tamponade", "OBSERVATION", 118, 127], ["basal", "ANATOMY_MODIFIER", 133, 138], ["mid", "ANATOMY_MODIFIER", 142, 145], ["posterior", "ANATOMY_MODIFIER", 146, 155], ["wall", "ANATOMY_MODIFIER", 156, 160], ["akinesis", "OBSERVATION", 161, 169], ["hypotensive", "OBSERVATION", 226, 237]]], ["She was emergently taken to the cardiac catheterization laboratory where coronary angiography revealed a 100% occlusion of an inferior distal branch of a large second obtuse marginal (Fig. 1.2).", [["cardiac", "ANATOMY", 32, 39], ["coronary", "ANATOMY", 73, 81], ["inferior distal branch", "ANATOMY", 126, 148], ["coronary", "MULTI-TISSUE_STRUCTURE", 73, 81], ["coronary angiography", "TEST", 73, 93], ["coronary", "ANATOMY", 73, 81], ["occlusion", "OBSERVATION", 110, 119], ["inferior", "ANATOMY_MODIFIER", 126, 134], ["distal", "ANATOMY_MODIFIER", 135, 141], ["branch", "ANATOMY_MODIFIER", 142, 148], ["large", "OBSERVATION_MODIFIER", 154, 159], ["second", "OBSERVATION_MODIFIER", 160, 166], ["obtuse marginal", "OBSERVATION", 167, 182]]], ["An intra-aortic balloon pump (IABP) was placed.", [["intra-aortic", "ANATOMY", 3, 15], ["intra-aortic balloon pump", "GENE_OR_GENE_PRODUCT", 3, 28], ["An intra-aortic balloon pump (IABP", "TREATMENT", 0, 34], ["intra-aortic", "ANATOMY", 3, 15], ["balloon pump", "OBSERVATION", 16, 28]]], ["Due to concern for potential ventricular wall rupture secondary to late presenting posterior MI, patient was taken to the operative room emergently and underwent a subxiphoid pericardial window with evacuation of 700 ml of old clotted blood.Follow-up ::: Case #1Patient's hemodynamic status improved immediately.", [["ventricular wall", "ANATOMY", 29, 45], ["pericardial", "ANATOMY", 175, 186], ["blood", "ANATOMY", 235, 240], ["ventricular wall rupture", "DISEASE", 29, 53], ["MI", "DISEASE", 93, 95], ["ventricular wall", "MULTI-TISSUE_STRUCTURE", 29, 45], ["patient", "ORGANISM", 97, 104], ["blood", "ORGANISM_SUBSTANCE", 235, 240], ["patient", "SPECIES", 97, 104], ["potential ventricular wall rupture", "PROBLEM", 19, 53], ["late presenting posterior MI", "PROBLEM", 67, 95], ["a subxiphoid pericardial window", "TREATMENT", 162, 193], ["evacuation", "TREATMENT", 199, 209], ["old clotted blood", "PROBLEM", 223, 240], ["ventricular", "ANATOMY", 29, 40], ["wall", "ANATOMY_MODIFIER", 41, 45], ["rupture", "OBSERVATION", 46, 53], ["posterior", "ANATOMY_MODIFIER", 83, 92], ["MI", "ANATOMY", 93, 95], ["subxiphoid", "ANATOMY_MODIFIER", 164, 174], ["pericardial", "ANATOMY", 175, 186], ["window", "OBSERVATION", 187, 193], ["700 ml", "OBSERVATION_MODIFIER", 213, 219], ["clotted blood", "OBSERVATION", 227, 240]]], ["Norepinephrine and IABP were weaned off.", [["Norepinephrine", "CHEMICAL", 0, 14], ["Norepinephrine", "CHEMICAL", 0, 14], ["IABP", "CHEMICAL", 19, 23], ["Norepinephrine", "SIMPLE_CHEMICAL", 0, 14], ["Norepinephrine", "TREATMENT", 0, 14], ["IABP", "TREATMENT", 19, 23]]], ["Post- operative TTE showed LV ejection fraction (LVEF) of 35\u201340% with akinesis of the posterior wall.", [["LV", "ANATOMY", 27, 29], ["posterior wall", "ANATOMY", 86, 100], ["LV", "MULTI-TISSUE_STRUCTURE", 27, 29], ["posterior wall", "MULTI-TISSUE_STRUCTURE", 86, 100], ["operative TTE", "TEST", 6, 19], ["LV ejection fraction", "TEST", 27, 47], ["LVEF", "TEST", 49, 53], ["akinesis of the posterior wall", "PROBLEM", 70, 100], ["LV", "ANATOMY", 27, 29], ["ejection fraction", "OBSERVATION", 30, 47], ["akinesis", "OBSERVATION", 70, 78], ["posterior", "ANATOMY_MODIFIER", 86, 95], ["wall", "ANATOMY_MODIFIER", 96, 100]]], ["Pt was eventually discharged home on 04/14/2020.Medical history ::: Case #2A 72-year-old female presented on 04/15/2020 at a peripheral hospital with acute onset of weakness, shortness of breath followed by a mechanical fall.", [["Pt", "CHEMICAL", 0, 2], ["weakness", "DISEASE", 165, 173], ["shortness of breath", "DISEASE", 175, 194], ["Pt", "CHEMICAL", 0, 2], ["female", "ORGANISM", 89, 95], ["weakness", "PROBLEM", 165, 173], ["shortness of breath", "PROBLEM", 175, 194], ["a mechanical fall", "PROBLEM", 207, 224], ["acute", "OBSERVATION_MODIFIER", 150, 155], ["weakness", "OBSERVATION", 165, 173], ["mechanical fall", "OBSERVATION", 209, 224]]], ["Prior to her presentation, patient reported four-day history of intermittent shortness of breath with exertion.", [["shortness of breath", "DISEASE", 77, 96], ["patient", "ORGANISM", 27, 34], ["patient", "SPECIES", 27, 34], ["intermittent shortness of breath", "PROBLEM", 64, 96]]], ["Vital signs were stable except tachycardia.", [["tachycardia", "DISEASE", 31, 42], ["Vital signs", "TEST", 0, 11], ["tachycardia", "PROBLEM", 31, 42], ["stable", "OBSERVATION", 17, 23]]], ["Physical exam was notable for a holosystolic murmur heard at the left lower sternal border and lungs were clear to auscultation.Investigations ::: Case #2Initial EKG showed remote inferior infarct and anterolateral ST segment elevations (Fig. 2.1).", [["left lower sternal border", "ANATOMY", 65, 90], ["lungs", "ANATOMY", 95, 100], ["inferior infarct", "ANATOMY", 180, 196], ["anterolateral ST segment", "ANATOMY", 201, 225], ["infarct", "DISEASE", 189, 196], ["lower", "ORGANISM_SUBDIVISION", 70, 75], ["sternal border", "MULTI-TISSUE_STRUCTURE", 76, 90], ["lungs", "ORGAN", 95, 100], ["Physical exam", "TEST", 0, 13], ["a holosystolic murmur", "PROBLEM", 30, 51], ["auscultation", "TEST", 115, 127], ["2Initial EKG", "TEST", 153, 165], ["remote inferior infarct", "PROBLEM", 173, 196], ["anterolateral ST segment elevations", "PROBLEM", 201, 236], ["Fig.", "TEST", 238, 242], ["holosystolic", "ANATOMY", 32, 44], ["murmur", "OBSERVATION", 45, 51], ["left", "ANATOMY_MODIFIER", 65, 69], ["lower", "ANATOMY_MODIFIER", 70, 75], ["sternal", "ANATOMY", 76, 83], ["border", "ANATOMY_MODIFIER", 84, 90], ["lungs", "ANATOMY", 95, 100], ["clear", "OBSERVATION", 106, 111], ["auscultation", "OBSERVATION", 115, 127], ["inferior", "ANATOMY_MODIFIER", 180, 188], ["infarct", "OBSERVATION", 189, 196], ["anterolateral", "ANATOMY_MODIFIER", 201, 214], ["ST segment", "ANATOMY", 215, 225], ["elevations", "OBSERVATION_MODIFIER", 226, 236]]], ["Laboratory studies showed initial troponin I of 49.2 ng/ml, brain natriuretic peptide 2660 pg/ml, serum lactic acid of 7.3 mg/L, white blood count (WBC) 34,000/ml.", [["brain", "ANATOMY", 60, 65], ["serum", "ANATOMY", 98, 103], ["white blood", "ANATOMY", 129, 140], ["lactic acid", "CHEMICAL", 104, 115], ["lactic acid", "CHEMICAL", 104, 115], ["troponin I", "GENE_OR_GENE_PRODUCT", 34, 44], ["brain natriuretic peptide", "GENE_OR_GENE_PRODUCT", 60, 85], ["serum", "ORGANISM_SUBSTANCE", 98, 103], ["lactic acid", "SIMPLE_CHEMICAL", 104, 115], ["blood", "ORGANISM_SUBSTANCE", 135, 140], ["troponin I", "PROTEIN", 34, 44], ["Laboratory studies", "TEST", 0, 18], ["initial troponin I", "TEST", 26, 44], ["brain natriuretic peptide", "TEST", 60, 85], ["serum lactic acid", "TEST", 98, 115], ["white blood count", "TEST", 129, 146], ["WBC", "TEST", 148, 151]]], ["COVID-19 PCR was negative.Management ::: Case #2Patient was given aspirin, ticagrelor and heparin and was transferred to the tertiary care center cardiac catheterization laboratory emergently.", [["cardiac", "ANATOMY", 146, 153], ["aspirin", "CHEMICAL", 66, 73], ["ticagrelor", "CHEMICAL", 75, 85], ["heparin", "CHEMICAL", 90, 97], ["aspirin", "CHEMICAL", 66, 73], ["ticagrelor", "CHEMICAL", 75, 85], ["aspirin", "SIMPLE_CHEMICAL", 66, 73], ["ticagrelor", "SIMPLE_CHEMICAL", 75, 85], ["heparin", "SIMPLE_CHEMICAL", 90, 97], ["COVID", "TEST", 0, 5], ["PCR", "TEST", 9, 12], ["aspirin", "TREATMENT", 66, 73], ["ticagrelor", "TREATMENT", 75, 85], ["heparin", "TREATMENT", 90, 97]]], ["Coronary angiography revealed serial 70% and 99% stenoses of the mid left anterior descending artery (LAD) (Fig. 2.2).", [["Coronary", "ANATOMY", 0, 8], ["left anterior descending artery", "ANATOMY", 69, 100], ["LAD", "ANATOMY", 102, 105], ["stenoses", "DISEASE", 49, 57], ["Coronary", "MULTI-TISSUE_STRUCTURE", 0, 8], ["anterior descending artery", "MULTI-TISSUE_STRUCTURE", 74, 100], ["LAD", "MULTI-TISSUE_STRUCTURE", 102, 105], ["Coronary angiography", "TEST", 0, 20], ["99% stenoses of the mid left anterior descending artery", "PROBLEM", 45, 100], ["Fig.", "TEST", 108, 112], ["stenoses", "OBSERVATION", 49, 57], ["mid", "ANATOMY_MODIFIER", 65, 68], ["left anterior descending artery", "ANATOMY", 69, 100], ["LAD", "ANATOMY", 102, 105]]], ["Ventriculography showed LVEF 30% with antero-apical and apical akinesis and evidence of a distal ventricular septal rupture (VSD).", [["antero-apical", "ANATOMY", 38, 51], ["distal ventricular septal", "ANATOMY", 90, 115], ["ventricular septal rupture", "DISEASE", 97, 123], ["ventricular septal", "MULTI-TISSUE_STRUCTURE", 97, 115], ["Ventriculography", "TEST", 0, 16], ["LVEF", "TEST", 24, 28], ["antero-apical and apical akinesis", "PROBLEM", 38, 71], ["a distal ventricular septal rupture", "PROBLEM", 88, 123], ["antero-apical", "ANATOMY_MODIFIER", 38, 51], ["apical", "ANATOMY_MODIFIER", 56, 62], ["akinesis", "OBSERVATION", 63, 71], ["distal", "ANATOMY_MODIFIER", 90, 96], ["ventricular septal", "ANATOMY", 97, 115], ["rupture", "OBSERVATION", 116, 123], ["VSD", "OBSERVATION", 125, 128]]], ["An IABP was inserted for hemodynamic support and cardiac surgery were consulted for VSD repair.", [["cardiac", "ANATOMY", 49, 56], ["cardiac", "ORGAN", 49, 56], ["An IABP", "TREATMENT", 0, 7], ["hemodynamic support", "TREATMENT", 25, 44], ["cardiac surgery", "TREATMENT", 49, 64], ["VSD repair", "TREATMENT", 84, 94], ["IABP", "OBSERVATION", 3, 7], ["repair", "OBSERVATION", 88, 94]]], ["TTE obtain showed LVEF 45% with distal LAD territory hypokinesis to akinesis with a distal non-restrictive VSD with left to right shunting (Video 2).", [["akinesis", "DISEASE", 68, 76], ["TTE", "TEST", 0, 3], ["LVEF", "TEST", 18, 22], ["distal LAD territory hypokinesis", "PROBLEM", 32, 64], ["akinesis", "PROBLEM", 68, 76], ["a distal non-restrictive VSD", "PROBLEM", 82, 110], ["left to right shunting", "PROBLEM", 116, 138], ["distal", "ANATOMY_MODIFIER", 32, 38], ["LAD", "ANATOMY", 39, 42], ["territory", "ANATOMY_MODIFIER", 43, 52], ["hypokinesis", "OBSERVATION", 53, 64], ["akinesis", "OBSERVATION", 68, 76], ["distal", "OBSERVATION_MODIFIER", 84, 90], ["non-restrictive VSD", "OBSERVATION", 91, 110], ["left", "ANATOMY_MODIFIER", 116, 120], ["right", "ANATOMY_MODIFIER", 124, 129], ["shunting", "OBSERVATION", 130, 138]]], ["Patient underwent a VSD repair with a polytetrafluoroethylene (PTFE) over collage-impregnated Dacron Hemashield patch with intra-operative echocardiogram showing residual small restrictive VSD.", [["polytetrafluoroethylene", "CHEMICAL", 38, 61], ["PTFE", "CHEMICAL", 63, 67], ["Patient", "SPECIES", 0, 7], ["a VSD repair", "TREATMENT", 18, 30], ["a polytetrafluoroethylene (PTFE) over collage-impregnated Dacron Hemashield patch", "TREATMENT", 36, 117], ["intra-operative echocardiogram", "TEST", 123, 153], ["residual small restrictive VSD", "PROBLEM", 162, 192], ["VSD", "ANATOMY", 20, 23], ["repair", "OBSERVATION", 24, 30], ["residual", "OBSERVATION_MODIFIER", 162, 170], ["small", "OBSERVATION_MODIFIER", 171, 176], ["restrictive VSD", "OBSERVATION", 177, 192]]], ["Post operatively, patient developed worsening cardiogenic shock requiring vasopressor and inotropic support over a period of 2 weeks.", [["cardiogenic shock", "DISEASE", 46, 63], ["patient", "ORGANISM", 18, 25], ["patient", "SPECIES", 18, 25], ["worsening cardiogenic shock", "PROBLEM", 36, 63], ["vasopressor", "TREATMENT", 74, 85], ["inotropic support", "TREATMENT", 90, 107], ["worsening", "OBSERVATION_MODIFIER", 36, 45], ["cardiogenic shock", "OBSERVATION", 46, 63], ["inotropic support", "OBSERVATION", 90, 107]]], ["Repeat TTE after 2 weeks showed persistent leak around the repair site.Follow-up ::: Case #2Given worsening hemodynamics, patient underwent a percutaneous closure of VSD using a 16 mm Amplatzer\u00ae post infarct VSD occluder after sizing it.", [["percutaneous", "ANATOMY", 142, 154], ["infarct", "DISEASE", 200, 207], ["patient", "ORGANISM", 122, 129], ["patient", "SPECIES", 122, 129], ["Repeat TTE", "TEST", 0, 10], ["persistent leak", "PROBLEM", 32, 47], ["the repair site", "TREATMENT", 55, 70], ["worsening hemodynamics", "PROBLEM", 98, 120], ["a percutaneous closure of VSD", "TREATMENT", 140, 169], ["a 16 mm Amplatzer\u00ae post infarct VSD occluder", "TREATMENT", 176, 220], ["persistent", "OBSERVATION_MODIFIER", 32, 42], ["leak", "OBSERVATION", 43, 47], ["repair site", "OBSERVATION", 59, 70], ["VSD", "OBSERVATION", 166, 169], ["infarct", "OBSERVATION", 200, 207], ["VSD occluder", "OBSERVATION", 208, 220]]], ["Follow up TTE showed persistent left to right shunt suggestive of VSD despite it appearing relatively smaller than before.", [["left", "ANATOMY", 32, 36], ["Follow up TTE", "TEST", 0, 13], ["persistent left to right shunt", "PROBLEM", 21, 51], ["VSD", "PROBLEM", 66, 69], ["persistent", "OBSERVATION_MODIFIER", 21, 31], ["left", "ANATOMY_MODIFIER", 32, 36], ["right", "ANATOMY_MODIFIER", 40, 45], ["shunt", "OBSERVATION", 46, 51], ["suggestive of", "UNCERTAINTY", 52, 65], ["VSD", "OBSERVATION", 66, 69], ["relatively", "OBSERVATION_MODIFIER", 91, 101], ["smaller", "OBSERVATION_MODIFIER", 102, 109]]], ["Patient's clinical status continued to deteriorate with increasing need for hemodynamic support and evidence of multiorgan failure over the course of next week.", [["multiorgan", "ANATOMY", 112, 122], ["multiorgan failure", "DISEASE", 112, 130], ["multiorgan", "ORGAN", 112, 122], ["Patient", "SPECIES", 0, 7], ["hemodynamic support", "TREATMENT", 76, 95], ["multiorgan failure", "PROBLEM", 112, 130], ["multiorgan failure", "OBSERVATION", 112, 130]]], ["Care was withdrawn by the family after another week of supportive management and patient expired on 05/12/2020.Medical history ::: Case #3A 53-year-old male presented on 05/30/2020 with 5-day history of progressively worsening chest pain, shortness of breath and diaphoresis.", [["chest", "ANATOMY", 227, 232], ["chest pain", "DISEASE", 227, 237], ["shortness of breath", "DISEASE", 239, 258], ["diaphoresis", "DISEASE", 263, 274], ["patient", "ORGANISM", 81, 88], ["male", "ORGANISM", 152, 156], ["chest", "ORGANISM_SUBDIVISION", 227, 232], ["patient", "SPECIES", 81, 88], ["supportive management", "TREATMENT", 55, 76], ["progressively worsening chest pain", "PROBLEM", 203, 237], ["shortness of breath", "PROBLEM", 239, 258], ["diaphoresis", "PROBLEM", 263, 274], ["worsening", "OBSERVATION_MODIFIER", 217, 226], ["chest", "ANATOMY", 227, 232], ["pain", "OBSERVATION", 233, 237]]], ["Vital signs were stable.", [["Vital signs", "TEST", 0, 11], ["stable", "OBSERVATION_MODIFIER", 17, 23]]], ["Physical examination was notable for a holosystolic murmur with radiation to the apex.Investigations ::: Case #3EKG showed sinus tachycardia, with ST segment elevations in the inferior leads and reciprocal depressions in the lateral leads (Fig. 3.1).", [["sinus", "ANATOMY", 123, 128], ["inferior leads", "ANATOMY", 176, 190], ["holosystolic murmur", "DISEASE", 39, 58], ["sinus tachycardia", "DISEASE", 123, 140], ["depressions", "DISEASE", 206, 217], ["sinus", "MULTI-TISSUE_STRUCTURE", 123, 128], ["Physical examination", "TEST", 0, 20], ["a holosystolic murmur", "PROBLEM", 37, 58], ["radiation to the apex", "PROBLEM", 64, 85], ["Case #3EKG", "TEST", 105, 115], ["sinus tachycardia", "PROBLEM", 123, 140], ["ST segment elevations in the inferior leads", "PROBLEM", 147, 190], ["reciprocal depressions in the lateral leads", "PROBLEM", 195, 238], ["Fig.", "TEST", 240, 244], ["holosystolic", "ANATOMY", 39, 51], ["murmur", "OBSERVATION", 52, 58], ["radiation", "OBSERVATION", 64, 73], ["apex", "ANATOMY_MODIFIER", 81, 85], ["sinus", "ANATOMY", 123, 128], ["tachycardia", "OBSERVATION", 129, 140], ["segment elevations", "OBSERVATION", 150, 168], ["inferior", "ANATOMY_MODIFIER", 176, 184], ["reciprocal depressions", "OBSERVATION", 195, 217], ["lateral", "ANATOMY_MODIFIER", 225, 232]]], ["Laboratory studies were significant for troponin I of 6.56 ng/ml and negative COVID-19 PCR.Management ::: Case #3Patient was given aspirin, ticagrelor and heparin and transferred emergently to the tertiary care center cardiac catheterization laboratory.", [["cardiac", "ANATOMY", 218, 225], ["aspirin", "CHEMICAL", 131, 138], ["ticagrelor", "CHEMICAL", 140, 150], ["heparin", "CHEMICAL", 155, 162], ["aspirin", "CHEMICAL", 131, 138], ["ticagrelor", "CHEMICAL", 140, 150], ["troponin I", "GENE_OR_GENE_PRODUCT", 40, 50], ["aspirin", "SIMPLE_CHEMICAL", 131, 138], ["ticagrelor", "SIMPLE_CHEMICAL", 140, 150], ["heparin", "SIMPLE_CHEMICAL", 155, 162], ["troponin I", "PROTEIN", 40, 50], ["Laboratory studies", "TEST", 0, 18], ["troponin I", "TEST", 40, 50], ["COVID", "TEST", 78, 83], ["PCR", "TEST", 87, 90], ["aspirin", "TREATMENT", 131, 138], ["ticagrelor", "TREATMENT", 140, 150], ["heparin", "TREATMENT", 155, 162], ["catheterization", "OBSERVATION", 226, 241]]], ["Coronary angiography revealed a 100% proximal RCA occlusion with left to right collaterals (Fig. 3.2).", [["Coronary", "ANATOMY", 0, 8], ["right collaterals", "ANATOMY", 73, 90], ["Coronary", "MULTI-TISSUE_STRUCTURE", 0, 8], ["RCA", "MULTI-TISSUE_STRUCTURE", 46, 49], ["Coronary angiography", "TEST", 0, 20], ["a 100% proximal RCA occlusion", "PROBLEM", 30, 59], ["Fig.", "TEST", 92, 96], ["proximal", "ANATOMY_MODIFIER", 37, 45], ["RCA", "ANATOMY", 46, 49], ["occlusion", "OBSERVATION", 50, 59], ["left", "ANATOMY_MODIFIER", 65, 69], ["right", "ANATOMY_MODIFIER", 73, 78], ["collaterals", "OBSERVATION", 79, 90]]], ["Ventriculogram showed an LVEF of 35% and distal ventricular septal rupture.", [["distal ventricular septal", "ANATOMY", 41, 66], ["ventricular septal rupture", "DISEASE", 48, 74], ["ventricular septal", "MULTI-TISSUE_STRUCTURE", 48, 66], ["Ventriculogram", "TEST", 0, 14], ["an LVEF", "TEST", 22, 29], ["distal ventricular septal rupture", "PROBLEM", 41, 74], ["LVEF", "OBSERVATION", 25, 29], ["35%", "OBSERVATION", 33, 36], ["distal", "ANATOMY_MODIFIER", 41, 47], ["ventricular septal", "ANATOMY", 48, 66], ["rupture", "OBSERVATION", 67, 74]]], ["TTE showed EF of 65\u201370% with large apical muscular ventricular septal defect with left to right shunting (Video 3).", [["apical muscular ventricular septal", "ANATOMY", 35, 69], ["muscular ventricular septal", "MULTI-TISSUE_STRUCTURE", 42, 69], ["EF", "PROTEIN", 11, 13], ["TTE", "TEST", 0, 3], ["EF", "TEST", 11, 13], ["large apical muscular ventricular septal defect", "PROBLEM", 29, 76], ["left to right shunting", "PROBLEM", 82, 104], ["large", "OBSERVATION_MODIFIER", 29, 34], ["apical", "ANATOMY_MODIFIER", 35, 41], ["muscular ventricular", "ANATOMY", 42, 62], ["septal", "ANATOMY_MODIFIER", 63, 69], ["defect", "OBSERVATION", 70, 76], ["left", "ANATOMY_MODIFIER", 82, 86], ["right", "ANATOMY_MODIFIER", 90, 95], ["shunting", "OBSERVATION", 96, 104]]], ["Patient was taken emergently for surgical repair of VSD with 2 Dacron patches.", [["Patient", "SPECIES", 0, 7], ["surgical repair", "TREATMENT", 33, 48], ["VSD", "PROBLEM", 52, 55], ["2 Dacron patches", "TREATMENT", 61, 77], ["VSD", "OBSERVATION", 52, 55], ["Dacron patches", "OBSERVATION", 63, 77]]], ["While taking the patient off cardiac bypass, patient developed significant bleeding from tears in the inferior wall of left ventricle.Follow-up ::: Case #3Due to persistent bleeding, patient expired while in the operation room.Medical history ::: Case #4A 72-year-old female presented to a peripheral hospital with 2 days of shortness of breath.", [["cardiac", "ANATOMY", 29, 36], ["inferior wall", "ANATOMY", 102, 115], ["left ventricle", "ANATOMY", 119, 133], ["bleeding", "DISEASE", 75, 83], ["tears", "DISEASE", 89, 94], ["bleeding", "DISEASE", 173, 181], ["shortness of breath", "DISEASE", 325, 344], ["patient", "ORGANISM", 17, 24], ["cardiac", "ORGAN", 29, 36], ["patient", "ORGANISM", 45, 52], ["inferior wall", "MULTI-TISSUE_STRUCTURE", 102, 115], ["left ventricle", "MULTI-TISSUE_STRUCTURE", 119, 133], ["patient", "ORGANISM", 183, 190], ["female", "ORGANISM", 268, 274], ["patient", "SPECIES", 17, 24], ["patient", "SPECIES", 45, 52], ["patient", "SPECIES", 183, 190], ["cardiac bypass", "TREATMENT", 29, 43], ["significant bleeding from tears", "PROBLEM", 63, 94], ["persistent bleeding", "PROBLEM", 162, 181], ["shortness of breath", "PROBLEM", 325, 344], ["bypass", "OBSERVATION", 37, 43], ["significant", "OBSERVATION_MODIFIER", 63, 74], ["bleeding", "OBSERVATION", 75, 83], ["tears", "OBSERVATION", 89, 94], ["inferior", "ANATOMY_MODIFIER", 102, 110], ["wall", "ANATOMY_MODIFIER", 111, 115], ["left ventricle", "ANATOMY", 119, 133], ["persistent", "OBSERVATION_MODIFIER", 162, 172], ["bleeding", "OBSERVATION", 173, 181]]], ["Patient reported symptoms of chest pain 1 week prior to arrival.", [["chest", "ANATOMY", 29, 34], ["chest pain", "DISEASE", 29, 39], ["chest", "ORGANISM_SUBDIVISION", 29, 34], ["Patient", "SPECIES", 0, 7], ["symptoms", "PROBLEM", 17, 25], ["chest pain", "PROBLEM", 29, 39], ["chest", "ANATOMY", 29, 34]]], ["Her initial vitals were unstable.", [["Her initial vitals", "TEST", 0, 18], ["unstable", "PROBLEM", 24, 32]]], ["She was transferred to tertiary care center for further care.Investigations ::: Case #4COVID PCR was negative.", [["further care", "TREATMENT", 48, 60], ["Case #4COVID PCR", "TEST", 80, 96]]], ["Upon arrival, the patient had severe lactic acidosis (ABG = pH 7.05 mmHg, pO2 134 mmHg, pCO2 18, bicarbonate 5 meq/L, lactic acid >12 mg/dl), was on BiPAP but was still following commands.", [["lactic acidosis", "DISEASE", 37, 52], ["bicarbonate", "CHEMICAL", 97, 108], ["lactic acid", "CHEMICAL", 118, 129], ["BiPAP", "CHEMICAL", 149, 154], ["bicarbonate", "CHEMICAL", 97, 108], ["lactic acid", "CHEMICAL", 118, 129], ["patient", "ORGANISM", 18, 25], ["lactic acid", "SIMPLE_CHEMICAL", 118, 129], ["patient", "SPECIES", 18, 25], ["severe lactic acidosis", "PROBLEM", 30, 52], ["ABG", "TEST", 54, 57], ["pH", "TEST", 60, 62], ["mmHg", "TEST", 68, 72], ["pO2", "TEST", 74, 77], ["mmHg", "TEST", 82, 86], ["pCO2", "TEST", 88, 92], ["bicarbonate", "TEST", 97, 108], ["lactic acid", "TEST", 118, 129], ["BiPAP", "TREATMENT", 149, 154], ["severe", "OBSERVATION_MODIFIER", 30, 36], ["lactic acidosis", "OBSERVATION", 37, 52]]], ["Shortly after arrival, an IABP was placed at bedside and she was emergently intubated in lieu of poor oxygenation.", [["an IABP", "TREATMENT", 23, 30], ["intubated", "TREATMENT", 76, 85], ["IABP", "OBSERVATION", 26, 30], ["poor oxygenation", "OBSERVATION", 97, 113]]], ["During this process, the patient had a pulseless electrical activity arrest requiring several rounds of cardiopulmonary resuscitation before achieving return of spontaneous circulation.", [["cardiopulmonary", "ANATOMY", 104, 119], ["pulseless electrical activity arrest", "DISEASE", 39, 75], ["patient", "ORGANISM", 25, 32], ["patient", "SPECIES", 25, 32], ["a pulseless electrical activity arrest", "PROBLEM", 37, 75], ["cardiopulmonary resuscitation", "TREATMENT", 104, 133], ["activity arrest", "OBSERVATION", 60, 75]]], ["TTE (Fig. 4.1) showed a serpiginous mid-apical infero-septal VSD; LVEF 40\u201345% with regional wall motion abnormalities consistent with recent anterior MI.Management ::: Case #4The patient was brought to the catheterization lab urgently and was found to have a severely stenotic LAD artery with evidence of thrombus.", [["serpiginous mid-apical infero-septal VSD", "ANATOMY", 24, 64], ["wall", "ANATOMY", 92, 96], ["stenotic LAD artery", "ANATOMY", 268, 287], ["thrombus", "ANATOMY", 305, 313], ["MI", "DISEASE", 150, 152], ["stenotic LAD artery", "DISEASE", 268, 287], ["thrombus", "DISEASE", 305, 313], ["wall", "MULTI-TISSUE_STRUCTURE", 92, 96], ["patient", "ORGANISM", 179, 186], ["LAD artery", "MULTI-TISSUE_STRUCTURE", 277, 287], ["thrombus", "PATHOLOGICAL_FORMATION", 305, 313], ["patient", "SPECIES", 179, 186], ["TTE", "TEST", 0, 3], ["Fig.", "TEST", 5, 9], ["a serpiginous mid-apical infero-septal VSD", "PROBLEM", 22, 64], ["LVEF", "TEST", 66, 70], ["regional wall motion abnormalities", "PROBLEM", 83, 117], ["recent anterior MI", "PROBLEM", 134, 152], ["a severely stenotic LAD artery", "PROBLEM", 257, 287], ["thrombus", "PROBLEM", 305, 313], ["serpiginous", "OBSERVATION_MODIFIER", 24, 35], ["infero-septal VSD", "ANATOMY", 47, 64], ["wall", "ANATOMY_MODIFIER", 92, 96], ["motion abnormalities", "OBSERVATION", 97, 117], ["consistent with", "UNCERTAINTY", 118, 133], ["anterior MI", "OBSERVATION", 141, 152], ["severely", "OBSERVATION_MODIFIER", 259, 267], ["stenotic", "OBSERVATION", 268, 276], ["LAD artery", "ANATOMY", 277, 287], ["thrombus", "OBSERVATION", 305, 313]]], ["The patient underwent successful stenting of the LAD artery with two drug eluting stents aided by aspiration thrombectomy (Fig. 4.2).", [["LAD artery", "ANATOMY", 49, 59], ["patient", "ORGANISM", 4, 11], ["LAD artery", "MULTI-TISSUE_STRUCTURE", 49, 59], ["patient", "SPECIES", 4, 11], ["successful stenting of the LAD artery", "TREATMENT", 22, 59], ["two drug eluting stents", "TREATMENT", 65, 88], ["aspiration thrombectomy", "TREATMENT", 98, 121], ["stenting", "OBSERVATION", 33, 41], ["LAD artery", "ANATOMY", 49, 59], ["drug", "OBSERVATION", 69, 73], ["eluting stents", "OBSERVATION", 74, 88], ["aspiration thrombectomy", "OBSERVATION", 98, 121]]], ["This improved the flow from TIMI 0 to TIMI 2.", [["TIMI", "TEST", 38, 42]]], ["At this stage, due to severe cardiogenic shock, the patient was supported with TandemHeart\u00ae percutaneous left ventricular assist device.", [["left ventricular", "ANATOMY", 105, 121], ["cardiogenic shock", "DISEASE", 29, 46], ["patient", "ORGANISM", 52, 59], ["ventricular", "MULTI-TISSUE_STRUCTURE", 110, 121], ["patient", "SPECIES", 52, 59], ["severe cardiogenic shock", "PROBLEM", 22, 46], ["TandemHeart\u00ae percutaneous left ventricular assist device", "TREATMENT", 79, 135], ["severe", "OBSERVATION_MODIFIER", 22, 28], ["cardiogenic shock", "OBSERVATION", 29, 46], ["left ventricular", "ANATOMY", 105, 121], ["assist device", "OBSERVATION", 122, 135]]], ["After a week of care, patient underwent percutaneous closure of the VSD with 25 mm Amplatzer\u00ae Cribriform device.", [["percutaneous", "ANATOMY", 40, 52], ["patient", "ORGANISM", 22, 29], ["patient", "SPECIES", 22, 29], ["percutaneous closure of the VSD", "TREATMENT", 40, 71], ["25 mm Amplatzer\u00ae Cribriform device", "TREATMENT", 77, 111], ["percutaneous closure", "OBSERVATION", 40, 60], ["VSD", "OBSERVATION", 68, 71], ["Cribriform device", "OBSERVATION", 94, 111]]], ["Transesophageal echocardiography showed no significant shunting thereafter (Fig. 4.3).Follow-up ::: Case #4Unfortunately, the hospital course was complicated by sepsis and multi-system organ failure, the patient expired approximately 2 weeks after VSD closure device implantation.DiscussionThe novel coronavirus 2 (SARS-CoV2), is a viral disease that leads to severe respiratory syndrome termed coronavirus disease 2019 (COVID-19) that has affected more than 10 million people and has killed more than half a million worldwide [1].", [["organ", "ANATOMY", 185, 190], ["sepsis", "DISEASE", 161, 167], ["multi-system organ failure", "DISEASE", 172, 198], ["viral disease", "DISEASE", 332, 345], ["respiratory syndrome", "DISEASE", 367, 387], ["coronavirus disease", "DISEASE", 395, 414], ["COVID-19", "CHEMICAL", 421, 429], ["organ", "ORGAN", 185, 190], ["patient", "ORGANISM", 204, 211], ["coronavirus 2", "ORGANISM", 300, 313], ["SARS-CoV2", "ORGANISM", 315, 324], ["people", "ORGANISM", 470, 476], ["patient", "SPECIES", 204, 211], ["people", "SPECIES", 470, 476], ["Transesophageal echocardiography", "TEST", 0, 32], ["significant shunting", "PROBLEM", 43, 63], ["Fig.", "TEST", 76, 80], ["sepsis", "PROBLEM", 161, 167], ["multi-system organ failure", "PROBLEM", 172, 198], ["VSD closure device implantation", "TREATMENT", 248, 279], ["The novel coronavirus", "PROBLEM", 290, 311], ["a viral disease", "PROBLEM", 330, 345], ["severe respiratory syndrome", "PROBLEM", 360, 387], ["coronavirus disease", "PROBLEM", 395, 414], ["COVID", "TEST", 421, 426], ["no", "UNCERTAINTY", 40, 42], ["significant", "OBSERVATION_MODIFIER", 43, 54], ["shunting", "OBSERVATION", 55, 63], ["sepsis", "OBSERVATION", 161, 167], ["multi-system organ", "OBSERVATION", 172, 190], ["failure", "OBSERVATION", 191, 198], ["closure", "OBSERVATION", 252, 259], ["device implantation", "OBSERVATION", 260, 279], ["viral disease", "OBSERVATION", 332, 345], ["severe", "OBSERVATION_MODIFIER", 360, 366], ["respiratory syndrome", "OBSERVATION", 367, 387], ["coronavirus disease", "OBSERVATION", 395, 414]]], ["Several measures including social distancing and #stayhome campaigns are being run.", [["#stayhome campaigns", "TREATMENT", 49, 68]]], ["However, due to COVID-19, nearly half of the public (48%) has delayed their health care as found by Kaiser Family Foundation poll [2].", [["COVID", "TEST", 16, 21]]], ["In the pre percutaneous coronary intervention era, the incidence of free wall rupture was 6%, papillary muscle rupture was 2% and ventricular septal defect was 2% [3].", [["coronary", "ANATOMY", 24, 32], ["wall", "ANATOMY", 73, 77], ["papillary muscle", "ANATOMY", 94, 110], ["ventricular septal", "ANATOMY", 130, 148], ["wall rupture", "DISEASE", 73, 85], ["muscle rupture", "DISEASE", 104, 118], ["ventricular septal defect", "DISEASE", 130, 155], ["coronary", "MULTI-TISSUE_STRUCTURE", 24, 32], ["free wall", "MULTI-TISSUE_STRUCTURE", 68, 77], ["papillary muscle", "TISSUE", 94, 110], ["ventricular septal", "MULTI-TISSUE_STRUCTURE", 130, 148], ["the pre percutaneous coronary intervention", "TREATMENT", 3, 45], ["free wall rupture", "PROBLEM", 68, 85], ["papillary muscle rupture", "PROBLEM", 94, 118], ["ventricular septal defect", "PROBLEM", 130, 155], ["percutaneous coronary", "ANATOMY", 11, 32], ["free", "OBSERVATION_MODIFIER", 68, 72], ["wall", "ANATOMY_MODIFIER", 73, 77], ["rupture", "OBSERVATION", 78, 85], ["papillary muscle", "ANATOMY", 94, 110], ["rupture", "OBSERVATION", 111, 118], ["ventricular septal", "ANATOMY", 130, 148], ["defect", "OBSERVATION", 149, 155]]], ["The incidences of all these complications decreased to 0.2% in the post PCI era and is rarely witnessed in areas where PCI is readily available [4,5].DiscussionAn important aspect of this case series was that there was already a suspicion of VSD in two of these cases because of the physical examination finding of murmur prior to arrival to the cardiac catheterization lab.", [["cardiac", "ANATOMY", 346, 353], ["VSD", "PATHOLOGICAL_FORMATION", 242, 245], ["all these complications", "PROBLEM", 18, 41], ["PCI", "TREATMENT", 119, 122], ["VSD", "PROBLEM", 242, 245], ["the physical examination", "TEST", 279, 303], ["murmur", "PROBLEM", 315, 321], ["complications", "OBSERVATION", 28, 41], ["VSD", "OBSERVATION", 242, 245], ["murmur", "OBSERVATION", 315, 321]]], ["It is important to auscultate these patients prior to bringing to the catheterization laboratory as it may impact the follow up management.", [["patients", "ORGANISM", 36, 44], ["patients", "SPECIES", 36, 44], ["the follow up management", "TREATMENT", 114, 138]]], ["Though a small case series, this rapid increase in post MI complications cases in less 2 months at these institutions highlights the \u201cunmeasured\u201d toll and impact of COVID-19 on patients during this pandemic.", [["MI", "DISEASE", 56, 58], ["COVID-19", "CHEMICAL", 165, 173], ["patients", "ORGANISM", 177, 185], ["patients", "SPECIES", 177, 185], ["a small case series", "PROBLEM", 7, 26], ["this rapid increase", "PROBLEM", 28, 47], ["post MI complications", "PROBLEM", 51, 72], ["COVID", "TEST", 165, 170], ["small", "OBSERVATION_MODIFIER", 9, 14], ["rapid", "OBSERVATION_MODIFIER", 33, 38], ["increase", "OBSERVATION_MODIFIER", 39, 47], ["post MI", "OBSERVATION_MODIFIER", 51, 58], ["complications", "OBSERVATION", 59, 72]]], ["This further highlights the crucial role that cardiologists could play in educating patients to recognize and seek medical help for their cardiovascular symptoms.ConclusionPost MI complications have high morbidity and mortality.", [["cardiovascular", "ANATOMY", 138, 152], ["cardiovascular symptoms", "DISEASE", 138, 161], ["MI", "DISEASE", 177, 179], ["patients", "ORGANISM", 84, 92], ["cardiovascular", "ANATOMICAL_SYSTEM", 138, 152], ["patients", "SPECIES", 84, 92], ["their cardiovascular symptoms", "PROBLEM", 132, 161], ["Post MI complications", "PROBLEM", 172, 193], ["high morbidity", "PROBLEM", 199, 213], ["high", "OBSERVATION_MODIFIER", 199, 203], ["morbidity", "OBSERVATION", 204, 213]]], ["Early identification may impact the outcomes and patients should be encouraged to seek health care for their cardiovascular symptoms during COVID pandemic.ConclusionThe following are the supplementary data related to this article.", [["cardiovascular", "ANATOMY", 109, 123], ["cardiovascular symptoms", "DISEASE", 109, 132], ["patients", "ORGANISM", 49, 57], ["cardiovascular", "ANATOMICAL_SYSTEM", 109, 123], ["patients", "SPECIES", 49, 57], ["their cardiovascular symptoms", "PROBLEM", 103, 132]]]], "PMC6977244": [["BackgroundIn April 2009, the influenza A (H1N1)pdm09 virus was detected in humans and, shortly after, provoked the first pandemic of the twenty-first century [1, 2].", [["influenza A (H1N1)pdm09 virus", "ORGANISM", 29, 58], ["humans", "ORGANISM", 75, 81], ["influenza A (H1N1", "SPECIES", 29, 46], ["humans", "SPECIES", 75, 81], ["influenza A (H1N1)pdm09 virus", "SPECIES", 29, 58], ["humans", "SPECIES", 75, 81], ["the influenza A (H1N1)pdm09 virus", "PROBLEM", 25, 58]]], ["Simultaneous to the global spread in humans, the virus emerged in pig farms across the world [3\u20136].", [["humans", "ORGANISM", 37, 43], ["pig", "ORGANISM", 66, 69], ["humans", "SPECIES", 37, 43], ["pig", "SPECIES", 66, 69], ["humans", "SPECIES", 37, 43], ["pig", "SPECIES", 66, 69], ["the virus", "TREATMENT", 45, 54], ["global", "OBSERVATION_MODIFIER", 20, 26], ["spread", "OBSERVATION", 27, 33]]], ["The porcine origin of the virus is uncontroversial and underlines the importance of the pig as a host for the virus [7].BackgroundInfluenza A virus (IAV) is a potential pathogen of zoonotic disease and causes worldwide important economic losses [8, 9].", [["Influenza A virus (IAV)", "DISEASE", 130, 153], ["zoonotic disease", "DISEASE", 181, 197], ["porcine", "ORGANISM", 4, 11], ["pig", "ORGANISM", 88, 91], ["Background", "ORGANISM", 120, 130], ["Influenza A virus", "ORGANISM", 130, 147], ["IAV", "ORGANISM", 149, 152], ["pig", "SPECIES", 88, 91], ["Influenza A virus", "SPECIES", 130, 147], ["pig", "SPECIES", 88, 91], ["Influenza A virus", "SPECIES", 130, 147], ["IAV", "SPECIES", 149, 152], ["the virus", "PROBLEM", 22, 31], ["the pig", "TREATMENT", 84, 91], ["the virus", "PROBLEM", 106, 115], ["BackgroundInfluenza A virus (IAV", "PROBLEM", 120, 152], ["zoonotic disease", "PROBLEM", 181, 197], ["porcine", "OBSERVATION_MODIFIER", 4, 11], ["origin", "OBSERVATION_MODIFIER", 12, 18], ["virus", "OBSERVATION", 26, 31], ["Influenza", "OBSERVATION", 130, 139], ["zoonotic disease", "OBSERVATION", 181, 197]]], ["Pathogenesis studies have shown that in pigs as well as in all other mammals viral infection and replication is limited to the respiratory tract [10].", [["respiratory tract", "ANATOMY", 127, 144], ["viral infection", "DISEASE", 77, 92], ["pigs", "ORGANISM", 40, 44], ["pigs", "SPECIES", 40, 44], ["pigs", "SPECIES", 40, 44], ["Pathogenesis studies", "TEST", 0, 20], ["all other mammals viral infection", "PROBLEM", 59, 92], ["viral", "OBSERVATION_MODIFIER", 77, 82], ["infection", "OBSERVATION", 83, 92], ["respiratory tract", "ANATOMY", 127, 144]]], ["Independent of the subtype, the disease can emerge both in a subclinical and in an acute way, with varying severity, showing febrile illness together with respiratory disease [4, 8, 11].", [["respiratory", "ANATOMY", 155, 166], ["febrile illness", "DISEASE", 125, 140], ["respiratory disease", "DISEASE", 155, 174], ["the disease", "PROBLEM", 28, 39], ["febrile illness", "PROBLEM", 125, 140], ["respiratory disease", "PROBLEM", 155, 174], ["disease", "OBSERVATION", 32, 39], ["respiratory disease", "OBSERVATION", 155, 174]]], ["An involvement in reproductive disorders, such as return to oestrus, abortion or small litters, is assumed, although a causal link could not be shown in all studies [12, 13].", [["reproductive disorders", "DISEASE", 18, 40], ["abortion", "DISEASE", 69, 77], ["reproductive disorders", "PROBLEM", 18, 40], ["oestrus", "PROBLEM", 60, 67], ["abortion", "PROBLEM", 69, 77], ["small litters", "PROBLEM", 81, 94], ["reproductive disorders", "OBSERVATION", 18, 40], ["small", "OBSERVATION_MODIFIER", 81, 86], ["litters", "OBSERVATION_MODIFIER", 87, 94]]], ["Numerous case reports as well as a case-control study on a naive Norwegian pig subpopulation describe the emergence of reproductive disorders in context with the infection with influenza A virus [14\u201317].", [["reproductive disorders", "DISEASE", 119, 141], ["infection", "DISEASE", 162, 171], ["influenza A virus", "DISEASE", 177, 194], ["pig", "ORGANISM", 75, 78], ["influenza A virus", "ORGANISM", 177, 194], ["pig", "SPECIES", 75, 78], ["influenza A virus", "SPECIES", 177, 194], ["pig", "SPECIES", 75, 78], ["influenza A virus", "SPECIES", 177, 194], ["a naive Norwegian pig subpopulation", "TREATMENT", 57, 92], ["reproductive disorders", "PROBLEM", 119, 141], ["the infection", "PROBLEM", 158, 171], ["influenza A virus", "PROBLEM", 177, 194], ["infection", "OBSERVATION", 162, 171]]], ["In contrast, there are few experimental studies investigating the pathogenesis and the clinical presentation of the reproductive losses [18\u201320].", [["few experimental studies", "TEST", 23, 47], ["the pathogenesis", "PROBLEM", 62, 78], ["the reproductive losses", "PROBLEM", 112, 135], ["few", "OBSERVATION_MODIFIER", 23, 26]]], ["The clinical presentation was not reproducible in these studies.", [["these studies", "TEST", 50, 63]]], ["Thus, a validation of a causal link between the virus infection and inadequate reproductive performance is still lacking.", [["infection", "DISEASE", 54, 63], ["the virus infection", "PROBLEM", 44, 63], ["inadequate reproductive performance", "PROBLEM", 68, 103]]], ["Subsequent to the emergence of the pandemic influenza A virus, a new vaccine against this subtype was developed.", [["influenza A virus", "DISEASE", 44, 61], ["influenza A virus", "ORGANISM", 44, 61], ["pandemic influenza A virus", "SPECIES", 35, 61], ["pandemic influenza A virus", "SPECIES", 35, 61], ["the pandemic influenza A virus", "PROBLEM", 31, 61], ["a new vaccine", "TREATMENT", 63, 76], ["this subtype", "PROBLEM", 85, 97]]], ["The results of the clinical studies for efficacy and safety were verified under field conditions in 315 farms infected with pandemic influenza A virus.", [["pandemic influenza A virus", "DISEASE", 124, 150], ["influenza A virus", "ORGANISM", 133, 150], ["pandemic influenza A virus", "SPECIES", 124, 150], ["pandemic influenza A virus", "SPECIES", 124, 150], ["the clinical studies", "TEST", 15, 35], ["pandemic influenza A virus", "PROBLEM", 124, 150]]], ["A majority of the sows in the affected farms where IAV was circulating showed remarkably reduced reproductive performance.", [["sows", "ORGANISM", 18, 22], ["IAV", "ORGANISM", 51, 54], ["IAV", "SPECIES", 51, 54], ["IAV", "PROBLEM", 51, 54], ["remarkably reduced reproductive performance", "PROBLEM", 78, 121], ["reduced", "OBSERVATION_MODIFIER", 89, 96], ["reproductive", "OBSERVATION_MODIFIER", 97, 109]]], ["The present longitudinal field study was conducted to evaluate the effect of pandemic IAV on the reproductive parameters and vaccination of animals in conventional sow herds.Clinical signs ::: ResultsClinical signs prior to vaccination were recorded in 129 farms (Additional file 1, Table S1).", [["IAV", "ORGANISM", 86, 89], ["The present longitudinal field study", "TEST", 0, 36], ["pandemic IAV", "TREATMENT", 77, 89], ["the reproductive parameters", "TEST", 93, 120], ["vaccination of animals", "TREATMENT", 125, 147], ["vaccination", "TREATMENT", 224, 235]]], ["Due to information bias, the clinical signs could not be evaluated in eight farms.", [["the clinical signs", "TEST", 25, 43]]], ["Reduced reproductive performance was observed in 79.8% (n = 103/129) of the farms.", [["Reduced reproductive performance", "PROBLEM", 0, 32]]], ["The clinical presentation was characterised by fever and respiratory disease (cough) in 62.8% (n = 81/129) and 61.2% (n = 79/129) of the farms, respectively.", [["respiratory", "ANATOMY", 57, 68], ["fever", "DISEASE", 47, 52], ["respiratory disease", "DISEASE", 57, 76], ["cough", "DISEASE", 78, 83], ["fever", "PROBLEM", 47, 52], ["respiratory disease", "PROBLEM", 57, 76], ["cough", "TEST", 78, 83], ["fever", "OBSERVATION", 47, 52], ["respiratory disease", "OBSERVATION", 57, 76]]], ["Dyspnoea was apparent in 17.1% (n = 22/129), reduced feed intake in 39.5% (n = 51/129) and apathy in 14.7% (n = 19/129) of the farms.Reproductive performance ::: ResultsAnalysis of the return to oestrus rate revealed, on average, a significant (p < 0.001) decline of 3.34% after immunisation (Table 1).", [["Dyspnoea", "DISEASE", 0, 8], ["apathy", "DISEASE", 91, 97], ["Dyspnoea", "PROBLEM", 0, 8], ["reduced feed intake", "PROBLEM", 45, 64], ["apathy", "TEST", 91, 97], ["oestrus rate", "TEST", 195, 207], ["significant", "OBSERVATION_MODIFIER", 232, 243]]]], "66aaa910eb2a4e8bfb50a0a3a7038982d517829e": [["IntroductionBoth A and B seasonal influenza virus types cause outbreaks and epidemics, while only type A has been known to cause pandemics (WHO, 2016) .", [["influenza virus", "DISEASE", 34, 49], ["B seasonal influenza virus", "ORGANISM", 23, 49], ["seasonal influenza virus", "SPECIES", 25, 49], ["B seasonal influenza virus", "SPECIES", 23, 49], ["A and B seasonal influenza virus types", "TREATMENT", 17, 55], ["epidemics", "PROBLEM", 76, 85]]], ["The pandemic influenza A (H1N1) pdm09 virus was first identified in humans in March/April 2009 and spread worldwide, including to the Kingdom of Saudi Arabia (KSA) (Al-Tawfiq et al., 2011; Balkhy et al., 2010 ; Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team et al., 2009; Uthman et al., 2014) .IntroductionThe KSA Ministry of Health (MOH) gold standard method for influenza A/H1N1 detection is the RealTime Ready Influenza A/H1N1 Detection Set (Roche Diagnostics GmbH, Germany) (Barb\u00e1s et al., 2012; Choi et al., 2010; thi Tham et al., 2012; Wenzel et al., 2010) .", [["influenza", "DISEASE", 13, 22], ["pandemic influenza A (H1N1) pdm09 virus", "ORGANISM", 4, 43], ["humans", "ORGANISM", 68, 74], ["Swine-Origin Influenza A (H1N1) Virus", "ORGANISM", 217, 254], ["influenza A (H1N1", "SPECIES", 13, 30], ["humans", "SPECIES", 68, 74], ["pandemic influenza A (H1N1) pdm09 virus", "SPECIES", 4, 43], ["humans", "SPECIES", 68, 74], ["influenza A/H1N1", "SPECIES", 380, 396], ["Influenza A/H1N1", "SPECIES", 429, 445], ["The pandemic influenza A (H1N1) pdm09 virus", "PROBLEM", 0, 43], ["influenza", "PROBLEM", 380, 389]]], ["This kit has high specificity but variable sensitivity (Barb\u00e1s et al., 2012; Choi et al., 2010; thi Tham et al., 2012; Wenzel et al., 2010) .", [["This kit", "TEST", 0, 8]]], ["In our laboratory, we use the Cepheid\u00ae Xpert Flu Assay multiplex real-time PCR (Cepheid) for differential, qualitative detection of influenza A, influenza B, and influenza A (H1N1) pdm09.", [["influenza A", "DISEASE", 132, 143], ["influenza B", "DISEASE", 145, 156], ["influenza A", "ORGANISM", 132, 143], ["influenza B", "ORGANISM", 145, 156], ["influenza A (H1N1) pdm09", "ORGANISM", 162, 186], ["influenza A (H1N1", "SPECIES", 162, 179], ["influenza A", "SPECIES", 132, 143], ["influenza A (H1N1) pdm09", "SPECIES", 162, 186], ["the Cepheid\u00ae", "TREATMENT", 26, 38], ["qualitative detection", "TEST", 107, 128], ["influenza", "PROBLEM", 132, 141], ["influenza B", "PROBLEM", 145, 156], ["influenza", "PROBLEM", 162, 171], ["pdm09", "PROBLEM", 181, 186]]], ["It has high specificity and sensitivity in nasopharyngeal samples (Novak-Weekley et al., 2012; Popowitch et al., 2011; Salez et al., 2012) .", [["nasopharyngeal samples", "ANATOMY", 43, 65], ["nasopharyngeal samples", "CANCER", 43, 65], ["nasopharyngeal samples", "TEST", 43, 65], ["high", "OBSERVATION_MODIFIER", 7, 11], ["nasopharyngeal", "ANATOMY", 43, 57]]], ["Overall, 99% agreement was observed between the two kits in a study on 102 clinical samples (Sohn et al., 2013) .", [["samples", "ANATOMY", 84, 91], ["a study", "TEST", 60, 67]]], ["Our study was designed to test the sensitivity and specificity of our Xpert Flu Assay with respect to the MOH-approved RealTime Ready Influenza A/ H1N1 Detection Set method on a larger series of 749 clinical samples.Patient Population and SpecimensInfluenza A/influenza A (H1N1) pdm09 testing was carried out on clinical specimens from 749 suspected MERS-CoV patients presenting to Johns Hopkins Aramco Healthcare facilities in the Eastern Province of KSA between April 2015 and February 2016.", [["samples", "ANATOMY", 208, 215], ["specimens", "ANATOMY", 321, 330], ["MERS-CoV", "DISEASE", 350, 358], ["Specimens", "ORGANISM", 239, 248], ["Influenza A/influenza A (H1N1) pdm09", "ORGANISM", 248, 284], ["MERS-CoV", "ORGANISM", 350, 358], ["patients", "ORGANISM", 359, 367], ["Patient", "SPECIES", 216, 223], ["patients", "SPECIES", 359, 367], ["Influenza A/influenza A (H1N1) pdm09", "SPECIES", 248, 284], ["MERS-CoV", "SPECIES", 350, 358], ["Our study", "TEST", 0, 9], ["the sensitivity", "TEST", 31, 46], ["our Xpert Flu Assay", "TEST", 66, 85], ["clinical samples", "TEST", 199, 215], ["Patient Population", "TEST", 216, 234], ["SpecimensInfluenza A", "TEST", 239, 259], ["influenza", "PROBLEM", 260, 269], ["pdm09 testing", "TEST", 279, 292], ["clinical specimens", "TEST", 312, 330]]], ["Table 1 shows the patient and sample characteristics (gender, age group, sample type, and location where sample collected).", [["patient", "ORGANISM", 18, 25], ["patient", "SPECIES", 18, 25]]], ["This testing is indicated by KSA MOH guidelines for patients who meet Category I [acute respiratory illness with clinical and/or radiological evidence of pulmonary parenchymal disease (pneumonia or acute respiratory distress syndrome)] or Category II (hospitalized patient with healthcare-associated pneumonia based on clinical and radiological evidence) criteria for possible MERS-CoV infection (Kingdom of Saudi Arabia Ministry of Health, 2017).", [["respiratory", "ANATOMY", 88, 99], ["pulmonary parenchymal", "ANATOMY", 154, 175], ["respiratory", "ANATOMY", 204, 215], ["respiratory illness", "DISEASE", 88, 107], ["pulmonary parenchymal disease", "DISEASE", 154, 183], ["pneumonia", "DISEASE", 185, 194], ["acute respiratory distress syndrome", "DISEASE", 198, 233], ["pneumonia", "DISEASE", 300, 309], ["MERS-CoV infection", "DISEASE", 377, 395], ["patients", "ORGANISM", 52, 60], ["pulmonary parenchymal", "MULTI-TISSUE_STRUCTURE", 154, 175], ["patient", "ORGANISM", 265, 272], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 377, 385], ["patients", "SPECIES", 52, 60], ["patient", "SPECIES", 265, 272], ["MERS-CoV", "SPECIES", 377, 385], ["This testing", "TEST", 0, 12], ["acute respiratory illness", "PROBLEM", 82, 107], ["pulmonary parenchymal disease", "PROBLEM", 154, 183], ["pneumonia", "PROBLEM", 185, 194], ["acute respiratory distress syndrome", "PROBLEM", 198, 233], ["pneumonia", "PROBLEM", 300, 309], ["MERS", "PROBLEM", 377, 381], ["CoV infection", "PROBLEM", 382, 395], ["pulmonary", "ANATOMY", 154, 163], ["parenchymal", "ANATOMY_MODIFIER", 164, 175], ["disease", "OBSERVATION", 176, 183], ["pneumonia", "OBSERVATION", 185, 194], ["acute", "OBSERVATION_MODIFIER", 198, 203], ["respiratory distress", "OBSERVATION", 204, 224], ["pneumonia", "OBSERVATION", 300, 309], ["CoV", "OBSERVATION_MODIFIER", 382, 385], ["infection", "OBSERVATION", 386, 395]]], ["The guidelines state that such patients should be simultaneously tested for other common viral and bacterial causes of community-acquired pneumonia (Kingdom of Saudi Arabia Ministry of Health, 2017).", [["pneumonia", "DISEASE", 138, 147], ["patients", "ORGANISM", 31, 39], ["patients", "SPECIES", 31, 39], ["other common viral and bacterial causes", "PROBLEM", 76, 115], ["community-acquired pneumonia", "PROBLEM", 119, 147], ["pneumonia", "OBSERVATION", 138, 147]]], ["Patient age ranged from 1 to 108 years (median 63 years).Patient Population and SpecimensTests were carried out at the Johns Hopkins Aramco Healthcare Centre in Dhahran City using the Cepheid\u00ae Xpert Flu Assay multiplex Diagnostic Microbiology and Infectious Disease 90 (2018) 280-285 real-time PCR (Cepheid) and by the MOH in Dammam using the RealTime Ready Influenza A/H1N1 Detection Set real-time PCR (Roche Diagnostics).", [["Infectious Disease", "DISEASE", 247, 265], ["Patient", "SPECIES", 0, 7], ["Patient", "SPECIES", 57, 64], ["Influenza A/H1N1", "SPECIES", 358, 374], ["SpecimensTests", "TEST", 80, 94], ["PCR", "TEST", 294, 297]]], ["Samples were collected following the user institution's standard procedures and placed into Viral Transport Medium (VTM) tubes (Cepheid).", [["Samples", "ANATOMY", 0, 7], ["Samples", "TEST", 0, 7], ["standard procedures", "TREATMENT", 56, 75], ["Viral Transport Medium (VTM) tubes (Cepheid", "TREATMENT", 92, 135]]], ["Two samples were collected per patient.", [["samples", "ANATOMY", 4, 11], ["patient", "ORGANISM", 31, 38], ["patient", "SPECIES", 31, 38], ["Two samples", "TEST", 0, 11]]], ["As per MOH regulations, the second sample was kept at 2-8\u00b0C for a maximum of 8 h until transportation to the MOH Dammam regional laboratory.", [["the second sample", "TEST", 24, 41]]], ["Samples were transferred on a daily basis.MOH Specimen Type and ProcessingOne volume of mucoid sample was mixed with 2 vol of bacterial lysis buffer, incubated at room temperature for 5 min, and then centrifuged for 5 min at 15,000 rpm.", [["Samples", "ANATOMY", 0, 7], ["mucoid sample", "ANATOMY", 88, 101], ["mucoid sample", "PROBLEM", 88, 101], ["bacterial lysis buffer", "TREATMENT", 126, 148], ["volume", "OBSERVATION_MODIFIER", 78, 84], ["mucoid", "OBSERVATION_MODIFIER", 88, 94], ["bacterial lysis", "OBSERVATION", 126, 141]]], ["Supernatant was collected and used for extraction of viral nucleic acid.MOH Nucleic Acid Extraction:Nucleic acid extraction was performed using MagNA Pure 96DNA and viral nucleic acid small volume kit on a Magna Pure 96 instrument (Roche Diagnostics, Indianapolis, IN, USA), according to the manufacturer's instructions.", [["Supernatant", "ANATOMY", 0, 11], ["nucleic acid", "CHEMICAL", 59, 71], ["Nucleic Acid", "CHEMICAL", 76, 88], ["Supernatant", "ORGANISM_SUBSTANCE", 0, 11], ["Nucleic Acid", "SIMPLE_CHEMICAL", 76, 88], ["Nucleic acid", "SIMPLE_CHEMICAL", 100, 112], ["extraction", "TREATMENT", 39, 49], ["viral nucleic acid", "TREATMENT", 53, 71], ["MOH Nucleic Acid Extraction", "TREATMENT", 72, 99], ["Nucleic acid extraction", "TREATMENT", 100, 123], ["MagNA Pure", "TEST", 144, 154], ["viral nucleic acid", "TEST", 165, 183], ["a Magna Pure", "TREATMENT", 204, 216], ["viral nucleic acid", "OBSERVATION", 53, 71]]], ["The Pathogen Universal-200 purification protocol was used.", [["purification protocol", "TREATMENT", 27, 48]]], ["A total of 200 \u03bcl volume of sample material was used for extraction, and the nucleic acids were eluted into 50 \u03bcl of elution buffer.MOH Reverse Transcription and DNA Amplification: RealTime Ready Influenza A/H1N1 Detection SetDetection of the influenza A (H1N1) pdm09 virus was performed by the MOH using RealTime Ready Influenza A/H1N1 Detection Set (Roche Diagnostics GmbH, Germany).", [["sample", "ANATOMY", 28, 34], ["nucleic acids", "SIMPLE_CHEMICAL", 77, 90], ["DNA", "CELLULAR_COMPONENT", 162, 165], ["influenza A (H1N1) pdm09 virus", "ORGANISM", 243, 273], ["influenza A (H1N1", "SPECIES", 243, 260], ["influenza A (H1N1) pdm09 virus", "SPECIES", 243, 273], ["A total of 200 \u03bcl volume of sample material", "TREATMENT", 0, 43], ["extraction", "TREATMENT", 57, 67], ["the nucleic acids", "TEST", 73, 90], ["elution buffer", "TREATMENT", 117, 131], ["the influenza A (H1N1) pdm09 virus", "PROBLEM", 239, 273], ["total", "OBSERVATION_MODIFIER", 2, 7]]], ["Amplification of each target (M2 and H1) was performed as one-step RT-PCR using RealTime Ready RNA Virus Master according to the manufacturer's instructions.", [["M2", "GENE_OR_GENE_PRODUCT", 30, 32], ["M2", "DNA", 30, 32], ["H1", "DNA", 37, 39], ["Amplification of each target (M2 and H1)", "TREATMENT", 0, 40], ["RealTime Ready RNA Virus Master", "TREATMENT", 80, 111]]], ["With the first PCR (M2 PCR), two sets of probes and primers (targeting human nucleic acid and influenza A/M2 gene) and four controls were used.", [["nucleic acid", "CHEMICAL", 77, 89], ["human", "ORGANISM", 71, 76], ["influenza A/M2", "GENE_OR_GENE_PRODUCT", 94, 108], ["M2 gene", "DNA", 106, 113], ["human", "SPECIES", 71, 76], ["human", "SPECIES", 71, 76], ["the first PCR", "TEST", 5, 18], ["PCR", "TEST", 23, 26], ["probes", "TEST", 41, 47], ["primers", "TEST", 52, 59], ["human nucleic acid", "TEST", 71, 89], ["influenza A/M2 gene", "TREATMENT", 94, 113]]], ["Controls included extracted control for human nucleic acid (internal sample control), commercial positive plasmid control for the whole PCR, negative extracted control (water), and no template negative control.", [["sample", "ANATOMY", 69, 75], ["plasmid", "ANATOMY", 106, 113], ["nucleic acid", "CHEMICAL", 46, 58], ["human", "ORGANISM", 40, 45], ["nucleic acid", "SIMPLE_CHEMICAL", 46, 58], ["human", "SPECIES", 40, 45], ["human", "SPECIES", 40, 45], ["human nucleic acid", "TREATMENT", 40, 58], ["internal sample control", "TREATMENT", 60, 83], ["commercial positive plasmid control", "TREATMENT", 86, 121], ["the whole PCR", "TEST", 126, 139], ["negative", "OBSERVATION", 193, 201]]], ["Three controls were used for the second PCR (H1 PCR): commercial positive plasmid control for the whole PCR, negative extracted control (water), and no template negative control.", [["plasmid", "ANATOMY", 74, 81], ["the second PCR", "TEST", 29, 43], ["H1 PCR", "TEST", 45, 51], ["commercial positive plasmid control", "TREATMENT", 54, 89], ["the whole PCR", "TEST", 94, 107], ["negative", "OBSERVATION", 161, 169]]], ["In addition, only one set of probes and primers targeting influenza A/H1 gene was used.MOH Reverse Transcription and DNA Amplification: RealTime Ready Influenza A/H1N1 Detection SetResults were validated after evaluating the results of all controls.", [["influenza A/H1", "ORGANISM", 58, 72], ["DNA", "CELLULAR_COMPONENT", 117, 120], ["influenza A/H1 gene", "DNA", 58, 77], ["influenza A/H1", "SPECIES", 58, 72], ["primers", "TREATMENT", 40, 47], ["influenza A/H1 gene", "TREATMENT", 58, 77]]], ["Results were interpreted as positive if the crossing point (Cp) value was \u226440, with the presence of a sigmoid curve.", [["Cp", "DNA", 60, 62], ["Cp) value", "TEST", 60, 69], ["a sigmoid curve", "TEST", 100, 115], ["sigmoid", "ANATOMY", 102, 109]]], ["Negative results were reported if no value or Cp value was N40, with the absence of a sigmoid curve.", [["Cp", "DNA", 46, 48], ["Cp value", "TEST", 46, 54], ["a sigmoid curve", "TEST", 84, 99], ["sigmoid", "ANATOMY", 86, 93]]], ["To report a sample as positive for influenza A/H1N1 (POS), the result had to be positive for both M2 PCR and H1 PCR.", [["sample", "ANATOMY", 12, 18], ["influenza A/H1N1", "DISEASE", 35, 51], ["influenza A/H1N1", "ORGANISM", 35, 51], ["POS", "CANCER", 53, 56], ["influenza A/H1N1", "SPECIES", 35, 51], ["H1", "SPECIES", 109, 111], ["a sample", "TEST", 10, 18], ["influenza", "PROBLEM", 35, 44], ["H1N1", "PROBLEM", 47, 51], ["M2 PCR", "TEST", 98, 104], ["H1 PCR", "TEST", 109, 115]]], ["Samples positive for only M2 PCR were considered influenza A M2 positive and negative for influenza A subtype H1N1 (FluA).", [["Samples", "ANATOMY", 0, 7], ["influenza A M2", "GENE_OR_GENE_PRODUCT", 49, 63], ["influenza A subtype H1N1", "ORGANISM", 90, 114], ["FluA", "CANCER", 116, 120], ["influenza A subtype H1N1", "SPECIES", 90, 114], ["influenza A subtype H1N1", "SPECIES", 90, 114], ["Samples", "TEST", 0, 7], ["M2 PCR", "TEST", 26, 32], ["influenza", "PROBLEM", 49, 58], ["influenza", "PROBLEM", 90, 99], ["negative for", "UNCERTAINTY", 77, 89]]], ["Samples negative for the first PCR (M2 PCR) did not undergo the second PCR (H1 PCR) and were considered negative for influenza A (NEG).Cepheid\u00ae Xpert Flu Assay ProcedureFor the Cepheid\u00ae Xpert Flu Assay procedure, samples were processed and tests carried out and interpreted according to the manufacturer's instructions (Cepheid).", [["Samples", "ANATOMY", 0, 7], ["samples", "ANATOMY", 213, 220], ["NEG", "CANCER", 130, 133], ["Samples", "TEST", 0, 7], ["the first PCR", "TEST", 21, 34], ["M2 PCR", "TEST", 36, 42], ["the second PCR (H1 PCR", "TEST", 60, 82], ["influenza", "PROBLEM", 117, 126], ["Cepheid\u00ae", "TREATMENT", 135, 143], ["the Cepheid\u00ae Xpert Flu Assay procedure", "TREATMENT", 173, 211], ["tests", "TEST", 240, 245]]], ["Briefly, samples were mixed/diluted in appropriate volumes with Universal Transport Medium, and 300 \u03bcl was transferred into the Xpert Flu Assay cartridge.", [["samples", "ANATOMY", 9, 16], ["Universal Transport Medium", "TREATMENT", 64, 90]]], ["Samples were tested on the GeneXpert Dx instrument according to the manufacturer's instructions.", [["Samples", "TEST", 0, 7]]], ["Results and amplification curves for samples and endogenous controls were reviewed.", [["samples", "ANATOMY", 37, 44], ["amplification curves", "TEST", 12, 32], ["samples", "TEST", 37, 44], ["endogenous controls", "TEST", 49, 68]]], ["Internal controls included Sample Processing Control (SPC) (Cepheid).", [["Internal controls", "TREATMENT", 0, 17]]], ["Each sample also included a Probe Check Control.", [["a Probe Check Control", "TREATMENT", 26, 47]]], ["New reagent kits were validated by retesting at least one known positive and one known negative patient sample.", [["patient", "ORGANISM", 96, 103], ["patient", "SPECIES", 96, 103], ["New reagent kits", "TEST", 0, 16], ["negative", "OBSERVATION", 87, 95]]], ["Failed controls were reviewed and repeated using fresh cartridges.", [["fresh cartridges", "TREATMENT", 49, 65]]], ["Possible failed results included invalid [control SPC failed OR FluA target RNA not detected/influenza A (H1N1) pdm09 target RNA is detected OR the sample was not properly processed OR PCR was inhibited], error (assay aborted), or no result (insufficient data collected).", [["influenza A (H1N1) pdm09", "ORGANISM", 93, 117], ["SPC failed OR FluA target RNA", "RNA", 50, 79], ["influenza A (H1N1) pdm09 target RNA", "RNA", 93, 128], ["invalid [control SPC", "TREATMENT", 33, 53], ["FluA target RNA", "TEST", 64, 79], ["influenza", "PROBLEM", 93, 102], ["H1N1", "PROBLEM", 106, 110], ["pdm09 target RNA", "PROBLEM", 112, 128], ["PCR", "TEST", 185, 188], ["error (assay", "TEST", 205, 217]]], ["Possible valid results included FluA+/H1N1+, FluA+/H1N1\u2212 or FluA\u2212/H1N1 \u2212.Statistical MethodsWe calculated the percentage agreement between the Cepheid\u00ae Xpert Flu Assay multiplex real-time PCR (Cepheid) and the RealTime Ready Influenza A/H1N1 Detection Set real-time PCR (Roche Diagnostics) using the Kappa statistic.", [["FluA", "GENE_OR_GENE_PRODUCT", 32, 36], ["FluA", "GENE_OR_GENE_PRODUCT", 45, 49], ["FluA\u2212/H1N1", "ORGANISM", 60, 70], ["FluA", "PROTEIN", 32, 36], ["FluA", "TEST", 32, 36], ["H1N1", "PROBLEM", 38, 42], ["FluA", "PROBLEM", 45, 49], ["H1N1", "PROBLEM", 51, 55], ["FluA\u2212", "PROBLEM", 60, 65], ["H1N1", "PROBLEM", 66, 70], ["the Kappa statistic", "TEST", 296, 315], ["H1N1", "OBSERVATION", 66, 70]]], ["Results were interpreted based on the guidelines that negative Cohen's kappa means no agreement between methods, 0-0.20 is slight, 0.21-0.40 is fair, 0.41-0.60 is moderate, 0.61-0.80 is substantial, and 0.81-1 is almost perfect agreement (Altman, 1991; Landis and Koch, 1977) .", [["Cohen's kappa", "TEST", 63, 76], ["methods", "TEST", 104, 111], ["slight", "OBSERVATION_MODIFIER", 123, 129], ["moderate", "OBSERVATION_MODIFIER", 163, 171], ["substantial", "OBSERVATION_MODIFIER", 186, 197]]], ["We measured the sensitivity and specificity of the Cepheid\u00ae Xpert Flu Assay multiplex real-time PCR by taking the MOH-approved RealTime Ready Influenza A/H1N1 Detection Set real-time method as the gold standard.", [["the sensitivity", "TEST", 12, 27], ["the Cepheid\u00ae Xpert", "TEST", 47, 65]]], ["True positives were defined as samples scored positive by the MOH method and also identified as positive by the Cepheid\u00ae Xpert Flu Assay for total FluA \u00b1 H1N1 pdm09 as appropriate.", [["samples", "ANATOMY", 31, 38], ["FluA", "GENE_OR_GENE_PRODUCT", 147, 151], ["FluA", "PROTEIN", 147, 151], ["True positives", "TEST", 0, 14], ["positives", "OBSERVATION", 5, 14]]], ["Sensitivity (true-positive rate) was calculated as the percentage of infections positively identified by both methods compared to the gold standard method only.", [["infections", "DISEASE", 69, 79], ["Sensitivity", "TEST", 0, 11], ["infections", "PROBLEM", 69, 79], ["infections", "OBSERVATION", 69, 79]]], ["Specificity (true-negative rate) was calculated as the percentage of samples identified as negative by both methods compared to the gold standard method only.", [["samples", "ANATOMY", 69, 76], ["Specificity", "TEST", 0, 11]]], ["Chi squared analysis was used to compare distribution of truepositive samples versus samples scored positive by the MOH method (total FluA \u00b1 H1N1 pdm09 as appropriate) but negative by the Cepheid\u00ae Xpert Flu Assay according to gender, age group, or location; P \u2264 0.05 was accepted as significant.", [["samples", "ANATOMY", 70, 77], ["samples", "ANATOMY", 85, 92], ["FluA", "PROTEIN", 134, 138], ["Chi squared analysis", "TEST", 0, 20], ["truepositive samples", "PROBLEM", 57, 77], ["samples scored positive", "PROBLEM", 85, 108], ["total FluA", "TEST", 128, 138], ["pdm09", "PROBLEM", 146, 151], ["significant", "OBSERVATION_MODIFIER", 283, 294]]], ["Student's t test was used to compare mean \u00b1 SD for Ct values for which assays gave discordant versus concordant results; P \u2264 0.05 was accepted as significant.Agreement Between Cepheid\u00ae Xpert Flu Assay and Roche RealTime Ready Influenza A/H1N1 Detection SetThere was overall 92.1% agreement between the Cepheid\u00ae Xpert Flu Assay multiplex real-time PCR (Cepheid) and the RealTime Ready Influenza A/H1N1 Detection Set real-time PCR (Roche Diagnostics) for detection of presence or absence of total FluA \u00b1 H1N1 pdm09 in the 749 samples ( Table 2 ).", [["samples", "ANATOMY", 524, 531], ["FluA", "GENE_OR_GENE_PRODUCT", 495, 499], ["FluA", "PROTEIN", 495, 499], ["Student's t test", "TEST", 0, 16], ["Ct values", "TEST", 51, 60], ["assays", "TEST", 71, 77], ["the Cepheid\u00ae", "TEST", 298, 310], ["total FluA", "PROBLEM", 489, 499], ["pdm09", "PROBLEM", 507, 512]]], ["The Kappa statistic was 0.710 (SE = 0.035; 95% confidence interval: 0.641-0.778), indicating substantial overall agreement.", [["The Kappa statistic", "TEST", 0, 19], ["SE", "TEST", 31, 33], ["substantial", "OBSERVATION_MODIFIER", 93, 104], ["overall agreement", "OBSERVATION", 105, 122]]], ["Eighty-four samples (11.2%) from the whole group were positive for both FluA and FluA (H1N1) pdm09 by both tests, i.e., true positives for FluA (H1N1) pdm09 ( Table 2) .Agreement Between Cepheid\u00ae Xpert Flu Assay and Roche RealTime Ready Influenza A/H1N1 Detection SetThe lowest concordance between the two tests was for detection of total FluA only (not FluA (H1N1) pdm09).", [["samples", "ANATOMY", 12, 19], ["samples", "CANCER", 12, 19], ["FluA", "GENE_OR_GENE_PRODUCT", 72, 76], ["FluA (H1N1) pdm09", "GENE_OR_GENE_PRODUCT", 81, 98], ["FluA", "GENE_OR_GENE_PRODUCT", 339, 343], ["FluA (H1N1) pdm09", "GENE_OR_GENE_PRODUCT", 354, 371], ["FluA", "PROTEIN", 72, 76], ["FluA", "PROTEIN", 339, 343], ["the whole group", "TEST", 33, 48], ["FluA", "TEST", 72, 76], ["FluA", "TEST", 81, 85], ["H1N1", "PROBLEM", 87, 91], ["pdm09", "PROBLEM", 93, 98], ["both tests", "TEST", 102, 112], ["FluA", "PROBLEM", 139, 143], ["H1N1", "PROBLEM", 145, 149], ["pdm09", "PROBLEM", 151, 156], ["the two tests", "TEST", 298, 311], ["total FluA", "TEST", 333, 343]]], ["Of the 11 samples scored FluA+/H1N1\u2212 by the RealTime Ready Influenza A/H1N1 Detection Set, 4 were scored identically by Cepheid\u00ae Xpert Flu Assay (Table 2 ) (36.4% percentage agreement).Sensitivity and Specificity of the Cepheid\u00ae Xpert Flu Assay MethodTaking the MOH-approved RealTime Ready Influenza A/H1N1 Detection Set as the gold standard, sensitivity (true-positive rate) of H1N1 detection by the Cepheid\u00ae Xpert Flu Assay was 84%, i.e., of the 100 samples scored H1N1+ by the RealTime Ready Influenza A/H1N1 Detection Set, 84 were also scored positive by Cepheid\u00ae Xpert Flu Assay multiplex real-time PCR ( Table 2 ).", [["samples", "ANATOMY", 10, 17], ["H1N1", "DISEASE", 379, 383], ["FluA", "GENE_OR_GENE_PRODUCT", 25, 29], ["FluA", "PROTEIN", 25, 29], ["RealTime Ready Influenza A/H1N1", "SPECIES", 44, 75], ["Influenza A/H1N1", "SPECIES", 290, 306], ["H1N1", "SPECIES", 379, 383], ["Influenza A/H1N1", "SPECIES", 495, 511], ["FluA", "TEST", 25, 29], ["H1N1", "PROBLEM", 31, 35], ["Sensitivity", "TEST", 185, 196], ["Specificity", "TEST", 201, 212], ["the Cepheid\u00ae", "TEST", 216, 228], ["H1N1 detection", "TEST", 379, 393], ["the Cepheid\u00ae Xpert Flu Assay", "TEST", 397, 425], ["H1N1", "PROBLEM", 467, 471], ["H1N1 Detection Set", "TEST", 507, 525]]], ["The specificity (true-negative rate) for H1N1 detection was 95.8%, i.e., of 649 samples scored negative for H1N1 by the RealTime Ready Influenza A/H1N1 Detection Set (either FluA only or NEG), 622 were also scored H1N1 negative by Cepheid\u00ae Xpert Flu Assay (either FluA\u2212/H1N1\u2212 or FluA+/H1N1\u2212) (Table 2) .", [["samples", "ANATOMY", 80, 87], ["samples", "CANCER", 80, 87], ["FluA", "PROTEIN", 279, 283], ["H1N1", "SPECIES", 41, 45], ["Influenza A/H1N1", "SPECIES", 135, 151], ["The specificity", "TEST", 0, 15], ["H1N1 detection", "TEST", 41, 55], ["H1N1", "PROBLEM", 108, 112], ["FluA", "TEST", 174, 178], ["H1N1", "PROBLEM", 214, 218], ["FluA\u2212", "TEST", 264, 269], ["H1N1", "PROBLEM", 270, 274], ["FluA", "TEST", 279, 283]]], ["Overall, 111 samples were detected as total FluA positive by the MOH gold standard method (FluA or POS), of which 90 were also scored positive by the Cepheid\u00ae Xpert Flu Assay (FluA+/H1N1+ or FluA+H1N1 \u2212), giving an overall sensitivity of 81.1%.", [["samples", "ANATOMY", 13, 20], ["samples", "CANCER", 13, 20], ["FluA", "GENE_OR_GENE_PRODUCT", 44, 48], ["FluA", "PROTEIN", 44, 48], ["FluA", "PROTEIN", 191, 195], ["total FluA", "TEST", 38, 48], ["FluA", "TEST", 176, 180], ["H1N1", "PROBLEM", 182, 186], ["FluA", "PROBLEM", 191, 195], ["H1N1", "PROBLEM", 196, 200], ["an overall sensitivity", "TEST", 212, 234]]], ["Six hundred thirty-eight samples were scored as FluA negative (FluA\u2212) by the gold standard method, of which 602 were also scored negative by the Cepheid\u00ae Xpert Flu Assay (FluA\u2212H1N1\u2212), giving an overall specificity of 94.4%.Sensitivity and Specificity of the Cepheid\u00ae Xpert Flu Assay MethodThere was no significant difference in the median H1N1 or total FluA C t values for the H1N1-positive Cepheid\u00ae Xpert Flu Assay results for samples which were concordant with the MOH gold standard method (median C t : H1N1 = 24.05, FluA = 22.15) and those that were discordant with the MOH gold standard method (median C t : H1N1 = 24.40, FluA = 23.20).", [["samples", "ANATOMY", 25, 32], ["samples", "ANATOMY", 428, 435], ["FluA", "GENE_OR_GENE_PRODUCT", 48, 52], ["FluA", "TEST", 48, 52], ["an overall specificity", "TEST", 191, 213], ["Sensitivity", "TEST", 223, 234], ["Specificity", "TEST", 239, 250], ["the Cepheid\u00ae", "TEST", 254, 266], ["total FluA C t values", "TEST", 347, 368], ["the H1N1", "TEST", 373, 381], ["H1N1", "PROBLEM", 506, 510], ["FluA", "TEST", 520, 524], ["H1N1", "PROBLEM", 613, 617], ["FluA", "TEST", 627, 631]]], ["There was also no significant difference in the C t values for samples scored POS by the MOH gold standard method which were concordant with the result obtained with the Cepheid\u00ae Xpert Flu Assay compared to those which were discordant (C t = 28.82 \u00b1 3.44 and 29.89 \u00b1 2.43 respectively; P = 0.250).Influence of GenderSensitivity and specificity of the tests were considered separately for samples from females (n = 359) and males (n = 390).", [["samples", "ANATOMY", 63, 70], ["samples", "ANATOMY", 388, 395], ["the C t values", "TEST", 44, 58], ["P", "TEST", 286, 287], ["the tests", "TEST", 347, 356], ["no", "UNCERTAINTY", 15, 17], ["significant", "OBSERVATION_MODIFIER", 18, 29], ["difference", "OBSERVATION_MODIFIER", 30, 40]]], ["For the samples from males, of 54 samples scored as positive for H1N1 pdm09 (POS) by the gold standard method, 42 (77.8%) were also scored positive by Cepheid\u00ae Xpert Flu Assay multiplex real-time PCR (FluA+/H1N1+) (Table 3) .", [["samples", "ANATOMY", 8, 15], ["samples", "ANATOMY", 34, 41], ["samples", "CANCER", 34, 41], ["the samples", "TEST", 4, 15], ["H1N1 pdm09", "PROBLEM", 65, 75], ["the gold standard method", "TEST", 85, 109], ["Cepheid\u00ae", "TEST", 151, 159], ["time PCR", "TEST", 191, 199], ["FluA", "TEST", 201, 205], ["H1N1", "PROBLEM", 207, 211]]], ["This gave 77.8% sensitivity for H1N1 detection by the Cepheid\u00ae Xpert Flu Assay compared to the MOH-approved RealTime Ready Influenza A/H1N1 Detection Set.", [["H1N1", "DISEASE", 32, 36], ["H1N1", "SPECIES", 32, 36], ["H1N1 detection", "TEST", 32, 46]]], ["The sensitivity was higher at 91.3% (for samples from females).", [["samples", "ANATOMY", 41, 48], ["The sensitivity", "TEST", 0, 15]]], ["However, the difference in the distribution between males and females of true-positive samples versus samples scored H1N1+/FluA+ by the MOH method and H1N1\u2212 by Cepheid\u00ae Xpert Flu Assay was not statistically significant (Chi-square statistic = 3.38; P = 0.07) ( Overall sensitivity for total FluA detection (total FluA \u00b1H1N1 pdm09) was 73.8% for males (45 out of 61) and 90.0% for females (45 out of 50), while specificity was 94.8% (312 out of 329) and 93.8% (290 out of 309) respectively (Table 3) .", [["samples", "ANATOMY", 87, 94], ["samples", "ANATOMY", 102, 109], ["FluA", "GENE_OR_GENE_PRODUCT", 123, 127], ["FluA", "PROTEIN", 291, 295], ["true-positive samples", "PROBLEM", 73, 94], ["samples", "TEST", 102, 109], ["H1N1", "PROBLEM", 117, 121], ["FluA", "PROBLEM", 123, 127], ["the MOH method", "TEST", 132, 146], ["H1N1", "PROBLEM", 151, 155], ["statistic", "TEST", 231, 240], ["P", "TEST", 249, 250], ["Overall sensitivity", "TEST", 261, 280], ["total FluA detection", "TEST", 285, 305], ["total FluA \u00b1H1N1 pdm09", "TEST", 307, 329], ["males", "TEST", 345, 350], ["females", "TEST", 380, 387], ["specificity", "TEST", 410, 421], ["difference", "OBSERVATION_MODIFIER", 13, 23], ["distribution", "OBSERVATION_MODIFIER", 31, 43]]], ["The difference between males and females in number of true-positive samples for total FluA \u00b1H1N1 pdm09 versus samples scored total FluA+ (POS or FluA) by the MOH method but negative by Cepheid\u00ae Xpert Flu Assay was statistically significant (Chi-square statistic = 4.72; P = 0.03).Influence of GenderThe age group distribution differed significantly between males and females, with a higher-than-predicted proportion of men and a lowerthan-predicted proportion of females being aged \u226580 years (Chi-square statistic = 16.07; P = 0.003) ( Table 4) .Influence of Age GroupTo determine if there was any variation in sensitivity and specificity of detection according to age of the patient from whom the sample was taken, the group was divided into age groups (Tables 1, 5).", [["samples", "ANATOMY", 68, 75], ["samples", "ANATOMY", 110, 117], ["FluA", "GENE_OR_GENE_PRODUCT", 86, 90], ["FluA+", "SIMPLE_CHEMICAL", 131, 136], ["men", "ORGANISM", 419, 422], ["patient", "ORGANISM", 676, 683], ["FluA", "PROTEIN", 86, 90], ["H1N1 pdm09", "PROTEIN", 92, 102], ["FluA", "PROTEIN", 131, 135], ["POS", "PROTEIN", 138, 141], ["FluA", "PROTEIN", 145, 149], ["men", "SPECIES", 419, 422], ["patient", "SPECIES", 676, 683], ["total FluA", "TEST", 80, 90], ["H1N1 pdm09", "PROBLEM", 92, 102], ["samples", "TEST", 110, 117], ["total FluA", "TEST", 125, 135], ["FluA", "TEST", 145, 149], ["the MOH method", "TEST", 154, 168], ["statistic", "TEST", 252, 261], ["P", "TEST", 270, 271]]], ["The sensitivity of the Cepheid\u00ae Xpert Flu Assay for detection of H1N1 by comparison to the gold standard method was 100% for the 0-19-year group.", [["H1N1", "DISEASE", 65, 69], ["H1N1", "SPECIES", 65, 69], ["H1N1", "PROBLEM", 65, 69]]], ["Sensitivity was lower for older age groups (Table 5 ), but the variation across age groups in distribution of true-positive samples for H1N1 versus samples which were positive for the MOH method and negative for the Xpert method was not statistically significant (Chi-square statistic = 5.76; P = 0.22).", [["samples", "ANATOMY", 124, 131], ["samples", "ANATOMY", 148, 155], ["H1N1", "ORGANISM", 136, 140], ["samples", "CANCER", 148, 155], ["Sensitivity", "TEST", 0, 11], ["H1N1", "PROBLEM", 136, 140], ["samples", "TEST", 148, 155], ["the MOH method", "TEST", 180, 194], ["the Xpert method", "TEST", 212, 228], ["Chi-square statistic", "TEST", 264, 284], ["P", "TEST", 293, 294]]], ["Specificity for H1N1 detection remained uniformly high across age groups (Table 5) .Influence of Age GroupSensitivity for overall FluA detection (FluA+/H1N1+ or FluA+/ H1N1\u2212) also dropped across the age groups from 100% for the 0-19year group to 50% for the \u226580-year group ( Table 5 ).", [["FluA", "GENE_OR_GENE_PRODUCT", 130, 134], ["FluA", "GENE_OR_GENE_PRODUCT", 146, 150], ["FluA", "PROTEIN", 130, 134], ["Specificity", "TEST", 0, 11], ["H1N1 detection", "TEST", 16, 30], ["Age GroupSensitivity", "TEST", 97, 117], ["overall FluA detection", "TEST", 122, 144], ["FluA", "TEST", 146, 150], ["H1N1", "PROBLEM", 152, 156], ["FluA", "PROBLEM", 161, 165], ["H1N1", "PROBLEM", 168, 172], ["high", "OBSERVATION_MODIFIER", 50, 54]]], ["The variation across age groups in number of true-positive samples for total FluA versus samples scored FluA positive for the MOH method (POS or FluA) but negative by the Cepheid method was statistically significant (Chisquare statistic = 13.30; P = 0.01).", [["samples", "ANATOMY", 59, 66], ["samples", "ANATOMY", 89, 96], ["FluA", "GENE_OR_GENE_PRODUCT", 77, 81], ["FluA", "GENE_OR_GENE_PRODUCT", 104, 108], ["FluA", "PROTEIN", 77, 81], ["FluA", "PROTEIN", 104, 108], ["total FluA", "TEST", 71, 81], ["FluA", "TEST", 104, 108], ["the MOH method", "TEST", 122, 136], ["the Cepheid method", "TEST", 167, 185], ["Chisquare statistic", "TEST", 217, 236], ["P", "TEST", 246, 247], ["variation", "OBSERVATION_MODIFIER", 4, 13]]], ["This was primarily attributable to the higher-than-predicted number of samples from patients aged over 80 years for whom there was a positive identification of FluA overall by the MOH method but a negative result for the Cepheid Xpert method.Influence of Sample TypeFor the nasopharyngeal swab (NASPH) (n = 677) samples, sensitivity for HIN1 detection was 84.0%, while sensitivity for overall FluA detection was 81.7%.", [["samples", "ANATOMY", 71, 78], ["nasopharyngeal swab", "ANATOMY", 274, 293], ["samples", "ANATOMY", 312, 319], ["patients", "ORGANISM", 84, 92], ["FluA", "GENE_OR_GENE_PRODUCT", 160, 164], ["nasopharyngeal swab", "MULTI-TISSUE_STRUCTURE", 274, 293], ["HIN1", "PROTEIN", 337, 341], ["FluA", "PROTEIN", 393, 397], ["patients", "SPECIES", 84, 92], ["the Cepheid Xpert method", "TEST", 217, 241], ["Sample", "TEST", 255, 261], ["the nasopharyngeal swab", "TEST", 270, 293], ["sensitivity", "TEST", 321, 332], ["HIN1 detection", "TEST", 337, 351], ["overall FluA detection", "TEST", 385, 407], ["higher", "OBSERVATION_MODIFIER", 39, 45], ["nasopharyngeal", "ANATOMY", 274, 288]]], ["Specificity was 95.5% and 94.1%, respectively.", [["Specificity", "TEST", 0, 11]]], ["For other sample types, there were insufficient numbers to draw firm conclusions, particularly with respect to sensitivity (Table 1) .Influence of LocationIt was difficult to draw firm conclusions on the sensitivity of detection in locations other than DH given the smaller numbers of samples from other locations (Table 1 ), in particular those scored positive by either method.", [["samples", "ANATOMY", 285, 292], ["sensitivity", "TEST", 111, 122], ["DH", "PROBLEM", 253, 255], ["smaller", "OBSERVATION_MODIFIER", 266, 273]]], ["For example, for the AH and AB samples, there were only four and six samples scored FluA+/H1N1+, respectively, or one and zero, respectively, for FluA+/H1N1\u2212 by the gold standard method.", [["AB samples", "ANATOMY", 28, 38], ["AB samples", "CANCER", 28, 38], ["FluA", "GENE_OR_GENE_PRODUCT", 84, 88], ["FluA", "GENE_OR_GENE_PRODUCT", 146, 150], ["FluA", "PROTEIN", 84, 88], ["FluA", "PROTEIN", 146, 150], ["the AH and AB samples", "TEST", 17, 38], ["six samples", "TEST", 65, 76], ["FluA", "TEST", 84, 88], ["H1N1", "PROBLEM", 90, 94], ["FluA", "TEST", 146, 150], ["H1N1", "PROBLEM", 152, 156]]], ["These low numbers precluded using these data in statistical analyses.", [["These low numbers", "PROBLEM", 0, 17], ["these data", "TEST", 34, 44], ["statistical analyses", "TEST", 48, 68]]], ["Specificity for H1N1 and FluA overall was uniformly high across all locations [AB: 100% (16/16) for both; DH: 95.5% (526/551) and 94.3% (511/ 543), respectively; AH: 97.8% (44/45) and 91.1% (41/45), respectively; RT: 96.3% (26/27) and 100% (26/26) respectively].Influence of LocationSensitivity was 82.5% (52 out of 63) and 78.9% (56 out of 71), respectively, for DH samples for H1N1 and FluA, respectively, while specificity was 95.5% (526/551) and 94.3% (511/543), respectively.", [["FluA", "GENE_OR_GENE_PRODUCT", 25, 29], ["Specificity", "TEST", 0, 11], ["H1N1", "PROBLEM", 16, 20], ["FluA", "TEST", 25, 29], ["AB", "TEST", 79, 81], ["AH", "TEST", 162, 164], ["RT", "TEST", 213, 215], ["LocationSensitivity", "TEST", 275, 294], ["DH samples", "TEST", 364, 374], ["H1N1", "PROBLEM", 379, 383], ["FluA", "TEST", 388, 392], ["specificity", "TEST", 414, 425], ["high", "OBSERVATION_MODIFIER", 52, 56]]], ["Sensitivity for RT samples was higher at 96.2% (25 out of 26) and 96.3% (26 out of 27), respectively.", [["samples", "ANATOMY", 19, 26], ["Sensitivity", "TEST", 0, 11], ["RT samples", "TEST", 16, 26]]], ["However, when the number of true-positive samples versus samples scored as H1N1+/FluA+ by the MOH method and negative by Cepheid\u00ae Xpert Flu Assay was compared between RT and DH, there was no statistically significant difference (Chi-square statistic = 2.92; P = 0.09).Influenza B DetectionUnlike the MOH-approved RealTime Ready Influenza A/H1N1 Detection Set, the Cepheid\u00ae Xpert Flu Assay can detect influenza B. In this study, seven samples gave a positive result for influenza B with negative results for influenza A and H1N1.", [["samples", "ANATOMY", 42, 49], ["samples", "ANATOMY", 57, 64], ["samples", "ANATOMY", 434, 441], ["influenza B", "DISEASE", 469, 480], ["influenza A and H1N1", "DISEASE", 507, 527], ["Cepheid\u00ae", "SIMPLE_CHEMICAL", 121, 129], ["influenza A", "ORGANISM", 507, 518], ["H1N1", "ORGANISM", 523, 527], ["Influenza", "SPECIES", 268, 277], ["Cepheid\u00ae", "SPECIES", 121, 129], ["influenza A", "SPECIES", 507, 518], ["true-positive samples", "TEST", 28, 49], ["samples", "TEST", 57, 64], ["H1N1", "PROBLEM", 75, 79], ["FluA", "TEST", 81, 85], ["the MOH method", "TEST", 90, 104], ["statistic", "TEST", 240, 249], ["P", "TEST", 258, 259], ["Influenza", "PROBLEM", 268, 277], ["influenza B.", "PROBLEM", 400, 412], ["this study", "TEST", 416, 426], ["seven samples", "TEST", 428, 441], ["influenza B", "PROBLEM", 469, 480], ["influenza", "PROBLEM", 507, 516], ["H1N1", "PROBLEM", 523, 527], ["no", "UNCERTAINTY", 188, 190], ["statistically", "OBSERVATION_MODIFIER", 191, 204], ["significant", "OBSERVATION_MODIFIER", 205, 216]]], ["Five of these samples gave a FluA\u2212/H1N1\u2212 result with the gold standard kit, while one gave a FluA+/H1N1+ and the other gave a FluA+/H1N1\u2212 result.DiscussionReal-time PCR-based tests are the methods of choice for FluA/H1N1 diagnosis as they are rapid and sensitive (Choi et al., 2010; Lam et al., 2010) .", [["samples", "ANATOMY", 14, 21], ["samples", "CANCER", 14, 21], ["FluA\u2212", "GENE_OR_GENE_PRODUCT", 29, 34], ["FluA", "GENE_OR_GENE_PRODUCT", 93, 97], ["FluA", "GENE_OR_GENE_PRODUCT", 126, 130], ["FluA/H1N1", "ORGANISM", 211, 220], ["FluA", "PROTEIN", 93, 97], ["FluA", "PROTEIN", 126, 130], ["FluA/H1N1", "SPECIES", 211, 220], ["these samples", "TEST", 8, 21], ["H1N1", "PROBLEM", 99, 103], ["H1N1", "PROBLEM", 132, 136], ["PCR", "TEST", 165, 168], ["based tests", "TEST", 169, 180], ["H1N1", "PROBLEM", 216, 220], ["H1N1", "OBSERVATION", 99, 103]]], ["In this study, 749 samples were taken in various locations in the Eastern Province of KSA from suspected MERS-CoV cases.", [["samples", "ANATOMY", 19, 26], ["MERS-CoV", "SPECIES", 105, 113], ["this study", "TEST", 3, 13]]], ["In the KSA, it is mandatory that such samples be submitted to the MOH for testing and that patients who meet Category I or II status are reflexively tested for other common bacterial and viral causes of communityacquired pneumonia, such as influenza (Kingdom of Saudi Arabia Ministry of Health, 2017).", [["samples", "ANATOMY", 38, 45], ["pneumonia", "DISEASE", 221, 230], ["influenza", "DISEASE", 240, 249], ["patients", "ORGANISM", 91, 99], ["patients", "SPECIES", 91, 99], ["testing", "TEST", 74, 81], ["other common bacterial and viral causes", "PROBLEM", 160, 199], ["communityacquired pneumonia", "PROBLEM", 203, 230], ["influenza", "PROBLEM", 240, 249], ["pneumonia", "OBSERVATION", 221, 230]]], ["We compared the results for influenza A/influenza A (H1N1) pdm09 identification between the gold standard method of choice of the MOH, the RealTime Ready Influenza A/H1N1 Detection Set, and the test used in our institution, the Cepheid\u00ae Xpert Flu Assay multiplex real-time PCR kit.DiscussionOverall, concordance was high.", [["influenza A/influenza A (H1N1) pdm09", "ORGANISM", 28, 64], ["influenza A (H1N1", "SPECIES", 40, 57], ["influenza A/influenza A (H1N1) pdm09", "SPECIES", 28, 64], ["Influenza A/H1N1", "SPECIES", 154, 170], ["influenza", "PROBLEM", 28, 37], ["influenza", "PROBLEM", 40, 49], ["the test", "TEST", 190, 198]]], ["However, if the RealTime Ready Influenza A/H1N1 Detection Set was taken as the gold standard, specificity of the Cepheid\u00ae Xpert Flu Assay was generally high, while sensitivity was lower.", [["Influenza A/H1N1", "ORGANISM", 31, 47], ["Influenza A/H1N1", "SPECIES", 31, 47], ["the Cepheid\u00ae Xpert Flu Assay", "TEST", 109, 137], ["sensitivity", "TEST", 164, 175]]], ["A significant trend towards lower sensitivity of total Influenza A (FluA) detection was observed in samples taken from males versus females and from older patients, although it was not statistically significant for influenza A (H1N1) pdm09 detection specifically.", [["samples", "ANATOMY", 100, 107], ["Influenza A", "ORGANISM", 55, 66], ["FluA", "GENE_OR_GENE_PRODUCT", 68, 72], ["samples", "CANCER", 100, 107], ["patients", "ORGANISM", 155, 163], ["influenza A (H1N1) pdm09", "ORGANISM", 215, 239], ["patients", "SPECIES", 155, 163], ["Influenza A", "SPECIES", 55, 66], ["A significant trend", "PROBLEM", 0, 19], ["total Influenza A (FluA) detection", "PROBLEM", 49, 83], ["influenza", "PROBLEM", 215, 224], ["significant", "OBSERVATION_MODIFIER", 2, 13], ["trend", "OBSERVATION_MODIFIER", 14, 19]]], ["A larger number of samples would be helpful in establishing if there was any significant trend in reduced sensitivity of influenza A (H1N1) pdm09 detection for males or for older patients.", [["samples", "ANATOMY", 19, 26], ["samples", "CANCER", 19, 26], ["influenza A (H1N1) pdm09", "ORGANISM", 121, 145], ["patients", "ORGANISM", 179, 187], ["patients", "SPECIES", 179, 187], ["influenza A (H1N1) pdm09", "SPECIES", 121, 145], ["influenza", "PROBLEM", 121, 130], ["larger", "OBSERVATION_MODIFIER", 2, 8]]], ["Reduced sensitivity of total FluA detection in older patients could be related to decreased viral shedding in older adults or to delayed presentation, which has been shown to influence sensitivity of other types of H1N1 diagnostic tests such as rapid antigen testing (Flamaing et al., 2003; Talbot et al., 2010) .", [["FluA", "CHEMICAL", 29, 33], ["FluA", "GENE_OR_GENE_PRODUCT", 29, 33], ["patients", "ORGANISM", 53, 61], ["FluA", "PROTEIN", 29, 33], ["patients", "SPECIES", 53, 61], ["total FluA detection", "TEST", 23, 43], ["decreased viral shedding", "PROBLEM", 82, 106], ["H1N1 diagnostic tests", "TEST", 215, 236], ["rapid antigen testing", "TEST", 245, 266], ["could be related to", "UNCERTAINTY", 62, 81], ["decreased", "OBSERVATION_MODIFIER", 82, 91], ["viral", "OBSERVATION", 92, 97]]], ["In our study, there was a higher-than-predicted proportion of older males compared to females aged \u226580 years, which could be relevant to the significantly reduced sensitivity of detection of FluA in samples from males versus females.", [["samples", "ANATOMY", 199, 206], ["FluA", "CHEMICAL", 191, 195], ["FluA", "GENE_OR_GENE_PRODUCT", 191, 195], ["samples", "CANCER", 199, 206], ["FluA", "PROTEIN", 191, 195], ["our study", "TEST", 3, 12], ["FluA in samples from males versus females", "PROBLEM", 191, 232], ["higher", "OBSERVATION_MODIFIER", 26, 32]]], ["Sensitivity of detection of influenza A (H1N1) pdm09 was also lower in males; while this was not statistically significant, the difference was approaching significance, and a larger sample number may allow a determination of whether this represents a real reduction in sensitivity.DiscussionThe relatively small number of tracheal and SPUIN samples prevented drawing firm conclusions on variation between different sample types.", [["tracheal", "ANATOMY", 322, 330], ["SPUIN samples", "ANATOMY", 335, 348], ["sample", "ANATOMY", 415, 421], ["influenza", "DISEASE", 28, 37], ["influenza A (H1N1) pdm09", "ORGANISM", 28, 52], ["tracheal", "MULTI-TISSUE_STRUCTURE", 322, 330], ["influenza A (H1N1) pdm09", "SPECIES", 28, 52], ["influenza", "PROBLEM", 28, 37], ["pdm09", "PROBLEM", 47, 52], ["a real reduction in sensitivity", "PROBLEM", 249, 280], ["tracheal and SPUIN samples", "TREATMENT", 322, 348], ["influenza", "OBSERVATION", 28, 37], ["lower", "OBSERVATION_MODIFIER", 62, 67], ["reduction", "OBSERVATION_MODIFIER", 256, 265], ["small", "OBSERVATION_MODIFIER", 306, 311], ["tracheal", "ANATOMY", 322, 330]]], ["Likewise, conclusions on influence of the location were limited by the relatively small numbers of positive samples from locations other than Dhahran city.DiscussionThe pandemic influenza A (H1N1) pdm09 virus (\"swine flu\") was first identified in humans in March/April 2009 in Mexico, Canada, and the United States (Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team et al., 2009 ).", [["samples", "ANATOMY", 108, 115], ["influenza", "DISEASE", 178, 187], ["swine flu", "DISEASE", 211, 220], ["pandemic influenza A (H1N1) pdm09 virus", "ORGANISM", 169, 208], ["humans", "ORGANISM", 247, 253], ["Influenza A", "ORGANISM", 335, 346], ["influenza A (H1N1", "SPECIES", 178, 195], ["swine", "SPECIES", 211, 216], ["humans", "SPECIES", 247, 253], ["pandemic influenza A (H1N1) pdm09 virus", "SPECIES", 169, 208], ["humans", "SPECIES", 247, 253], ["The pandemic influenza A (H1N1) pdm09 virus", "PROBLEM", 165, 208], ["small", "OBSERVATION_MODIFIER", 82, 87], ["numbers", "OBSERVATION_MODIFIER", 88, 95], ["positive", "OBSERVATION", 99, 107]]], ["Subsequently, it spread worldwide by person-to-person contact, including to the KSA (Al-Tawfiq et al., 2011; Balkhy et al., 2010; Uthman et al., 2014) .", [["person", "SPECIES", 37, 43]]], ["In June 2009, WHO declared that influenza A (H1N1) pdm09 had reached pandemic level phase 6.", [["influenza A (H1N1) pdm09", "DISEASE", 32, 56], ["influenza A (H1N1) pdm09", "ORGANISM", 32, 56], ["influenza A (H1N1", "PROBLEM", 32, 49], ["pdm09", "PROBLEM", 51, 56]]], ["In order to prevent and control influenza outbreaks, epidemics, and pandemics and initiate appropriate and timely antiviral treatment, rapid and accurate diagnostic methods are essential.", [["influenza", "DISEASE", 32, 41], ["influenza outbreaks", "PROBLEM", 32, 51], ["epidemics", "PROBLEM", 53, 62], ["pandemics", "TREATMENT", 68, 77], ["timely antiviral treatment", "TREATMENT", 107, 133]]], ["Clinical presentations of different seasonal flu strains, including influenza A (H1N1) , 2009) .", [["influenza A", "DISEASE", 68, 79], ["influenza A", "ORGANISM", 68, 79], ["different seasonal flu strains", "PROBLEM", 26, 56], ["influenza A (H1N1)", "PROBLEM", 68, 86], ["flu strains", "OBSERVATION", 45, 56]]], ["Diagnostic methods of choice are therefore currently based on molecular techniques, in particular, the real-time PCR as in the kits used in this study, which have the advantages of being rapid and sensitive (Choi et al., 2010; Lam et al., 2010) .", [["molecular techniques", "TEST", 62, 82], ["this study", "TEST", 140, 150]]], ["The RealTime Ready Influenza A/H1N1 Detection Set (Roche Diagnostics GmbH, Germany) incorporates a generic influenza virus A PCR targeting the matrix protein-2 \"M2 gene\" (M2 PCR) and a specific PCR targeting the variable part of hemagglutinin (HA) of influenza A (H1N1) pdm09 (H1 PCR) (Barb\u00e1s et al., 2012; Choi et al., 2010; thi Tham et al., 2012; Wenzel et al., 2010) .", [["matrix protein-2", "GENE_OR_GENE_PRODUCT", 143, 159], ["M2", "GENE_OR_GENE_PRODUCT", 161, 163], ["hemagglutinin", "GENE_OR_GENE_PRODUCT", 229, 242], ["influenza A (H1N1) pdm09", "ORGANISM", 251, 275], ["matrix protein-2 \"M2 gene", "DNA", 143, 168], ["hemagglutinin", "PROTEIN", 229, 242], ["HA", "PROTEIN", 244, 246], ["Influenza A/H1N1", "SPECIES", 19, 35], ["a generic influenza virus", "PROBLEM", 97, 122], ["A PCR", "TEST", 123, 128], ["the matrix protein", "TEST", 139, 157], ["M2 PCR", "TEST", 171, 177], ["a specific PCR", "TEST", 183, 197], ["hemagglutinin (HA", "PROBLEM", 229, 246], ["influenza", "PROBLEM", 251, 260], ["pdm09", "PROBLEM", 270, 275], ["H1 PCR", "TEST", 277, 283], ["influenza virus", "OBSERVATION", 107, 122]]], ["This kit has been shown to have specificity of 97%-100% in detection of both influenza A and of influenza A (H1N1) pdm09 in comparison to the US Centers for Disease Control and Prevention/WHO real-time PCR protocol (Choi et al., 2010; thi Tham et al., 2012) .", [["influenza A", "DISEASE", 77, 88], ["influenza A (H1N1) pdm09", "ORGANISM", 96, 120], ["influenza A (H1N1", "SPECIES", 96, 113], ["influenza A", "SPECIES", 77, 88], ["influenza A (H1N1) pdm09", "SPECIES", 96, 120], ["specificity", "TEST", 32, 43], ["both influenza A", "PROBLEM", 72, 88], ["influenza", "PROBLEM", 96, 105], ["pdm09", "PROBLEM", 115, 120], ["Disease Control", "TREATMENT", 157, 172], ["influenza", "OBSERVATION", 77, 86]]], ["Sensitivity results have been more variable.", [["Sensitivity", "TEST", 0, 11]]], ["In one study of 1341 nasopharyngeal (NP) samples collected in Argentina in 2009, sensitivity for seasonal influenza A detection in the presence or absence of influenza A (H1N1) pdm09 was 75.4%, sensitivity for influenza A (H1N1) pdm09 detection was 76.4%, and sensitivity for detection of influenza A only was 53.3% (Barb\u00e1s et al., 2012) .", [["nasopharyngeal", "ANATOMY", 21, 35], ["samples", "ANATOMY", 41, 48], ["influenza A", "DISEASE", 106, 117], ["influenza", "DISEASE", 158, 167], ["influenza A", "DISEASE", 289, 300], ["nasopharyngeal", "CANCER", 21, 35], ["influenza A (H1N1) pdm09", "ORGANISM", 158, 182], ["influenza A (H1N1) pdm09", "ORGANISM", 210, 234], ["influenza A (H1N1) pdm09", "SPECIES", 158, 182], ["one study", "TEST", 3, 12], ["nasopharyngeal (NP) samples", "TEST", 21, 48], ["seasonal influenza", "PROBLEM", 97, 115], ["influenza", "PROBLEM", 158, 167], ["pdm09", "TEST", 177, 182], ["sensitivity", "TEST", 194, 205], ["influenza", "PROBLEM", 210, 219], ["pdm09 detection", "TEST", 229, 244], ["sensitivity", "TEST", 260, 271], ["influenza", "PROBLEM", 289, 298], ["nasopharyngeal", "ANATOMY", 21, 35]]], ["However, other studies suggested that sensitivity of newer generations of the kit was moderate to good, between 85.8% and 88% for influenza A (M2 PCR) and approximately 88.2% for influenza A (H1N1) pdm09 (H1 PCR), and was comparable to other molecular tests (Choi et al., 2010; thi Tham et al., 2012; Wenzel et al., 2010) .DiscussionIn our laboratory, we use an alternative real-time PCR method, the Cepheid\u00ae Xpert Flu Assay multiplex real-time PCR (Cepheid).", [["influenza A (H1N1) pdm09", "ORGANISM", 179, 203], ["influenza A (H1N1) pdm09", "SPECIES", 179, 203], ["H1", "SPECIES", 205, 207], ["other studies", "TEST", 9, 22], ["the kit", "TEST", 74, 81], ["influenza A (M2 PCR", "TEST", 130, 149], ["influenza", "PROBLEM", 179, 188], ["H1N1", "PROBLEM", 192, 196], ["pdm09", "PROBLEM", 198, 203], ["H1 PCR", "TEST", 205, 211], ["the Cepheid\u00ae Xpert", "TEST", 396, 414]]], ["It allows differential, qualitative detection of viral RNA from influenza A, influenza B, and influenza A (H1N1) pdm09.", [["influenza A", "DISEASE", 64, 75], ["influenza B", "DISEASE", 77, 88], ["influenza A", "ORGANISM", 64, 75], ["influenza B", "ORGANISM", 77, 88], ["influenza A (H1N1) pdm09", "ORGANISM", 94, 118], ["viral RNA", "RNA", 49, 58], ["influenza A (H1N1", "SPECIES", 94, 111], ["influenza A", "SPECIES", 64, 75], ["influenza A (H1N1) pdm09", "SPECIES", 94, 118], ["qualitative detection", "TEST", 24, 45], ["viral RNA", "PROBLEM", 49, 58], ["influenza", "PROBLEM", 64, 73], ["influenza B", "PROBLEM", 77, 88], ["influenza", "PROBLEM", 94, 103], ["pdm09", "PROBLEM", 113, 118], ["viral RNA", "OBSERVATION", 49, 58]]], ["In this study, we nominated the MOH-approved RealTime Ready Influenza A/H1N1 Detection Set as the gold standard.", [["Influenza A/H1N1", "SPECIES", 60, 76], ["this study", "TEST", 3, 13]]], ["However, there is some evidence to suggest that the Cepheid\u00ae Xpert Flu Assay may be more sensitive than the RealTime Ready Influenza A/H1N1 Detection Set in comparison to other molecular tests or to culture detection (Barb\u00e1s et al., 2012; Choi et al., 2010; Novak-Weekley et al., 2012; Popowitch et al., 2011; Salez et al., 2012; Sohn et al., 2013; thi Tham et al., 2012; Wenzel et al., 2010) .", [["Influenza A/H1N1", "SPECIES", 123, 139], ["the Cepheid\u00ae Xpert Flu Assay", "TEST", 48, 76], ["other molecular tests", "TEST", 171, 192], ["culture detection", "TEST", 199, 216], ["some evidence to suggest", "UNCERTAINTY", 18, 42]]], ["The Xpert assay has been previously shown to be 100% specific for detection of seasonal influenza A and influenza A (H1N1) pdm09 in NP samples compared both to other molecular tests and to culture testing (Novak-Weekley et al., 2012; Popowitch et al., 2011; Salez et al., 2012) .", [["NP samples", "ANATOMY", 132, 142], ["influenza A", "DISEASE", 88, 99], ["seasonal influenza A", "ORGANISM", 79, 99], ["influenza A (H1N1) pdm09", "ORGANISM", 104, 128], ["NP samples", "CANCER", 132, 142], ["influenza A (H1N1", "SPECIES", 104, 121], ["seasonal influenza A", "SPECIES", 79, 99], ["The Xpert assay", "TEST", 0, 15], ["seasonal influenza A", "PROBLEM", 79, 99], ["influenza", "PROBLEM", 104, 113], ["H1N1", "PROBLEM", 117, 121], ["pdm09", "PROBLEM", 123, 128], ["NP samples", "TEST", 132, 142], ["other molecular tests", "TEST", 160, 181], ["culture testing", "TEST", 189, 204], ["influenza", "OBSERVATION", 88, 97]]], ["Furthermore, its sensitivity in comparison to other molecular tests was 100% for seasonal influenza A and between 90% and 98.4% for influenza A (H1N1) pdm09, 90%-100% for seasonal influenza A in comparison to culture detection, and 100% for influenza A (H1N1) pdm09 in comparison to culture detection (Novak-Weekley et al., 2012; Popowitch et al., 2011; Salez et al., 2012) .", [["influenza A (H1N1) pdm09", "DISEASE", 132, 156], ["influenza A (H1N1) pdm09", "ORGANISM", 132, 156], ["influenza A (H1N1) pdm09", "ORGANISM", 241, 265], ["seasonal influenza A", "SPECIES", 81, 101], ["influenza A (H1N1) pdm09", "SPECIES", 132, 156], ["seasonal influenza A", "SPECIES", 171, 191], ["other molecular tests", "TEST", 46, 67], ["seasonal influenza A", "PROBLEM", 81, 101], ["influenza", "PROBLEM", 132, 141], ["pdm09", "TEST", 151, 156], ["seasonal influenza A", "PROBLEM", 171, 191], ["culture detection", "TEST", 209, 226], ["influenza", "PROBLEM", 241, 250], ["pdm09", "PROBLEM", 260, 265], ["culture detection", "TEST", 283, 300], ["Novak", "TEST", 302, 307]]], ["In a small comparison study of 102 clinical samples in Korea, overall, 99% agreement was observed between the Cepheid\u00ae Xpert Flu Assay multiplex real-time PCR kit and the RealTime Ready Influenza A/H1N1 Detection Set (Sohn et al., 2013) .", [["samples", "ANATOMY", 44, 51], ["a small comparison study", "TEST", 3, 27], ["small", "OBSERVATION_MODIFIER", 5, 10]]], ["The Xpert kit requires less time for test performance, including less hands-on time (Sohn et al., 2013) .", [["test performance", "TEST", 37, 53]]], ["Another important advantage is that the Xpert kit can also detect influenza B. While influenza B infections cause epidemics more rarely than the A strains, they nevertheless do cause human illness and are incorporated in the seasonal influenza vaccines (WHO, 2016) .DiscussionHowever, recent studies have suggested that caution is needed in interpretation of automatic results generated by the Cepheid\u00ae Xpert Flu Assay which result in false-negatives (Engelmann et al., 2017) .", [["influenza B infections", "DISEASE", 85, 107], ["influenza", "DISEASE", 234, 243], ["influenza B.", "ORGANISM", 66, 78], ["influenza B infections", "ORGANISM", 85, 107], ["human", "ORGANISM", 183, 188], ["human", "SPECIES", 183, 188], ["human", "SPECIES", 183, 188], ["the Xpert kit", "TEST", 36, 49], ["influenza B.", "PROBLEM", 66, 78], ["influenza B infections", "PROBLEM", 85, 107], ["epidemics", "PROBLEM", 114, 123], ["the A strains", "PROBLEM", 141, 154], ["human illness", "PROBLEM", 183, 196], ["recent studies", "TEST", 285, 299]]], ["Careful examination of amplification curves and endpoints is recommended to avoid reporting of such false-negatives.", [["Careful examination of amplification curves", "TEST", 0, 43], ["such false-negatives", "PROBLEM", 95, 115]]], ["In our study, we observed no significant difference in median and endpoint C t values for Cepheid\u00ae Xpert Flu Assay which were concordant with the Roche assay compared to those which were discordant.", [["our study", "TEST", 3, 12], ["endpoint C t values", "TEST", 66, 85], ["Cepheid\u00ae Xpert Flu Assay", "TEST", 90, 114], ["the Roche assay", "TEST", 142, 157], ["no", "UNCERTAINTY", 26, 28], ["significant", "OBSERVATION_MODIFIER", 29, 40], ["difference", "OBSERVATION_MODIFIER", 41, 51]]], ["Nevertheless, this remains a concern with use of the Cepheid\u00ae Xpert Flu Assay (Engelmann et al., 2017) .DiscussionSensitivity of the Cepheid\u00ae Xpert Flu Assay can also vary according to genetic drift resulting in different seasonal influenza strains (Stellrecht et al., 2017) .", [["influenza", "DISEASE", 231, 240], ["the Cepheid\u00ae Xpert Flu Assay", "TREATMENT", 129, 157], ["genetic drift", "PROBLEM", 185, 198], ["different seasonal influenza strains", "PROBLEM", 212, 248]]], ["Sensitivity of the Cepheid\u00ae Xpert Flu Assay was 85.2%, with different limits of detection depending on strain.", [["Sensitivity", "TEST", 0, 11], ["the Cepheid\u00ae Xpert Flu Assay", "TEST", 15, 43], ["strain", "PROBLEM", 103, 109]]], ["Thus, it is recommended that strain-associated variances should be carefully monitored for the Cepheid\u00ae Xpert Flu Assay (Stellrecht et al., 2017) .DiscussionLimitations of our study included the relatively small number of samples from sites other than Dhahran City and of sample types other than NP swabs.", [["samples", "ANATOMY", 222, 229], ["strain-associated variances", "PROBLEM", 29, 56], ["our study", "TEST", 172, 181], ["NP swabs", "TREATMENT", 296, 304], ["small", "OBSERVATION_MODIFIER", 206, 211]]], ["We had no information concerning underlying or subsequent conditions of the patients.", [["patients", "ORGANISM", 76, 84], ["patients", "SPECIES", 76, 84]]], ["Another limitation was that duplicate samples were taken from patients and the two assays were not performed on the same sample; thus, there is the possibility that there may be differences in sample quality which could contribute to discordance between assays.", [["samples", "ANATOMY", 38, 45], ["sample", "ANATOMY", 193, 199], ["patients", "ORGANISM", 62, 70], ["patients", "SPECIES", 62, 70], ["duplicate samples", "TEST", 28, 45], ["the two assays", "TEST", 75, 89], ["assays", "TEST", 254, 260], ["may be", "UNCERTAINTY", 171, 177]]], ["The fact that C t values did not differ for either assay between discordant and concordant samples suggests that this is unlikely, but it remains a possible limitation.DiscussionOver 200,000 respiratory deaths are estimated to have occurred globally during the 2009/2010 influenza A (H1N1) pdm09 pandemic, with 80% of deaths in people younger than 65 years (Dawood et al., 2012) .", [["samples", "ANATOMY", 91, 98], ["respiratory deaths", "DISEASE", 191, 209], ["influenza A (H1N1) pdm09 pandemic", "DISEASE", 271, 304], ["deaths", "DISEASE", 318, 324], ["/2010 influenza A (H1N1) pdm09", "ORGANISM", 265, 295], ["people", "ORGANISM", 328, 334], ["people", "SPECIES", 328, 334], ["2009/2010 influenza A (H1N1) pdm09 pandemic", "SPECIES", 261, 304], ["C t values", "TEST", 14, 24], ["assay", "TEST", 51, 56], ["respiratory deaths", "PROBLEM", 191, 209], ["respiratory deaths", "OBSERVATION", 191, 209]]], ["In the Eastern Province of KSA, 587 cases were detected from samples sent to the MOH by the Saudi Aramco Medical Services Organization (SAMSO) between June and October 2009, an incidence of 3.5 per 1000 (Herzallah et al., 2011) .", [["samples", "ANATOMY", 61, 68]]], ["Infection was particularly common among younger people.", [["Infection", "DISEASE", 0, 9], ["people", "ORGANISM", 48, 54], ["people", "SPECIES", 48, 54], ["Infection", "PROBLEM", 0, 9]]], ["It is therefore vital to be vigilant in monitoring potential outbreaks of this disease in the KSA.", [["this disease in the KSA", "PROBLEM", 74, 97]]], ["Testing samples both on site in the Johns Hopkins Aramco Healthcare Centre using the Cepheid\u00ae Xpert Flu Assay and in the MOH laboratory using the RealTime Ready Influenza A/H1N1 Detection Set may help expedite detection of cases and improve reliability of detection in the Eastern Province.", [["samples", "ANATOMY", 8, 15], ["Testing samples", "TEST", 0, 15]]], ["This should help with prevention and control of outbreaks, and with initiation of appropriate and timely antiviral treatment.", [["outbreaks", "PROBLEM", 48, 57], ["timely antiviral treatment", "TREATMENT", 98, 124]]], ["However, the lower agreement between the tests in terms of positive results should be borne in mind, in particular for males and for older patients.", [["patients", "ORGANISM", 139, 147], ["patients", "SPECIES", 139, 147], ["the tests", "TEST", 37, 46]]]], "eb92e971f0f611b2bfbabb1807cfe569011a6f28": [["Contents lists available at ScienceDirectMedical Hypotheses journal homepage: www.elsevier.com/locate/mehyLetter to EditorsCorrelation between atmospheric particulate matter and antibiotic resistance: A hypothesis Dear Editors, the Italian National Health System, universally recognized as one of the best in the world also by recent studies [1] , has faced two important health threats in recent years, in addition to the current SARS-CoV-2 epidemic: Italy is in first place in Europe both for premature deaths due to exposure to PM 2.5 fine particulate matter (58,600 deaths in 2016) [2] and for the number of deaths due to infections caused by antibioticresistant bacteria (over 10,700 in 2015, 1/3 out of the total of the European Union) [3] , with the latter data confirmed not only by the high quantity of prescriptions of these drugs for medical use [4] , but also and above all by the large percentage of sales for veterinary applications and zootechnics [5] .Letter to EditorsTherefore, a question arises: could there be a connection between these two apparently so different phenomena?", [["SARS", "DISEASE", 431, 435], ["deaths", "DISEASE", 505, 511], ["deaths", "DISEASE", 570, 576], ["deaths", "DISEASE", 612, 618], ["infections", "DISEASE", 626, 636], ["premature deaths", "PROBLEM", 495, 511], ["infections", "PROBLEM", 626, 636], ["antibioticresistant bacteria", "PROBLEM", 647, 675], ["these drugs", "TREATMENT", 829, 840], ["different phenomena", "PROBLEM", 1075, 1094], ["infections", "OBSERVATION", 626, 636]]], ["PM 2.5 or lower particles could adsorb fragments of nuclear or plasmid DNA [6] from the environmental resistome or from bacteria (not only pathogenic) that are dead but resistant or multiresistant (both environmental and hospital), therefore containing Antibiotic Resistance Genes (ARGs), and disseminate them everywhere through the wind or other atmospheric manifestations.Letter to EditorsThese DNA fragments could later penetrate, using PM 2.5 or lower particles as carriers (also biocompatible), into other bacteria (also of different genres) which could exploit them evolutionarily to obtain new characteristics of resistance, integrating these genes in their nuclear genome or in their plasmids (therefore transferring them to other germs by conjugation, a mode already favored by PM 2.5 particles [7] ) with a mechanism similar to bacterial transformation or biolistic method, widely used in research laboratories.Letter to EditorsIn this way, high concentrations of atmospheric particulate matter, already a cause of death in itself, could passively and actively favor the propagation of the phenomenon of antibiotic resistance, with its burden of disease.", [["nuclear", "ANATOMY", 52, 59], ["plasmid", "ANATOMY", 63, 70], ["nuclear genome", "ANATOMY", 665, 679], ["plasmids", "ANATOMY", 692, 700], ["germs", "ANATOMY", 739, 744], ["death", "DISEASE", 1025, 1030], ["nuclear", "CELLULAR_COMPONENT", 52, 59], ["DNA", "CELLULAR_COMPONENT", 71, 74], ["DNA", "CELLULAR_COMPONENT", 397, 400], ["nuclear", "CELLULAR_COMPONENT", 665, 672], ["DNA fragments", "DNA", 397, 410], ["nuclear genome", "DNA", 665, 679], ["plasmids", "DNA", 692, 700], ["lower particles", "PROBLEM", 10, 25], ["plasmid DNA", "PROBLEM", 63, 74], ["the environmental resistome", "PROBLEM", 84, 111], ["bacteria", "PROBLEM", 120, 128], ["pathogenic", "PROBLEM", 139, 149], ["dead", "PROBLEM", 160, 164], ["multiresistant", "PROBLEM", 182, 196], ["Antibiotic Resistance Genes", "TREATMENT", 253, 280], ["other atmospheric manifestations", "PROBLEM", 341, 373], ["These DNA fragments", "PROBLEM", 391, 410], ["other bacteria", "PROBLEM", 505, 519], ["resistance", "PROBLEM", 620, 630], ["a mechanism", "PROBLEM", 815, 826], ["bacterial transformation", "PROBLEM", 838, 862], ["biolistic method", "TREATMENT", 866, 882], ["death", "PROBLEM", 1025, 1030], ["antibiotic resistance", "TREATMENT", 1114, 1135], ["disease", "PROBLEM", 1156, 1163], ["bacteria", "OBSERVATION", 120, 128], ["multiresistant", "OBSERVATION_MODIFIER", 182, 196], ["atmospheric manifestations", "OBSERVATION", 347, 373], ["bacterial transformation", "OBSERVATION", 838, 862], ["atmospheric particulate matter", "OBSERVATION", 974, 1004], ["antibiotic resistance", "OBSERVATION", 1114, 1135], ["disease", "OBSERVATION", 1156, 1163]]], ["With this in mind, health costs of air pollution should be reviewed, also adding the possible share of costs due to hospitalizations for infectious diseases from antibiotic-resistant germs.", [["germs", "ANATOMY", 183, 188], ["infectious diseases", "DISEASE", 137, 156], ["germs", "ORGAN", 183, 188], ["air pollution", "TREATMENT", 35, 48], ["infectious diseases", "PROBLEM", 137, 156], ["antibiotic", "TREATMENT", 162, 172], ["resistant germs", "PROBLEM", 173, 188], ["air pollution", "OBSERVATION", 35, 48]]]], "a6244f25cbc3cdd063e3bd4435eae530803f1b3e": [["42Controlling the COVID-19 pandemic will require a massive expansion of testing for SARS-CoV- 43 2 in several different clinical and epidemiological contexts.", [["SARS", "DISEASE", 84, 88], ["SARS-CoV- 43", "SPECIES", 84, 96], ["a massive expansion of testing", "TEST", 49, 79], ["SARS", "TEST", 84, 88], ["CoV", "TEST", 89, 92]]], ["Until recently, nasopharyngeal (NP) 44 swabs were the United States Centers for Disease Control and Prevention's (CDC) preferred and the swab was then placed into the collection tube for transport 15 .", [["nasopharyngeal", "ANATOMY", 16, 30], ["swab", "ANATOMY", 137, 141], ["nasopharyngeal", "CANCER", 16, 30], ["tube", "TISSUE", 178, 182], ["nasopharyngeal (NP)", "TREATMENT", 16, 35], ["Disease Control", "TREATMENT", 80, 95], ["the swab", "TREATMENT", 133, 141], ["nasopharyngeal", "ANATOMY", 16, 30], ["tube", "OBSERVATION", 178, 182]]], ["The NP-swab sample was 114 collected from a single naris by standard technique: insertion to appropriate depth, 10 rotations, 115 removal, and placement into transport-media tube containing VTM 4 .", [["NP-swab sample", "ANATOMY", 4, 18], ["tube", "TISSUE", 174, 178], ["The NP-swab sample", "TEST", 0, 18], ["removal", "TREATMENT", 130, 137], ["placement into transport-media tube", "TREATMENT", 143, 178], ["media tube", "OBSERVATION", 168, 178]]], ["To maximize collection of 116 material from the nares, in all cases sampling using the nasal swab (both nares) was performed 117 first, before the NP swab.", [["nares", "ANATOMY", 48, 53], ["nasal swab", "ANATOMY", 87, 97], ["nares", "ANATOMY", 104, 109], ["nares", "ORGANISM_SUBDIVISION", 48, 53], ["nasal swab", "MULTI-TISSUE_STRUCTURE", 87, 97], ["nares", "ORGANISM_SUBDIVISION", 104, 109], ["collection of 116 material from the nares", "PROBLEM", 12, 53], ["the nasal swab", "TEST", 83, 97], ["the NP swab", "TEST", 143, 154], ["116 material", "OBSERVATION_MODIFIER", 26, 38], ["nares", "ANATOMY", 48, 53], ["nasal swab", "ANATOMY", 87, 97]]], ["118 Sample processing and testing.", [["Sample processing", "TEST", 4, 21], ["testing", "TEST", 26, 33]]], ["Samples were sent to the BIDMC Clinical Microbiology 119 Laboratories for testing.", [["Samples", "TEST", 0, 7], ["testing", "TEST", 74, 81]]], ["Dry swabs were eluted in 2mL of Abbott mWash1 (100mM Tris with 120 guanidinium isothiocyanate (GITC) and detergent).", [["swabs", "ANATOMY", 4, 9], ["guanidinium isothiocyanate", "CHEMICAL", 67, 93], ["GITC", "CHEMICAL", 95, 99], ["Tris", "CHEMICAL", 53, 57], ["guanidinium isothiocyanate", "CHEMICAL", 67, 93], ["GITC", "CHEMICAL", 95, 99], ["guanidinium isothiocyanate", "SIMPLE_CHEMICAL", 67, 93], ["GITC", "SIMPLE_CHEMICAL", 95, 99], ["Dry swabs", "TEST", 0, 9], ["120 guanidinium isothiocyanate", "TREATMENT", 63, 93]]], ["Swabs transported in GITC buffer were 121 supplemented with 1mL of Abbott mWash1 solution to achieve minimum volume requirements 122 for testing.", [["Swabs", "ANATOMY", 0, 5], ["Swabs", "TREATMENT", 0, 5], ["Abbott mWash1 solution", "TREATMENT", 67, 89], ["minimum volume requirements", "TREATMENT", 101, 128], ["testing", "TEST", 137, 144]]], ["Tests were performed with 1.5mL of sample media using the Abbott RealTime 123 SARS-CoV-2 assay for EUA for use with nasopharyngeal and nasal swabs 18 .", [["nasopharyngeal", "ANATOMY", 116, 130], ["nasal swabs", "ANATOMY", 135, 146], ["EUA", "CHEMICAL", 99, 102], ["nasopharyngeal", "CANCER", 116, 130], ["Tests", "TEST", 0, 5], ["CoV", "TEST", 83, 86], ["nasopharyngeal and nasal swabs", "TREATMENT", 116, 146], ["nasopharyngeal", "ANATOMY", 116, 130], ["nasal", "ANATOMY", 135, 140]]], ["This dual-target 124 assay detects both the SARS-CoV-2 RdRp (RNA-dependent RNA polymerase) and N 125 (nucleocapsid) genes with an in-lab verified LoD of 100 copies/mL 6,17 .", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 44, 54], ["RNA-dependent RNA polymerase", "GENE_OR_GENE_PRODUCT", 61, 89], ["N 125", "GENE_OR_GENE_PRODUCT", 95, 100], ["SARS-CoV-2 RdRp (RNA-dependent RNA polymerase) and N 125 (nucleocapsid) genes", "DNA", 44, 121], ["SARS-CoV", "SPECIES", 44, 52], ["the SARS", "TEST", 40, 48], ["CoV", "TEST", 49, 52], ["RdRp (RNA-dependent RNA polymerase", "TREATMENT", 55, 89]]], ["126 Statistical analyses.", [["Statistical analyses", "TEST", 4, 24]]], ["RT-PCR results reported categorically as either positive or negative, and 127 these were used for concordance testing by Cohen's kappa 19 .", [["RT-PCR", "TEST", 0, 6], ["concordance testing", "TEST", 98, 117]]], ["128 For analyses based on cycle-threshold (Ct) values, for discordant samples (positive nasal-129 swab/negative NP-swab result or vice versa), the negative result was assigned a Ct value of 37, 130 the total number of cycles run.", [["samples", "ANATOMY", 70, 77], ["nasal", "ANATOMY", 88, 93], ["analyses", "TEST", 8, 16], ["cycle-threshold", "TEST", 26, 41], ["Ct) values", "TEST", 43, 53], ["discordant samples", "TEST", 59, 77], ["nasal", "TEST", 88, 93], ["swab", "TEST", 98, 102], ["a Ct value", "TEST", 176, 186], ["nasal", "ANATOMY", 88, 93]]], ["Conversion to viral load was performed as described previously 6 .", [["Conversion to viral load", "TEST", 0, 24], ["viral load", "OBSERVATION", 14, 24]]], ["131 We tested whether Ct values for a given set of nasal swabs differed from the Ct values for the 132 paired NP swabs (the controls) using Wilcoxon's paired t-test.", [["nasal swabs", "ANATOMY", 51, 62], ["nasal swabs", "MULTI-TISSUE_STRUCTURE", 51, 62], ["Ct values", "TEST", 22, 31], ["nasal swabs", "TEST", 51, 62], ["the Ct values", "TEST", 77, 90], ["Wilcoxon's paired t-test", "TEST", 140, 164]]], ["This tested the null hypothesis 133 that values for controls and prototypes are drawn from the same underlying distribution; p>0.05 134 was interpreted as no difference.", [["the null hypothesis", "TEST", 12, 31]]], ["We used bootstrapping to test whether the n results for a 135 given arm exhibited appreciable differences from others, specifically by testing whether a given 136 arm differed from random samples from (i) results pooled across the three arms that used the 137 same nasal-swab sampling procedure or (ii) all results.", [["random samples", "TEST", 181, 195], ["same nasal-swab sampling procedure", "TREATMENT", 260, 294]]], ["For each bootstrap test, we sampled n 138 data points at random from the larger pool to create a synthetic dataset, calculating Cohen's 139 kappa on this synthetic dataset, and repeating this process for 100,000 synthetic datasets to 140 create a distribution (histogram) of kappa values; this distribution constitutes a null model of the 141 kappa one would expect to observe by chance in a sample of n results, given the data in the 142 larger pool.", [["each bootstrap test", "TEST", 4, 23], ["this synthetic dataset", "TEST", 149, 171], ["synthetic datasets", "TEST", 212, 230], ["kappa values", "TEST", 275, 287], ["the data", "TEST", 419, 427]]], ["Using this distribution, we then calculated the probability of observing a kappa at 143 least as high as the kappa actually observed for the n results from a given arm, to test for 144 .", [["a kappa", "TEST", 73, 80], ["arm", "ANATOMY", 164, 167]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)42The copyright holder for this preprint this version posted June 14, 2020.", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["med", "ANATOMY", 105, 108]]], ["Table 1 shows the numbers of patients tested in each of the six arms of our nasal-vs.", [["nasal", "ANATOMY", 76, 81], ["patients", "ORGANISM", 29, 37], ["patients", "SPECIES", 29, 37], ["nasal", "ANATOMY", 76, 81]]], ["NP-swab 156 study.", [["NP-swab 156 study", "TEST", 0, 17]]], ["Visual inspection of plots of the Ct values of the nasal swab vs. NP-swab controls 157 suggested worse performance for nasal swabs across all six arms, with no obvious differences 158 between the two swab procedures or among the dry-swab, VTM, or GITC collection methods 159 (Fig. 2) .", [["nasal swab", "ANATOMY", 51, 61], ["nasal swabs", "ANATOMY", 119, 130], ["nasal swab", "MULTI-TISSUE_STRUCTURE", 51, 61], ["nasal swabs", "MULTI-TISSUE_STRUCTURE", 119, 130], ["Visual inspection", "TEST", 0, 17], ["the Ct values", "TEST", 30, 43], ["the nasal swab", "TEST", 47, 61], ["NP-swab controls", "TEST", 66, 82], ["nasal swabs", "TEST", 119, 130], ["obvious differences", "PROBLEM", 160, 179], ["the two swab procedures", "TEST", 192, 215], ["the dry-swab", "TEST", 225, 237], ["VTM", "TEST", 239, 242], ["GITC collection methods", "TEST", 247, 270], ["nasal", "ANATOMY", 51, 56], ["swab", "OBSERVATION", 57, 61]]], ["Statistical testing confirmed that results for each arm were indistinguishable from the 160 overall results, supporting the functional equivalence of all swab/transport-condition 161 combinations ( Table 2) .", [["Statistical testing", "TEST", 0, 19]]], ["For concordant positives, comparison of Ct values between nasal and 162 NP swabs showed higher Cts for nasal swabs than for NP swabs, suggesting slightly but 163 consistently lower yield from the nasal swabs (Wilcoxon p=9\u00d710 -11 ).", [["nasal", "ANATOMY", 58, 63], ["nasal swabs", "ANATOMY", 103, 114], ["NP swabs", "ANATOMY", 124, 132], ["nasal swabs", "ANATOMY", 196, 207], ["nasal", "ORGAN", 58, 63], ["nasal swabs", "MULTI-TISSUE_STRUCTURE", 196, 207], ["Ct values", "TEST", 40, 49], ["nasal", "TEST", 58, 63], ["NP swabs", "TEST", 72, 80], ["higher Cts", "PROBLEM", 88, 98], ["nasal swabs", "TEST", 103, 114], ["NP swabs", "TEST", 124, 132], ["the nasal swabs", "TEST", 192, 207], ["Wilcoxon p", "TEST", 209, 219], ["nasal", "ANATOMY", 58, 63], ["nasal", "ANATOMY", 196, 201]]], ["Consistent with this 164 conclusion, there was a marked increase in false negatives for NP-swabs with higher Ct values 165 (lower viral loads), resulting in low concordance overall (Cohen's kappa=0.49) (Fig. 2) .", [["a marked increase in false negatives", "PROBLEM", 47, 83], ["NP", "TEST", 88, 90], ["higher Ct values", "TEST", 102, 118], ["lower viral loads", "TEST", 124, 141], ["Cohen's kappa", "TEST", 182, 195], ["marked", "OBSERVATION_MODIFIER", 49, 55], ["increase", "OBSERVATION_MODIFIER", 56, 64], ["false negatives", "OBSERVATION", 68, 83]]], ["166 Our overall finding of low concordance was in contrast to some previous reports, which have 167 found nasal-swab collection to exhibit excellent sensitivity as well as Ct-value concordance 13,15 , 168 but was consistent with others 10,14 , including, for example, one recent study at a New York, 169 USA, hospital that also noted lower nasal-swab concordance for higher Ct values 16 .", [["nasal-swab", "ANATOMY", 106, 116], ["nasal-swab collection", "PROBLEM", 106, 127], ["Ct-value concordance", "TEST", 172, 192], ["lower nasal-swab concordance", "TEST", 334, 362], ["higher Ct values", "TEST", 367, 383], ["low concordance", "OBSERVATION_MODIFIER", 27, 42], ["nasal", "ANATOMY", 106, 111], ["consistent with", "UNCERTAINTY", 213, 228], ["lower", "ANATOMY_MODIFIER", 334, 339], ["nasal", "ANATOMY", 340, 345]]], ["Close 170 review of these previous reports revealed that they differed in the type of specimen and/or result 171 they used as a reference (e.g. any test-sample positive versus using NP swabs as the gold 172 standard) and in the parameters they used in order to describe test performance (e.g. positive 173 percent agreement versus sensitivity).", [["specimen", "ANATOMY", 86, 94], ["any test", "TEST", 144, 152], ["NP swabs", "TEST", 182, 190], ["test performance", "TEST", 270, 286], ["sensitivity", "TEST", 331, 342]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)155The copyright holder for this preprint this version posted June 14, 2020. . https://doi.org/10.1101/2020.06.12.20128736 doi: medRxiv preprint contingency-table data from these reports to facilitate comparison to each other and to our own 175 results (Table 3) .", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["med", "ANATOMY", 105, 108]]], ["Notably, many of these studies used a modified version of the CDC assay that 176 did not report a LoD.", [["these studies", "TEST", 17, 30], ["the CDC assay", "TEST", 58, 71]]], ["Furthermore, of the studies that report the Ct values of their results, no 177 viral-load conversion was provided, which is important since different RT-PCR assays and 178 platforms have unique conversions between Ct value and viral load.", [["the studies", "TEST", 16, 27], ["the Ct values", "TEST", 40, 53], ["viral-load conversion", "TREATMENT", 79, 100], ["different RT-PCR assays", "TEST", 140, 163], ["Ct value", "TEST", 214, 222], ["viral load", "TEST", 227, 237], ["viral load", "OBSERVATION", 227, 237]]], ["Therefore, we were unable 179 to systematically compare nasal-swab performance at low viral loads in these reports.", [["nasal-swab", "ANATOMY", 56, 66], ["nasal-swab performance", "TEST", 56, 78]]], ["These varied between studies, our results suggest these differences are unlikely to affect detection).", [["studies", "TEST", 21, 28]]], ["184 We therefore revisited the trend we observed of a rise in nasal-swab-negative discordant results 185 (false negatives) with higher Ct value.", [["nasal", "ANATOMY", 62, 67], ["nasal-swab", "TEST", 62, 72], ["higher Ct value", "PROBLEM", 128, 143], ["nasal", "ANATOMY", 62, 67]]], ["Recently we demonstrated that Ct values for the SARS- 186 CoV-2 RT-PCR assay and platform used in the present study are reliable quantitative measures 187 of viral load, and introduced a conversion from Ct value to viral load 6 .", [["SARS- 186 CoV", "SPECIES", 48, 61], ["Ct values", "TEST", 30, 39], ["the SARS", "TEST", 44, 52], ["CoV", "TEST", 58, 61], ["RT-PCR assay", "TEST", 64, 76], ["the present study", "TEST", 98, 115], ["viral load", "TEST", 158, 168], ["Ct value", "TEST", 203, 211], ["viral load", "PROBLEM", 215, 225]]], ["Building on those findings, 188 here we asked what the concordance would have been, for our nasal-vs.-NP data, had the LoD 189 of our assay been higher than its actual 100 copies/mL.", [["the LoD", "TEST", 115, 122], ["our assay", "TEST", 130, 139]]], ["Specifically, we re-calculated kappa for 190 different LoD cutoffs, and found that kappa rose steeply from ~0.5 (low concordance) to 0.8-0.9 191 (excellent concordance) as the LoD cutoff was increased from 100 copies/mL through 1,000 192 copies/mL and beyond (Fig. 3 ).", [["different LoD cutoffs", "TEST", 45, 66], ["kappa", "TEST", 83, 88], ["the LoD cutoff", "TEST", 172, 186]]], ["This finding strongly supports the view that nasal swabs miss 193 many if not most patients with low viral load (below ~1,000 copies/mL), but is reliable for 194 patients with medium or high viral loads, potentially resolving disagreements among previous 195 reports.", [["nasal swabs", "ANATOMY", 45, 56], ["nasal swabs", "MULTI-TISSUE_STRUCTURE", 45, 56], ["patients", "ORGANISM", 83, 91], ["patients", "ORGANISM", 162, 170], ["patients", "SPECIES", 83, 91], ["patients", "SPECIES", 162, 170], ["nasal swabs", "TEST", 45, 56], ["low viral load", "PROBLEM", 97, 111], ["high viral loads", "PROBLEM", 186, 202], ["viral loads", "OBSERVATION", 191, 202]]], ["196197It is widely acknowledged that resolving the damage that the COVID-19 pandemic has wrought 198 to health, the economy, and society will require distributing and scaling up testing to CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 14, 2020. . https://doi.org/10.1101/2020.06.12.20128736 doi: medRxiv preprint processes.", [["196197", "CHEMICAL", 0, 6], ["CC", "CHEMICAL", 189, 191], ["196197", "SPECIES", 0, 6], ["the damage", "PROBLEM", 47, 57], ["the COVID", "TEST", 63, 72], ["CC", "TEST", 189, 191], ["The copyright holder", "TREATMENT", 390, 410], ["med", "ANATOMY", 294, 297]]], ["Reflecting this interest in nasal swabs, the US CDC has removed the \"preference\" 206 specification for NP swabs from their interim guidance and note that nasal swabs are an 207 acceptable alternative specimen as of 29 April 2020 4 .", [["nasal swabs", "ANATOMY", 28, 39], ["nasal swabs", "ANATOMY", 154, 165], ["specimen", "ANATOMY", 200, 208], ["nasal swabs", "MULTI-TISSUE_STRUCTURE", 28, 39], ["nasal swabs", "MULTI-TISSUE_STRUCTURE", 154, 165], ["nasal swabs", "TEST", 28, 39], ["the US CDC", "TEST", 41, 51], ["NP swabs", "TREATMENT", 103, 111], ["nasal swabs", "TEST", 154, 165], ["nasal", "ANATOMY", 154, 159]]], ["However, confidence in population-scale 208 testing strategies based on nasal swabs is complicated by conflicting reports as to how well they 209 perform relative NP swabs, the antecedent gold standard, as we have described.", [["nasal swabs", "ANATOMY", 72, 83], ["nasal swabs", "MULTI-TISSUE_STRUCTURE", 72, 83], ["testing strategies", "TEST", 44, 62], ["nasal swabs", "TEST", 72, 83], ["relative NP swabs", "TEST", 154, 171]]], ["210 Our results strongly suggest that concordance between nasal and NP swabs depends on the 211 LoD of the PCR assay used to measure positivity, with high concordance for medium-to-high 212 viral loads and low concordance for low viral loads, which may lie below the LoDs of various 213 assays currently in widespread use (Fig. 3) 6 .", [["nasal", "ANATOMY", 58, 63], ["NP swabs", "ANATOMY", 68, 76], ["nasal", "ORGANISM_SUBDIVISION", 58, 63], ["nasal and NP swabs", "TREATMENT", 58, 76], ["the PCR assay", "TEST", 103, 116], ["high 212 viral loads", "PROBLEM", 181, 201], ["low viral loads", "PROBLEM", 226, 241], ["nasal", "ANATOMY", 58, 63], ["viral loads", "OBSERVATION", 230, 241]]], ["We find that nasal swab samples reliably detect 214 patients with viral loads \u22651,000 copies/mL but miss many patients who have lower viral loads, 215 the majority in our study 6 .", [["nasal swab samples", "ANATOMY", 13, 31], ["nasal swab samples", "ORGANISM_SUBSTANCE", 13, 31], ["patients", "ORGANISM", 52, 60], ["patients", "ORGANISM", 109, 117], ["patients", "SPECIES", 52, 60], ["patients", "SPECIES", 109, 117], ["nasal swab samples", "TEST", 13, 31], ["viral loads", "PROBLEM", 66, 77], ["lower viral loads", "PROBLEM", 127, 144], ["our study", "TEST", 166, 175], ["nasal", "ANATOMY", 13, 18]]], ["A complete biological explanation will require further study; however, 216 one possibility is that in cases of high viral load, replicating virus may be more likely to spread to is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 14, 2020. . https://doi.org/10.1101/2020.06.12.20128736 doi: medRxiv preprint protocols, suggesting that lower sensitivity of nasal swab sampling is an overall limitation of the 238 anatomical location of nasal swabs and that the protocols and media conditions we tested are 239 interchangeable.", [["nasal swab", "ANATOMY", 502, 512], ["nasal swabs", "ANATOMY", 581, 592], ["nasal swab", "MULTI-TISSUE_STRUCTURE", 502, 512], ["nasal swabs", "MULTI-TISSUE_STRUCTURE", 581, 592], ["further study", "TEST", 47, 60], ["high viral load", "PROBLEM", 111, 126], ["replicating virus", "PROBLEM", 128, 145], ["The copyright holder", "TREATMENT", 312, 332], ["medRxiv preprint protocols", "TREATMENT", 437, 463], ["nasal swab sampling", "TEST", 502, 521], ["nasal swabs", "TEST", 581, 592], ["the protocols", "TREATMENT", 602, 615], ["media conditions", "TEST", 620, 636], ["viral load", "OBSERVATION", 116, 126], ["med", "ANATOMY", 216, 219], ["nasal", "ANATOMY", 502, 507], ["nasal", "ANATOMY", 581, 586]]], ["Thus, for patients above a critical threshold of 1,000 copies/mL (Fig. 2) , nasal 240 swabs collected in VTM, GITC transport medium, and as dry swabs are all likely to perform 241 equally well in the population, providing multiple potential options for specimen acquisition.", [["swabs", "ANATOMY", 86, 91], ["specimen", "ANATOMY", 253, 261], ["patients", "ORGANISM", 10, 18], ["patients", "SPECIES", 10, 18], ["nasal 240 swabs", "TREATMENT", 76, 91], ["GITC transport medium", "TREATMENT", 110, 131], ["specimen acquisition", "TEST", 253, 273], ["nasal", "ANATOMY", 76, 81]]], ["242 Our results suggest several settings in which nasal swabs may and may not best be used.", [["nasal swabs", "ANATOMY", 50, 61], ["nasal swabs", "MULTI-TISSUE_STRUCTURE", 50, 61], ["nasal swabs", "TREATMENT", 50, 61], ["several", "OBSERVATION_MODIFIER", 24, 31]]], ["Peak is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 14, 2020. . https://doi.org/10.1101/2020.06.12.20128736 doi: medRxiv preprint Procedures 1 and 2 as in Methods and Fig. 1 .", [["The copyright holder", "TREATMENT", 139, 159], ["medRxiv preprint Procedures", "TREATMENT", 264, 291], ["med", "ANATOMY", 43, 46]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 14, 2020.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 14, 2020.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["As reasonably needed, tilt the patient's head back to improve access to the anterior nares.", [["head", "ANATOMY", 41, 45], ["anterior nares", "ANATOMY", 76, 90], ["patient", "ORGANISM", 31, 38], ["head", "ORGANISM_SUBDIVISION", 41, 45], ["anterior nares", "MULTI-TISSUE_STRUCTURE", 76, 90], ["patient", "SPECIES", 31, 38], ["head", "ANATOMY", 41, 45], ["anterior", "ANATOMY_MODIFIER", 76, 84], ["nares", "ANATOMY", 85, 90]]], ["For each naris (nostril), perform following.", [["nostril", "ORGAN", 16, 23], ["naris", "ANATOMY", 9, 14]]], ["Insert the swab tip into the nostril and press against the inner wall of the naris.", [["swab tip", "ANATOMY", 11, 19], ["nostril", "ANATOMY", 29, 36], ["inner wall", "ANATOMY", 59, 69], ["swab tip", "MULTI-TISSUE_STRUCTURE", 11, 19], ["nostril", "ORGAN", 29, 36], ["inner wall", "MULTI-TISSUE_STRUCTURE", 59, 69], ["naris", "CANCER", 77, 82], ["the swab tip", "TREATMENT", 7, 19], ["swab", "OBSERVATION", 11, 15], ["tip", "OBSERVATION_MODIFIER", 16, 19], ["nostril", "ANATOMY", 29, 36], ["inner", "ANATOMY_MODIFIER", 59, 64], ["wall", "ANATOMY_MODIFIER", 65, 69], ["naris", "ANATOMY", 77, 82]]], ["Press against the exterior naris, so that you may feel the pressure applied by the swab against your finger.", [["finger", "ANATOMY", 101, 107], ["swab", "ORGANISM_SUBDIVISION", 83, 87], ["finger", "ORGANISM_SUBDIVISION", 101, 107], ["the pressure", "TEST", 55, 67], ["exterior naris", "ANATOMY", 18, 32]]], ["Rotate the swab for 10 seconds, against the pressure of your finger (clockwise, counterclockwise, or both).", [["finger", "ANATOMY", 61, 67], ["finger", "ORGANISM_SUBDIVISION", 61, 67], ["finger", "ANATOMY", 61, 67]]], ["Remove swab from first naris and repeat on the opposite naris.", [["swab", "ANATOMY", 7, 11], ["swab", "ORGANISM_SUBSTANCE", 7, 11], ["swab", "TREATMENT", 7, 11]]], ["After thoroughly swabbing each nares, place swab into the appropriate tube. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)(which was not certified by peer review)The copyright holder for this preprint this version posted June 14, 2020. . https://doi.org/10.1101/2020.06.12.20128736 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)(which was not certified by peer review)The copyright holder for this preprint this version posted June 14, 2020. . https://doi.org/10.1101/2020.06.12.20128736 doi: medRxiv preprint", [["nares", "ANATOMY", 31, 36], ["tube", "ANATOMY", 70, 74], ["nares", "ORGANISM_SUBDIVISION", 31, 36], ["tube", "TISSUE", 70, 74], ["thoroughly swabbing each nares", "TREATMENT", 6, 36], ["swab", "TREATMENT", 44, 48], ["The copyright holder", "TREATMENT", 251, 271], ["The copyright holder", "TREATMENT", 568, 588], ["medRxiv", "TREATMENT", 693, 700], ["tube", "OBSERVATION", 70, 74], ["med", "ANATOMY", 114, 117], ["med", "ANATOMY", 431, 434]]]], "c36a351bdaa827b958ab0c6062fe6c5b24b93eee": [["INTRODUCTIONSince December 2019, China has been experiencing an outbreak of COVID-19, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).", [["COVID-19", "CHEMICAL", 76, 84], ["acute respiratory syndrome coronavirus", "DISEASE", 103, 141], ["SARS-CoV-2", "ORGANISM", 145, 155], ["COVID-19", "SPECIES", 76, 84], ["severe acute respiratory syndrome coronavirus", "SPECIES", 96, 141], ["SARS-CoV-2", "SPECIES", 145, 155], ["COVID", "TEST", 76, 81], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 96, 141], ["severe", "OBSERVATION_MODIFIER", 96, 102], ["acute", "OBSERVATION_MODIFIER", 103, 108], ["respiratory syndrome", "OBSERVATION", 109, 129]]], ["This disease has spread rapidly to multiple countries and become responsible for the greatest pandemic of the century, as declared by the WHO.", [["This disease", "PROBLEM", 0, 12], ["disease", "OBSERVATION", 5, 12]]], ["The clinical spectrum encompasses asymptomatic infection, mild upper respiratory tract illness, and severe viral pneumonia with respiratory failure (1), with a high mortality estimated around 2% in diagnosed patients (2) .", [["upper respiratory tract", "ANATOMY", 63, 86], ["respiratory", "ANATOMY", 128, 139], ["infection", "DISEASE", 47, 56], ["upper respiratory tract illness", "DISEASE", 63, 94], ["viral pneumonia", "DISEASE", 107, 122], ["respiratory failure", "DISEASE", 128, 147], ["tract", "ORGANISM_SUBDIVISION", 81, 86], ["patients", "ORGANISM", 208, 216], ["patients", "SPECIES", 208, 216], ["asymptomatic infection", "PROBLEM", 34, 56], ["mild upper respiratory tract illness", "PROBLEM", 58, 94], ["severe viral pneumonia", "PROBLEM", 100, 122], ["respiratory failure", "PROBLEM", 128, 147], ["a high mortality", "PROBLEM", 158, 174], ["asymptomatic", "OBSERVATION_MODIFIER", 34, 46], ["infection", "OBSERVATION", 47, 56], ["mild", "OBSERVATION_MODIFIER", 58, 62], ["upper", "ANATOMY_MODIFIER", 63, 68], ["respiratory tract", "ANATOMY", 69, 86], ["severe", "OBSERVATION_MODIFIER", 100, 106], ["viral", "OBSERVATION_MODIFIER", 107, 112], ["pneumonia", "OBSERVATION", 113, 122], ["respiratory failure", "OBSERVATION", 128, 147], ["high", "OBSERVATION_MODIFIER", 160, 164]]], ["Identification of an efficient therapy has now become a major health emergency to avoid health system saturation, especially the medical capabilities of respiratory resuscitation.", [["respiratory", "ANATOMY", 153, 164], ["an efficient therapy", "TREATMENT", 18, 38], ["respiratory resuscitation", "TREATMENT", 153, 178], ["efficient therapy", "OBSERVATION", 21, 38], ["respiratory resuscitation", "OBSERVATION", 153, 178]]], ["A large number of clinical trials is currently underway, but no treatment of proven efficacy is known at present.", [["clinical trials", "TREATMENT", 18, 33], ["treatment", "TREATMENT", 64, 73], ["large", "OBSERVATION_MODIFIER", 2, 7], ["number", "OBSERVATION_MODIFIER", 8, 14]]], ["The lack of data from large-scale clinical trials involving COVID-19 patients hampers reliable statistical analyses.", [["patients", "ORGANISM", 69, 77], ["patients", "SPECIES", 69, 77], ["COVID", "TEST", 60, 65]]], ["In this context of emergency, an in-depth analysis of published preliminary data may help to improve our understanding of disease outcomes and shed light upon potentially efficacious treatment strategies.THE INITIAL FOCUS ON HYDROXYCHLOROQUINESince the discovery that the anti-malarial drug hydroxychloroquine (h-CQ) efficiently inhibits SARS-CoV-2 infection in vitro (3), numerous clinical studies have been undertaken to test its safety and efficacy in the treatment of COVID-19 associated pneumonia (4).", [["hydroxychloroquine", "CHEMICAL", 291, 309], ["h-CQ", "CHEMICAL", 311, 315], ["infection", "DISEASE", 349, 358], ["COVID-19", "CHEMICAL", 472, 480], ["pneumonia", "DISEASE", 492, 501], ["hydroxychloroquine", "CHEMICAL", 291, 309], ["h-CQ", "CHEMICAL", 311, 315], ["COVID-19", "CHEMICAL", 472, 480], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 291, 309], ["h-CQ", "SIMPLE_CHEMICAL", 311, 315], ["SARS-CoV-2", "ORGANISM", 338, 348], ["COVID-19", "SIMPLE_CHEMICAL", 472, 480], ["SARS-CoV-2", "SPECIES", 338, 348], ["disease outcomes", "PROBLEM", 122, 138], ["efficacious treatment strategies", "TREATMENT", 171, 203], ["the anti-malarial drug hydroxychloroquine", "TREATMENT", 268, 309], ["SARS", "PROBLEM", 338, 342], ["CoV-2 infection", "PROBLEM", 343, 358], ["numerous clinical studies", "TEST", 373, 398], ["COVID-19 associated pneumonia", "PROBLEM", 472, 501], ["pneumonia", "OBSERVATION", 492, 501]]], ["Although preliminary observations from China claimed h-CQ benefit (4), two subsequent publications reported contradictory results on its ability to reduce viral carriage (5, 6) .HYDROXYCHLOROQUINE IN CHINAIn Shanghai, Chen et al. evaluated the efficacy of h-CQ (400 mg daily for 5 days) in the treatment of 30 symptomatic Chinese patients with COVID-19 (5) .", [["h-CQ", "CHEMICAL", 256, 260], ["h-CQ", "CHEMICAL", 256, 260], ["COVID-19", "CHEMICAL", 344, 352], ["h-CQ", "SIMPLE_CHEMICAL", 256, 260], ["patients", "ORGANISM", 330, 338], ["patients", "SPECIES", 330, 338], ["viral carriage", "PROBLEM", 155, 169], ["HYDROXYCHLOROQUINE", "TREATMENT", 178, 196], ["h-CQ", "TREATMENT", 256, 260], ["COVID", "TEST", 344, 349]]], ["They demonstrated that the viral carriage of nasopharyngeal samples (evaluated by PCR at day 7 post-inclusion) was not statistically different between h-CQ and control groups at the end of the follow up.", [["nasopharyngeal samples", "ANATOMY", 45, 67], ["CQ", "CHEMICAL", 153, 155], ["nasopharyngeal samples", "CANCER", 45, 67], ["CQ", "SIMPLE_CHEMICAL", 153, 155], ["the viral carriage of nasopharyngeal samples", "PROBLEM", 23, 67], ["PCR", "TEST", 82, 85], ["viral", "OBSERVATION_MODIFIER", 27, 32], ["nasopharyngeal", "ANATOMY", 45, 59]]], ["Given that the median duration of viral shedding in COVID-19 has been reported to be around 20 days in Chinese patients (1), it is interesting to note that the viral carriage rapidly decreased in both groups after 4 days of treatment, with 90% of patients proved to be SARS-CoV-2 negative at day 7.", [["COVID-19", "CHEMICAL", 52, 60], ["SARS", "DISEASE", 269, 273], ["patients", "ORGANISM", 111, 119], ["patients", "ORGANISM", 247, 255], ["CoV-2", "ORGANISM", 274, 279], ["patients", "SPECIES", 111, 119], ["patients", "SPECIES", 247, 255], ["viral shedding", "PROBLEM", 34, 48], ["the viral carriage", "PROBLEM", 156, 174], ["treatment", "TREATMENT", 224, 233], ["SARS", "TEST", 269, 273], ["CoV", "TEST", 274, 277], ["decreased", "OBSERVATION_MODIFIER", 183, 192]]], ["Interestingly, all patients included in this study also received some therapies recommended by the National Health Commission (NHC) of China, in particular 100% of them received inhalation of the antiviral cytokine interferon (IFN)-\u03b1-2b.TYPE I INTERFERON NEBULIZATION IN THE TREATMENT OF COVID-19 PATIENTSType I IFNs (including IFN-\u03b1 and IFN-\u03b2) are antiviral cytokines produced by bronchial epithelial cells in response to viral infection.", [["bronchial epithelial cells", "ANATOMY", 381, 407], ["viral infection", "DISEASE", 423, 438], ["patients", "ORGANISM", 19, 27], ["interferon (IFN)-\u03b1-2b", "GENE_OR_GENE_PRODUCT", 215, 236], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 328, 333], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 338, 343], ["bronchial epithelial cells", "CELL", 381, 407], ["antiviral cytokine interferon (IFN)-\u03b1-2b", "PROTEIN", 196, 236], ["IFNs", "PROTEIN", 312, 316], ["IFN", "PROTEIN", 328, 331], ["\u03b1", "PROTEIN", 332, 333], ["IFN", "PROTEIN", 338, 341], ["-\u03b2", "PROTEIN", 341, 343], ["antiviral cytokines", "PROTEIN", 349, 368], ["bronchial epithelial cells", "CELL_TYPE", 381, 407], ["patients", "SPECIES", 19, 27], ["this study", "TEST", 40, 50], ["some therapies", "TREATMENT", 65, 79], ["inhalation", "TREATMENT", 178, 188], ["the antiviral cytokine interferon (IFN)", "TREATMENT", 192, 231], ["TYPE I INTERFERON NEBULIZATION", "TREATMENT", 237, 267], ["COVID", "TEST", 288, 293], ["IFN", "TEST", 328, 331], ["IFN", "TREATMENT", 338, 341], ["antiviral cytokines", "PROBLEM", 349, 368], ["bronchial epithelial cells", "PROBLEM", 381, 407], ["viral infection", "PROBLEM", 423, 438], ["INTERFERON NEBULIZATION", "OBSERVATION", 244, 267], ["bronchial", "ANATOMY", 381, 390], ["epithelial cells", "OBSERVATION", 391, 407], ["viral infection", "OBSERVATION", 423, 438]]], ["They display the ability to bind the surface of infected and neighboring cells and promote the induction of around 300 different IFN-inducible genes (ISGs) that subsequently prevent virus protein trafficking, virus RNA synthesis or virion assembly and release (7).TYPE I INTERFERON NEBULIZATION IN THE TREATMENT OF COVID-19 PATIENTSIn vitro, type I IFN inhibits the replication of both SARS-CoV (8) and SARS-CoV-2 (9) (pre-printed publication).", [["surface", "ANATOMY", 37, 44], ["cells", "ANATOMY", 73, 78], ["surface", "CELLULAR_COMPONENT", 37, 44], ["cells", "CELL", 73, 78], ["IFN-inducible genes", "GENE_OR_GENE_PRODUCT", 129, 148], ["type I IFN", "GENE_OR_GENE_PRODUCT", 342, 352], ["SARS-CoV", "ORGANISM", 386, 394], ["infected and neighboring cells", "CELL_TYPE", 48, 78], ["IFN-inducible genes", "DNA", 129, 148], ["ISGs", "DNA", 150, 154], ["type I IFN", "PROTEIN", 342, 352], ["SARS-CoV", "SPECIES", 386, 394], ["SARS-CoV-2", "SPECIES", 403, 413], ["infected and neighboring cells", "PROBLEM", 48, 78], ["the induction", "TREATMENT", 91, 104], ["inducible genes (ISGs)", "PROBLEM", 133, 155], ["virus protein trafficking", "PROBLEM", 182, 207], ["virus RNA synthesis", "TREATMENT", 209, 228], ["TYPE I INTERFERON NEBULIZATION", "TREATMENT", 264, 294], ["COVID", "TEST", 315, 320], ["type I IFN", "PROBLEM", 342, 352], ["CoV", "TEST", 391, 394], ["SARS", "PROBLEM", 403, 407], ["CoV", "TEST", 408, 411], ["infected", "OBSERVATION", 48, 56], ["INTERFERON NEBULIZATION", "OBSERVATION", 271, 294]]], ["Therefore, the rapid decrease of SARS-CoV-2 carriage observed in the patients of the Chen et al. study may be linked to atomized IFN-\u03b1-2b therapy (5) .", [["SARS", "DISEASE", 33, 37], ["atomized IFN-\u03b1-2b", "CHEMICAL", 120, 137], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 33, 43], ["patients", "ORGANISM", 69, 77], ["IFN-\u03b1-2b", "GENE_OR_GENE_PRODUCT", 129, 137], ["IFN", "PROTEIN", 129, 132], ["\u03b1", "PROTEIN", 133, 134], ["patients", "SPECIES", 69, 77], ["the rapid decrease of SARS", "PROBLEM", 11, 37], ["study", "TEST", 97, 102], ["IFN", "TEST", 129, 132], ["2b therapy", "TREATMENT", 135, 145], ["rapid", "OBSERVATION_MODIFIER", 15, 20], ["decrease", "OBSERVATION_MODIFIER", 21, 29]]], ["In line with this hypothesis, Liu et al. claimed that a combination therapy of low-dose systematic corticosteroids, lopinavir/ritonavir, and atomization inhalation of IFN-\u03b1-2b participated to the observed 0% mortality in their COVID-19 patients in Shenzen, China (10) .", [["lopinavir/ritonavir", "CHEMICAL", 116, 135], ["IFN-\u03b1-2b", "CHEMICAL", 167, 175], ["lopinavir", "CHEMICAL", 116, 125], ["ritonavir", "CHEMICAL", 126, 135], ["lopinavir", "SIMPLE_CHEMICAL", 116, 125], ["ritonavir", "SIMPLE_CHEMICAL", 126, 135], ["IFN-\u03b1-2b", "GENE_OR_GENE_PRODUCT", 167, 175], ["patients", "ORGANISM", 236, 244], ["IFN", "PROTEIN", 167, 170], ["patients", "SPECIES", 236, 244], ["a combination therapy", "TREATMENT", 54, 75], ["low-dose systematic corticosteroids", "TREATMENT", 79, 114], ["lopinavir", "TREATMENT", 116, 125], ["ritonavir", "TREATMENT", 126, 135], ["atomization inhalation", "TREATMENT", 141, 163], ["IFN", "TREATMENT", 167, 170]]], ["According to Chen et al., the use of inhaled IFN is also associated with decreased mortality in COVID-19 patients from Wuhan (OR = 2,32 IC95% [1,36;3,97] calculated by our group using the Miettinen method) (11) .", [["IFN", "CHEMICAL", 45, 48], ["patients", "ORGANISM", 105, 113], ["IFN", "PROTEIN", 45, 48], ["patients", "SPECIES", 105, 113], ["inhaled IFN", "TREATMENT", 37, 48], ["decreased mortality", "PROBLEM", 73, 92]]], ["More recently, Maiti et al. suggested that a polymorphism in the gene encoding IFIH1 (InterFeron-Induced Helicase 1), a host protein that senses the presence of viral RNA and subsequently promotes IFN production, may render African-American more vulnerable to SARS-CoV-2 infection.", [["SARS", "DISEASE", 260, 264], ["infection", "DISEASE", 271, 280], ["IFIH1", "GENE_OR_GENE_PRODUCT", 79, 84], ["InterFeron-Induced Helicase 1", "GENE_OR_GENE_PRODUCT", 86, 115], ["IFN", "GENE_OR_GENE_PRODUCT", 197, 200], ["SARS-CoV-2", "ORGANISM", 260, 270], ["IFIH1", "PROTEIN", 79, 84], ["InterFeron", "PROTEIN", 86, 96], ["Induced Helicase 1", "PROTEIN", 97, 115], ["viral RNA", "RNA", 161, 170], ["IFN", "PROTEIN", 197, 200], ["SARS-CoV", "SPECIES", 260, 268], ["a polymorphism", "PROBLEM", 43, 57], ["the gene encoding IFIH1 (InterFeron-Induced Helicase", "TREATMENT", 61, 113], ["a host protein", "TREATMENT", 118, 132], ["viral RNA", "PROBLEM", 161, 170], ["SARS", "PROBLEM", 260, 264], ["CoV-2 infection", "PROBLEM", 265, 280], ["viral RNA", "OBSERVATION", 161, 170], ["infection", "OBSERVATION", 271, 280]]], ["This observation lead the author to suggest that type I IFN supplement could be developed as an effective treatment for SARS-CoV-2 (12) .TYPE I INTERFERON NEBULIZATION IN THE TREATMENT OF COVID-19 PATIENTSAtomized IFN-\u03b1-2b is currently the first treatment cited by the Chinese NHC for COVID-19 (13) .", [["IFN", "CHEMICAL", 56, 59], ["SARS", "DISEASE", 120, 124], ["IFN-\u03b1-2b", "CHEMICAL", 214, 222], ["COVID-19", "CHEMICAL", 285, 293], ["type I IFN", "GENE_OR_GENE_PRODUCT", 49, 59], ["SARS-CoV-2", "ORGANISM", 120, 130], ["IFN-\u03b1-2b", "GENE_OR_GENE_PRODUCT", 214, 222], ["IFN", "PROTEIN", 56, 59], ["IFN", "PROTEIN", 214, 217], ["\u03b1", "PROTEIN", 218, 219], ["SARS-CoV", "SPECIES", 120, 128], ["type I IFN supplement", "TREATMENT", 49, 70], ["an effective treatment", "TREATMENT", 93, 115], ["SARS", "PROBLEM", 120, 124], ["CoV", "TEST", 125, 128], ["TYPE I INTERFERON NEBULIZATION", "TREATMENT", 137, 167], ["COVID", "TEST", 188, 193], ["IFN", "TEST", 214, 217], ["COVID", "TEST", 285, 290], ["INTERFERON NEBULIZATION", "OBSERVATION", 144, 167]]], ["Indeed, clinical nebulization of IFN-\u03b1 has been historically used in China to treat viral pneumonia associated with SARS-CoV, middle east respiratory syndrome coronavirus (MERS) and respiratory syncytial virus (14, 15) .", [["IFN-\u03b1", "CHEMICAL", 33, 38], ["viral pneumonia", "DISEASE", 84, 99], ["SARS-CoV", "DISEASE", 116, 124], ["respiratory syndrome coronavirus", "DISEASE", 138, 170], ["respiratory syncytial virus", "DISEASE", 182, 209], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 33, 38], ["SARS-CoV", "ORGANISM", 116, 124], ["middle east respiratory syndrome coronavirus", "ORGANISM", 126, 170], ["respiratory syncytial virus", "ORGANISM", 182, 209], ["IFN-\u03b1", "PROTEIN", 33, 38], ["respiratory syncytial virus", "SPECIES", 182, 209], ["SARS-CoV", "SPECIES", 116, 124], ["middle east respiratory syndrome coronavirus", "SPECIES", 126, 170], ["respiratory syncytial virus", "SPECIES", 182, 209], ["clinical nebulization of IFN", "TREATMENT", 8, 36], ["viral pneumonia", "PROBLEM", 84, 99], ["SARS", "PROBLEM", 116, 120], ["CoV", "PROBLEM", 121, 124], ["middle east respiratory syndrome coronavirus", "PROBLEM", 126, 170], ["respiratory syncytial virus", "PROBLEM", 182, 209], ["pneumonia", "OBSERVATION", 90, 99], ["middle", "ANATOMY_MODIFIER", 126, 132], ["respiratory syndrome", "OBSERVATION", 138, 158], ["respiratory", "ANATOMY", 182, 193], ["syncytial virus", "OBSERVATION", 194, 209]]], ["Its efficiency in treating severe bronchiolitis appears to be superior to the parenteral route 1 and to expose to fewer undesirable effects, including hematological toxicity, fever, and depression (15) .HYDROXYCHLOROQUINE IN FRANCEH-CQ was also evaluated in France, and the conclusion of the authors differed from the Chinese study.", [["bronchiolitis", "DISEASE", 34, 47], ["hematological toxicity", "DISEASE", 151, 173], ["fever", "DISEASE", 175, 180], ["depression", "DISEASE", 186, 196], ["severe bronchiolitis", "PROBLEM", 27, 47], ["the parenteral route", "TREATMENT", 74, 94], ["hematological toxicity", "PROBLEM", 151, 173], ["fever", "PROBLEM", 175, 180], ["depression", "PROBLEM", 186, 196], ["HYDROXYCHLOROQUINE IN FRANCEH-CQ", "TREATMENT", 203, 235], ["the Chinese study", "TEST", 314, 331], ["efficiency", "OBSERVATION_MODIFIER", 4, 14], ["severe", "OBSERVATION_MODIFIER", 27, 33], ["bronchiolitis", "OBSERVATION", 34, 47], ["fewer", "OBSERVATION_MODIFIER", 114, 119], ["undesirable", "OBSERVATION", 120, 131], ["hematological toxicity", "OBSERVATION", 151, 173]]], ["On March 20th of 2020, Gautret et al. undertook an open label, non-randomized clinical trial in 42 patients with confirmed COVID-19, aimed to evaluate the effect of h-CQ (200 mg TID for 10 days) on SARS-CoV-2 respiratory viral load (6) .", [["h-CQ", "CHEMICAL", 165, 169], ["TID", "CHEMICAL", 178, 181], ["h-CQ", "CHEMICAL", 165, 169], ["TID", "CHEMICAL", 178, 181], ["patients", "ORGANISM", 99, 107], ["h-CQ", "SIMPLE_CHEMICAL", 165, 169], ["patients", "SPECIES", 99, 107], ["COVID", "TEST", 123, 128], ["h-CQ", "TREATMENT", 165, 169], ["SARS", "TEST", 198, 202], ["CoV", "TEST", 203, 206], ["respiratory viral load", "TEST", 209, 231]]], ["They observed that h-CQ treatment led to a reduction of viral carriage at day 6.", [["h-CQ", "CHEMICAL", 19, 23], ["h-CQ", "CHEMICAL", 19, 23], ["h-CQ", "SIMPLE_CHEMICAL", 19, 23], ["h-CQ treatment", "TREATMENT", 19, 33], ["viral carriage", "PROBLEM", 56, 70]]], ["However, when excluding asymptomatic patients as well as patients symptomatic for more than 8 days (potentially in remission phase) none of 1 http://en.cnki.com.cn/Article_en/CJFDTotal-EKYX200305019.htm the seven patients in the control group and only two among the 10 patients treated with h-CQ alone became viral carriage negative (NS; p = 0.48) at day 6 (statistical sensitivity analysis performed ourselves).", [["h-CQ", "CHEMICAL", 291, 295], ["patients", "ORGANISM", 37, 45], ["patients", "ORGANISM", 57, 65], ["patients", "ORGANISM", 213, 221], ["patients", "ORGANISM", 269, 277], ["h-CQ", "SIMPLE_CHEMICAL", 291, 295], ["patients", "SPECIES", 37, 45], ["patients", "SPECIES", 57, 65], ["patients", "SPECIES", 213, 221], ["patients", "SPECIES", 269, 277], ["h-CQ", "TREATMENT", 291, 295], ["viral carriage", "PROBLEM", 309, 323], ["NS", "TREATMENT", 334, 336], ["statistical sensitivity analysis", "TEST", 358, 390]]], ["In contrast, a subgroup of six patients treated with both h-CQ and azithromycin (500 mg on day 1, followed by 250 mg daily for the subsequent 4 days) converted to viral carriage negative status at day 6.", [["h-CQ", "CHEMICAL", 58, 62], ["azithromycin", "CHEMICAL", 67, 79], ["h-CQ", "CHEMICAL", 58, 62], ["azithromycin", "CHEMICAL", 67, 79], ["patients", "ORGANISM", 31, 39], ["h-CQ", "SIMPLE_CHEMICAL", 58, 62], ["azithromycin", "SIMPLE_CHEMICAL", 67, 79], ["patients", "SPECIES", 31, 39], ["both h-CQ", "TREATMENT", 53, 62], ["azithromycin", "TREATMENT", 67, 79]]], ["In line with this observation, a subsequent set of data published by Gautret et al. on March 27th of 2020 showed a rapid fall of nasopharyngeal viral load in 80 patients (5 asymptomatic) treated exclusively with a combination of h-CQ and azithromycin, with 74% of patients becoming SARS-CoV-2 negative at day 6 and 83% negative at day 7 (16) .AZITHROMYCIN IN THE TREATMENT OF COVID-19 PATIENTSApart from its anti-bacterial role, azithromycin has been reported to increase rhinovirus-induced type I and type III IFN response in bronchial epithelial cells from healthy donors (17) asthmatic individuals (18) and patients with chronic obstructive pulmonary disease (19) .", [["nasopharyngeal", "ANATOMY", 129, 143], ["bronchial epithelial cells", "ANATOMY", 527, 553], ["pulmonary", "ANATOMY", 644, 653], ["h-CQ", "CHEMICAL", 229, 233], ["azithromycin", "CHEMICAL", 238, 250], ["SARS", "DISEASE", 282, 286], ["azithromycin", "CHEMICAL", 429, 441], ["chronic obstructive pulmonary disease", "DISEASE", 624, 661], ["h-CQ", "CHEMICAL", 229, 233], ["azithromycin", "CHEMICAL", 238, 250], ["COVID-19", "CHEMICAL", 376, 384], ["azithromycin", "CHEMICAL", 429, 441], ["nasopharyngeal", "ORGAN", 129, 143], ["patients", "ORGANISM", 161, 169], ["h-CQ", "SIMPLE_CHEMICAL", 229, 233], ["azithromycin", "SIMPLE_CHEMICAL", 238, 250], ["patients", "ORGANISM", 264, 272], ["azithromycin", "SIMPLE_CHEMICAL", 429, 441], ["rhinovirus", "ORGANISM", 472, 482], ["type III IFN", "GENE_OR_GENE_PRODUCT", 502, 514], ["bronchial epithelial cells", "CELL", 527, 553], ["donors", "ORGANISM", 567, 573], ["patients", "ORGANISM", 610, 618], ["pulmonary", "ORGAN", 644, 653], ["IFN", "PROTEIN", 511, 514], ["bronchial epithelial cells", "CELL_TYPE", 527, 553], ["patients", "SPECIES", 161, 169], ["patients", "SPECIES", 264, 272], ["patients", "SPECIES", 610, 618], ["a rapid fall of nasopharyngeal viral load", "PROBLEM", 113, 154], ["h-CQ", "TREATMENT", 229, 233], ["azithromycin", "TREATMENT", 238, 250], ["SARS", "PROBLEM", 282, 286], ["CoV", "TEST", 287, 290], ["AZITHROMYCIN", "TREATMENT", 343, 355], ["COVID", "TEST", 376, 381], ["its anti-bacterial role", "TREATMENT", 404, 427], ["azithromycin", "TREATMENT", 429, 441], ["rhinovirus", "PROBLEM", 472, 482], ["type I", "PROBLEM", 491, 497], ["type III IFN response", "PROBLEM", 502, 523], ["bronchial epithelial cells", "PROBLEM", 527, 553], ["asthmatic individuals", "PROBLEM", 579, 600], ["chronic obstructive pulmonary disease", "PROBLEM", 624, 661], ["nasopharyngeal", "ANATOMY", 129, 143], ["viral load", "OBSERVATION", 144, 154], ["rhinovirus", "OBSERVATION", 472, 482], ["bronchial epithelial cells", "OBSERVATION", 527, 553], ["chronic", "OBSERVATION_MODIFIER", 624, 631], ["obstructive", "OBSERVATION_MODIFIER", 632, 643], ["pulmonary", "ANATOMY", 644, 653], ["disease", "OBSERVATION", 654, 661]]], ["Azithromycin amelioration of viral-induced IFN also protects against Zika virus infection (20) and reduces the recurrence of severe lower respiratory tract illnesses in children (21) .", [["lower respiratory tract", "ANATOMY", 132, 155], ["Azithromycin", "CHEMICAL", 0, 12], ["IFN", "CHEMICAL", 43, 46], ["Zika virus infection", "DISEASE", 69, 89], ["lower respiratory tract illnesses", "DISEASE", 132, 165], ["Azithromycin", "CHEMICAL", 0, 12], ["Azithromycin", "SIMPLE_CHEMICAL", 0, 12], ["IFN", "GENE_OR_GENE_PRODUCT", 43, 46], ["Zika virus", "ORGANISM", 69, 79], ["lower", "ORGANISM_SUBDIVISION", 132, 137], ["respiratory tract", "ORGANISM_SUBDIVISION", 138, 155], ["children", "ORGANISM", 169, 177], ["IFN", "PROTEIN", 43, 46], ["children", "SPECIES", 169, 177], ["Zika virus", "SPECIES", 69, 79], ["Azithromycin amelioration", "TREATMENT", 0, 25], ["viral-induced IFN", "TREATMENT", 29, 46], ["Zika virus infection", "PROBLEM", 69, 89], ["severe lower respiratory tract illnesses", "PROBLEM", 125, 165], ["viral", "OBSERVATION", 29, 34], ["recurrence", "OBSERVATION_MODIFIER", 111, 121], ["severe", "OBSERVATION_MODIFIER", 125, 131], ["lower", "ANATOMY_MODIFIER", 132, 137], ["respiratory tract", "ANATOMY", 138, 155]]], ["In the study by Gautret et al. (6, 16) , the potential anti-viral role of azithromycin was mentioned but not discussed in detail since they mainly focused on h-CQ.", [["azithromycin", "CHEMICAL", 74, 86], ["azithromycin", "CHEMICAL", 74, 86], ["azithromycin", "SIMPLE_CHEMICAL", 74, 86], ["h-CQ", "SIMPLE_CHEMICAL", 158, 162], ["h-CQ", "PROTEIN", 158, 162], ["the study", "TEST", 3, 12], ["azithromycin", "TREATMENT", 74, 86]]], ["However, the possibility must be considered that azithromycin may be responsible for the rapid reduction of viral carriage in this subgroup of h-CQ-treated French patients.ANTI-INFLAMMATORY PROPERTIES OF BOTH ATOMIZED TYPE I IFN AND AZITHROMYCINBeyond the viral infection, accumulating evidence suggests that a subgroup of patients with severe COVID-19 develop a severe inflammatory syndrome (associated with a dramatical rise in type II IFN and IL-6 serum levels), enhancing disease severity and mortality (22) .", [["serum", "ANATOMY", 451, 456], ["azithromycin", "CHEMICAL", 49, 61], ["h-CQ", "CHEMICAL", 143, 147], ["viral infection", "DISEASE", 256, 271], ["inflammatory syndrome", "DISEASE", 370, 391], ["azithromycin", "CHEMICAL", 49, 61], ["azithromycin", "SIMPLE_CHEMICAL", 49, 61], ["h-CQ", "SIMPLE_CHEMICAL", 143, 147], ["patients", "ORGANISM", 163, 171], ["patients", "ORGANISM", 323, 331], ["type II IFN", "GENE_OR_GENE_PRODUCT", 430, 441], ["IL-6", "GENE_OR_GENE_PRODUCT", 446, 450], ["serum", "ORGANISM_SUBSTANCE", 451, 456], ["type II IFN", "PROTEIN", 430, 441], ["IL", "PROTEIN", 446, 448], ["patients", "SPECIES", 163, 171], ["patients", "SPECIES", 323, 331], ["azithromycin", "TREATMENT", 49, 61], ["viral carriage", "PROBLEM", 108, 122], ["the viral infection", "PROBLEM", 252, 271], ["severe COVID", "PROBLEM", 337, 349], ["a severe inflammatory syndrome", "PROBLEM", 361, 391], ["a dramatical rise in type II IFN", "PROBLEM", 409, 441], ["IL", "TEST", 446, 448], ["serum levels", "TEST", 451, 463], ["enhancing disease severity", "PROBLEM", 466, 492], ["rapid", "OBSERVATION_MODIFIER", 89, 94], ["reduction", "OBSERVATION_MODIFIER", 95, 104], ["viral carriage", "OBSERVATION", 108, 122], ["INFLAMMATORY", "OBSERVATION", 177, 189], ["viral", "OBSERVATION_MODIFIER", 256, 261], ["infection", "OBSERVATION", 262, 271], ["severe", "OBSERVATION_MODIFIER", 363, 369], ["inflammatory syndrome", "OBSERVATION", 370, 391], ["enhancing", "OBSERVATION_MODIFIER", 466, 475], ["disease", "OBSERVATION", 476, 483]]], ["In this condition both atomized type I IFN and azithromycin may be beneficial as they can also downregulate inflammation (7, 23) and in particular type II IFN pathway in vitro (18, 24) .DISCUSSIONThese very recent preliminary data suggest a potential therapeutic benefit of type I IFN pathway stimulation, which may become a key approach in treating COVID-19, possibly in association with direct antiviral agents.", [["IFN", "CHEMICAL", 39, 42], ["azithromycin", "CHEMICAL", 47, 59], ["inflammation", "DISEASE", 108, 120], ["COVID-19", "CHEMICAL", 350, 358], ["azithromycin", "CHEMICAL", 47, 59], ["COVID-19", "CHEMICAL", 350, 358], ["type I IFN", "GENE_OR_GENE_PRODUCT", 32, 42], ["azithromycin", "SIMPLE_CHEMICAL", 47, 59], ["type II IFN", "GENE_OR_GENE_PRODUCT", 147, 158], ["type I IFN", "GENE_OR_GENE_PRODUCT", 274, 284], ["COVID-19", "CELL", 350, 358], ["atomized type I IFN", "PROTEIN", 23, 42], ["IFN", "PROTEIN", 155, 158], ["IFN", "PROTEIN", 281, 284], ["azithromycin", "TREATMENT", 47, 59], ["inflammation", "PROBLEM", 108, 120], ["type I IFN pathway stimulation", "TREATMENT", 274, 304], ["COVID", "TEST", 350, 355], ["direct antiviral agents", "TREATMENT", 389, 412], ["inflammation", "OBSERVATION", 108, 120]]], ["The currently ongoing Solidarity and Discovery clinical trials, both of which include an arm of patients treated with IFN-\u03b2-1a administered subcutaneously in combination with ritonavir and lopinavir, will help to explore this hypothesis (25) .", [["subcutaneously", "ANATOMY", 140, 154], ["IFN-\u03b2-1a", "CHEMICAL", 118, 126], ["ritonavir", "CHEMICAL", 175, 184], ["lopinavir", "CHEMICAL", 189, 198], ["ritonavir", "CHEMICAL", 175, 184], ["lopinavir", "CHEMICAL", 189, 198], ["patients", "ORGANISM", 96, 104], ["IFN-\u03b2-1a", "GENE_OR_GENE_PRODUCT", 118, 126], ["ritonavir", "SIMPLE_CHEMICAL", 175, 184], ["lopinavir", "SIMPLE_CHEMICAL", 189, 198], ["IFN", "PROTEIN", 118, 121], ["patients", "SPECIES", 96, 104], ["IFN", "TREATMENT", 118, 121], ["\u03b2", "TREATMENT", 122, 123], ["ritonavir", "TREATMENT", 175, 184], ["lopinavir", "TREATMENT", 189, 198], ["arm", "ANATOMY", 89, 92]]], ["In comparison with this strategy, atomized IFN, which has already shown benefit in China, has the advantage to directly target the lungs and to reduce the risks of systemic side effects.", [["lungs", "ANATOMY", 131, 136], ["IFN", "CHEMICAL", 43, 46], ["lungs", "ORGAN", 131, 136], ["atomized IFN", "PROTEIN", 34, 46], ["systemic side effects", "PROBLEM", 164, 185], ["lungs", "ANATOMY", 131, 136]]], ["However, it might raise concerns about nebulization side effects, including preservative toxicity, pharmacokinetics, and potential viral dispersion.", [["toxicity", "DISEASE", 89, 97], ["nebulization side effects", "PROBLEM", 39, 64], ["preservative toxicity", "PROBLEM", 76, 97], ["potential viral dispersion", "PROBLEM", 121, 147], ["potential", "UNCERTAINTY", 121, 130], ["viral dispersion", "OBSERVATION", 131, 147]]], ["For these reasons, we suggest that pulmonary nebulization of type I IFN may be useful for patients with a moderate to severe form of the disease and that azithromycin may represent an interesting strategy for patients with less aggressive forms.", [["pulmonary", "ANATOMY", 35, 44], ["type I IFN", "CHEMICAL", 61, 71], ["azithromycin", "CHEMICAL", 154, 166], ["azithromycin", "CHEMICAL", 154, 166], ["pulmonary", "ORGAN", 35, 44], ["type I IFN", "GENE_OR_GENE_PRODUCT", 61, 71], ["patients", "ORGANISM", 90, 98], ["azithromycin", "SIMPLE_CHEMICAL", 154, 166], ["patients", "ORGANISM", 209, 217], ["type I IFN", "PROTEIN", 61, 71], ["patients", "SPECIES", 90, 98], ["patients", "SPECIES", 209, 217], ["pulmonary nebulization of type I IFN", "TREATMENT", 35, 71], ["the disease", "PROBLEM", 133, 144], ["azithromycin", "TREATMENT", 154, 166], ["pulmonary", "ANATOMY", 35, 44], ["disease", "OBSERVATION", 137, 144]]], ["In favor of this strategy, azithromycin presents the advantage of being cheap, easily applicable to outpatient care and raising less safety concerns than h-CQ, in particular cardiovascular complications.", [["cardiovascular", "ANATOMY", 174, 188], ["azithromycin", "CHEMICAL", 27, 39], ["cardiovascular complications", "DISEASE", 174, 202], ["azithromycin", "CHEMICAL", 27, 39], ["azithromycin", "SIMPLE_CHEMICAL", 27, 39], ["h-CQ", "SIMPLE_CHEMICAL", 154, 158], ["cardiovascular", "ANATOMICAL_SYSTEM", 174, 188], ["this strategy", "TREATMENT", 12, 25], ["azithromycin", "TREATMENT", 27, 39], ["outpatient care", "TREATMENT", 100, 115], ["particular cardiovascular complications", "PROBLEM", 163, 202], ["cardiovascular", "ANATOMY", 174, 188], ["complications", "OBSERVATION", 189, 202]]], ["Regarding drug safety, it has to be underlined that under specific conditions type I IFN response can increase the susceptibility to bacterial assault (26, 27) .", [["bacterial assault", "DISEASE", 133, 150], ["type I IFN", "GENE_OR_GENE_PRODUCT", 78, 88], ["IFN", "PROTEIN", 85, 88], ["the susceptibility to bacterial assault", "PROBLEM", 111, 150], ["bacterial", "OBSERVATION_MODIFIER", 133, 142], ["assault", "OBSERVATION", 143, 150]]], ["In particular, bacterial infections have been noted in patients receiving prolonged systemic IFN-\u03b1-2b therapy for chronic hepatitis C virus infection (28) (29) (30) .", [["bacterial infections", "DISEASE", 15, 35], ["IFN-\u03b1-2b", "CHEMICAL", 93, 101], ["chronic hepatitis C virus infection", "DISEASE", 114, 149], ["patients", "ORGANISM", 55, 63], ["IFN-\u03b1-2b", "GENE_OR_GENE_PRODUCT", 93, 101], ["chronic hepatitis C virus", "ORGANISM", 114, 139], ["IFN", "PROTEIN", 93, 96], ["patients", "SPECIES", 55, 63], ["hepatitis C virus", "SPECIES", 122, 139], ["hepatitis C virus", "SPECIES", 122, 139], ["bacterial infections", "PROBLEM", 15, 35], ["prolonged systemic IFN", "TREATMENT", 74, 96], ["2b therapy", "TREATMENT", 99, 109], ["chronic hepatitis C virus infection", "PROBLEM", 114, 149], ["bacterial", "OBSERVATION_MODIFIER", 15, 24], ["infections", "OBSERVATION", 25, 35], ["chronic", "OBSERVATION_MODIFIER", 114, 121], ["hepatitis", "OBSERVATION", 122, 131]]], ["Since preliminary data obtained in China suggest that patients under type I IFN therapy may rapidly become viral carriage negative, a close monitoring of the viral load may be useful to limit treatment duration and subsequent bacterial infection.", [["bacterial infection", "DISEASE", 226, 245], ["patients", "ORGANISM", 54, 62], ["type I IFN", "GENE_OR_GENE_PRODUCT", 69, 79], ["IFN", "PROTEIN", 76, 79], ["patients", "SPECIES", 54, 62], ["preliminary data", "TEST", 6, 22], ["type I IFN therapy", "TREATMENT", 69, 87], ["viral carriage", "PROBLEM", 107, 121], ["a close monitoring", "TEST", 132, 150], ["the viral load", "PROBLEM", 154, 168], ["treatment duration", "TREATMENT", 192, 210], ["subsequent bacterial infection", "PROBLEM", 215, 245], ["bacterial", "OBSERVATION_MODIFIER", 226, 235], ["infection", "OBSERVATION", 236, 245]]], ["In this context, the use of azithromycin for outpatient care may even be more favorable than the use of type I IFN itself, given that its anti-bacterial properties may also prevent secondary infections that can occur in association with COVID-19.", [["azithromycin", "CHEMICAL", 28, 40], ["infections", "DISEASE", 191, 201], ["azithromycin", "CHEMICAL", 28, 40], ["COVID-19", "CHEMICAL", 237, 245], ["azithromycin", "SIMPLE_CHEMICAL", 28, 40], ["type I IFN", "GENE_OR_GENE_PRODUCT", 104, 114], ["type I IFN", "PROTEIN", 104, 114], ["azithromycin", "TREATMENT", 28, 40], ["outpatient care", "TREATMENT", 45, 60], ["type I IFN", "TREATMENT", 104, 114], ["its anti-bacterial properties", "TREATMENT", 134, 163], ["secondary infections", "PROBLEM", 181, 201], ["COVID", "TEST", 237, 242], ["secondary", "OBSERVATION_MODIFIER", 181, 190], ["infections", "OBSERVATION", 191, 201]]], ["Nevertheless, the risk of antibiotic resistance linked to an excessive use of azithromycin should not be neglected.", [["azithromycin", "CHEMICAL", 78, 90], ["azithromycin", "CHEMICAL", 78, 90], ["azithromycin", "SIMPLE_CHEMICAL", 78, 90], ["antibiotic resistance", "PROBLEM", 26, 47], ["azithromycin", "TREATMENT", 78, 90], ["antibiotic resistance", "OBSERVATION", 26, 47]]], ["Further researches are clearly needed to examine these hypotheses.AUTHOR CONTRIBUTIONSThe authors shared their multidisciplinary skills on the analysis of the best possible therapeutic options to treat COVID-19, based on published or pre-printed data.", [["COVID", "DISEASE", 202, 207], ["COVID", "TEST", 202, 207]]], ["AM, LH, and MB developed the initial hypotheses and wrote the manuscript.", [["MB", "TEST", 12, 14]]]], "eca69ae519d4195fc87d1ec8cf39c1835f17f661": [["As a consequence, some pilot reforms are introduced only in the public sector.", [["some pilot reforms", "TREATMENT", 18, 36], ["pilot reforms", "OBSERVATION", 23, 36]]], ["As example is the implementation of a Diagnostics Related Group-(DRG)-based payment presented at the end of the first section of this Chapter.", [["Group-(DRG)", "TREATMENT", 58, 69]]], ["In the United States, for instance, when the DRG-based payment was introduced, it was designed for Medicare patient (patients aged over 65) without focusing on a specific hospital ownership by also targeting private hospitals.Institutional ContextOwnership After the implementation of the \"three-tier public provision system\", most hospitals were under the direct supervision of the Health Ministry, with support from local Health Offices.", [["patient", "ORGANISM", 108, 115], ["patients", "ORGANISM", 117, 125], ["patient", "SPECIES", 108, 115], ["patients", "SPECIES", 117, 125]]], ["Nevertheless, some remained dependent on state-owned companies or the army.", [["dependent", "OBSERVATION_MODIFIER", 28, 37]]], ["Whatever the governing body, the healthcare supply was provided by the public sector.Institutional ContextToday, health centres in both rural and urban areas are split between public and private structures.", [["body", "ANATOMY", 23, 27], ["body", "ORGANISM_SUBDIVISION", 23, 27], ["split", "OBSERVATION", 162, 167]]], ["There is still a certain number of governing bodies, ministries or state-owned companies that are directly involved in the management of hospitals.", [["certain", "OBSERVATION_MODIFIER", 17, 24], ["number", "OBSERVATION_MODIFIER", 25, 31]]], ["For instance, the People's Liberation Army (PLA) and some large state-owned industries, such as the railways, have their own hospitals and medical schools.", [["People", "SPECIES", 18, 24], ["large", "OBSERVATION_MODIFIER", 58, 63]]], ["Most hospitals and medical schools affiliated with the PLA are considered to be of a high quality and provide services to political leaders.", [["PLA", "CHEMICAL", 55, 58]]], ["The \"non-profit\" category mainly consists of organizations owned by government and companies (available data do not permit a disaggregation of the non-profit category by ownership) This fragmented structure is a hurdle to the implementation of any hospital reform, with four main ministries involved: the National Development and Reform Commission (NDRC), the Ministry of Human Resources and Social Security (MoHRSS), the Ministry of Finance (MoF) and obviously the Ministry of Health (MoH).", [["Human", "ORGANISM", 372, 377], ["Human", "SPECIES", 372, 377]]], ["The effect of the reforms implemented may be affected by this multiplicity of governing bodies.Governing BodiesThe SARS epidemics in 2003 has crystallized the importance of public health and care.", [["SARS", "DISEASE", 115, 119], ["may be", "UNCERTAINTY", 38, 44]]], ["Many experts and officials have pointed out the flaws in the health system that led to the quick spread of the SARS virus.", [["SARS", "DISEASE", 111, 115], ["SARS virus", "ORGANISM", 111, 121], ["SARS virus", "SPECIES", 111, 121], ["the SARS virus", "PROBLEM", 107, 121]]], ["4 It made various and important policy initiatives at the central level.", [["central", "ANATOMY_MODIFIER", 58, 65]]], ["In reality, these reforms involve a large numbers of governing bodies.", [["large", "OBSERVATION_MODIFIER", 36, 41], ["numbers", "OBSERVATION_MODIFIER", 42, 49], ["governing bodies", "OBSERVATION", 53, 69]]], ["In parallel, the China Insurance Regulatory Commission (CIRC) has a mission to encourage the development of a private health insurance market.Governing BodiesAnother example is any reform touching hospital human resources.", [["human", "ORGANISM", 206, 211], ["human", "SPECIES", 206, 211], ["human", "SPECIES", 206, 211]]], ["The Office of Central Institutional Organization, the Ministry of Education as well as MoHRSS, because it manages the career of civil servants, are necessarily involved.Governing BodiesDaily governance is also complex.", [["Central", "ANATOMY_MODIFIER", 14, 21]]], ["As a result, public hospitals may receive conflicting policies and regulations.Governing BodiesIn addition, for the execution of policies, many other bodies are involved: authorities at provincial level, district level and city level, bureaus of Labour and Social Security, Health and Finance.", [["conflicting policies", "TREATMENT", 42, 62]]], ["This huge number of stakeholders shows the complexity of hospital reform in China.", [["huge", "OBSERVATION_MODIFIER", 5, 9], ["number", "OBSERVATION_MODIFIER", 10, 16]]], ["If the central government defines the general direction and objectives, this actual implementation takes place under steering at a more granular level-provincial and below.", [["central", "ANATOMY_MODIFIER", 7, 14]]], ["This, combined with a large financial autonomy, makes it possible to factor in local specificities in the actual execution of reforms but can also generate important territorial inequalities.", [["large", "OBSERVATION_MODIFIER", 22, 27]]], ["A costly reform implemented in an area hit by economic downturn will not produce the same effect as when implemented in a soaring region.Governing BodiesTo mitigate this risk, each authority in charge of implementation at the local level is given measurable targets, for instance, the number of people covered by public health insurance at a certain date.", [["people", "ORGANISM", 295, 301], ["people", "SPECIES", 295, 301]]], ["These targets are cascaded into the individual objectives of local political leaders, having a direct impact on their career advancement and promotion into the party's apparatus.", [["their career advancement", "TREATMENT", 112, 136]]], ["Nonetheless, many health reform objectives are not easily quantifiable, for instance better governance, leaving widespread nuances in interpretation.Evolution of FundingAt the beginning of the 1980s, the central government was paying for 60% of hospital expenditure.", [["Funding", "OBSERVATION", 162, 169]]], ["6 By this, public hospitals were authorized to deliver paid services and to make profits, but were made responsible for their losses and debts.", [["their losses and debts", "PROBLEM", 120, 142]]], ["They are also entitled to enter into joint ventures with private companies, including setting up for-profit departments within the public hospital itself.", [["joint", "ANATOMY", 37, 42]]], ["As a result of this 1992 reform, bigger hospital structures developed, as well as improved quality, thanks to the acquisition of high-tech equipment.Evolution of FundingSince then, public hospitals in China have the particularity that they behave as companies, aiming to maximize profit through investment and price setting, while being governed as any traditional public structure.", [["high-tech equipment", "TREATMENT", 129, 148]]], ["They are the sole recipient of public funding, 7 be it from the central or local governments.", [["public funding", "TREATMENT", 31, 45], ["central", "ANATOMY_MODIFIER", 64, 71]]], ["Staff management is under the supervision of central governing bodies, mainly the MoRHSS, from both a resource allocation perspective as well as individual career management.", [["individual career management", "TREATMENT", 145, 173], ["central", "ANATOMY_MODIFIER", 45, 52]]], ["They are able to determine their price policy, which can turn out to be a problem in cases where they are in a monopoly situation in certain geographical areas, and hence without the market regulation of pricing.Evolution of FundingBy 2003 central government funding had fallen to 8% of hospital expenditure.", [["central", "OBSERVATION_MODIFIER", 240, 247]]], ["The fall in state financing was offset by charging for medicines and diagnosis procedures.", [["medicines", "TREATMENT", 55, 64], ["fall", "OBSERVATION", 4, 8]]], ["In China, as in many other Asian countries, patients do not consult doctors in their doctor's office-outside any healthcare facilities-but in the hospital outpatient department.", [["patients", "ORGANISM", 44, 52], ["patients", "SPECIES", 44, 52]]], ["Prescriptions are given at the end of the consultation by default (patients are not asked if they want to purchase them).", [["patients", "ORGANISM", 67, 75], ["patients", "SPECIES", 67, 75], ["Prescriptions", "TREATMENT", 0, 13]]], ["The total cost is the sum of the price of the consultation and that of the prescribed medicine.", [["the prescribed medicine", "TREATMENT", 71, 94], ["total", "OBSERVATION_MODIFIER", 4, 9]]], ["Patients do not have an explicit choice in not accepting the doctor's prescription.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]], ["In this context, prescription prices can be varied in order to compensate for the fall in the hospital's central funding.", [["prescription prices", "TREATMENT", 17, 36], ["the fall", "PROBLEM", 78, 86]]], ["This practice has been severely questioned during the recent healthcare reforms in China.", [["severely", "OBSERVATION_MODIFIER", 23, 31]]], ["The overprescription of medicine and the over-use of high-tech equipment for diagnostic purposes have often been identified as the cause of the rapid increase in healthcare expenditure (Eggleston et al., 2008a 8 ; 9 .", [["medicine", "TREATMENT", 24, 32], ["high-tech equipment", "TREATMENT", 53, 72], ["diagnostic purposes", "TEST", 77, 96], ["the rapid increase in healthcare expenditure", "PROBLEM", 140, 184], ["rapid", "OBSERVATION_MODIFIER", 144, 149], ["increase", "OBSERVATION_MODIFIER", 150, 158]]], ["It is very likely that these factors affect the demand for and use of healthcare.Evolution of FundingFollowing the 1992-reform, some public facilities set up healthcare centres with a fee-for-service payment.", [["very likely", "UNCERTAINTY", 6, 17]]], ["The healthcare prevention programme was then neglected: epidemic control, health education, maternal and child health all suffered.Evolution of FundingThe 2003 SARS epidemic put the public health role of public hospitals to the forefront again.", [["SARS", "DISEASE", 160, 164]]], ["The negative side-effects of financial autonomy appeared sharply in that context.", [["negative side", "OBSERVATION_MODIFIER", 4, 17]]], ["This led to a clear split between medical operations and hospital management functions.", [["medical operations", "TREATMENT", 34, 52], ["hospital management", "TREATMENT", 57, 76], ["clear", "OBSERVATION_MODIFIER", 14, 19], ["split", "OBSERVATION_MODIFIER", 20, 25]]], ["12 Nonetheless, in 2008, health expenditure for pharmaceutical products still accounted for 43% of total health expenditure.", [["pharmaceutical products", "TREATMENT", 48, 71]]], ["13 This compares with a 17% average share in Organisation for Economic Co-operation and Development (OECD) countries.", [["Economic Co-operation", "TREATMENT", 62, 83]]], ["Nearly 40 million surgeries were performed in China in 2015.", [["Nearly 40 million surgeries", "TREATMENT", 0, 27]]], ["This figure is nearly one-sixth of the world's total surgical operations.", [["total surgical operations", "TREATMENT", 47, 72], ["surgical operations", "OBSERVATION", 53, 72]]], ["The biggest share of procedures is in the obstetrical and gynecological areas, followed by digestive and gastrointestinal system procedures.", [["digestive", "ANATOMY", 91, 100], ["gastrointestinal system", "ANATOMY", 105, 128], ["digestive", "ORGAN", 91, 100], ["procedures", "TREATMENT", 21, 31], ["gastrointestinal system procedures", "TREATMENT", 105, 139], ["biggest", "OBSERVATION_MODIFIER", 4, 11], ["procedures", "OBSERVATION", 21, 31], ["obstetrical", "ANATOMY", 42, 53], ["gynecological", "ANATOMY", 58, 71], ["gastrointestinal system", "ANATOMY", 105, 128]]], ["A huge portion of this expenditure was for high-tech tests and unnecessary drugs.\" 16, 17Improving Healthcare Quality and Reducing Hospital Expenditure FundingIn the 1980s, the main objective of the regulator was to make it possible for hospitals to acquire technology and to improve their level of quality.", [["unnecessary drugs", "TREATMENT", 63, 80], ["huge", "OBSERVATION_MODIFIER", 2, 6]]], ["In parallel, the aim was also to reduce the burden of hospital expenditure funding.", [["hospital expenditure funding", "TREATMENT", 54, 82]]], ["The series of reforms implied three main changes:Improving Healthcare Quality and Reducing Hospital Expenditure Funding\u2022 Financial autonomy of public hospitals \u2022 Managerial autonomy for a part of public hospital staff \u2022 Financial incentives for physicians to profit.Improving Healthcare Quality and Reducing Hospital Expenditure FundingFinancial autonomy of public hospitals: This has been achieved at the expense of accessibility for many.", [["main", "OBSERVATION_MODIFIER", 36, 40]]], ["In 1990, per capital health expenditure in urban areas was still contained at a very low level of RMB 26, whereas it reached more than RMB 1,000 in 2013.Improving Healthcare Quality and Reducing Hospital Expenditure FundingAnother effect of the financial autonomy of public hospital has been a certain loss of authorities over medical practices.Improving Healthcare Quality and Reducing Hospital Expenditure FundingManagerial autonomy: In parallel, hospitals have autonomy in personnel management for their for-profit activity.", [["personnel management", "TREATMENT", 476, 496]]], ["The objective function of medical personnel includes an increasing component of profit maximization.Improving Healthcare Quality and Reducing Hospital Expenditure FundingFinancial incentives for physicians: In public hospitals, physicians are civil servants (bianzhi) 18 .", [["profit maximization", "TREATMENT", 80, 99]]], ["In such cases, it is a win-win situation for both medical personnel and hospital management.Improving Healthcare Quality and Reducing Hospital Expenditure FundingIn addition, this healthcare system nurtures the pre-existing practices of bribes and other types of corruption.", [["hospital management", "TREATMENT", 72, 91]]], ["They tend to become widespread, creating an increasingly tense atmosphere between patients and hospital personnel.Funding of Public Hospitals TodayThe Chinese healthcare system has long been accused of failing to efficiently deliver healthcare services at an affordable cost.", [["patients", "ORGANISM", 82, 90], ["patients", "SPECIES", 82, 90], ["increasingly", "OBSERVATION_MODIFIER", 44, 56], ["tense", "OBSERVATION", 57, 62]]], ["Figure 4 .3 shows the different sources of funding.", [["Figure", "TEST", 0, 6]]], ["It is quite striking that direct public funding from the government only represents a minimal share of the total (8%).", [["minimal", "OBSERVATION_MODIFIER", 86, 93]]], ["In reality, the involvement is more pronounced with indirect funding through public health insurance set up in both rural and urban areas.", [["more pronounced", "OBSERVATION_MODIFIER", 31, 46]]], ["Companies also participate in the financing of healthcare, accounting for almost one-third of the total.Funding of Public Hospitals TodayPatients' share accounts for 50% of hospital revenue, but patients usually do not bear the total costs, as part is covered by public or private health insurance.", [["patients", "ORGANISM", 195, 203], ["patients", "SPECIES", 195, 203]]], ["The covered part has been increasing steadily over the past few years.", [["increasing", "OBSERVATION_MODIFIER", 26, 36], ["steadily", "OBSERVATION_MODIFIER", 37, 45]]], ["In the end, patients' out-of-pocket payments rose from 20% in 1980 to 59% in 2000, but then decreased to a current rate of around 35%).", [["patients", "ORGANISM", 12, 20], ["patients", "SPECIES", 12, 20]]], ["7.Early Forms of Prospective Payment in ChinaSome experiments, presented here, aimed at switching from a fee-forservice payment to any form of prospective payment.", [["prospective payment", "TREATMENT", 143, 162]]], ["The goal is to modify incentives for healthcare providers: from driving up service prices to introducing and encouraging competition with a price ceiling system.", [["a price ceiling system", "TREATMENT", 138, 160]]], ["In urban areas, the insurance schemes existing before the economic reform were based on a principle of regulated pricing.", [["the insurance schemes", "TREATMENT", 16, 37]]], ["Total funding is around $7 million.", [["funding", "OBSERVATION", 6, 13]]], ["Source: Hospital interviews; government statistics 2010, \"Healthcare in China,\" A Kieger Report on the Chinese Healthcare Market 2015. www.mckinsey.com/...service/healthcare%20systems%20and%20 services/health%20international/hi10_china_healthcare_reform.ashx Insurance (BMI) scheme was introduced, a mechanism to contain expenditure from the demand side was implemented (the Medical Savings Accounts-MSA).", [["Insurance (BMI) scheme", "TREATMENT", 259, 281]]], ["On the supply side, there was no change in the provider payment introduced by central government.", [["no", "UNCERTAINTY", 30, 32], ["change", "OBSERVATION_MODIFIER", 33, 39]]], ["However, at local government level, examples of the implementation of some form of prospective payment can found from the early BMI pilot.Early Forms of Prospective Payment in ChinaIn 1997, the Social Insurance Bureau of Hainan province implemented a prospective payment, concerning six key hospitals.", [["prospective payment", "TREATMENT", 83, 102]]], ["Besides, spending growth on expensive drugs and high-tech services was reduced dramatically.", [["expensive drugs", "TREATMENT", 28, 43], ["high-tech services", "TREATMENT", 48, 66]]], ["23 The defined limits of these studies concerns the fact that the data were not available to control for the potential reduction of quality of care, risk selection and cost shifting to the uninsured.", [["these studies", "TEST", 25, 38], ["the data", "TEST", 62, 70], ["risk selection", "TREATMENT", 149, 163]]], ["Implementation of similar forms of prospective payment systems were nonetheless implemented in many areas throughout China, as in Qingdao, Shandong province, for instance.", [["prospective payment systems", "TREATMENT", 35, 62]]], ["25 However, lack of information about the impact on the healthcare level of quality prevents any conclusion being drawn.First Implementation of the DRG Payment in ChinaThe Diagnosis Related Group (DRG) payment is a reimbursement scheme that was first implemented in the United States at the beginning of the 1980s.", [["the DRG Payment", "TREATMENT", 144, 159]]], ["This type of payment is a form of prospective payment system and consists of a lump sum based on the pathology and procedures to be carried out on the patient.", [["patient", "ORGANISM", 151, 158], ["patient", "SPECIES", 151, 158], ["prospective payment system", "TREATMENT", 34, 60], ["a lump sum", "PROBLEM", 77, 87], ["the pathology", "TEST", 97, 110], ["procedures", "TREATMENT", 115, 125], ["lump", "OBSERVATION", 79, 83]]], ["A categorization of pathologies, diagnoses and actions is made ex-ante.", [["pathologies", "PROBLEM", 20, 31], ["pathologies", "OBSERVATION", 20, 31]]], ["All patients are affected in one these categories, collectively called the Diagnosis Related Group (DRG).First Implementation of the DRG Payment in ChinaEach DRG defines a pathology, associated diagnoses and all procedures already implemented or yet to be implemented.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["the DRG Payment", "TREATMENT", 129, 144], ["all procedures", "TREATMENT", 208, 222]]], ["This way, each patient falls into a DRG and each DRG corresponds to a predefined lump sum, based on the expenses the hospital has to incur to carry out treatment for this type of patient.", [["patient", "ORGANISM", 15, 22], ["DRG", "MULTI-TISSUE_STRUCTURE", 36, 39], ["DRG", "MULTI-TISSUE_STRUCTURE", 49, 52], ["patient", "ORGANISM", 179, 186], ["patient", "SPECIES", 15, 22], ["patient", "SPECIES", 179, 186], ["a DRG", "PROBLEM", 34, 39], ["each DRG", "PROBLEM", 44, 52], ["treatment", "TREATMENT", 152, 161]]], ["The advantage of this lump sum is that it is not correlated with the treatment actually performed while covering the theoretical expenses necessary to cure the patient.", [["lump", "ANATOMY", 22, 26], ["patient", "ORGANISM", 160, 167], ["patient", "SPECIES", 160, 167], ["the treatment", "TREATMENT", 65, 78]]], ["This gives an incentive to limit cost, explaining why this type of payment is widespread, not only in China but in a vast majority of OECD countries.First Implementation of the DRG Payment in ChinaThe efficiency of such a system relies heavily on the quality of the information system that goes with it.", [["the DRG Payment", "TREATMENT", 173, 188], ["DRG", "OBSERVATION", 177, 180], ["efficiency", "OBSERVATION_MODIFIER", 201, 211]]], ["It is quite complex, as, for each patient, information regarding diagnoses, procedures and comorbidities is to be collected and compiled.", [["patient", "ORGANISM", 34, 41], ["patient", "SPECIES", 34, 41], ["comorbidities", "PROBLEM", 91, 104], ["complex", "OBSERVATION_MODIFIER", 12, 19]]], ["China aims at putting in place a comprehensive information system with medical history and patient admission details.", [["patient", "ORGANISM", 91, 98], ["patient", "SPECIES", 91, 98]]], ["This project is still in the early stages though.First Implementation of the DRG Payment in ChinaZhenjiang, a BMI pilot city, started to experiment with a DRG payment system for 82 diseases.", [["the DRG Payment", "TREATMENT", 73, 88], ["a DRG payment system", "TREATMENT", 153, 173], ["82 diseases", "PROBLEM", 178, 189], ["early", "OBSERVATION_MODIFIER", 29, 34], ["stages", "OBSERVATION_MODIFIER", 35, 41]]], ["26 The reimbursement rate for each disease was set according to average expenditure incurred over the previous three years in treating each disease, minus any \"unreasonable\" expenditure.", [["The reimbursement rate", "TEST", 3, 25], ["each disease", "PROBLEM", 30, 42], ["each disease", "PROBLEM", 135, 147]]], ["27 In 2003, the average spending for diseases using the DRG payment was 25% lower than the province average in hospitals of the same level.", [["diseases", "PROBLEM", 37, 45], ["the DRG payment", "TREATMENT", 52, 67]]], ["Once again, because of the poor quality of data at the micro-level, studies on the impact of the DRG payment system on the quality of care and risk of selection impact have unfortunately not been published yet.First Implementation of the DRG Payment in ChinaAfter that, DRG-based payment systems spread across China, for instance, in cities such as Guangzhou, Dalian, Liushou and Mudanjiang.", [["the DRG Payment", "TREATMENT", 234, 249], ["DRG", "OBSERVATION", 238, 241], ["DRG", "ANATOMY", 270, 273]]], ["However, this DRG-based payment is still restricted to specific diseases.", [["DRG", "MULTI-TISSUE_STRUCTURE", 14, 17], ["this DRG", "TEST", 9, 17], ["specific diseases", "PROBLEM", 55, 72], ["DRG", "OBSERVATION", 14, 17]]], ["Besides, these cities also use different prospective payment systems alongside a fixed charge per inpatient.", [["different prospective payment systems", "TREATMENT", 31, 68], ["a fixed charge", "TREATMENT", 79, 93]]], ["Studies on this aspect provided less strong evidence for DRG-based payments or other forms of prospective payment on a reduction of healthcare spending.", [["DRG", "PROBLEM", 57, 60]]], ["28, 29, 30 Following the BMI offices' example, some local offices of NCMS (public health insurance for inhabitants in rural areas) 31 adopted a prospective payment system to reimburse the health providers.", [["NCMS", "CHEMICAL", 69, 73]]], ["For instance, two counties in Shaanxi province adopted a fixed-price reimbursement system for some selected THCs and selected county hospitals according to specific criteria.", [["a fixed-price reimbursement system", "TREATMENT", 55, 89]]], ["32 Some providers moved from a FFS service to a prospective payment system but not in conjunction with a public insurance scheme.", [["a prospective payment system", "TREATMENT", 46, 74]]], ["In Heilongjiang province, by the end of 2000, 16 hospitals started to use a DRG-based payment system.", [["a DRG-based payment system", "TREATMENT", 74, 100]]], ["33, 34 So far, there is no scientific study paper on the effect on quality of care or strong evidence on healthcare expenditure.First Implementation of the DRG Payment in ChinaTo date, there are two main viable DRG systems, the Beijing-DRG (2011) and the C-DRG system set up by the NHFPC (2017).", [["scientific study", "TEST", 27, 43], ["the C-DRG system", "TEST", 251, 267], ["no", "UNCERTAINTY", 24, 26], ["main", "OBSERVATION_MODIFIER", 199, 203], ["viable", "OBSERVATION_MODIFIER", 204, 210], ["DRG systems", "OBSERVATION", 211, 222], ["DRG", "ANATOMY", 236, 239]]], ["Because of inconclusive results, in 2017, these different forms of prospective payment are still being studied and this is an on-going field of research.Is the Private Hospital Sector Really Booming?We use here \"private\" in a wider sense, to cover all hospital structures apart from the public ones (minying), be it through joint ventures, cooperatives or private structures with capital from mainly Hong-Kong, Macao, Taiwan but also all over the world.Is the Private Hospital Sector Really Booming?Until 1980, it was legally impossible to set up a private hospital.", [["prospective payment", "TREATMENT", 67, 86], ["joint", "ANATOMY", 324, 329]]], ["Nonetheless, the average size of private hospitals is much smaller than public hospitals.", [["average", "OBSERVATION_MODIFIER", 17, 24], ["size", "OBSERVATION_MODIFIER", 25, 29], ["much", "OBSERVATION_MODIFIER", 54, 58], ["smaller", "OBSERVATION_MODIFIER", 59, 66]]], ["In terms of level, according to the official hospital classification, the percentage of publicly owned hospitals by admissions is 96% for Level 3 and 91% for Level 2 hospitals.", [["Level", "TEST", 138, 143]]], ["As a result, 90% of Chinese patients choose to visit public hospitals.", [["patients", "ORGANISM", 28, 36], ["patients", "SPECIES", 28, 36]]], ["36 The picture is quite the opposite in the United States, where public hospitals make up 15% of total hospitals and only 27% of patient visits.", [["patient", "ORGANISM", 129, 136], ["patient", "SPECIES", 129, 136]]], ["37 Nonetheless, the private hospital sector has been steadily increasing over the past few years.", [["steadily", "OBSERVATION_MODIFIER", 53, 61], ["increasing", "OBSERVATION_MODIFIER", 62, 72]]], ["The number of public hospitals grew from roughly 5400 in 2008 to 10,877 in 2014.", [["number", "OBSERVATION_MODIFIER", 4, 10]]], ["38 From 2012 to 2013, the number of patients treated in a private hospital grew by 1.1%.", [["patients", "ORGANISM", 36, 44], ["patients", "SPECIES", 36, 44]]], ["We can then observe a constant increasing trend but no sharp change (Fig. 4.5) .Is the Private Hospital Sector Really Booming?In rural zones though, the situation is totally different.", [["a constant increasing trend", "PROBLEM", 20, 47], ["sharp change", "PROBLEM", 55, 67], ["rural", "ANATOMY_MODIFIER", 129, 134], ["zones", "ANATOMY_MODIFIER", 135, 140]]], ["A large part of primary care is carried out in dispensaries that are now almost exclusively private and paid for on a fee-for-service mode.", [["large", "OBSERVATION_MODIFIER", 2, 7]]], ["Until very recently, the information on the public or private status of a hospital was not made available in official statistics.Is the Private Hospital Sector Really Booming?In conclusion, the number of private healthcare facilities is increasing but, in terms of number of visits, there is no private hospital boom.How to Explain the Difficulty of Growing the Private Hospital Sector?The Ministry of Health has stated on various occasion that it wants to develop the private health sector.", [["no", "UNCERTAINTY", 292, 294]]], ["The decrease in public funding has led to a deregulation of healthcare pricing.", [["decrease", "OBSERVATION_MODIFIER", 4, 12], ["public funding", "OBSERVATION", 16, 30]]], ["This is very similar to the mechanism in place in the United States for a large part of the population.", [["large", "OBSERVATION_MODIFIER", 74, 79]]], ["39 Private hospitals have been addressing, as a priority, three markets segments: high-end healthcare for expats and the affluent local population, healthcare targeted to very specific pathologies and finally healthcare in direct competition with that offered by public hospitals.How to Explain the Difficulty of Growing the Private Hospital Sector?The first segment enjoys sold growth.", [["growth", "OBSERVATION_MODIFIER", 379, 385]]], ["\"Half of our outpatients are expats working or living in China, such as diplomats and executives of foreign-invested companies.", [["outpatients", "ORGANISM", 13, 24], ["outpatients", "SPECIES", 13, 24]]], ["We sell by word of mouth,\" said Zhu Ying, President of the Beijing Bayley & Jackson Medical Centre in downtown Beijing, a private hospital with headquarters in Hong Kong.", [["mouth", "ANATOMY", 19, 24], ["mouth", "ORGANISM_SUBDIVISION", 19, 24], ["mouth", "ANATOMY", 19, 24]]], ["However, so far, this phenomenon is too new to draw an conclusion apart from this initial assessment.How to Explain the Difficulty of Growing the Private Hospital Sector?In the third segment, that of private hospitals in competition with public structures, the former sometimes have to face distorted competition, through public subventions.", [["this initial assessment", "TEST", 77, 100], ["third segment", "ANATOMY_MODIFIER", 177, 190]]], ["This difficulty in attracting patients seems hard to understand in the context of dissatisfaction over the service provided by public hospitals, but it actually sheds light on the priority criteria of patients/customers.", [["patients", "ORGANISM", 30, 38], ["patients", "ORGANISM", 201, 209], ["patients", "SPECIES", 30, 38], ["patients", "SPECIES", 201, 209]]], ["The quality and reliability offered by public hospital, through their high level of equipment and skilled and trained personnel, prevails over the annoyance of congestion and the price of care.How to Explain the Difficulty of Growing the Private Hospital Sector?As mentioned previously, recruitment of highly skilled professionals is one of the main obstacles to the development of private hospitals.", [["congestion", "DISEASE", 160, 170], ["congestion", "PROBLEM", 160, 170], ["congestion", "OBSERVATION", 160, 170]]], ["It addresses Community Healthcare Centres 42 (CHCs) but the configuration is identical for private hospitals: \"A few cities have tried to force more patients to go to CHCs, but these efforts have generally been unsuccessful.", [["patients", "ORGANISM", 149, 157], ["patients", "SPECIES", 149, 157]]], ["In January 2010, for example, one local government implemented a policy of requiring patients with certain chronic diseases to be treated at a CHC before they could receive care at a class III hospital.", [["chronic diseases", "DISEASE", 107, 123], ["CHC", "DISEASE", 143, 146], ["patients", "ORGANISM", 85, 93], ["patients", "SPECIES", 85, 93], ["certain chronic diseases", "PROBLEM", 99, 123]]], ["However, the local department of health withdrew this policy one month later, saying that the quality of the CHCs needed to be improved before the policy could be implemented.\" 43 The status and financial obstacles to hiring well-known professionals in private hospitals creates a vicious circle.", [["vicious circle", "OBSERVATION", 281, 295]]], ["For both patients and professionals, this type of structure tends to become a second choice, when public hospitals are not an option.", [["patients", "ORGANISM", 9, 17], ["patients", "SPECIES", 9, 17]]], ["The story of An Hua and Li Peng provides a good example.", [["Li", "CHEMICAL", 24, 26], ["Hua", "ANATOMY", 16, 19]]], ["Where they work, they have to deal with an extended number of working hours, an excessive number of patients and a patienthospital staff antagonistic climate.", [["patients", "ORGANISM", 100, 108], ["patients", "SPECIES", 100, 108]]], ["However, according to them, the size of private facilities is too small to attract a sufficient number of patients; the healthcare equipment is too limited; and the professional environment does not provide a sufficiently stimulating setting in which to work and grow.", [["patients", "ORGANISM", 106, 114], ["patients", "SPECIES", 106, 114], ["size", "OBSERVATION_MODIFIER", 32, 36], ["too small to", "OBSERVATION_MODIFIER", 62, 74]]], ["45 In parallel, another obstacle to the development of private hospitals is the restrictive conditions on the reimbursement of healthcare expenses by public insurance.", [["the restrictive conditions", "PROBLEM", 76, 102], ["parallel", "OBSERVATION_MODIFIER", 6, 14], ["restrictive", "OBSERVATION", 80, 91]]], ["However, a main part of the population can only afford to get healthcare access using public insurance.", [["main", "OBSERVATION_MODIFIER", 11, 15]]], ["As a consequence, the restrictive rule of public insurance excludes a large part of the population from access to private facilities.", [["restrictive", "OBSERVATION_MODIFIER", 22, 33], ["large", "OBSERVATION_MODIFIER", 70, 75]]], ["46 It would be interesting to assess the effect of such a change on the individual's preference in the choice of healthcare providers.How to Explain the Difficulty of Growing the Private Hospital Sector?So far, if some reforms have tended to develop the private health sector, there are still some keys determinants that limit this central state support.A True Story of the Challenges Behind Opening a ClinicYu Ying, a former physician in a famous Beijing hospital, the Peking Union Medical College Hospital, is a key figure and spokesperson for public hospital doctors.", [["this central state support", "TREATMENT", 327, 353]]], ["A series of administrative constraints and barriers prevented her from opening a centre there.", [["administrative constraints", "TREATMENT", 12, 38]]], ["Having resigned from her previous hospital and given up her civil servant status, returning to the public sector was no longer an option.", [["no longer", "UNCERTAINTY", 117, 126]]], ["During this time, she used her Weibo blog to explain part of her difficulties and the obstacles encountered along the way.", [["her Weibo blog", "TREATMENT", 27, 41], ["her difficulties", "PROBLEM", 61, 77]]], ["In March 2014, she used her Weibo account to explicitly address the authorities about her situation asking, \"Which deputy of the National People's Congress can tell me why it is so difficult for a doctor, who has worked in the country's top-grade hospital for 12 years and has held a doctorate degree after eight years of professional medical education, to open a regular clinic through formal channels?\" 48 The timing was perfect.", [["People", "SPECIES", 138, 144], ["professional medical education", "TREATMENT", 322, 352]]], ["It was between the plenary session of the National People's Congress and the Chinese People's Political Consultative Conference, allowing a strong echo to her protest.", [["People", "SPECIES", 51, 57], ["People", "SPECIES", 85, 91], ["a strong echo", "TEST", 138, 151]]], ["She is now the CEO of a private general clinic in Beijing city run by the Amcare group, 49 a public-private partnership joint venture, two and a half years after having resigned from a top public hospital.", [["joint", "ANATOMY", 120, 125]]], ["In order to facilitate the development of the private hospital sector, it also allows a lowering of the entry barriers for private medical institutes with foreign capital.", [["foreign capital", "OBSERVATION", 155, 170]]], ["As a pilot experiment, some local governments have lifter some constraints on public hospitals: for instance, experimenting with the privatization of public hospitals.The Model-Chains of Private Specialized HospitalsCurrently, the private healthcare market has developed a model based on chains of private specialized hospitals.", [["a pilot experiment", "TREATMENT", 3, 21], ["Chains", "OBSERVATION_MODIFIER", 177, 183]]], ["More specifically, the medical services provided by the private sector are mostly for dental treatment, ophthalmology and plastic surgery, as well as diagnosis labs and centres.", [["dental treatment", "TREATMENT", 86, 102], ["diagnosis labs", "TEST", 150, 164]]], ["These sectors are medical sectors where customized services may generate higher margins.", [["higher", "OBSERVATION_MODIFIER", 73, 79], ["margins", "OBSERVATION_MODIFIER", 80, 87]]], ["In 2014, US-based Warburg Pincus LLC invested $100 million in Beijingbased AmCare Women's and Children's Hospital to support its expansion.", [["Women", "SPECIES", 82, 87], ["Children", "SPECIES", 94, 102], ["US", "TEST", 9, 11]]], ["Today AmCare accounts for about half of the high-end healthcare market for women and children in Beijing, which is now dominated by private hospitals.", [["women", "ORGANISM", 75, 80], ["children", "ORGANISM", 85, 93], ["women", "SPECIES", 75, 80], ["children", "SPECIES", 85, 93]]], ["Foreign hospital chain investors, such as Chindex have built up high-end chain hospitals in smaller size in China.", [["smaller", "OBSERVATION_MODIFIER", 92, 99], ["size", "OBSERVATION_MODIFIER", 100, 104], ["China", "ANATOMY", 108, 113]]], ["52 A cluster of private medical companies and hospitals owned by people from the city of Putian, commonly known as the \"Putian clan\" (Putian ji), also constitutes great power in the healthcare industry as over 80% of private medical companies in China are affiliated with the Putian clan.", [["people", "ORGANISM", 65, 71], ["people", "SPECIES", 65, 71], ["cluster", "OBSERVATION_MODIFIER", 5, 12]]], ["Until recently, a patient admitted into a private hospital was not eligible for reimbursement from public insurance.", [["patient", "ORGANISM", 18, 25], ["patient", "SPECIES", 18, 25]]], ["This constraint is progressively eased, in one province after the other.", [["progressively", "OBSERVATION_MODIFIER", 19, 32], ["eased", "OBSERVATION_MODIFIER", 33, 38]]], ["Rules tend to vary depending on the area, but there is an increasing number of cases for which care provided in private healthcare centres can be covered by public insurance schemes.Public Funding and Private Healthcare ProvidersIn addition, in some provinces or municipalities, private hospitals can be directly subsidized.", [["increasing", "OBSERVATION_MODIFIER", 58, 68]]], ["54, 55Challenges for Private Health EstablishmentsIn future, key factors private health structures need to develop are: (1) patient recognition that private health establishments can be as trustworthy This point (1) is a prerequisite condition.", [["patient", "ORGANISM", 124, 131], ["patient", "SPECIES", 124, 131], ["a prerequisite condition", "PROBLEM", 219, 243]]], ["The over-arching goal of profit maximization must not contaminate the level of quality provided.", [["profit maximization", "TREATMENT", 25, 44]]], ["As witnesses, doctors previously employed by Putian clan hospitals, stated that to achieve profit targets set by their superiors they performed unnecessary medical treatments.", [["unnecessary medical treatments", "TREATMENT", 144, 174]]], ["56 A necessary challenge will be to make a profit without undermining the level of quality provided.Challenges for Private Health EstablishmentsEven at a slower pace than anticipated, things are starting to change and the private sector is now showing significant growth.", [["A necessary challenge", "TREATMENT", 3, 24], ["significant growth", "PROBLEM", 252, 270]]], ["From 2008 through 2014, patient visits to private hospitals have increased by 12.5% from third trimester 2013 to third trimester 2014, overstepping the growth of visits to public hospitals, which have grown at 7.9% on a quarter-to-quarter basis.", [["patient", "ORGANISM", 24, 31], ["patient", "SPECIES", 24, 31]]], ["Depending on the period, each school of thought has had the upper hand in the direction given to reform.", [["upper hand", "ORGANISM_SUBDIVISION", 60, 70], ["upper", "ANATOMY_MODIFIER", 60, 65]]], ["The Third Plenum of the 18th Central Committee of the Communist Party, in November 2013, emphasized a higher priority for economic growth.", [["economic growth", "PROBLEM", 122, 137], ["Third", "OBSERVATION_MODIFIER", 4, 9], ["Plenum", "OBSERVATION_MODIFIER", 10, 16]]], ["Therefore, the conditions required for the development of the private sector in the healthcare market are fully in place with favourable policies.Challenges for Private Health EstablishmentsIn a near future, with this preferential environment and the ongoing governmental commitment, a rapid growth of the private sector is to be expected.", [["rapid", "OBSERVATION_MODIFIER", 286, 291], ["growth", "OBSERVATION_MODIFIER", 292, 298]]], ["The other consequence could be to limit the demand for public hospital access (for in-and outpatients) and reduce congestion in the Level 3 and 3AAA public hospitals.Challenges for Private Health EstablishmentsThese forecasts on the effect of a more prominent presence of private healthcare providers in the healthcare market are based on a major assumption: that the income or wealth of a society is equitably distributed.", [["congestion", "DISEASE", 114, 124], ["congestion", "PROBLEM", 114, 124], ["congestion", "OBSERVATION", 114, 124], ["more prominent", "OBSERVATION_MODIFIER", 245, 259], ["society", "OBSERVATION", 390, 397]]], ["The hypothesis is very strong and very restrictive.", [["very restrictive", "PROBLEM", 34, 50], ["very", "OBSERVATION_MODIFIER", 18, 22], ["strong", "OBSERVATION", 23, 29], ["restrictive", "OBSERVATION", 39, 50]]], ["With increasing income inequality, the part of the population who cannot afford to access to healthcare will increase.", [["increasing", "OBSERVATION_MODIFIER", 5, 15], ["income inequality", "OBSERVATION", 16, 33]]], ["An adequate and efficient alternative may be universal healthcare access for all.", [["adequate", "OBSERVATION", 3, 11]]], ["While this may be too costly for society it may avoid the failure of the market in providing equal access to healthcare.", [["the failure of the market", "PROBLEM", 54, 79], ["failure", "OBSERVATION", 58, 65]]]], "PMC7050048": [["IntroductionAgeing is often characterised by a progressive decline in immune response, resulting in increased susceptibility to infections and poor response to vaccination [1].", [["infections", "DISEASE", 128, 138], ["a progressive decline in immune response", "PROBLEM", 45, 85], ["increased susceptibility to infections", "PROBLEM", 100, 138], ["progressive", "OBSERVATION_MODIFIER", 47, 58], ["immune response", "OBSERVATION", 70, 85], ["infections", "OBSERVATION", 128, 138]]], ["Clinical observations suggest that lower respiratory tract infections may contribute to the pathogenesis of asthma and are important triggers for asthma exacerbations [2].", [["lower respiratory tract", "ANATOMY", 35, 58], ["respiratory tract infections", "DISEASE", 41, 69], ["asthma", "DISEASE", 108, 114], ["asthma", "DISEASE", 146, 152], ["lower respiratory tract", "ORGANISM_SUBDIVISION", 35, 58], ["Clinical observations", "TEST", 0, 21], ["lower respiratory tract infections", "PROBLEM", 35, 69], ["asthma", "PROBLEM", 108, 114], ["asthma exacerbations", "PROBLEM", 146, 166], ["lower", "ANATOMY_MODIFIER", 35, 40], ["respiratory tract", "ANATOMY", 41, 58], ["asthma", "OBSERVATION", 108, 114]]], ["Asthma in the elderly seems to be a distinct phenotype with higher severity and exacerbation rates [3], which may be associated with the deterioration of immune function observed in the airways in the aged population [4].IntroductionThe airway microbiome might have a profound role on the development, persistence, and clinical course of chronic inflammatory diseases like asthma and chronic obstructive pulmonary disease [5].", [["airways", "ANATOMY", 186, 193], ["airway", "ANATOMY", 237, 243], ["pulmonary", "ANATOMY", 404, 413], ["Asthma", "DISEASE", 0, 6], ["inflammatory diseases", "DISEASE", 346, 367], ["asthma", "DISEASE", 373, 379], ["chronic obstructive pulmonary disease", "DISEASE", 384, 421], ["airways", "MULTI-TISSUE_STRUCTURE", 186, 193], ["airway", "MULTI-TISSUE_STRUCTURE", 237, 243], ["pulmonary", "ORGAN", 404, 413], ["Asthma", "PROBLEM", 0, 6], ["a distinct phenotype", "PROBLEM", 34, 54], ["higher severity", "PROBLEM", 60, 75], ["exacerbation rates", "PROBLEM", 80, 98], ["immune function", "PROBLEM", 154, 169], ["chronic inflammatory diseases", "PROBLEM", 338, 367], ["asthma", "PROBLEM", 373, 379], ["chronic obstructive pulmonary disease", "PROBLEM", 384, 421], ["higher severity", "OBSERVATION_MODIFIER", 60, 75], ["immune function", "OBSERVATION", 154, 169], ["airways", "ANATOMY", 186, 193], ["airway", "ANATOMY", 237, 243], ["profound", "OBSERVATION_MODIFIER", 268, 276], ["chronic", "OBSERVATION_MODIFIER", 338, 345], ["inflammatory", "OBSERVATION", 346, 358], ["asthma", "OBSERVATION", 373, 379], ["chronic", "OBSERVATION_MODIFIER", 384, 391], ["obstructive", "OBSERVATION_MODIFIER", 392, 403], ["pulmonary", "ANATOMY", 404, 413], ["disease", "OBSERVATION", 414, 421]]], ["The presence of respiratory viruses during childhood has been identified as a significant risk factor for asthma in adolescences and adults [6], while similar observations have been made for atypical bacteria [7].", [["respiratory viruses", "DISEASE", 16, 35], ["asthma", "DISEASE", 106, 112], ["respiratory viruses", "PROBLEM", 16, 35], ["asthma", "PROBLEM", 106, 112], ["atypical bacteria", "PROBLEM", 191, 208], ["respiratory viruses", "OBSERVATION", 16, 35]]], ["Viruses, such as rhinovirus, respiratory syncytial virus, or parainfluenza viruses, are the most common causative factors for asthma exacerbation [8].", [["respiratory syncytial virus", "DISEASE", 29, 56], ["parainfluenza viruses", "DISEASE", 61, 82], ["asthma", "DISEASE", 126, 132], ["rhinovirus", "ORGANISM", 17, 27], ["respiratory syncytial virus", "ORGANISM", 29, 56], ["parainfluenza viruses", "ORGANISM", 61, 82], ["respiratory syncytial virus", "SPECIES", 29, 56], ["parainfluenza", "SPECIES", 61, 74], ["respiratory syncytial virus", "SPECIES", 29, 56], ["parainfluenza viruses", "SPECIES", 61, 82], ["Viruses", "PROBLEM", 0, 7], ["rhinovirus", "PROBLEM", 17, 27], ["respiratory syncytial virus", "PROBLEM", 29, 56], ["parainfluenza viruses", "PROBLEM", 61, 82], ["asthma exacerbation", "PROBLEM", 126, 145], ["respiratory", "ANATOMY", 29, 40], ["syncytial virus", "OBSERVATION", 41, 56], ["parainfluenza viruses", "OBSERVATION", 61, 82]]], ["In clinically stable periods of asthma, both viruses and bacteria are detected in the airways [9, 10], but the significance of the persistent presence of those pathogens in the airways remains unclear.", [["airways", "ANATOMY", 86, 93], ["airways", "ANATOMY", 177, 184], ["asthma", "DISEASE", 32, 38], ["airways", "MULTI-TISSUE_STRUCTURE", 86, 93], ["airways", "MULTI-TISSUE_STRUCTURE", 177, 184], ["asthma", "PROBLEM", 32, 38], ["both viruses", "PROBLEM", 40, 52], ["bacteria", "PROBLEM", 57, 65], ["those pathogens in the airways", "PROBLEM", 154, 184], ["clinically", "OBSERVATION_MODIFIER", 3, 13], ["stable", "OBSERVATION_MODIFIER", 14, 20], ["asthma", "OBSERVATION", 32, 38], ["viruses", "OBSERVATION", 45, 52], ["bacteria", "OBSERVATION_MODIFIER", 57, 65], ["airways", "ANATOMY", 86, 93], ["persistent", "OBSERVATION_MODIFIER", 131, 141], ["pathogens", "OBSERVATION", 160, 169], ["airways", "ANATOMY", 177, 184]]], ["While the majority of studies indicate that the detection rate of respiratory viruses in patients with asthma and healthy subjects is similar [10], they have been found to differ with regard to the bacterial composition of the airways [11].IntroductionInformation on the respiratory pathogens of the lower airways and their relationship with the nature of asthma in elderly asthmatics is limited, mostly because of the risk and inconvenience associated with direct and invasive methods of airway lumen sampling.", [["airways", "ANATOMY", 227, 234], ["respiratory", "ANATOMY", 271, 282], ["lower airways", "ANATOMY", 300, 313], ["airway lumen", "ANATOMY", 489, 501], ["respiratory viruses", "DISEASE", 66, 85], ["asthma", "DISEASE", 103, 109], ["asthma", "DISEASE", 356, 362], ["patients", "ORGANISM", 89, 97], ["airways", "MULTI-TISSUE_STRUCTURE", 227, 234], ["lower airways", "MULTI-TISSUE_STRUCTURE", 300, 313], ["airway lumen", "MULTI-TISSUE_STRUCTURE", 489, 501], ["patients", "SPECIES", 89, 97], ["respiratory viruses", "PROBLEM", 66, 85], ["asthma", "PROBLEM", 103, 109], ["the bacterial composition of the airways", "PROBLEM", 194, 234], ["asthma", "PROBLEM", 356, 362], ["elderly asthmatics", "PROBLEM", 366, 384], ["airway lumen sampling", "TREATMENT", 489, 510], ["respiratory viruses", "OBSERVATION", 66, 85], ["bacterial", "OBSERVATION", 198, 207], ["airways", "ANATOMY", 227, 234], ["lower", "ANATOMY_MODIFIER", 300, 305], ["airways", "ANATOMY", 306, 313], ["asthma", "OBSERVATION", 356, 362], ["airway lumen", "OBSERVATION", 489, 501]]], ["Induced sputum (IS) allows for non-invasive assessment of lower airway inflammation and can be employed to detect respiratory pathogens in the lower respiratory tract.", [["sputum", "ANATOMY", 8, 14], ["lower airway", "ANATOMY", 58, 70], ["respiratory", "ANATOMY", 114, 125], ["lower respiratory tract", "ANATOMY", 143, 166], ["airway inflammation", "DISEASE", 64, 83], ["airway", "ORGANISM_SUBDIVISION", 64, 70], ["lower respiratory", "ORGANISM_SUBDIVISION", 143, 160], ["tract", "ORGANISM_SUBDIVISION", 161, 166], ["Induced sputum", "PROBLEM", 0, 14], ["non-invasive assessment", "TEST", 31, 54], ["lower airway inflammation", "PROBLEM", 58, 83], ["respiratory pathogens in the lower respiratory tract", "PROBLEM", 114, 166], ["sputum", "OBSERVATION", 8, 14], ["lower", "ANATOMY_MODIFIER", 58, 63], ["airway", "ANATOMY", 64, 70], ["inflammation", "OBSERVATION", 71, 83], ["pathogens", "OBSERVATION", 126, 135], ["lower", "ANATOMY_MODIFIER", 143, 148], ["respiratory tract", "ANATOMY", 149, 166]]], ["This technique was chosen for the present study, to test the hypothesis that elderly patients with asthma display a different profile of respiratory pathogens in the airways as compared to non-elderly asthmatics, and that this profile may be related to local airway and/or systemic inflammation.Patients ::: Material and methodsTwenty-nine clinically stable, non-smoking patients with moderate or severe persistent asthma, 15 elderly (above 65 years of age) and 14 non-elderly (aged 30-49 years), were included to the study.", [["respiratory", "ANATOMY", 137, 148], ["airways", "ANATOMY", 166, 173], ["airway", "ANATOMY", 259, 265], ["asthma", "DISEASE", 99, 105], ["respiratory pathogens", "DISEASE", 137, 158], ["inflammation", "DISEASE", 282, 294], ["asthma", "DISEASE", 415, 421], ["patients", "ORGANISM", 85, 93], ["airways", "MULTI-TISSUE_STRUCTURE", 166, 173], ["airway", "MULTI-TISSUE_STRUCTURE", 259, 265], ["Patients", "ORGANISM", 295, 303], ["patients", "ORGANISM", 371, 379], ["patients", "SPECIES", 85, 93], ["Patients", "SPECIES", 295, 303], ["patients", "SPECIES", 371, 379], ["the present study", "TEST", 30, 47], ["asthma", "PROBLEM", 99, 105], ["respiratory pathogens in the airways", "PROBLEM", 137, 173], ["non-elderly asthmatics", "PROBLEM", 189, 211], ["local airway", "PROBLEM", 253, 265], ["systemic inflammation", "PROBLEM", 273, 294], ["moderate or severe persistent asthma", "PROBLEM", 385, 421], ["the study", "TEST", 514, 523], ["respiratory pathogens", "OBSERVATION", 137, 158], ["airways", "ANATOMY", 166, 173], ["may be related to", "UNCERTAINTY", 235, 252], ["local", "ANATOMY_MODIFIER", 253, 258], ["airway", "ANATOMY", 259, 265], ["systemic", "OBSERVATION_MODIFIER", 273, 281], ["inflammation", "OBSERVATION", 282, 294], ["stable", "OBSERVATION_MODIFIER", 351, 357], ["moderate", "OBSERVATION_MODIFIER", 385, 393], ["severe", "OBSERVATION_MODIFIER", 397, 403], ["persistent", "OBSERVATION_MODIFIER", 404, 414], ["asthma", "OBSERVATION", 415, 421]]], ["None of the individuals demonstrated any symptoms of infection or had used antibiotics or oral corticosteroids for six weeks prior to the procedure.", [["oral", "ANATOMY", 90, 94], ["infection", "DISEASE", 53, 62], ["individuals", "ORGANISM", 12, 23], ["oral", "ORGANISM_SUBDIVISION", 90, 94], ["any symptoms of infection", "PROBLEM", 37, 62], ["antibiotics", "TREATMENT", 75, 86], ["oral corticosteroids", "TREATMENT", 90, 110], ["the procedure", "TREATMENT", 134, 147], ["infection", "OBSERVATION", 53, 62]]], ["The level of asthma control was established according to Global Initiative for Asthma (GINA) 2011 guidelines [12] and assessed by the Asthma Control Test (ACT) [13].", [["asthma", "DISEASE", 13, 19], ["Asthma", "DISEASE", 79, 85], ["Asthma", "DISEASE", 134, 140], ["asthma control", "TREATMENT", 13, 27], ["Asthma", "PROBLEM", 79, 85], ["asthma", "OBSERVATION", 13, 19]]], ["Severe asthma was defined according to the American Thoracic Society (ATS) Workshop 2000 criteria [14].", [["asthma", "DISEASE", 7, 13], ["Severe asthma", "PROBLEM", 0, 13], ["asthma", "OBSERVATION", 7, 13], ["Thoracic", "ANATOMY", 52, 60]]], ["Spirometry was performed according to European Respiratory Society (ERS) standards [15], using a PNEUMO RS spirometer (Abcmed Artmed, Krak\u00f3w, Poland).", [["Spirometry", "TEST", 0, 10], ["a PNEUMO RS spirometer", "TREATMENT", 95, 117], ["PNEUMO", "ANATOMY", 97, 103]]], ["The panel of skin prick tests (Allergopharma, Reinbek, Germany) included the following allergens: Dermatophagoides pteronyssinus, Dermatophagoides farinae, cat, dog, rabbit, hamster, guinea pig, rat, swine, birch, grass mix, mugwort, plantain, Alternaria tenuis, and Cladosporium herbarum.", [["skin", "ANATOMY", 13, 17], ["hamster", "ANATOMY", 174, 181], ["skin", "ORGAN", 13, 17], ["Dermatophagoides pteronyssinus", "ORGANISM", 98, 128], ["Dermatophagoides farinae", "ORGANISM", 130, 154], ["cat", "ORGANISM", 156, 159], ["dog", "ORGANISM", 161, 164], ["rabbit", "ORGANISM", 166, 172], ["hamster", "ORGANISM", 174, 181], ["guinea pig", "ORGANISM", 183, 193], ["rat", "ORGANISM", 195, 198], ["swine", "ORGANISM", 200, 205], ["birch", "ORGANISM_SUBDIVISION", 207, 212], ["mugwort", "ORGANISM_SUBDIVISION", 225, 232], ["plantain", "ORGANISM_SUBDIVISION", 234, 242], ["Alternaria tenuis", "ORGANISM", 244, 261], ["Cladosporium herbarum", "ORGANISM", 267, 288], ["Dermatophagoides pteronyssinus", "SPECIES", 98, 128], ["Dermatophagoides farinae", "SPECIES", 130, 154], ["cat", "SPECIES", 156, 159], ["dog", "SPECIES", 161, 164], ["rabbit", "SPECIES", 166, 172], ["hamster", "SPECIES", 174, 181], ["guinea pig", "SPECIES", 183, 193], ["rat", "SPECIES", 195, 198], ["swine", "SPECIES", 200, 205], ["plantain", "SPECIES", 234, 242], ["Alternaria tenuis", "SPECIES", 244, 261], ["Cladosporium herbarum", "SPECIES", 267, 288], ["Dermatophagoides pteronyssinus", "SPECIES", 98, 128], ["Dermatophagoides farinae", "SPECIES", 130, 154], ["rabbit", "SPECIES", 166, 172], ["hamster", "SPECIES", 174, 181], ["pig", "SPECIES", 190, 193], ["rat", "SPECIES", 195, 198], ["swine", "SPECIES", 200, 205], ["Alternaria tenuis", "SPECIES", 244, 261], ["Cladosporium herbarum", "SPECIES", 267, 288], ["The panel", "TEST", 0, 9], ["skin prick tests", "TEST", 13, 29], ["guinea pig", "TREATMENT", 183, 193], ["plantain", "TREATMENT", 234, 242], ["Alternaria tenuis", "PROBLEM", 244, 261], ["skin", "ANATOMY", 13, 17], ["Alternaria tenuis", "OBSERVATION", 244, 261]]], ["A positive result was defined as a wheal of 3 mm or more in diameter.", [["3 mm", "OBSERVATION_MODIFIER", 44, 48], ["diameter", "OBSERVATION_MODIFIER", 60, 68]]], ["Atopy was diagnosed as the presence of at least one positive skin test.FeNO measurement ::: Material and methodsFeNO was measured by using the online single breath method with NIOX (Aerocrine, Solna, Sweden), according to ATS guidelines [16].", [["skin", "ANATOMY", 61, 65], ["skin", "ORGAN", 61, 65], ["FeNO", "GENE_OR_GENE_PRODUCT", 112, 116], ["FeNO measurement", "TEST", 71, 87], ["methodsFeNO", "TEST", 105, 116], ["the online single breath method", "TREATMENT", 139, 170], ["NIOX (Aerocrine", "TREATMENT", 176, 191], ["positive", "OBSERVATION", 52, 60], ["skin", "ANATOMY", 61, 65]]], ["The measurement was performed before the sputum induction.Sputum induction ::: Material and methodsSputum induction was performed according to Pin et al. with some modifications [17, 18].", [["sputum", "ANATOMY", 41, 47], ["Sputum", "ANATOMY", 58, 64], ["Sputum", "ANATOMY", 99, 105], ["Sputum", "ORGANISM_SUBSTANCE", 58, 64], ["The measurement", "TEST", 0, 15], ["the sputum induction", "TREATMENT", 37, 57], ["methodsSputum induction", "TREATMENT", 92, 115]]], ["Briefly, patients received 200 \u00b5g of salbutamol from a metered dose inhaler followed by inhalation of increasing doses of hypertonic saline solution (3%, 4%, 5%) using an ultrasonic nebuliser UltraNeb (Devilbiss Health Care Inc., Somerset, USA).", [["salbutamol", "CHEMICAL", 37, 47], ["salbutamol", "CHEMICAL", 37, 47], ["patients", "ORGANISM", 9, 17], ["salbutamol", "SIMPLE_CHEMICAL", 37, 47], ["patients", "SPECIES", 9, 17], ["salbutamol", "TREATMENT", 37, 47], ["a metered dose inhaler", "TREATMENT", 53, 75], ["hypertonic saline solution", "TREATMENT", 122, 148], ["an ultrasonic nebuliser UltraNeb", "TREATMENT", 168, 200]]], ["Patients were asked to expectorate sputum after gargling mouthwash.", [["sputum", "ANATOMY", 35, 41], ["Patients", "ORGANISM", 0, 8], ["sputum", "ORGANISM_SUBSTANCE", 35, 41], ["Patients", "SPECIES", 0, 8], ["gargling mouthwash", "TREATMENT", 48, 66]]], ["Spirometry was performed before the procedure, 15 minutes after salbutamol inhalation, and every seven minutes after the start of the saline nebulisation.", [["salbutamol", "CHEMICAL", 64, 74], ["salbutamol", "CHEMICAL", 64, 74], ["salbutamol", "SIMPLE_CHEMICAL", 64, 74], ["saline", "SIMPLE_CHEMICAL", 134, 140], ["Spirometry", "TEST", 0, 10], ["the procedure", "TREATMENT", 32, 45], ["salbutamol inhalation", "TREATMENT", 64, 85], ["the saline nebulisation", "TREATMENT", 130, 153]]], ["When their FEV1 decreased by 20% or more, the sputum induction was stopped.Processing and analysis of the induced sputum ::: Material and methodsThe sputum sample was kept on ice and processed within two hours.", [["sputum", "ANATOMY", 46, 52], ["sputum", "ANATOMY", 114, 120], ["sputum sample", "ANATOMY", 149, 162], ["their FEV1", "TEST", 5, 15], ["the sputum induction", "TREATMENT", 42, 62], ["the induced sputum", "PROBLEM", 102, 120], ["The sputum sample", "TEST", 145, 162], ["sputum", "OBSERVATION", 149, 155]]], ["Dithiothreitol (DTT) (Sigma Aldrich, St Louis, USA) was added to the selected plaques of sputum and mixed for 15 min on ice.", [["plaques", "ANATOMY", 78, 85], ["sputum", "ANATOMY", 89, 95], ["Dithiothreitol", "CHEMICAL", 0, 14], ["DTT", "CHEMICAL", 16, 19], ["Dithiothreitol", "CHEMICAL", 0, 14], ["DTT", "CHEMICAL", 16, 19], ["Dithiothreitol", "SIMPLE_CHEMICAL", 0, 14], ["DTT", "SIMPLE_CHEMICAL", 16, 19], ["Sigma Aldrich", "SIMPLE_CHEMICAL", 22, 35], ["St Louis", "ORGANISM", 37, 45], ["sputum", "ORGANISM_SUBSTANCE", 89, 95], ["Dithiothreitol (DTT", "TREATMENT", 0, 19], ["Sigma Aldrich, St Louis, USA)", "TREATMENT", 22, 51], ["sputum", "OBSERVATION", 89, 95]]], ["The sample was filtered using a 52-\u00b5cm nylon gauze (Surtex, Lodz, Poland).", [["sample", "ANATOMY", 4, 10], ["a 52-\u00b5cm nylon gauze (Surtex", "TREATMENT", 30, 58]]], ["The total cell count was measured using a haemocytometer and centrifuged.", [["cell", "ANATOMY", 10, 14], ["cell", "CELL", 10, 14], ["The total cell count", "TEST", 0, 20], ["a haemocytometer", "TREATMENT", 40, 56]]], ["The cell pellets were resuspended with phosphate-buffered saline (PBS), and 75 \u00b5l of this cell suspension was used to perform the cytospin slides stained with RapiHem solution, a variant of May-Gr\u00fcnwald-Giemsa staining (Aqua-Med, Lodz, Poland).", [["cell", "ANATOMY", 4, 8], ["cell", "ANATOMY", 90, 94], ["phosphate", "CHEMICAL", 39, 48], ["phosphate", "CHEMICAL", 39, 48], ["cell", "CELL", 4, 8], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 39, 64], ["cell", "CELL", 90, 94], ["RapiHem", "SIMPLE_CHEMICAL", 159, 166], ["The cell pellets", "TREATMENT", 0, 16], ["phosphate-buffered saline (PBS", "TREATMENT", 39, 69], ["this cell suspension", "TREATMENT", 85, 105], ["the cytospin slides", "TEST", 126, 145], ["RapiHem solution", "TREATMENT", 159, 175], ["cell pellets", "OBSERVATION", 4, 16], ["Med", "ANATOMY", 225, 228]]], ["Only smears with less than 50% of non-squamous cells were considered to be adequate for the differential cell counting.", [["non-squamous cells", "ANATOMY", 34, 52], ["cell", "ANATOMY", 105, 109], ["cells", "CELL", 47, 52], ["cell", "CELL", 105, 109], ["non-squamous cells", "CELL_TYPE", 34, 52], ["smears", "TEST", 5, 11], ["non-squamous cells", "PROBLEM", 34, 52], ["the differential cell counting", "TEST", 88, 118], ["differential cell counting", "OBSERVATION", 92, 118]]], ["On each slide, 300 cells were counted, and the macrophage, lymphocyte, neutrophil, and eosinophil values were expressed as percentages of the total number of inflammatory cells.", [["cells", "ANATOMY", 19, 24], ["macrophage", "ANATOMY", 47, 57], ["lymphocyte", "ANATOMY", 59, 69], ["neutrophil", "ANATOMY", 71, 81], ["eosinophil", "ANATOMY", 87, 97], ["inflammatory cells", "ANATOMY", 158, 176], ["cells", "CELL", 19, 24], ["macrophage", "CELL", 47, 57], ["lymphocyte", "CELL", 59, 69], ["neutrophil", "CELL", 71, 81], ["eosinophil", "CELL", 87, 97], ["cells", "CELL", 171, 176], ["macrophage", "CELL_TYPE", 47, 57], ["lymphocyte", "CELL_TYPE", 59, 69], ["neutrophil", "CELL_TYPE", 71, 81], ["eosinophil", "CELL_TYPE", 87, 97], ["inflammatory cells", "CELL_TYPE", 158, 176], ["the macrophage", "TEST", 43, 57], ["lymphocyte", "TEST", 59, 69], ["neutrophil", "TEST", 71, 81], ["eosinophil values", "TEST", 87, 104], ["inflammatory cells", "PROBLEM", 158, 176], ["macrophage", "ANATOMY", 47, 57], ["lymphocyte", "ANATOMY", 59, 69], ["eosinophil values", "OBSERVATION", 87, 104], ["total", "OBSERVATION_MODIFIER", 142, 147], ["number", "OBSERVATION_MODIFIER", 148, 154], ["inflammatory cells", "OBSERVATION", 158, 176]]], ["The supernatants were stored frozen at \u201380\u00b0 for further analysis.Detection of bacteria ::: Material and methodsBacterial DNA was extracted from 200 \u00b5l of each sputum specimen using a QIAamp MinElute Virus Spin Kit (Qiagen, Valencia, USA), according to the manufacturer\u2019s instructions.", [["supernatants", "ANATOMY", 4, 16], ["sputum specimen", "ANATOMY", 159, 174], ["DNA", "CELLULAR_COMPONENT", 121, 124], ["further analysis", "TEST", 48, 64], ["bacteria", "PROBLEM", 78, 86], ["Material and methodsBacterial DNA", "PROBLEM", 91, 124], ["each sputum specimen", "TEST", 154, 174], ["a QIAamp MinElute Virus", "TREATMENT", 181, 204], ["bacteria", "OBSERVATION", 78, 86], ["Bacterial DNA", "OBSERVATION", 111, 124]]], ["A qualitative in vitro test, Seeplex PneumoBacter ACE Detection (Seegene, Seoul, South Korea) was used for the detection of six pathogens: Mycoplasma pneumoniae (MP), Legionella pneumophila (LP), Streptococcus pneumoniae (SP), Haemophilus influenzae (HI), Bordetella pertussis (BP), and Chlamydophila pneumoniae (CP).", [["Mycoplasma pneumoniae", "DISEASE", 139, 160], ["Legionella pneumophila", "DISEASE", 167, 189], ["Haemophilus influenzae", "DISEASE", 227, 249], ["Bordetella pertussis", "DISEASE", 256, 276], ["Chlamydophila pneumoniae", "DISEASE", 287, 311], ["Mycoplasma pneumoniae", "ORGANISM", 139, 160], ["MP", "GENE_OR_GENE_PRODUCT", 162, 164], ["Legionella pneumophila", "ORGANISM", 167, 189], ["LP)", "ORGANISM", 191, 194], ["Streptococcus pneumoniae", "ORGANISM", 196, 220], ["SP)", "ORGANISM", 222, 225], ["Haemophilus influenzae", "ORGANISM", 227, 249], ["HI)", "ORGANISM", 251, 254], ["Bordetella pertussis", "ORGANISM", 256, 276], ["BP)", "ORGANISM", 278, 281], ["Chlamydophila pneumoniae", "ORGANISM", 287, 311], ["CP", "CANCER", 313, 315], ["Mycoplasma pneumoniae", "SPECIES", 139, 160], ["Legionella pneumophila", "SPECIES", 167, 189], ["Streptococcus pneumoniae", "SPECIES", 196, 220], ["Haemophilus influenzae", "SPECIES", 227, 249], ["Bordetella pertussis", "SPECIES", 256, 276], ["Chlamydophila pneumoniae", "SPECIES", 287, 311], ["Mycoplasma pneumoniae", "SPECIES", 139, 160], ["Legionella pneumophila", "SPECIES", 167, 189], ["Streptococcus pneumoniae", "SPECIES", 196, 220], ["Haemophilus influenzae", "SPECIES", 227, 249], ["HI", "SPECIES", 251, 253], ["Bordetella pertussis", "SPECIES", 256, 276], ["Chlamydophila pneumoniae", "SPECIES", 287, 311], ["A qualitative in vitro test", "TEST", 0, 27], ["six pathogens", "PROBLEM", 124, 137], ["Mycoplasma pneumoniae", "PROBLEM", 139, 160], ["Legionella pneumophila", "PROBLEM", 167, 189], ["LP", "TEST", 191, 193], ["Streptococcus pneumoniae", "PROBLEM", 196, 220], ["Haemophilus influenzae", "PROBLEM", 227, 249], ["HI", "PROBLEM", 251, 253], ["Bordetella pertussis", "PROBLEM", 256, 276], ["BP", "TEST", 278, 280], ["Chlamydophila pneumoniae", "PROBLEM", 287, 311], ["CP", "PROBLEM", 313, 315], ["Mycoplasma pneumoniae", "OBSERVATION", 139, 160], ["Legionella pneumophila", "OBSERVATION", 167, 189], ["Streptococcus pneumoniae", "OBSERVATION", 196, 220], ["Chlamydophila pneumoniae", "OBSERVATION", 287, 311]]], ["The multiplex PCR products were visualised by electrophoresis on 2% agarose gel.Detection of viruses ::: Material and methodsViral DNA or RNA was extracted from sputum using a QIAamp\u00ae MinElute\u00ae Virus Spin Kit (Qiagen), according to the manufacturer\u2019s instructions.", [["sputum", "ANATOMY", 161, 167], ["agarose", "SIMPLE_CHEMICAL", 68, 75], ["Viral", "ORGANISM", 125, 130], ["DNA", "CELLULAR_COMPONENT", 131, 134], ["sputum", "ORGANISM_SUBSTANCE", 161, 167], ["The multiplex PCR products", "TREATMENT", 0, 26], ["electrophoresis", "TEST", 46, 61], ["2% agarose gel", "TREATMENT", 65, 79], ["Material and methodsViral DNA", "PROBLEM", 105, 134], ["RNA", "PROBLEM", 138, 141], ["sputum", "TEST", 161, 167], ["a QIAamp\u00ae MinElute\u00ae Virus Spin Kit (Qiagen)", "TREATMENT", 174, 217], ["viruses", "OBSERVATION", 93, 100], ["Viral DNA", "OBSERVATION", 125, 134]]], ["To synthesise cDNA, reverse transcription was performed using a RevertAid H Minus First-Strand cDNA Synthesis Kit (Thermo Fisher Scientific Inc., Waltham, USA).", [["cDNA", "DNA", 14, 18]]], ["Each cDNA was subjected to multiplex PCR using a SEEPLEX RV15 ACE Detection Kit (Seegene), according to the manufacturer\u2019s instructions.", [["cDNA", "DNA", 5, 9], ["multiplex PCR", "TEST", 27, 40], ["a SEEPLEX RV15 ACE Detection Kit", "TREATMENT", 47, 79]]], ["The multiplex PCR detected rhinoviruses (HRV) and enteroviruses (HEV), parainfluenza viruses 1 (PIV1), 2 (PIV2), 3 (PIV3), and 4 (PIV4), influenza viruses A (FluA) and B (FluB), respiratory syncytial viruses A (RSVA) and B (RSVB), coronaviruses (229E/NL63 and OC43), adenovirus (AdV), human metapneumovirus (MPV), and human bocaviruses 1/2/3/4 (HBoV).", [["parainfluenza viruses", "DISEASE", 71, 92], ["influenza viruses", "DISEASE", 137, 154], ["respiratory syncytial viruses", "DISEASE", 178, 207], ["rhinoviruses", "ORGANISM", 27, 39], ["HEV", "ORGANISM", 65, 68], ["parainfluenza viruses 1", "ORGANISM", 71, 94], ["PIV1", "GENE_OR_GENE_PRODUCT", 96, 100], ["2", "GENE_OR_GENE_PRODUCT", 103, 104], ["PIV2", "GENE_OR_GENE_PRODUCT", 106, 110], ["3", "GENE_OR_GENE_PRODUCT", 113, 114], ["PIV3", "GENE_OR_GENE_PRODUCT", 116, 120], ["4", "GENE_OR_GENE_PRODUCT", 127, 128], ["PIV4", "GENE_OR_GENE_PRODUCT", 130, 134], ["influenza viruses A", "ORGANISM", 137, 156], ["FluA", "GENE_OR_GENE_PRODUCT", 158, 162], ["B (FluB), respiratory syncytial viruses A", "ORGANISM", 168, 209], ["RSVA", "GENE_OR_GENE_PRODUCT", 211, 215], ["B", "GENE_OR_GENE_PRODUCT", 221, 222], ["RSVB", "GENE_OR_GENE_PRODUCT", 224, 228], ["coronaviruses", "ORGANISM", 231, 244], ["229E/NL63", "ORGANISM", 246, 255], ["OC43", "GENE_OR_GENE_PRODUCT", 260, 264], ["adenovirus", "ORGANISM", 267, 277], ["AdV", "ORGANISM", 279, 282], ["human metapneumovirus", "ORGANISM", 285, 306], ["MPV", "ORGANISM", 308, 311], ["human", "ORGANISM", 318, 323], ["bocaviruses 1/2/3/4", "ORGANISM", 324, 343], ["HBoV", "ORGANISM", 345, 349], ["parainfluenza viruses", "SPECIES", 71, 92], ["human", "SPECIES", 285, 290], ["metapneumovirus", "SPECIES", 291, 306], ["human", "SPECIES", 318, 323], ["HRV", "SPECIES", 41, 44], ["HEV", "SPECIES", 65, 68], ["parainfluenza viruses 1", "SPECIES", 71, 94], ["respiratory syncytial viruses A", "SPECIES", 178, 209], ["RSVA", "SPECIES", 211, 215], ["RSVB", "SPECIES", 224, 228], ["AdV", "SPECIES", 279, 282], ["human metapneumovirus", "SPECIES", 285, 306], ["MPV", "SPECIES", 308, 311], ["human bocaviruses 1/2/3/4", "SPECIES", 318, 343], ["HBoV", "SPECIES", 345, 349], ["The multiplex PCR", "TEST", 0, 17], ["rhinoviruses", "PROBLEM", 27, 39], ["HRV", "TEST", 41, 44], ["enteroviruses", "PROBLEM", 50, 63], ["HEV", "TEST", 65, 68], ["parainfluenza viruses", "PROBLEM", 71, 92], ["influenza viruses", "PROBLEM", 137, 154], ["A (FluA)", "TEST", 155, 163], ["B (FluB)", "TEST", 168, 176], ["respiratory syncytial viruses", "PROBLEM", 178, 207], ["RSVA", "TEST", 211, 215], ["B (RSVB)", "TEST", 221, 229], ["coronaviruses", "PROBLEM", 231, 244], ["OC43", "TEST", 260, 264], ["adenovirus", "PROBLEM", 267, 277], ["human metapneumovirus (MPV)", "TREATMENT", 285, 312], ["human bocaviruses", "TREATMENT", 318, 335], ["rhinoviruses", "OBSERVATION", 27, 39], ["parainfluenza viruses", "OBSERVATION", 71, 92], ["respiratory", "ANATOMY", 178, 189], ["syncytial viruses", "OBSERVATION", 190, 207]]], ["The multiplex PCR products were visualised by electrophoresis on 2% agarose gel.Inflammatory markers in serum ::: Material and methodsThe serum concentrations of total IgE (kU/l) were determined by ImmunoCAP Total IgE (Phadia AB, Uppsala, Sweden), and the concentrations of ECP (\u00b5g/l) were determined using ImmunoCAP ECP (Phadia AB, Upsala, Sweden), according to the manufacturer\u2019s instructions.Periostin in induced sputum supernatants ::: Material and methodsPeriostin was measured in the IS supernatants using an enzyme-linked immunoassay (USCN Life Science Inc., Wuhan, Hubei, China), according to the manufacturer\u2019s instructions.Statistical analysis ::: Material and methodsComparisons between the groups were performed with the non-parametric Mann-Whitney U test.", [["serum", "ANATOMY", 104, 109], ["serum", "ANATOMY", 138, 143], ["sputum supernatants", "ANATOMY", 416, 435], ["supernatants", "ANATOMY", 493, 505], ["Periostin", "CHEMICAL", 395, 404], ["Periostin", "CHEMICAL", 460, 469], ["agarose", "SIMPLE_CHEMICAL", 68, 75], ["serum", "ORGANISM_SUBSTANCE", 104, 109], ["serum", "ORGANISM_SUBSTANCE", 138, 143], ["IgE", "GENE_OR_GENE_PRODUCT", 168, 171], ["ECP", "GENE_OR_GENE_PRODUCT", 274, 277], ["Periostin", "GENE_OR_GENE_PRODUCT", 395, 404], ["Periostin", "GENE_OR_GENE_PRODUCT", 460, 469], ["Inflammatory markers", "PROTEIN", 80, 100], ["IgE", "PROTEIN", 168, 171], ["IgE", "PROTEIN", 214, 217], ["ECP", "PROTEIN", 274, 277], ["Periostin", "PROTEIN", 395, 404], ["The multiplex PCR products", "TREATMENT", 0, 26], ["electrophoresis", "TEST", 46, 61], ["2% agarose gel", "TREATMENT", 65, 79], ["Inflammatory markers", "TEST", 80, 100], ["The serum concentrations", "TEST", 134, 158], ["total IgE", "TEST", 162, 171], ["ImmunoCAP", "TEST", 198, 207], ["ECP", "TEST", 274, 277], ["ImmunoCAP ECP", "TEST", 307, 320], ["Periostin in induced sputum supernatants", "PROBLEM", 395, 435], ["methodsPeriostin", "PROBLEM", 453, 469], ["an enzyme", "TEST", 512, 521], ["sputum supernatants", "OBSERVATION", 416, 435], ["Periostin", "OBSERVATION", 460, 469]]], ["The statistical analysis was performed using Statistica (StatSoft, USA); p values < 0.05 were accepted as statistically significant.Statistical analysis ::: Material and methodsThe study was approved by the local Bioethics Committee, and all study subjects provided their informed consent.The presence of respiratory pathogens in the IS ::: ResultsThe molecular technique revealed the presence of S. pneumoniae in the IS from all asthmatic patients, both elderly and non-elderly, and H. influenzae in half the patients from each group (Table 3).", [["respiratory pathogens", "DISEASE", 305, 326], ["asthmatic", "DISEASE", 430, 439], ["S. pneumoniae", "ORGANISM", 397, 410], ["patients", "ORGANISM", 440, 448], ["H. influenzae", "ORGANISM", 484, 497], ["patients", "ORGANISM", 510, 518], ["S. pneumoniae", "SPECIES", 397, 410], ["patients", "SPECIES", 440, 448], ["H. influenzae", "SPECIES", 484, 497], ["patients", "SPECIES", 510, 518], ["S. pneumoniae", "SPECIES", 397, 410], ["H. influenzae", "SPECIES", 484, 497], ["The statistical analysis", "TEST", 0, 24], ["p values", "TEST", 73, 81], ["The study", "TEST", 177, 186], ["respiratory pathogens", "PROBLEM", 305, 326], ["The molecular technique", "TEST", 348, 371], ["S. pneumoniae", "PROBLEM", 397, 410], ["H. influenzae", "PROBLEM", 484, 497], ["respiratory pathogens", "OBSERVATION", 305, 326], ["pneumoniae", "OBSERVATION", 400, 410], ["asthmatic", "OBSERVATION", 430, 439]]], ["Chlamydophilapneumoniae was detected in one subject from the elderly group and one from the non-elderly group.", [["Chlamydophilapneumoniae", "CHEMICAL", 0, 23], ["Chlamydophilapneumoniae", "SIMPLE_CHEMICAL", 0, 23], ["Chlamydophilapneumoniae", "PROBLEM", 0, 23]]], ["All sputa were negative for M. pneumoniae, Legionella, and B. pertussis.The presence of respiratory pathogens in the IS ::: ResultsRespiratory viruses were detected in the induced sputum from the majority of patients in both groups: in 11 (73.3%) elderly and 10 (71.4%) non-elderly individuals.", [["sputum", "ANATOMY", 180, 186], ["respiratory pathogens", "DISEASE", 88, 109], ["M. pneumoniae", "ORGANISM", 28, 41], ["B. pertussis", "ORGANISM", 59, 71], ["patients", "ORGANISM", 208, 216], ["M. pneumoniae", "SPECIES", 28, 41], ["B. pertussis", "SPECIES", 59, 71], ["patients", "SPECIES", 208, 216], ["M. pneumoniae", "SPECIES", 28, 41], ["B. pertussis", "SPECIES", 59, 71], ["All sputa", "TEST", 0, 9], ["M. pneumoniae", "PROBLEM", 28, 41], ["Legionella", "PROBLEM", 43, 53], ["B. pertussis", "PROBLEM", 59, 71], ["respiratory pathogens", "PROBLEM", 88, 109], ["ResultsRespiratory viruses", "PROBLEM", 124, 150], ["the induced sputum", "PROBLEM", 168, 186], ["pneumoniae", "OBSERVATION", 31, 41], ["respiratory pathogens", "OBSERVATION", 88, 109], ["viruses", "OBSERVATION", 143, 150], ["sputum", "OBSERVATION", 180, 186]]], ["The most commonly detected virus was Flu A followed by RSV A and RSV B (Table 3).", [["Flu A", "CHEMICAL", 37, 42], ["Flu A", "CANCER", 37, 42], ["RSV A", "ORGANISM", 55, 60], ["RSV B", "ORGANISM", 65, 70], ["Flu A", "SPECIES", 37, 42], ["RSV", "SPECIES", 55, 58], ["RSV", "SPECIES", 65, 68], ["virus", "OBSERVATION", 27, 32]]], ["No differences were observed in the detection rates of viruses between elderly and non-elderly patients.Association between the presence of virus in the IS with clinical and inflammatory markers ::: ResultsNeither asthma severity according to GINA or ATS criteria nor current asthma control assessed by the ACT were found to correlate with the presence of respiratory pathogens in the IS of asthmatics patients.", [["respiratory", "ANATOMY", 356, 367], ["asthma", "DISEASE", 214, 220], ["asthma", "DISEASE", 276, 282], ["respiratory pathogens", "DISEASE", 356, 377], ["patients", "ORGANISM", 95, 103], ["patients", "ORGANISM", 402, 410], ["patients", "SPECIES", 95, 103], ["patients", "SPECIES", 402, 410], ["virus", "PROBLEM", 140, 145], ["asthma severity", "PROBLEM", 214, 229], ["current asthma control", "PROBLEM", 268, 290], ["respiratory pathogens", "PROBLEM", 356, 377], ["virus", "OBSERVATION", 140, 145], ["asthma", "OBSERVATION", 276, 282], ["respiratory", "ANATOMY", 356, 367], ["pathogens", "OBSERVATION", 368, 377]]], ["In elderly asthmatics, but not in the non-elderly group, a few associations between the presence of specific respiratory viruses in the IS and respiratory function/immunological parameters were found.", [["respiratory", "ANATOMY", 143, 154], ["respiratory viruses", "DISEASE", 109, 128], ["elderly asthmatics", "PROBLEM", 3, 21], ["specific respiratory viruses", "PROBLEM", 100, 128], ["immunological parameters", "TEST", 164, 188], ["elderly", "OBSERVATION_MODIFIER", 3, 10], ["asthmatics", "OBSERVATION", 11, 21], ["respiratory viruses", "OBSERVATION", 109, 128], ["respiratory function", "OBSERVATION", 143, 163]]], ["Flu A-positive patients had lower FVC% predicted than negative ones (81.8% pred. \u00b119.9 vs. 100.4 % pred. \u00b112,9; p < 0.05).", [["patients", "ORGANISM", 15, 23], ["patients", "SPECIES", 15, 23], ["lower FVC", "TEST", 28, 37]]], ["The presence of RSV B was associated with a lower percentage of lymphocytes in the IS (28.7% \u00b112.6 vs. 5.5 % \u00b19.5; p < 0.05), and the RSV A-positive patients had lower tIgE concentration in the serum than RSV A-negative elderly individuals (19.2 kU/l \u00b117.7 vs. 85.2 kU/l \u00b164.1; p < 0.05).DiscussionThis study is the first to use the IS technique to compare detection rates of respiratory pathogens in the airways of elderly and non-elderly patients with asthma.", [["lymphocytes", "ANATOMY", 64, 75], ["serum", "ANATOMY", 194, 199], ["respiratory", "ANATOMY", 376, 387], ["airways", "ANATOMY", 405, 412], ["respiratory pathogens", "DISEASE", 376, 397], ["asthma", "DISEASE", 454, 460], ["RSV", "ORGANISM", 16, 19], ["lymphocytes", "CELL", 64, 75], ["RSV", "ORGANISM", 134, 137], ["patients", "ORGANISM", 149, 157], ["tIgE", "SIMPLE_CHEMICAL", 168, 172], ["serum", "ORGANISM_SUBSTANCE", 194, 199], ["RSV", "ORGANISM", 205, 208], ["airways", "MULTI-TISSUE_STRUCTURE", 405, 412], ["patients", "ORGANISM", 440, 448], ["lymphocytes", "CELL_TYPE", 64, 75], ["tIgE", "PROTEIN", 168, 172], ["patients", "SPECIES", 149, 157], ["patients", "SPECIES", 440, 448], ["RSV", "SPECIES", 16, 19], ["RSV", "SPECIES", 134, 137], ["RSV", "SPECIES", 205, 208], ["RSV B", "PROBLEM", 16, 21], ["a lower percentage of lymphocytes", "PROBLEM", 42, 75], ["p", "TEST", 115, 116], ["the RSV", "TEST", 130, 137], ["lower tIgE concentration", "PROBLEM", 162, 186], ["the serum", "TEST", 190, 199], ["kU", "TEST", 246, 248], ["vs.", "TEST", 257, 260], ["kU", "TEST", 266, 268], ["p", "TEST", 278, 279], ["This study", "TEST", 298, 308], ["the IS technique", "TREATMENT", 329, 345], ["respiratory pathogens", "PROBLEM", 376, 397], ["asthma", "PROBLEM", 454, 460], ["RSV", "OBSERVATION", 16, 19], ["lower", "OBSERVATION_MODIFIER", 44, 49], ["percentage", "OBSERVATION_MODIFIER", 50, 60], ["lymphocytes", "OBSERVATION", 64, 75], ["respiratory pathogens", "OBSERVATION", 376, 397], ["airways", "ANATOMY", 405, 412], ["asthma", "OBSERVATION", 454, 460]]], ["The total number of positive samples and the profile of respiratory pathogens detected in the induced sputum by molecular techniques were found to be similar in elderly and non-elderly individuals.", [["samples", "ANATOMY", 29, 36], ["sputum", "ANATOMY", 102, 108], ["positive samples", "PROBLEM", 20, 36], ["respiratory pathogens", "PROBLEM", 56, 77], ["the induced sputum", "PROBLEM", 90, 108], ["total", "OBSERVATION_MODIFIER", 4, 9], ["positive samples", "OBSERVATION_MODIFIER", 20, 36], ["respiratory pathogens", "OBSERVATION", 56, 77]]], ["Bronchial asthma, although heterogeneous, has been considered to be, on average, more severe in the elderly population and associated with increased exacerbation rates mostly related to respiratory infections [19].", [["Bronchial", "ANATOMY", 0, 9], ["respiratory", "ANATOMY", 186, 197], ["Bronchial asthma", "DISEASE", 0, 16], ["respiratory infections", "DISEASE", 186, 208], ["Bronchial asthma", "PROBLEM", 0, 16], ["increased exacerbation rates", "PROBLEM", 139, 167], ["respiratory infections", "PROBLEM", 186, 208], ["asthma", "OBSERVATION", 10, 16], ["heterogeneous", "OBSERVATION_MODIFIER", 27, 40], ["considered to be", "UNCERTAINTY", 51, 67], ["more", "OBSERVATION_MODIFIER", 81, 85], ["severe", "OBSERVATION_MODIFIER", 86, 92], ["increased", "OBSERVATION_MODIFIER", 139, 148], ["exacerbation", "OBSERVATION", 149, 161], ["respiratory", "ANATOMY", 186, 197], ["infections", "OBSERVATION", 198, 208]]], ["Our elderly patients tended to have, on average, more severe disease, as expressed by lower respiratory function, and less current asthma control over the previous four weeks, demonstrated by GINA criteria and a lower mean ACT score.", [["respiratory", "ANATOMY", 92, 103], ["asthma", "DISEASE", 131, 137], ["patients", "ORGANISM", 12, 20], ["ACT", "PROTEIN", 223, 226], ["patients", "SPECIES", 12, 20], ["more severe disease", "PROBLEM", 49, 68], ["lower respiratory function", "PROBLEM", 86, 112], ["less current asthma control", "PROBLEM", 118, 145], ["a lower mean ACT score", "PROBLEM", 210, 232], ["severe", "OBSERVATION_MODIFIER", 54, 60], ["disease", "OBSERVATION", 61, 68], ["respiratory function", "OBSERVATION", 92, 112], ["asthma", "OBSERVATION", 131, 137]]], ["In addition, the elderly patients had higher sputum eosinophilia and lymphocytosis levels than the non-elderly patients, suggesting the presence of different types of airway inflammation in senior individuals.", [["sputum", "ANATOMY", 45, 51], ["airway", "ANATOMY", 167, 173], ["eosinophilia", "DISEASE", 52, 64], ["lymphocytosis", "DISEASE", 69, 82], ["airway inflammation", "DISEASE", 167, 186], ["patients", "ORGANISM", 25, 33], ["patients", "ORGANISM", 111, 119], ["airway", "MULTI-TISSUE_STRUCTURE", 167, 173], ["patients", "SPECIES", 25, 33], ["patients", "SPECIES", 111, 119], ["higher sputum eosinophilia", "PROBLEM", 38, 64], ["lymphocytosis levels", "PROBLEM", 69, 89], ["airway inflammation", "PROBLEM", 167, 186], ["sputum eosinophilia", "OBSERVATION", 45, 64], ["lymphocytosis", "OBSERVATION", 69, 82], ["airway", "ANATOMY", 167, 173], ["inflammation", "OBSERVATION", 174, 186]]], ["Although a previous study documents a tendency toward neutrophilic inflammation in the IS from elderly asthmatics, no correlation between neutrophilia and severity of the disease was found [20].", [["neutrophilic", "ANATOMY", 54, 66], ["inflammation", "DISEASE", 67, 79], ["neutrophilia", "DISEASE", 138, 150], ["a previous study", "TEST", 9, 25], ["a tendency toward neutrophilic inflammation", "PROBLEM", 36, 79], ["elderly asthmatics", "PROBLEM", 95, 113], ["neutrophilia", "PROBLEM", 138, 150], ["the disease", "PROBLEM", 167, 178], ["neutrophilic", "OBSERVATION_MODIFIER", 54, 66], ["inflammation", "OBSERVATION", 67, 79], ["elderly", "OBSERVATION_MODIFIER", 95, 102], ["asthmatics", "OBSERVATION", 103, 113], ["disease", "OBSERVATION", 171, 178]]], ["Another study found older asthmatics with fixed obstruction to have a higher percentage of eosinophils and elevated levels of ECP in the induced sputum compared to their peers with chronic obstructive pulmonary disease (COPD), despite an increased percentage of neutrophils in the sputum [21].", [["eosinophils", "ANATOMY", 91, 102], ["sputum", "ANATOMY", 145, 151], ["pulmonary", "ANATOMY", 201, 210], ["neutrophils", "ANATOMY", 262, 273], ["sputum", "ANATOMY", 281, 287], ["obstruction", "DISEASE", 48, 59], ["chronic obstructive pulmonary disease", "DISEASE", 181, 218], ["COPD", "DISEASE", 220, 224], ["asthmatics", "ORGANISM", 26, 36], ["eosinophils", "CELL", 91, 102], ["ECP", "GENE_OR_GENE_PRODUCT", 126, 129], ["pulmonary", "ORGAN", 201, 210], ["neutrophils", "CELL", 262, 273], ["eosinophils", "CELL_TYPE", 91, 102], ["ECP", "PROTEIN", 126, 129], ["neutrophils", "CELL_TYPE", 262, 273], ["Another study", "TEST", 0, 13], ["older asthmatics", "PROBLEM", 20, 36], ["fixed obstruction", "PROBLEM", 42, 59], ["a higher percentage of eosinophils", "PROBLEM", 68, 102], ["elevated levels of ECP", "PROBLEM", 107, 129], ["the induced sputum", "PROBLEM", 133, 151], ["chronic obstructive pulmonary disease", "PROBLEM", 181, 218], ["COPD)", "PROBLEM", 220, 225], ["an increased percentage of neutrophils", "PROBLEM", 235, 273], ["the sputum", "TEST", 277, 287], ["asthmatics", "OBSERVATION", 26, 36], ["fixed", "OBSERVATION_MODIFIER", 42, 47], ["obstruction", "OBSERVATION", 48, 59], ["higher", "OBSERVATION_MODIFIER", 70, 76], ["percentage", "OBSERVATION_MODIFIER", 77, 87], ["eosinophils", "OBSERVATION", 91, 102], ["elevated", "OBSERVATION_MODIFIER", 107, 115], ["levels", "OBSERVATION_MODIFIER", 116, 122], ["sputum", "OBSERVATION", 145, 151], ["chronic", "OBSERVATION_MODIFIER", 181, 188], ["obstructive", "OBSERVATION_MODIFIER", 189, 200], ["pulmonary", "ANATOMY", 201, 210], ["disease", "OBSERVATION", 211, 218], ["COPD", "OBSERVATION", 220, 224], ["increased", "OBSERVATION_MODIFIER", 238, 247], ["percentage", "OBSERVATION_MODIFIER", 248, 258], ["neutrophils", "OBSERVATION", 262, 273]]], ["Thus, the increased percentage of eosinophils in the IS of elderly patients in our study may reflect the proposed inflammatory profile in the airway mucosa of this population of asthmatics.", [["eosinophils", "ANATOMY", 34, 45], ["airway mucosa", "ANATOMY", 142, 155], ["eosinophils", "CELL", 34, 45], ["patients", "ORGANISM", 67, 75], ["airway mucosa", "MULTI-TISSUE_STRUCTURE", 142, 155], ["asthmatics", "ORGANISM", 178, 188], ["eosinophils", "CELL_TYPE", 34, 45], ["patients", "SPECIES", 67, 75], ["the increased percentage of eosinophils", "PROBLEM", 6, 45], ["our study", "TEST", 79, 88], ["the proposed inflammatory profile in the airway mucosa", "PROBLEM", 101, 155], ["asthmatics", "PROBLEM", 178, 188], ["increased", "OBSERVATION_MODIFIER", 10, 19], ["percentage", "OBSERVATION_MODIFIER", 20, 30], ["eosinophils", "OBSERVATION", 34, 45], ["inflammatory", "OBSERVATION", 114, 126], ["airway mucosa", "ANATOMY", 142, 155], ["asthmatics", "OBSERVATION", 178, 188]]], ["On the other hand, mean levels of surrogate markers of the airway eosinophilic inflammation (FeNO, ECP, and sputum periostin) were similar in both groups, not confirming differences in the type of inflammation between groups.DiscussionAgeing has been associated with several immune abnormalities in both the innate and adaptive immune systems, and consequently with deceased immune response to infections [1].", [["airway", "ANATOMY", 59, 65], ["sputum", "ANATOMY", 108, 114], ["inflammation", "DISEASE", 197, 209], ["infections", "DISEASE", 394, 404], ["airway eosinophilic", "PATHOLOGICAL_FORMATION", 59, 78], ["FeNO", "GENE_OR_GENE_PRODUCT", 93, 97], ["ECP", "GENE_OR_GENE_PRODUCT", 99, 102], ["periostin", "GENE_OR_GENE_PRODUCT", 115, 124], ["ECP", "PROTEIN", 99, 102], ["sputum periostin", "PROTEIN", 108, 124], ["the airway eosinophilic inflammation", "PROBLEM", 55, 91], ["FeNO", "TEST", 93, 97], ["ECP", "TEST", 99, 102], ["sputum periostin", "TEST", 108, 124], ["inflammation between groups", "PROBLEM", 197, 224], ["several immune abnormalities", "PROBLEM", 267, 295], ["infections", "PROBLEM", 394, 404], ["airway", "ANATOMY", 59, 65], ["eosinophilic inflammation", "OBSERVATION", 66, 91], ["inflammation", "OBSERVATION", 197, 209]]], ["In this context, the observation of similar detection rate and profile of respiratory pathogens in the induced sputum is rather unexpected.", [["sputum", "ANATOMY", 111, 117], ["similar detection rate", "TEST", 36, 58], ["respiratory pathogens", "PROBLEM", 74, 95], ["the induced sputum", "PROBLEM", 99, 117], ["respiratory pathogens", "OBSERVATION", 74, 95], ["sputum", "OBSERVATION", 111, 117]]], ["However, our patients had stable asthma during the sputum sampling, and one cannot exclude that the difference in the microbiome between elderly and non-elderly asthmatics might be seen during the disease exacerbationsDiscussionAlthough respiratory pathogens have been detected with increased frequency during asthma exacerbations, they may persist in the airways of asthmatics between exacerbation episodes, and it has been postulated that latent or persistent infection may contribute to the chronicity of the airway inflammation [22].", [["sputum", "ANATOMY", 51, 57], ["airways", "ANATOMY", 356, 363], ["airway", "ANATOMY", 512, 518], ["asthma", "DISEASE", 33, 39], ["respiratory pathogens", "DISEASE", 237, 258], ["asthma exacerbations", "DISEASE", 310, 330], ["infection", "DISEASE", 462, 471], ["airway inflammation", "DISEASE", 512, 531], ["patients", "ORGANISM", 13, 21], ["asthmatics", "ORGANISM", 161, 171], ["airways", "MULTI-TISSUE_STRUCTURE", 356, 363], ["airway", "MULTI-TISSUE_STRUCTURE", 512, 518], ["patients", "SPECIES", 13, 21], ["stable asthma", "PROBLEM", 26, 39], ["the sputum sampling", "TEST", 47, 66], ["non-elderly asthmatics", "PROBLEM", 149, 171], ["the disease exacerbations", "PROBLEM", 193, 218], ["respiratory pathogens", "PROBLEM", 237, 258], ["increased frequency during asthma exacerbations", "PROBLEM", 283, 330], ["asthmatics", "PROBLEM", 367, 377], ["exacerbation episodes", "PROBLEM", 386, 407], ["persistent infection", "PROBLEM", 451, 471], ["the airway inflammation", "PROBLEM", 508, 531], ["stable", "OBSERVATION_MODIFIER", 26, 32], ["asthma", "OBSERVATION", 33, 39], ["increased", "OBSERVATION_MODIFIER", 283, 292], ["airways", "ANATOMY", 356, 363], ["asthmatics", "OBSERVATION", 367, 377], ["latent", "OBSERVATION_MODIFIER", 441, 447], ["persistent", "OBSERVATION_MODIFIER", 451, 461], ["infection", "OBSERVATION", 462, 471], ["airway", "ANATOMY", 512, 518], ["inflammation", "OBSERVATION", 519, 531]]], ["However, a cross-sectional study by Harju et al. [9] reports similar detection rates of respiratory viruses in the IS of patients with clinically stable asthma and healthy controls.", [["respiratory viruses", "DISEASE", 88, 107], ["asthma", "DISEASE", 153, 159], ["patients", "ORGANISM", 121, 129], ["patients", "SPECIES", 121, 129], ["a cross-sectional study", "TEST", 9, 32], ["respiratory viruses", "PROBLEM", 88, 107], ["clinically stable asthma and healthy controls", "PROBLEM", 135, 180], ["respiratory viruses", "OBSERVATION", 88, 107], ["stable", "OBSERVATION_MODIFIER", 146, 152], ["asthma", "OBSERVATION", 153, 159]]], ["Similarly, in a prospective study by Tucharelli et al. [23] the detection rates of 14 respiratory viruses were comparable in clinically stable asthmatics and in healthy controls at three time points.", [["a prospective study", "TEST", 14, 33], ["the detection rates", "TEST", 60, 79], ["14 respiratory viruses", "PROBLEM", 83, 105], ["respiratory viruses", "OBSERVATION", 86, 105], ["stable", "OBSERVATION_MODIFIER", 136, 142], ["asthmatics", "OBSERVATION", 143, 153]]], ["Accordingly, in non-bronchoscopic bronchoalveolar lavage (BAL), the percentage of viral detection did not vary between asthmatic children and controls [24].", [["bronchoalveolar lavage", "ANATOMY", 34, 56], ["BAL", "ANATOMY", 58, 61], ["asthmatic", "DISEASE", 119, 128], ["bronchoalveolar lavage", "MULTI-TISSUE_STRUCTURE", 34, 56], ["BAL", "MULTI-TISSUE_STRUCTURE", 58, 61], ["children", "ORGANISM", 129, 137], ["children", "SPECIES", 129, 137], ["non-bronchoscopic bronchoalveolar lavage", "TEST", 16, 56], ["viral detection", "TEST", 82, 97], ["bronchoalveolar lavage", "OBSERVATION", 34, 56], ["viral", "OBSERVATION", 82, 87]]], ["In contrast, the presence of HRV in the lung tissue samples from stable patients was found to be higher in asthmatics than in healthy controls [25].", [["lung tissue samples", "ANATOMY", 40, 59], ["lung tissue samples", "TISSUE", 40, 59], ["patients", "ORGANISM", 72, 80], ["patients", "SPECIES", 72, 80], ["HRV in the lung tissue samples", "PROBLEM", 29, 59], ["lung", "ANATOMY", 40, 44], ["tissue", "OBSERVATION", 45, 51], ["stable", "OBSERVATION_MODIFIER", 65, 71], ["higher", "OBSERVATION_MODIFIER", 97, 103]]], ["Thus, the presence or absence of respiratory pathogens in BAL or induced sputum may not reflect the persistence of infection of the airway mucosa.DiscussionAlthough the detection rate and profile of respiratory viruses in IS was similar in elderly and non-elderly patients with asthma, the presence of pathogens was associated with some clinical characteristics only in older subjects.", [["BAL", "ANATOMY", 58, 61], ["sputum", "ANATOMY", 73, 79], ["airway mucosa", "ANATOMY", 132, 145], ["infection", "DISEASE", 115, 124], ["respiratory viruses", "DISEASE", 199, 218], ["asthma", "DISEASE", 278, 284], ["BAL", "ORGANISM_SUBSTANCE", 58, 61], ["airway mucosa", "MULTI-TISSUE_STRUCTURE", 132, 145], ["patients", "ORGANISM", 264, 272], ["patients", "SPECIES", 264, 272], ["respiratory pathogens in BAL", "PROBLEM", 33, 61], ["induced sputum", "PROBLEM", 65, 79], ["infection of the airway mucosa", "PROBLEM", 115, 145], ["the detection rate", "TEST", 165, 183], ["respiratory viruses", "PROBLEM", 199, 218], ["asthma", "PROBLEM", 278, 284], ["pathogens", "PROBLEM", 302, 311], ["respiratory pathogens", "OBSERVATION", 33, 54], ["may not reflect", "UNCERTAINTY", 80, 95], ["infection", "OBSERVATION", 115, 124], ["airway mucosa", "ANATOMY", 132, 145], ["respiratory viruses", "OBSERVATION", 199, 218], ["asthma", "OBSERVATION", 278, 284], ["pathogens", "OBSERVATION", 302, 311]]], ["The presence of Influenza A virus in the airways of stable asthma patients (without any clinical signs of infection) was associated with lower respiratory function and RSV B with a lower percentage of lymphocytes in the IS.", [["airways", "ANATOMY", 41, 48], ["respiratory", "ANATOMY", 143, 154], ["lymphocytes", "ANATOMY", 201, 212], ["Influenza A virus", "DISEASE", 16, 33], ["asthma", "DISEASE", 59, 65], ["infection", "DISEASE", 106, 115], ["Influenza A virus", "ORGANISM", 16, 33], ["airways", "MULTI-TISSUE_STRUCTURE", 41, 48], ["patients", "ORGANISM", 66, 74], ["lymphocytes", "CELL", 201, 212], ["lymphocytes", "CELL_TYPE", 201, 212], ["Influenza A virus", "SPECIES", 16, 33], ["patients", "SPECIES", 66, 74], ["Influenza A virus", "SPECIES", 16, 33], ["RSV", "SPECIES", 168, 171], ["Influenza A virus", "PROBLEM", 16, 33], ["stable asthma patients", "PROBLEM", 52, 74], ["infection", "PROBLEM", 106, 115], ["lower respiratory function", "PROBLEM", 137, 163], ["RSV B", "PROBLEM", 168, 173], ["Influenza", "OBSERVATION", 16, 25], ["virus", "OBSERVATION", 28, 33], ["airways", "ANATOMY", 41, 48], ["stable", "OBSERVATION_MODIFIER", 52, 58], ["asthma", "OBSERVATION", 59, 65], ["infection", "OBSERVATION", 106, 115], ["respiratory function", "OBSERVATION", 143, 163], ["lower percentage", "OBSERVATION_MODIFIER", 181, 197], ["lymphocytes", "OBSERVATION", 201, 212]]], ["In a study by Wo\u015b et al. [25] the presence of HRV was associated with lower spirometric parameters as compared to HRV-negative subjects.", [["a study", "TEST", 3, 10], ["HRV", "PROBLEM", 46, 49], ["lower spirometric parameters", "PROBLEM", 70, 98], ["HRV", "TEST", 114, 117]]], ["Furthermore, in our study the presence of RSV B was associated with a lower percentage of lymphocytes in the IS and the RSV A with lower total IgE concentration in the serum in elderly individuals; however, the significance of this findings remains unclear.DiscussionOur study has several limitations.", [["lymphocytes", "ANATOMY", 90, 101], ["serum", "ANATOMY", 168, 173], ["RSV", "ORGANISM", 42, 45], ["B", "ORGANISM", 46, 47], ["lymphocytes", "CELL", 90, 101], ["RSV", "ORGANISM", 120, 123], ["IgE", "GENE_OR_GENE_PRODUCT", 143, 146], ["serum", "ORGANISM_SUBSTANCE", 168, 173], ["lymphocytes", "CELL_TYPE", 90, 101], ["IgE", "PROTEIN", 143, 146], ["RSV", "SPECIES", 42, 45], ["RSV", "SPECIES", 120, 123], ["our study", "TEST", 16, 25], ["RSV B", "PROBLEM", 42, 47], ["a lower percentage of lymphocytes", "PROBLEM", 68, 101], ["lower total IgE concentration", "TREATMENT", 131, 160], ["DiscussionOur study", "TEST", 257, 276], ["RSV", "OBSERVATION", 42, 45], ["lower", "OBSERVATION_MODIFIER", 70, 75], ["percentage", "OBSERVATION_MODIFIER", 76, 86], ["lymphocytes", "OBSERVATION", 90, 101], ["RSV", "OBSERVATION", 120, 123], ["IgE concentration", "OBSERVATION", 143, 160]]], ["The groups were relatively small, which may have affected the variability of results.", [["relatively", "OBSERVATION_MODIFIER", 16, 26], ["small", "OBSERVATION_MODIFIER", 27, 32]]], ["The samples were collected during late autumn and winter, which may be connected with more frequent exposure to respiratory infections.", [["samples", "ANATOMY", 4, 11], ["respiratory", "ANATOMY", 112, 123], ["respiratory infections", "DISEASE", 112, 134], ["The samples", "TEST", 0, 11], ["respiratory infections", "PROBLEM", 112, 134], ["respiratory", "ANATOMY", 112, 123], ["infections", "OBSERVATION", 124, 134]]], ["Qualitative RT-PCR did not allow active replication indicating active infection to be distinguished from residuals of viral or bacterial DNA or RNA from past infections.", [["infection", "DISEASE", 70, 79], ["infections", "DISEASE", 158, 168], ["DNA", "CELLULAR_COMPONENT", 137, 140], ["viral or bacterial DNA", "DNA", 118, 140], ["Qualitative RT-PCR", "TEST", 0, 18], ["active replication", "PROBLEM", 33, 51], ["active infection", "PROBLEM", 63, 79], ["viral or bacterial DNA", "PROBLEM", 118, 140], ["RNA", "PROBLEM", 144, 147], ["past infections", "PROBLEM", 153, 168], ["active", "OBSERVATION_MODIFIER", 63, 69], ["infection", "OBSERVATION", 70, 79], ["viral", "OBSERVATION", 118, 123], ["bacterial DNA", "OBSERVATION", 127, 140], ["infections", "OBSERVATION", 158, 168]]], ["The discrepancies between the positivity rates of the respiratory bacteria and viruses shown in the above-mentioned studies may be related to different methods of obtaining samples and detecting pathogens.", [["samples", "ANATOMY", 173, 180], ["the positivity rates", "TEST", 26, 46], ["the respiratory bacteria", "PROBLEM", 50, 74], ["viruses", "PROBLEM", 79, 86], ["pathogens", "PROBLEM", 195, 204], ["positivity", "OBSERVATION_MODIFIER", 30, 40], ["respiratory bacteria", "OBSERVATION", 54, 74], ["viruses", "OBSERVATION", 79, 86], ["may be related to", "UNCERTAINTY", 124, 141]]], ["Supernatants from induced sputum were used as source material, and multiplex RT PCR assays were used for analysis.", [["Supernatants", "ANATOMY", 0, 12], ["sputum", "ANATOMY", 26, 32], ["sputum", "ORGANISM_SUBSTANCE", 26, 32], ["induced sputum", "PROBLEM", 18, 32], ["source material", "TEST", 46, 61], ["multiplex RT PCR assays", "TEST", 67, 90], ["analysis", "TEST", 105, 113], ["sputum", "OBSERVATION", 26, 32]]], ["Harju et al. [9] report higher detection rates of viruses in induced sputum and throat swab samples compared to gelatine-filtered expired air, EBC, or nasal swabs.", [["sputum", "ANATOMY", 69, 75], ["throat swab samples", "ANATOMY", 80, 99], ["nasal swabs", "ANATOMY", 151, 162], ["throat swab samples", "ORGANISM_SUBSTANCE", 80, 99], ["gelatine", "SIMPLE_CHEMICAL", 112, 120], ["nasal swabs", "MULTI-TISSUE_STRUCTURE", 151, 162], ["viruses", "PROBLEM", 50, 57], ["induced sputum", "PROBLEM", 61, 75], ["throat swab samples", "TEST", 80, 99], ["gelatine", "TEST", 112, 120], ["EBC", "TEST", 143, 146], ["nasal swabs", "PROBLEM", 151, 162], ["viruses", "OBSERVATION", 50, 57], ["throat", "ANATOMY", 80, 86], ["nasal", "ANATOMY", 151, 156]]], ["However, viral identification was not consistent between these methods or during the follow-up period.", [["viral identification", "TEST", 9, 29]]], ["In a study by Falsey et al. [26] the identification of Bordetella pertussis in IS differed between supernatants and cells from patients with exacerbation of asthma.", [["supernatants", "ANATOMY", 99, 111], ["cells", "ANATOMY", 116, 121], ["Bordetella pertussis", "DISEASE", 55, 75], ["asthma", "DISEASE", 157, 163], ["Bordetella pertussis", "ORGANISM", 55, 75], ["cells", "CELL", 116, 121], ["patients", "ORGANISM", 127, 135], ["Bordetella pertussis", "SPECIES", 55, 75], ["patients", "SPECIES", 127, 135], ["Bordetella pertussis", "SPECIES", 55, 75], ["a study", "TEST", 3, 10], ["Bordetella pertussis", "PROBLEM", 55, 75], ["exacerbation", "PROBLEM", 141, 153], ["asthma", "PROBLEM", 157, 163], ["pertussis", "OBSERVATION", 66, 75], ["asthma", "OBSERVATION", 157, 163]]], ["Hence, our results should be further confirmed in studies involving larger patient populations and, if possible, more direct airway sampling techniques.ConclusionsIn summary, our findings indicate that, despite some differences in the clinical and inflammatory characteristics of asthma between elderly and non-elderly patients, the microbial composition of IS samples from stable patients is similar.", [["airway", "ANATOMY", 125, 131], ["samples", "ANATOMY", 361, 368], ["asthma", "DISEASE", 280, 286], ["patient", "ORGANISM", 75, 82], ["airway", "MULTI-TISSUE_STRUCTURE", 125, 131], ["patients", "ORGANISM", 319, 327], ["patients", "ORGANISM", 381, 389], ["patient", "SPECIES", 75, 82], ["patients", "SPECIES", 319, 327], ["patients", "SPECIES", 381, 389], ["direct airway sampling techniques", "TEST", 118, 151], ["asthma", "PROBLEM", 280, 286], ["larger", "OBSERVATION_MODIFIER", 68, 74], ["inflammatory", "OBSERVATION_MODIFIER", 248, 260], ["asthma", "OBSERVATION", 280, 286], ["stable", "OBSERVATION_MODIFIER", 374, 380], ["similar", "OBSERVATION_MODIFIER", 393, 400]]]], "cddbec166688aaf25aa6e2e6dc76a90668ba9e9d": [["IntroductionThe InterFeron Inducible TransMembrane (IFITM) protein family of viral restriction factors was defined in 2009 in a screen for host-modifying proteins of influenza A virus (IAV) infection [1] .", [["influenza A virus (IAV) infection", "DISEASE", 166, 199], ["InterFeron Inducible TransMembrane", "GENE_OR_GENE_PRODUCT", 16, 50], ["IFITM", "GENE_OR_GENE_PRODUCT", 52, 57], ["influenza A virus", "ORGANISM", 166, 183], ["IAV", "ORGANISM", 185, 188], ["InterFeron Inducible TransMembrane (IFITM) protein family", "PROTEIN", 16, 73], ["viral restriction factors", "PROTEIN", 77, 102], ["host-modifying proteins", "PROTEIN", 139, 162], ["influenza A virus", "SPECIES", 166, 183], ["influenza A virus", "SPECIES", 166, 183], ["IAV", "SPECIES", 185, 188], ["The InterFeron Inducible TransMembrane (IFITM)", "TREATMENT", 12, 58], ["viral restriction factors", "PROBLEM", 77, 102], ["influenza A virus (IAV) infection", "PROBLEM", 166, 199]]], ["Initially identified over 30 years ago [2] , and named 9-27 (IFITM1), 1-8D (IFITM2) and 1-8U (IFITM3) [3] , these proteins received little attention until human IFITM3 depletion was found to enhance IAV infection in cell culture assays.", [["cell", "ANATOMY", 216, 220], ["infection", "DISEASE", 203, 212], ["1-8D", "GENE_OR_GENE_PRODUCT", 70, 74], ["IFITM2", "GENE_OR_GENE_PRODUCT", 76, 82], ["1-8U", "GENE_OR_GENE_PRODUCT", 88, 92], ["IFITM3) [3", "GENE_OR_GENE_PRODUCT", 94, 104], ["human", "ORGANISM", 155, 160], ["IFITM3", "GENE_OR_GENE_PRODUCT", 161, 167], ["IAV", "ORGANISM", 199, 202], ["cell", "CELL", 216, 220], ["IFITM3", "PROTEIN", 161, 167], ["human", "SPECIES", 155, 160], ["human", "SPECIES", 155, 160], ["IAV", "SPECIES", 199, 202], ["these proteins", "TREATMENT", 108, 122], ["little attention", "TREATMENT", 132, 148], ["human IFITM3 depletion", "PROBLEM", 155, 177], ["IAV infection", "PROBLEM", 199, 212], ["cell culture assays", "TEST", 216, 235], ["IAV", "OBSERVATION_MODIFIER", 199, 202], ["infection", "OBSERVATION", 203, 212]]], ["Conversely, overexpression of IFITM3, or the closely related IFITM1 and IFITM2, could inhibit IAV replication [1] .", [["IFITM3", "GENE_OR_GENE_PRODUCT", 30, 36], ["IFITM1", "GENE_OR_GENE_PRODUCT", 61, 67], ["IFITM2", "GENE_OR_GENE_PRODUCT", 72, 78], ["IFITM3", "PROTEIN", 30, 36], ["IFITM1", "PROTEIN", 61, 67], ["IFITM2", "PROTEIN", 72, 78], ["IAV", "SPECIES", 94, 97], ["IFITM3", "PROBLEM", 30, 36], ["IAV replication", "TREATMENT", 94, 109]]], ["Studies in mice and humans have suggested that IFITM3, at least, also protects against IAV infection in vivo [4, 5] .", [["IFITM3", "CHEMICAL", 47, 53], ["IAV infection", "DISEASE", 87, 100], ["mice", "ORGANISM", 11, 15], ["humans", "ORGANISM", 20, 26], ["IFITM3", "GENE_OR_GENE_PRODUCT", 47, 53], ["IAV", "ORGANISM", 87, 90], ["IFITM3", "PROTEIN", 47, 53], ["mice", "SPECIES", 11, 15], ["humans", "SPECIES", 20, 26], ["mice", "SPECIES", 11, 15], ["humans", "SPECIES", 20, 26], ["IAV", "SPECIES", 87, 90], ["IFITM3", "PROBLEM", 47, 53], ["IAV infection", "PROBLEM", 87, 100], ["infection", "OBSERVATION", 91, 100]]], ["However, the IFITM proteins are not IAV-specific and, in cell culture at least, have broad-spectrum antiviral activity [6] , though in some systems they may enhance cellular infection of human coronavirus OC43 [7] and human papillomavirus 16 [8] .IntroductionShortly after the identification of IFITM1-3 as antiviral factors, over-expression of IFITM3 was shown to cause an accumulation of intact IAV particles in endocytic organelles [9] , suggesting that IFITM3 interfered with viral entry following endocytosis.", [["cell culture", "ANATOMY", 57, 69], ["cellular", "ANATOMY", 165, 173], ["endocytic organelles", "ANATOMY", 414, 434], ["infection", "DISEASE", 174, 183], ["IFITM", "GENE_OR_GENE_PRODUCT", 13, 18], ["cell", "CELL", 57, 61], ["cellular", "CELL", 165, 173], ["human", "ORGANISM", 187, 192], ["coronavirus OC43 [7]", "ORGANISM", 193, 213], ["human papillomavirus 16", "ORGANISM", 218, 241], ["IFITM1-3", "GENE_OR_GENE_PRODUCT", 295, 303], ["IFITM3", "GENE_OR_GENE_PRODUCT", 345, 351], ["endocytic organelles", "CELLULAR_COMPONENT", 414, 434], ["IFITM3", "GENE_OR_GENE_PRODUCT", 457, 463], ["IFITM proteins", "PROTEIN", 13, 27], ["IFITM1", "PROTEIN", 295, 301], ["antiviral factors", "PROTEIN", 307, 324], ["IFITM3", "PROTEIN", 345, 351], ["IFITM3", "PROTEIN", 457, 463], ["human", "SPECIES", 187, 192], ["coronavirus", "SPECIES", 193, 204], ["human", "SPECIES", 218, 223], ["papillomavirus", "SPECIES", 224, 238], ["human coronavirus", "SPECIES", 187, 204], ["human papillomavirus 16", "SPECIES", 218, 241], ["the IFITM proteins", "TEST", 9, 27], ["IAV", "PROBLEM", 36, 39], ["cell culture", "TEST", 57, 69], ["broad-spectrum antiviral activity", "TREATMENT", 85, 118], ["cellular infection of human coronavirus OC43", "PROBLEM", 165, 209], ["human papillomavirus", "TEST", 218, 238], ["IFITM1", "TEST", 295, 301], ["antiviral factors", "TREATMENT", 307, 324], ["IFITM3", "PROBLEM", 345, 351], ["an accumulation of intact IAV particles", "PROBLEM", 371, 410], ["IFITM3", "PROBLEM", 457, 463], ["antiviral activity", "OBSERVATION", 100, 118], ["infection", "OBSERVATION", 174, 183], ["intact IAV particles", "OBSERVATION", 390, 410]]], ["Furthermore, this activity was dependent on localisation of IFITM3 to endosomes [10] .", [["endosomes", "ANATOMY", 70, 79], ["IFITM3", "GENE_OR_GENE_PRODUCT", 60, 66], ["endosomes", "CELLULAR_COMPONENT", 70, 79], ["IFITM3", "PROTEIN", 60, 66]]], ["More recent studies suggested that IFITM over-expression may increase membrane rigidity and positive curvature, preventing the early events in membrane fusion [11] .", [["membrane", "ANATOMY", 70, 78], ["membrane", "ANATOMY", 143, 151], ["rigidity", "DISEASE", 79, 87], ["IFITM", "GENE_OR_GENE_PRODUCT", 35, 40], ["membrane", "CELLULAR_COMPONENT", 70, 78], ["membrane", "CELLULAR_COMPONENT", 143, 151], ["IFITM", "PROTEIN", 35, 40], ["recent studies", "TEST", 5, 19], ["increase membrane rigidity", "PROBLEM", 61, 87], ["positive curvature", "PROBLEM", 92, 110], ["the early events", "PROBLEM", 123, 139], ["membrane fusion", "TREATMENT", 143, 158], ["membrane rigidity", "OBSERVATION", 70, 87], ["positive curvature", "OBSERVATION", 92, 110], ["membrane fusion", "OBSERVATION", 143, 158]]], ["Alternatively, IFITM protein interaction with vesicle membrane protein associated protein A (VAPA), disrupts cholesterol homeostasis and may increase membrane rigidity [12] .", [["vesicle membrane", "ANATOMY", 46, 62], ["membrane", "ANATOMY", 150, 158], ["cholesterol", "CHEMICAL", 109, 120], ["rigidity", "DISEASE", 159, 167], ["cholesterol", "CHEMICAL", 109, 120], ["IFITM", "GENE_OR_GENE_PRODUCT", 15, 20], ["vesicle membrane protein associated protein A", "GENE_OR_GENE_PRODUCT", 46, 91], ["VAPA", "GENE_OR_GENE_PRODUCT", 93, 97], ["cholesterol", "SIMPLE_CHEMICAL", 109, 120], ["membrane", "CELLULAR_COMPONENT", 150, 158], ["IFITM protein", "PROTEIN", 15, 28], ["vesicle membrane protein associated protein A", "PROTEIN", 46, 91], ["VAPA", "PROTEIN", 93, 97], ["IFITM protein interaction", "PROBLEM", 15, 40], ["vesicle membrane protein", "TEST", 46, 70], ["disrupts cholesterol homeostasis", "PROBLEM", 100, 132], ["increase membrane rigidity", "PROBLEM", 141, 167], ["increase", "OBSERVATION_MODIFIER", 141, 149], ["membrane rigidity", "OBSERVATION", 150, 167]]], ["However, more recent work has questioned the role of cholesterol [13, 14] .", [["cholesterol", "CHEMICAL", 53, 64], ["cholesterol", "CHEMICAL", 53, 64], ["cholesterol", "SIMPLE_CHEMICAL", 53, 64], ["13, 14]", "SIMPLE_CHEMICAL", 66, 73]]], ["Thus, the precise molecular mechanism(s) for IFITM inhibition of viral entry remains to be established.IntroductionFrom their first descriptions, the IFITM proteins were thought to be membrane proteins [15] .", [["membrane", "ANATOMY", 184, 192], ["IFITM", "GENE_OR_GENE_PRODUCT", 45, 50], ["IFITM", "GENE_OR_GENE_PRODUCT", 150, 155], ["membrane", "CELLULAR_COMPONENT", 184, 192], ["IFITM", "PROTEIN", 45, 50], ["IFITM proteins", "PROTEIN", 150, 164], ["membrane proteins", "PROTEIN", 184, 201], ["IFITM inhibition", "TREATMENT", 45, 61], ["viral entry", "PROBLEM", 65, 76], ["the IFITM proteins", "TEST", 146, 164], ["membrane proteins", "PROBLEM", 184, 201]]], ["Indeed, sequence analyses identified two hydrophobic, putative membrane interacting domains in each of the proteins.", [["membrane", "ANATOMY", 63, 71], ["membrane", "CELLULAR_COMPONENT", 63, 71], ["hydrophobic, putative membrane interacting domains", "PROTEIN", 41, 91], ["sequence analyses", "TEST", 8, 25], ["hydrophobic", "OBSERVATION_MODIFIER", 41, 52]]], ["Additional studies demonstrated palmitoylation of cysteine residues adjacent to the hydrophobic domains, a post-translational modification indicative of membrane proteins [16] .", [["membrane", "ANATOMY", 153, 161], ["cysteine", "CHEMICAL", 50, 58], ["cysteine", "CHEMICAL", 50, 58], ["cysteine", "AMINO_ACID", 50, 58], ["membrane", "CELLULAR_COMPONENT", 153, 161], ["hydrophobic domains", "PROTEIN", 84, 103], ["membrane proteins", "PROTEIN", 153, 170], ["Additional studies", "TEST", 0, 18], ["palmitoylation of cysteine residues", "TREATMENT", 32, 67], ["the hydrophobic domains", "PROBLEM", 80, 103], ["membrane proteins", "PROBLEM", 153, 170], ["cysteine residues", "OBSERVATION", 50, 67]]], ["However, the membrane topology of the IFITM proteins has remained ambiguous.", [["membrane", "ANATOMY", 13, 21], ["membrane", "CELLULAR_COMPONENT", 13, 21], ["IFITM", "GENE_OR_GENE_PRODUCT", 38, 43], ["IFITM proteins", "PROTEIN", 38, 52], ["the IFITM proteins", "TEST", 34, 52]]], ["Initially, they were suggested to be dual pass, transmembrane proteins with both N-and Cterminal domains (NTD and CTD) exposed extracellularly and a conserved intracellular loop (CIL) (Fig. 1, model 1) .", [["intracellular", "ANATOMY", 159, 172], ["intracellular loop", "CELLULAR_COMPONENT", 159, 177], ["transmembrane proteins", "PROTEIN", 48, 70], ["N-and Cterminal domains", "PROTEIN", 81, 104], ["NTD", "PROTEIN", 106, 109], ["CTD", "PROTEIN", 114, 117], ["conserved intracellular loop", "PROTEIN", 149, 177], ["CIL", "PROTEIN", 179, 182], ["transmembrane proteins", "TEST", 48, 70], ["both N-and Cterminal domains", "TREATMENT", 76, 104], ["a conserved intracellular loop (CIL", "TREATMENT", 147, 182], ["intracellular loop", "OBSERVATION", 159, 177]]], ["This model was based on the ability of antibodies against unknown IFITM1 external epitopes to aggregate leukaemia cells [15, 17] , immunoprecipitation of extracellular radiolabelled IFITM1 [18] and the accessibility of IFITM3 NTD and CTD epitope tags at the cell surface by FACS and immunofluorescence assays, respectively [1] .IntroductionThis topology was subsequently challenged by studies demonstrating that the NTD and CIL domain of IFITM3 are posttranslationally modified by cytoplasmic enzymes [10, 19] .", [["leukaemia cells", "ANATOMY", 104, 119], ["extracellular", "ANATOMY", 154, 167], ["cell surface", "ANATOMY", 258, 270], ["cytoplasmic", "ANATOMY", 481, 492], ["leukaemia", "DISEASE", 104, 113], ["IFITM1", "GENE_OR_GENE_PRODUCT", 66, 72], ["leukaemia cells", "CELL", 104, 119], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 154, 167], ["IFITM3", "GENE_OR_GENE_PRODUCT", 219, 225], ["cell surface", "CELLULAR_COMPONENT", 258, 270], ["IFITM3", "GENE_OR_GENE_PRODUCT", 438, 444], ["cytoplasmic", "ORGANISM_SUBSTANCE", 481, 492], ["antibodies", "PROTEIN", 39, 49], ["IFITM1 external epitopes", "PROTEIN", 66, 90], ["leukaemia cells", "CELL_TYPE", 104, 119], ["IFITM3 NTD", "PROTEIN", 219, 229], ["CTD epitope tags", "PROTEIN", 234, 250], ["NTD", "PROTEIN", 416, 419], ["CIL domain", "PROTEIN", 424, 434], ["IFITM3", "PROTEIN", 438, 444], ["cytoplasmic enzymes", "PROTEIN", 481, 500], ["antibodies", "TREATMENT", 39, 49], ["unknown IFITM1 external epitopes to aggregate leukaemia cells", "PROBLEM", 58, 119], ["extracellular radiolabelled IFITM1", "TEST", 154, 188], ["IFITM3 NTD", "PROBLEM", 219, 229], ["CTD epitope tags", "PROBLEM", 234, 250], ["FACS", "TEST", 274, 278], ["immunofluorescence assays", "TEST", 283, 308], ["the NTD", "PROBLEM", 412, 419], ["CIL domain of IFITM3", "TREATMENT", 424, 444], ["cytoplasmic enzymes", "TEST", 481, 500], ["leukaemia cells", "OBSERVATION", 104, 119], ["IFITM3 NTD", "OBSERVATION", 219, 229]]], ["Moreover, engineered myristoylation and prenylation sites at the NTD and CTD of murine IFITM3 can be detected as lipidated with selective chemical reporters alk-12 and alk-FOH, respectively [19] .", [["murine", "ORGANISM", 80, 86], ["IFITM3", "GENE_OR_GENE_PRODUCT", 87, 93], ["alk-12", "SIMPLE_CHEMICAL", 157, 163], ["alk-FOH", "SIMPLE_CHEMICAL", 168, 175], ["engineered myristoylation and prenylation sites", "PROTEIN", 10, 57], ["NTD", "PROTEIN", 65, 68], ["CTD", "PROTEIN", 73, 76], ["murine IFITM3", "PROTEIN", 80, 93], ["alk", "PROTEIN", 168, 171], ["murine", "SPECIES", 80, 86], ["engineered myristoylation", "TREATMENT", 10, 35], ["prenylation sites", "TREATMENT", 40, 57], ["CTD of murine IFITM3", "TREATMENT", 73, 93], ["alk", "TEST", 157, 160], ["alk", "TEST", 168, 171], ["prenylation sites", "OBSERVATION", 40, 57]]], ["These data suggested that both the NTD and CTD of IFITM3 are intracellular, and that the two hydrophobic sequences, enter, but do not span, the lipid bilayer [19] (Fig. 1, model 2) .", [["intracellular", "ANATOMY", 61, 74], ["IFITM3", "GENE_OR_GENE_PRODUCT", 50, 56], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 61, 74], ["NTD", "PROTEIN", 35, 38], ["CTD", "PROTEIN", 43, 46], ["IFITM3", "PROTEIN", 50, 56], ["These data", "TEST", 0, 10], ["the two hydrophobic sequences", "TEST", 85, 114], ["the lipid bilayer", "TEST", 140, 157], ["Fig.", "TEST", 164, 168], ["NTD", "OBSERVATION", 35, 38]]], ["Murine IFITM1 was also proposed to have this topology [20] .IntroductionBased on multiple approaches a third model has since been proposed for mu IFITM3, with the NTD and CIL facing the cytoplasm and the CTD located in the extracellular space, or within the lumen of vesicular organelles [21] (Fig. 1, model 3) .", [["cytoplasm", "ANATOMY", 186, 195], ["extracellular space", "ANATOMY", 223, 242], ["lumen", "ANATOMY", 258, 263], ["vesicular organelles", "ANATOMY", 267, 287], ["Murine", "ORGANISM", 0, 6], ["IFITM1", "GENE_OR_GENE_PRODUCT", 7, 13], ["mu IFITM3", "GENE_OR_GENE_PRODUCT", 143, 152], ["CIL", "CANCER", 171, 174], ["cytoplasm", "ORGANISM_SUBSTANCE", 186, 195], ["extracellular space", "CELLULAR_COMPONENT", 223, 242], ["lumen", "IMMATERIAL_ANATOMICAL_ENTITY", 258, 263], ["vesicular organelles", "CELLULAR_COMPONENT", 267, 287], ["Murine IFITM1", "PROTEIN", 0, 13], ["mu IFITM3", "PROTEIN", 143, 152], ["NTD", "PROTEIN", 163, 166], ["CIL", "PROTEIN", 171, 174], ["CTD", "PROTEIN", 204, 207], ["Murine", "SPECIES", 0, 6], ["mu IFITM3", "TREATMENT", 143, 152], ["the NTD", "TREATMENT", 159, 166], ["the CTD", "PROBLEM", 200, 207], ["CTD", "OBSERVATION", 204, 207], ["extracellular space", "ANATOMY", 223, 242], ["lumen", "ANATOMY_MODIFIER", 258, 263], ["vesicular", "ANATOMY_MODIFIER", 267, 276]]], ["While this manuscript was under revision, an additional study suggested a similar topology for human IFITM3 [22] .", [["human", "ORGANISM", 95, 100], ["human", "SPECIES", 95, 100], ["human", "SPECIES", 95, 100], ["revision", "TREATMENT", 32, 40], ["an additional study", "TEST", 42, 61]]], ["However, it remains unclear whether C-terminal epitope tags influence the topology, and whether the proposed topology applies to other human IFITM proteins.IntroductionUsing immunofluorescence microscopy, protease cleavage assays, immuno-electron microscopy and biotin-labelling approaches, our data support the notion that the NTD of human IFITM1 is located in the cytoplasm, while the CTD is extracellular (Fig. 1, model 3) .", [["cytoplasm", "ANATOMY", 366, 375], ["extracellular", "ANATOMY", 394, 407], ["biotin", "CHEMICAL", 262, 268], ["C", "CHEMICAL", 36, 37], ["biotin", "CHEMICAL", 262, 268], ["human", "ORGANISM", 135, 140], ["IFITM", "GENE_OR_GENE_PRODUCT", 141, 146], ["biotin", "SIMPLE_CHEMICAL", 262, 268], ["human", "ORGANISM", 335, 340], ["IFITM1", "GENE_OR_GENE_PRODUCT", 341, 347], ["cytoplasm", "ORGANISM_SUBSTANCE", 366, 375], ["CTD", "GENE_OR_GENE_PRODUCT", 387, 390], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 394, 407], ["C-terminal epitope tags", "PROTEIN", 36, 59], ["human IFITM proteins", "PROTEIN", 135, 155], ["protease", "PROTEIN", 205, 213], ["NTD", "PROTEIN", 328, 331], ["human IFITM1", "PROTEIN", 335, 347], ["CTD", "PROTEIN", 387, 390], ["human", "SPECIES", 135, 140], ["human", "SPECIES", 335, 340], ["human", "SPECIES", 135, 140], ["human", "SPECIES", 335, 340], ["C-terminal epitope tags", "PROBLEM", 36, 59], ["human IFITM proteins", "TREATMENT", 135, 155], ["IntroductionUsing immunofluorescence microscopy", "TEST", 156, 203], ["protease cleavage assays", "TEST", 205, 229], ["electron microscopy", "TEST", 238, 257], ["biotin-labelling approaches", "TREATMENT", 262, 289], ["human IFITM1", "TREATMENT", 335, 347]]], ["We provide evidence that the presence of a HAtag at the IFITM1 C-terminus does not induce this topology.", [["C", "CHEMICAL", 63, 64], ["HAtag", "GENE_OR_GENE_PRODUCT", 43, 48], ["HAtag", "PROTEIN", 43, 48], ["IFITM1 C-terminus", "PROTEIN", 56, 73], ["a HAtag", "PROBLEM", 41, 48]]], ["We also show that, although human IFITM2 and IFITM3 reside predominantly in intracellular membranes, they adopt the same topology.", [["intracellular membranes", "ANATOMY", 76, 99], ["human", "ORGANISM", 28, 33], ["IFITM2", "GENE_OR_GENE_PRODUCT", 34, 40], ["IFITM3", "GENE_OR_GENE_PRODUCT", 45, 51], ["intracellular membranes", "CELLULAR_COMPONENT", 76, 99], ["human IFITM2", "PROTEIN", 28, 40], ["IFITM3", "PROTEIN", 45, 51], ["human", "SPECIES", 28, 33], ["human", "SPECIES", 28, 33], ["intracellular membranes", "OBSERVATION", 76, 99]]], ["Together our data are consistent with the recently proposed model for mu IFITM3 [21] , but not with that proposed for mu IFITM1 [20] .Materials and MethodsCell lines and constructs A549 (adenocarcinoma of human lung epithelia) cell lines stably expressing C-terminally HA-tagged human (hu) IFITM1, IFITM2 or IFITM3, as well as untransfected A549 cells [23] , were cultured in Ham's F-12-GlutaMAX media (tissue culture reagents were from Life Technologies, unless indicated otherwise) supplemented with 10% (v/v) foetal calf serum (FCS) (PAA) and 1% (v/v) Penicillin/Streptomycin (Pen/Strep, 10,000 unit/ml/10,000 mg/ ml).", [["Cell lines", "ANATOMY", 155, 165], ["A549", "ANATOMY", 181, 185], ["adenocarcinoma", "ANATOMY", 187, 201], ["lung epithelia) cell lines", "ANATOMY", 211, 237], ["A549 cells", "ANATOMY", 341, 351], ["tissue culture", "ANATOMY", 403, 417], ["serum", "ANATOMY", 524, 529], ["F-12-GlutaMAX", "CHEMICAL", 382, 395], ["PAA", "CHEMICAL", 537, 540], ["Penicillin", "CHEMICAL", 555, 565], ["Streptomycin", "CHEMICAL", 566, 578], ["PAA", "CHEMICAL", 537, 540], ["Penicillin", "CHEMICAL", 555, 565], ["Streptomycin", "CHEMICAL", 566, 578], ["Cell lines", "CELL", 155, 165], ["constructs A549", "CELL", 170, 185], ["adenocarcinoma", "CANCER", 187, 201], ["human", "ORGANISM", 205, 210], ["lung epithelia) cell lines", "CELL", 211, 237], ["human", "ORGANISM", 279, 284], ["(hu) IFITM1", "GENE_OR_GENE_PRODUCT", 285, 296], ["IFITM2", "GENE_OR_GENE_PRODUCT", 298, 304], ["IFITM3", "GENE_OR_GENE_PRODUCT", 308, 314], ["A549 cells", "CELL", 341, 351], ["Ham", "CELL", 376, 379], ["F-12-GlutaMAX", "SIMPLE_CHEMICAL", 382, 395], ["tissue", "TISSUE", 403, 409], ["foetal", "ORGANISM", 512, 518], ["calf", "ORGANISM", 519, 523], ["serum", "ORGANISM_SUBSTANCE", 524, 529], ["FCS", "ORGANISM_SUBSTANCE", 531, 534], ["PAA", "SIMPLE_CHEMICAL", 537, 540], ["v) Penicillin", "SIMPLE_CHEMICAL", 552, 565], ["Streptomycin", "SIMPLE_CHEMICAL", 566, 578], ["Pen", "ORGANISM", 580, 583], ["Strep", "SIMPLE_CHEMICAL", 584, 589], ["A549", "CELL_LINE", 181, 185], ["human lung epithelia) cell lines", "CELL_LINE", 205, 237], ["C-terminally HA", "PROTEIN", 256, 271], ["tagged human (hu) IFITM1", "PROTEIN", 272, 296], ["IFITM2", "PROTEIN", 298, 304], ["IFITM3", "PROTEIN", 308, 314], ["untransfected A549 cells", "CELL_LINE", 327, 351], ["human", "SPECIES", 205, 210], ["human", "SPECIES", 279, 284], ["calf", "SPECIES", 519, 523], ["human", "SPECIES", 205, 210], ["human", "SPECIES", 279, 284], ["Materials", "TREATMENT", 134, 143], ["MethodsCell lines", "TREATMENT", 148, 165], ["constructs A549 (adenocarcinoma of human lung epithelia", "PROBLEM", 170, 225], ["cell lines", "TEST", 227, 237], ["terminally HA", "PROBLEM", 258, 271], ["IFITM3", "PROBLEM", 308, 314], ["A549 cells", "TEST", 341, 351], ["Ham's F", "TEST", 376, 383], ["GlutaMAX media", "TREATMENT", 387, 401], ["tissue culture reagents", "TEST", 403, 426], ["foetal calf serum", "TEST", 512, 529], ["Penicillin", "TREATMENT", 555, 565], ["Streptomycin (Pen/Strep", "TREATMENT", 566, 589], ["consistent with", "UNCERTAINTY", 22, 37], ["Cell lines", "OBSERVATION", 155, 165], ["adenocarcinoma", "OBSERVATION", 187, 201], ["lung", "ANATOMY", 211, 215], ["epithelia", "ANATOMY_MODIFIER", 216, 225], ["cell lines", "OBSERVATION", 227, 237], ["calf", "ANATOMY", 519, 523]]], ["HEK293T cells were cultured in DMEM-GlutaMAX supplemented with 10% (v/v) FCS and 1% (v/v) Pen/Strep.", [["HEK293T cells", "ANATOMY", 0, 13], ["GlutaMAX", "CHEMICAL", 36, 44], ["HEK293T cells", "CELL", 0, 13], ["HEK293T cells", "CELL_LINE", 0, 13], ["HEK293T cells", "TEST", 0, 13], ["DMEM", "TEST", 31, 35], ["GlutaMAX", "TREATMENT", 36, 44], ["FCS", "TEST", 73, 76], ["Strep", "PROBLEM", 94, 99], ["Strep", "OBSERVATION", 94, 99]]], ["All cell lines were maintained at 37uC and 5% CO 2 .", [["cell lines", "ANATOMY", 4, 14], ["CO 2", "CHEMICAL", 46, 50], ["cell lines", "CELL", 4, 14], ["cell lines", "CELL_LINE", 4, 14], ["All cell lines", "TREATMENT", 0, 14], ["cell lines", "OBSERVATION", 4, 14]]], ["Untagged IFITM1 and IFITM1-Vstop (a construct with a stop codon after Val109) were purchased from GeneArt and cloned into BamH1/ Not1 sites of pcDNA3.1.", [["Val", "CHEMICAL", 70, 73], ["IFITM1", "GENE_OR_GENE_PRODUCT", 9, 15], ["IFITM1-Vstop", "GENE_OR_GENE_PRODUCT", 20, 32], ["BamH1", "GENE_OR_GENE_PRODUCT", 122, 127], ["Not1", "GENE_OR_GENE_PRODUCT", 129, 133], ["pcDNA3", "GENE_OR_GENE_PRODUCT", 143, 149], ["IFITM1", "PROTEIN", 9, 15], ["IFITM1", "DNA", 20, 26], ["Vstop", "DNA", 27, 32], ["stop codon", "DNA", 53, 63], ["GeneArt", "DNA", 98, 105], ["BamH1/ Not1 sites", "DNA", 122, 139], ["pcDNA3", "DNA", 143, 149], ["IFITM1", "TEST", 9, 15], ["IFITM1", "TEST", 20, 26], ["a stop codon", "TREATMENT", 51, 63], ["GeneArt", "TREATMENT", 98, 105], ["pcDNA3", "TREATMENT", 143, 149]]], ["Constructs were confirmed by sequencing (Source BioScience).AntibodiesRat anti-HA (100 mg/ml, clone 3F10, Roche), mouse anti-HA (1 mg/ml, clone HA.11, 16B12 Covance), rabbit anti-IFITM1-NTD (100 mg/ml, Sigma), rabbit anti-IFITM3-NTD (250 mg/ml, Abgent), rabbit anti-VDAC (1 mg/ml, Abcam), rabbit anticalreticulin (Thermo Scientific), mouse anti-tubulin (clone DM1A, ascites fluid, Sigma), goat anti-rat Alexa-488, goat antirabbit Alexa-488, goat anti-mouse Alexa-594 and goat anti-rabbit Alexa-647 (all 2 mg/ml, Life Technologies), goat anti-rabbit IRDye 680 and goat anti-mouse IRDye 800 (1 mg/ml, Li-COR), and wheat germ agglutinin (WGA) conjugated to Alexa-647 fluorophore (1 mg/ml, Invitrogen), were used at the dilutions given below.Permeabilised immunofluorescenceCells cultured on coverslips were fixed in 3% (w/v) formaldehyde (FA) (TAAB) in phosphate buffered saline (PBS) for 15 minutes (min), quenched with 50 mM NH 4 Cl and 0.2% (w/ v) bovine serum albumin (BSA, Sigma) in PBS (PBS/BSA) for 15 min and then permeabilised in PBS/BSA and 0.05% (w/v) saponin (Sigma) (permeabilisation buffer [PB]) for 30 min at room temperature (RT).", [["ascites fluid", "ANATOMY", 366, 379], ["coverslips", "ANATOMY", 788, 798], ["serum", "ANATOMY", 955, 960], ["anti-IFITM3", "CHEMICAL", 217, 228], ["anti-VDAC", "CHEMICAL", 261, 270], ["ascites", "DISEASE", 366, 373], ["Alexa-488", "CHEMICAL", 403, 412], ["Alexa-488", "CHEMICAL", 430, 439], ["Alexa-594", "CHEMICAL", 457, 466], ["Alexa-647", "CHEMICAL", 488, 497], ["IRDye 800", "CHEMICAL", 579, 588], ["Alexa-647", "CHEMICAL", 654, 663], ["formaldehyde", "CHEMICAL", 822, 834], ["FA", "CHEMICAL", 836, 838], ["TAAB", "CHEMICAL", 841, 845], ["phosphate", "CHEMICAL", 850, 859], ["NH 4 Cl", "CHEMICAL", 924, 931], ["BSA", "CHEMICAL", 1040, 1043], ["Alexa-488", "CHEMICAL", 430, 439], ["Alexa-647", "CHEMICAL", 488, 497], ["Alexa-647", "CHEMICAL", 654, 663], ["formaldehyde", "CHEMICAL", 822, 834], ["TAAB", "CHEMICAL", 841, 845], ["phosphate", "CHEMICAL", 850, 859], ["NH 4 Cl", "CHEMICAL", 924, 931], ["saponin", "CHEMICAL", 1060, 1067], ["anti-HA", "GENE_OR_GENE_PRODUCT", 74, 81], ["Roche", "ORGANISM", 106, 111], ["mouse", "ORGANISM", 114, 119], ["anti-HA", "GENE_OR_GENE_PRODUCT", 120, 127], ["rabbit", "ORGANISM", 167, 173], ["anti-IFITM1-NTD", "SIMPLE_CHEMICAL", 174, 189], ["rabbit", "ORGANISM", 210, 216], ["anti-IFITM3-NTD", "SIMPLE_CHEMICAL", 217, 232], ["rabbit", "ORGANISM", 254, 260], ["anti-VDAC", "SIMPLE_CHEMICAL", 261, 270], ["Abcam", "GENE_OR_GENE_PRODUCT", 281, 286], ["rabbit", "ORGANISM", 289, 295], ["anticalreticulin", "SIMPLE_CHEMICAL", 296, 312], ["mouse", "ORGANISM", 334, 339], ["anti-tubulin", "GENE_OR_GENE_PRODUCT", 340, 352], ["clone", "ORGANISM", 354, 359], ["DM1A", "ORGANISM", 360, 364], ["fluid", "ORGANISM_SUBSTANCE", 374, 379], ["goat", "ORGANISM", 389, 393], ["Alexa-488", "SIMPLE_CHEMICAL", 403, 412], ["goat", "ORGANISM", 414, 418], ["Alexa-488", "SIMPLE_CHEMICAL", 430, 439], ["goat", "ORGANISM", 441, 445], ["Alexa-594", "SIMPLE_CHEMICAL", 457, 466], ["goat", "ORGANISM", 471, 475], ["Alexa-647", "SIMPLE_CHEMICAL", 488, 497], ["goat", "ORGANISM", 532, 536], ["IRDye 680", "SIMPLE_CHEMICAL", 549, 558], ["goat", "ORGANISM", 563, 567], ["IRDye 800", "SIMPLE_CHEMICAL", 579, 588], ["Li-COR", "SIMPLE_CHEMICAL", 599, 605], ["wheat germ agglutinin", "SIMPLE_CHEMICAL", 612, 633], ["WGA", "SIMPLE_CHEMICAL", 635, 638], ["Alexa-647 fluorophore", "SIMPLE_CHEMICAL", 654, 675], ["/v) formaldehyde", "SIMPLE_CHEMICAL", 818, 834], ["FA", "SIMPLE_CHEMICAL", 836, 838], ["TAAB", "SIMPLE_CHEMICAL", 841, 845], ["phosphate buffered saline", "SIMPLE_CHEMICAL", 850, 875], ["NH 4 Cl", "SIMPLE_CHEMICAL", 924, 931], ["bovine", "ORGANISM", 948, 954], ["serum", "ORGANISM_SUBSTANCE", 955, 960], ["albumin", "SIMPLE_CHEMICAL", 961, 968], ["BSA", "SIMPLE_CHEMICAL", 970, 973], ["Sigma", "SIMPLE_CHEMICAL", 975, 980], ["PBS", "SIMPLE_CHEMICAL", 985, 988], ["BSA", "SIMPLE_CHEMICAL", 994, 997], ["BSA", "SIMPLE_CHEMICAL", 1040, 1043], ["/v) saponin", "SIMPLE_CHEMICAL", 1056, 1067], ["Sigma)", "SIMPLE_CHEMICAL", 1069, 1075], ["Rat anti-HA", "PROTEIN", 70, 81], ["mouse anti-HA", "PROTEIN", 114, 127], ["mouse anti-tubulin", "PROTEIN", 334, 352], ["clone DM1A", "PROTEIN", 354, 364], ["goat anti-rat Alexa-488", "PROTEIN", 389, 412], ["goat antirabbit Alexa-488", "PROTEIN", 414, 439], ["goat anti-mouse Alexa-594", "PROTEIN", 441, 466], ["goat anti-rabbit Alexa-647", "PROTEIN", 471, 497], ["goat anti-rabbit IRDye 680", "PROTEIN", 532, 558], ["goat anti-mouse IRDye 800", "PROTEIN", 563, 588], ["Li-COR", "PROTEIN", 599, 605], ["wheat germ agglutinin", "PROTEIN", 612, 633], ["WGA", "PROTEIN", 635, 638], ["mouse", "SPECIES", 114, 119], ["rabbit", "SPECIES", 167, 173], ["rabbit", "SPECIES", 210, 216], ["rabbit", "SPECIES", 254, 260], ["rabbit", "SPECIES", 289, 295], ["mouse", "SPECIES", 334, 339], ["goat", "SPECIES", 389, 393], ["anti-rat", "SPECIES", 394, 402], ["goat", "SPECIES", 414, 418], ["goat", "SPECIES", 441, 445], ["anti-mouse", "SPECIES", 446, 456], ["goat", "SPECIES", 471, 475], ["anti-rabbit", "SPECIES", 476, 487], ["goat", "SPECIES", 532, 536], ["anti-rabbit", "SPECIES", 537, 548], ["goat", "SPECIES", 563, 567], ["anti-mouse", "SPECIES", 568, 578], ["wheat", "SPECIES", 612, 617], ["bovine", "SPECIES", 948, 954], ["Rat", "SPECIES", 70, 73], ["mouse", "SPECIES", 114, 119], ["rabbit", "SPECIES", 167, 173], ["rabbit", "SPECIES", 210, 216], ["rabbit", "SPECIES", 254, 260], ["rabbit", "SPECIES", 289, 295], ["mouse", "SPECIES", 334, 339], ["goat", "SPECIES", 389, 393], ["goat", "SPECIES", 414, 418], ["goat", "SPECIES", 441, 445], ["Alexa-594", "SPECIES", 457, 466], ["goat", "SPECIES", 471, 475], ["Alexa-647", "SPECIES", 488, 497], ["goat", "SPECIES", 532, 536], ["goat", "SPECIES", 563, 567], ["wheat", "SPECIES", 612, 617], ["Alexa-647", "SPECIES", 654, 663], ["AntibodiesRat anti-HA", "TREATMENT", 60, 81], ["mouse anti-HA", "TREATMENT", 114, 127], ["clone HA", "TREATMENT", 138, 146], ["rabbit anti-IFITM1-NTD", "TREATMENT", 167, 189], ["rabbit anti-IFITM3-NTD", "TREATMENT", 210, 232], ["Abgent", "TREATMENT", 245, 251], ["rabbit anti-VDAC", "TREATMENT", 254, 270], ["Abcam", "TREATMENT", 281, 286], ["rabbit anticalreticulin", "TREATMENT", 289, 312], ["mouse anti-tubulin (clone DM1A", "TREATMENT", 334, 364], ["ascites fluid", "TREATMENT", 366, 379], ["goat anti-rat Alexa", "TEST", 389, 408], ["goat anti-mouse Alexa", "TREATMENT", 441, 462], ["goat anti-rabbit Alexa", "TREATMENT", 471, 493], ["Life Technologies", "TREATMENT", 512, 529], ["goat anti-rabbit IRDye", "TREATMENT", 532, 554], ["goat anti-mouse IRDye", "TREATMENT", 563, 584], ["wheat germ agglutinin", "TREATMENT", 612, 633], ["Alexa", "TREATMENT", 654, 659], ["fluorophore", "TREATMENT", 664, 675], ["Invitrogen", "TREATMENT", 686, 696], ["Permeabilised immunofluorescenceCells", "PROBLEM", 738, 775], ["coverslips", "TEST", 788, 798], ["phosphate buffered saline", "TREATMENT", 850, 875], ["bovine serum albumin", "TEST", 948, 968], ["BSA", "TEST", 970, 973], ["PBS/BSA", "TEST", 990, 997], ["BSA", "TEST", 1040, 1043], ["ascites", "ANATOMY", 366, 373]]], ["Primary antibodies were diluted in PB and incubated with the coverslips for 1 hour (h).", [["PB", "ORGANISM_SUBSTANCE", 35, 37], ["Primary antibodies", "TREATMENT", 0, 18], ["the coverslips", "TREATMENT", 57, 71]]], ["Unbound antibody was washed off with PB (365 min).", [["Unbound antibody", "TREATMENT", 0, 16]]], ["Primary antibodies were detected with appropriate secondary antibodies conjugated to Alexa-488, Alexa-594 or Alexa-647, again, diluted in PB.", [["Alexa-488", "CHEMICAL", 85, 94], ["Alexa-594", "CHEMICAL", 96, 105], ["Alexa-647", "CHEMICAL", 109, 118], ["Alexa-488", "CHEMICAL", 85, 94], ["Alexa-594", "CHEMICAL", 96, 105], ["Alexa-647", "CHEMICAL", 109, 118], ["Alexa-488", "SIMPLE_CHEMICAL", 85, 94], ["Alexa-594", "SIMPLE_CHEMICAL", 96, 105], ["Alexa-647", "SIMPLE_CHEMICAL", 109, 118], ["PB", "CELL", 138, 140], ["antibodies", "PROTEIN", 8, 18], ["secondary antibodies", "PROTEIN", 50, 70], ["Alexa-594", "SPECIES", 96, 105], ["Alexa-647", "SPECIES", 109, 118], ["Primary antibodies", "TEST", 0, 18], ["Alexa", "TEST", 85, 90], ["Alexa", "TREATMENT", 96, 101], ["Alexa", "TREATMENT", 109, 114]]], ["Coverslips were mounted on Mowiol (Sigma) and imaged using a Leica TSC SPE confocal microscope.Intact cell immunofluorescenceCells cultured on coverslips were washed with ice cold PBS/ BSA then incubated with primary antibodies on ice for 1 h in ice cold PBS/BSA.", [["cell", "ANATOMY", 102, 106], ["Cells", "ANATOMY", 125, 130], ["coverslips", "ANATOMY", 143, 153], ["cell", "CELL", 102, 106], ["Cells", "CELL", 125, 130], ["BSA", "SIMPLE_CHEMICAL", 185, 188], ["BSA", "SIMPLE_CHEMICAL", 259, 262], ["primary antibodies", "PROTEIN", 209, 227], ["a Leica TSC SPE", "TREATMENT", 59, 74], ["coverslips", "TEST", 143, 153], ["ice cold PBS/ BSA", "TREATMENT", 171, 188], ["primary antibodies on ice", "TREATMENT", 209, 234], ["cell immunofluorescence", "OBSERVATION", 102, 125], ["BSA", "ANATOMY", 259, 262]]], ["Cells were washed to remove unbound antibody and fixed in ice cold 3% FA for 1 h (30 min on ice and 30 min at RT).", [["Cells", "ANATOMY", 0, 5], ["FA", "CHEMICAL", 70, 72], ["Cells", "CELL", 0, 5], ["FA", "SIMPLE_CHEMICAL", 70, 72], ["unbound antibody", "PROTEIN", 28, 44], ["unbound antibody", "TEST", 28, 44]]], ["Primary antibodies were detected with appropriate secondary antibodies in PBS/BSA.", [["BSA", "SIMPLE_CHEMICAL", 78, 81], ["antibodies", "PROTEIN", 8, 18], ["secondary antibodies", "PROTEIN", 50, 70], ["Primary antibodies", "TEST", 0, 18], ["appropriate secondary antibodies in PBS/BSA", "TREATMENT", 38, 81], ["BSA", "ANATOMY", 78, 81]]], ["Cells were processed and imaged as described above.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5]]], ["Wheat germ agglutinin staining WGA-Alexa-647 was bound to cells on ice for 10 min.", [["cells", "ANATOMY", 58, 63], ["WGA-Alexa-647", "CHEMICAL", 31, 44], ["Wheat germ agglutinin", "GENE_OR_GENE_PRODUCT", 0, 21], ["Alexa-647", "SIMPLE_CHEMICAL", 35, 44], ["cells", "CELL", 58, 63], ["Alexa-647", "PROTEIN", 35, 44], ["Wheat", "SPECIES", 0, 5], ["Wheat", "SPECIES", 0, 5], ["Wheat germ agglutinin staining WGA", "PROBLEM", 0, 34], ["germ agglutinin", "OBSERVATION", 6, 21]]], ["The cells were then washed four times with PBS/BSA and labelled using the intact cell staining procedure described above.Antibody feedingCells cultured on coverslips were incubated in media containing rat anti-HA for 3 h at 37uC.", [["cells", "ANATOMY", 4, 9], ["cell", "ANATOMY", 81, 85], ["Cells", "ANATOMY", 137, 142], ["coverslips", "ANATOMY", 155, 165], ["cells", "CELL", 4, 9], ["BSA", "SIMPLE_CHEMICAL", 47, 50], ["cell", "CELL", 81, 85], ["Cells", "CELL", 137, 142], ["coverslips", "CELL", 155, 165], ["rat", "ORGANISM", 201, 204], ["rat", "SPECIES", 201, 204], ["rat", "SPECIES", 201, 204], ["The cells", "TREATMENT", 0, 9], ["PBS/BSA", "TREATMENT", 43, 50], ["the intact cell staining procedure", "TREATMENT", 70, 104], ["Antibody feeding", "TREATMENT", 121, 137], ["coverslips", "TEST", 155, 165], ["rat anti-HA", "TREATMENT", 201, 212], ["intact cell", "OBSERVATION", 74, 85], ["staining procedure", "OBSERVATION", 86, 104]]], ["Unbound antibody was removed, and the cells then rinsed in PBS, fixed and permeabilised (as above) before incubation with anti-rat Alexa-488 in PB.", [["cells", "ANATOMY", 38, 43], ["Alexa-488", "CHEMICAL", 131, 140], ["Alexa-488", "CHEMICAL", 131, 140], ["cells", "CELL", 38, 43], ["Alexa-488", "SIMPLE_CHEMICAL", 131, 140], ["PB", "CELL", 144, 146], ["anti-rat Alexa-488", "PROTEIN", 122, 140], ["Unbound antibody", "TEST", 0, 16], ["anti-rat Alexa", "TREATMENT", 122, 136]]], ["Cells were mounted and imaged as described above.Antibody feedingFor all immunofluorescence, the antibodies were used as follows: rat anti-HA 1:100, rabbit anti-IFITM1-NTD 1:200, rabbit anti-IFITM3-NTD 1:200, mouse anti-tubulin 1:100, goat anti-rat Alexa-488, goat anti-rabbit Alexa-488, goat anti-mouse Alexa-594 and goat anti-rabbit Alexa-647 all 1:500 and WGA-Alexa-647 1:200.", [["Cells", "ANATOMY", 0, 5], ["WGA-Alexa-647", "CHEMICAL", 359, 372], ["Alexa-647", "CHEMICAL", 335, 344], ["Cells", "CELL", 0, 5], ["rat", "ORGANISM", 130, 133], ["anti-HA", "GENE_OR_GENE_PRODUCT", 134, 141], ["rabbit", "ORGANISM", 149, 155], ["anti-IFITM1", "GENE_OR_GENE_PRODUCT", 156, 167], ["rabbit", "ORGANISM", 179, 185], ["anti-IFITM3", "GENE_OR_GENE_PRODUCT", 186, 197], ["mouse", "ORGANISM", 209, 214], ["anti-tubulin", "GENE_OR_GENE_PRODUCT", 215, 227], ["goat", "ORGANISM", 235, 239], ["Alexa-488", "SIMPLE_CHEMICAL", 249, 258], ["goat", "ORGANISM", 260, 264], ["Alexa-488", "SIMPLE_CHEMICAL", 277, 286], ["goat", "ORGANISM", 288, 292], ["Alexa-594", "SIMPLE_CHEMICAL", 304, 313], ["goat", "ORGANISM", 318, 322], ["Alexa-647", "SIMPLE_CHEMICAL", 335, 344], ["WGA-Alexa-647 1:200", "SIMPLE_CHEMICAL", 359, 378], ["antibodies", "PROTEIN", 97, 107], ["rat anti-HA 1:100", "PROTEIN", 130, 147], ["rabbit anti-IFITM1", "PROTEIN", 149, 167], ["NTD 1:200", "PROTEIN", 168, 177], ["rabbit anti-IFITM3", "PROTEIN", 179, 197], ["NTD 1:200", "PROTEIN", 198, 207], ["mouse anti-tubulin 1:100", "PROTEIN", 209, 233], ["goat anti-rat Alexa-488", "PROTEIN", 235, 258], ["goat anti-rabbit Alexa-488", "PROTEIN", 260, 286], ["goat anti-mouse Alexa-594", "PROTEIN", 288, 313], ["goat anti-rabbit Alexa-647 all 1:500 and WGA-Alexa-647 1:200", "PROTEIN", 318, 378], ["rat", "SPECIES", 130, 133], ["rabbit", "SPECIES", 149, 155], ["rabbit", "SPECIES", 179, 185], ["mouse", "SPECIES", 209, 214], ["goat", "SPECIES", 235, 239], ["goat", "SPECIES", 260, 264], ["anti-rabbit", "SPECIES", 265, 276], ["goat", "SPECIES", 288, 292], ["anti-mouse", "SPECIES", 293, 303], ["goat", "SPECIES", 318, 322], ["anti-rabbit", "SPECIES", 323, 334], ["rat", "SPECIES", 130, 133], ["rabbit", "SPECIES", 149, 155], ["rabbit", "SPECIES", 179, 185], ["mouse", "SPECIES", 209, 214], ["goat", "SPECIES", 235, 239], ["goat", "SPECIES", 260, 264], ["goat", "SPECIES", 288, 292], ["Alexa-594", "SPECIES", 304, 313], ["goat anti-rabbit Alexa-647", "SPECIES", 318, 344], ["Antibody feeding", "TEST", 49, 65], ["all immunofluorescence", "TEST", 69, 91], ["the antibodies", "TEST", 93, 107], ["rat anti-HA", "TEST", 130, 141], ["rabbit anti-IFITM1", "TEST", 149, 167], ["rabbit anti-IFITM3", "TREATMENT", 179, 197], ["mouse anti-tubulin", "TREATMENT", 209, 227], ["goat anti-rat Alexa", "TEST", 235, 254], ["goat anti-rabbit Alexa", "TEST", 260, 282], ["goat anti-mouse Alexa", "TEST", 288, 309]]], ["Nuclei were stained with Hoechst-33258 (Sigma).Image analysisTo calculate the Pearson's R-value and Mander's correlation coefficients, M1 and M2, individual cells were segmented and analysed using the JACoP plugin on ImageJ software [24] .", [["Nuclei", "ANATOMY", 0, 6], ["cells", "ANATOMY", 157, 162], ["Hoechst-33258", "CHEMICAL", 25, 38], ["Hoechst-33258", "CHEMICAL", 25, 38], ["Nuclei", "ORGANISM_SUBSTANCE", 0, 6], ["Hoechst-33258", "SIMPLE_CHEMICAL", 25, 38], ["cells", "CELL", 157, 162], ["M1", "CELL_LINE", 135, 137], ["M2", "CELL_LINE", 142, 144], ["Image analysisTo", "TEST", 47, 63], ["the Pearson's R-value", "TEST", 74, 95], ["Mander's correlation coefficients", "TEST", 100, 133]]], ["For M1 and M2 values, a Costes' automatic threshold was applied (as described [24] ).", [["a Costes' automatic threshold", "PROBLEM", 22, 51], ["M2", "ANATOMY", 11, 13]]], ["To calculate the relative areas of yellow, red and green signals, images were initially split into the red and green component channels.", [["red and green component channels", "PROTEIN", 103, 135], ["yellow, red and green signals", "PROBLEM", 35, 64], ["images", "TEST", 66, 72], ["relative", "OBSERVATION_MODIFIER", 17, 25], ["areas", "OBSERVATION_MODIFIER", 26, 31], ["yellow", "OBSERVATION", 35, 41], ["green signals", "OBSERVATION", 51, 64], ["red", "OBSERVATION", 103, 106], ["green", "OBSERVATION", 111, 116], ["component channels", "OBSERVATION", 117, 135]]], ["These two images were then processed with the 'AND' function in ImageJ (producing an image of pixels that are only both red AND green).", [["an image of pixels", "TEST", 82, 100]]], ["This image was subject to a manual threshold to observe only cellular structures and remove background noise.", [["cellular structures", "ANATOMY", 61, 80], ["cellular structures", "TISSUE", 61, 80], ["This image", "TEST", 0, 10], ["a manual threshold", "TEST", 26, 44], ["background noise", "PROBLEM", 92, 108]]], ["The pixel area was then calculated and these pixels defined as ''yellow.''", [["The pixel area", "TREATMENT", 0, 14], ["yellow", "PROBLEM", 65, 71], ["pixel", "OBSERVATION_MODIFIER", 4, 9], ["area", "OBSERVATION_MODIFIER", 10, 14]]], ["The ''yellow'' pixels were then superimposed on the red and green single channel images, and removed from each of these (such that a pixel defined as ''yellow'' cannot be considered ''red or ''green'').", [["The ''yellow'' pixels", "TREATMENT", 0, 21], ["green single channel images", "TEST", 60, 87], ["a pixel defined as ''yellow''", "TREATMENT", 131, 160]]], ["The same approach of applying a threshold was then taken on the red channel to calculate the pixel area, with these being defined as ''red.''", [["a threshold", "TREATMENT", 30, 41], ["the red channel", "TREATMENT", 60, 75]]], ["Again, once calculated, these ''red'' pixels were super-imposed on the green channel image and removed.", [["these ''red'' pixels", "PROBLEM", 24, 44], ["the green channel image", "TEST", 67, 90]]], ["This allowed a threshold to be applied to the green channel and the area of the remaining pixels calculated.", [["remaining pixels", "OBSERVATION", 80, 96]]], ["The relative area for each colour was calculated for each field of view and the mean average of all values calculated.qRT-PCRThe endogenous levels of IFITM1, 2, and 3 mRNA in A549 and HEK293T cells were measured by QuantiTect SYBR green qRT-PCR (Qiagen) using the primers described in Table 1 and the following thermocycling conditions: RT step -50uC for 30 min.", [["A549", "ANATOMY", 175, 179], ["HEK293T cells", "ANATOMY", 184, 197], ["qRT-PCRThe", "GENE_OR_GENE_PRODUCT", 118, 128], ["IFITM1", "GENE_OR_GENE_PRODUCT", 150, 156], ["2", "GENE_OR_GENE_PRODUCT", 158, 159], ["3", "GENE_OR_GENE_PRODUCT", 165, 166], ["A549", "CELL", 175, 179], ["HEK293T cells", "CELL", 184, 197], ["IFITM1, 2, and 3 mRNA", "RNA", 150, 171], ["A549", "CELL_LINE", 175, 179], ["HEK293T cells", "CELL_LINE", 184, 197], ["qRT", "TEST", 118, 121], ["IFITM1", "TEST", 150, 156], ["HEK293T cells", "TEST", 184, 197], ["PCR", "TEST", 241, 244], ["the primers", "TREATMENT", 260, 271], ["RT step", "TEST", 337, 344], ["area", "OBSERVATION_MODIFIER", 13, 17]]], ["PCR steps -95uC for 15 min, 94uC for 15 s; 35 cycles of (94uC, 15 s; 60uC, 30 s; 72uC, 30 s) in a reaction volume of 50 ml.qRT-PCRTotal RNA was extracted from a known number of cells (between 2.4610 5 and 5.9610 5 ) and quantitated (RNeasy minikit): 100 ng was used as a template in each qRT-PCR reaction.qRT-PCRFive standards from 10 7 -10 3 copies were made using plasmids encoding the transcripts of human IFITM1, 2, and 3, using the following formula:qRT-PCRx g =\u00bdplasmid length | 660| 6:022 | 10 23~y molecules Using the standards for each transcript, the quantity of transcript was determined relative to the standard curve for 100 ng input RNA.", [["cells", "ANATOMY", 177, 182], ["qRT-PCRTotal", "GENE_OR_GENE_PRODUCT", 123, 135], ["cells", "CELL", 177, 182], ["human", "ORGANISM", 403, 408], ["IFITM1", "GENE_OR_GENE_PRODUCT", 409, 415], ["2", "GENE_OR_GENE_PRODUCT", 417, 418], ["3", "GENE_OR_GENE_PRODUCT", 424, 425], ["qRT-PCRTotal RNA", "RNA", 123, 139], ["plasmids", "DNA", 366, 374], ["human IFITM1, 2, and 3", "DNA", 403, 425], ["100 ng input RNA", "RNA", 634, 650], ["human", "SPECIES", 403, 408], ["human", "SPECIES", 403, 408], ["PCR steps", "TEST", 0, 9], ["a reaction volume", "TREATMENT", 96, 113], ["PCRTotal RNA", "PROBLEM", 127, 139], ["a template in each qRT", "TREATMENT", 269, 291], ["PCR reaction", "PROBLEM", 292, 304], ["qRT", "TEST", 305, 308], ["plasmids", "TREATMENT", 366, 374], ["the standard curve", "TREATMENT", 611, 629], ["PCRTotal RNA", "ANATOMY", 127, 139]]], ["The number of copies per cell was estimated by dividing the total number of cells by the total RNA extracted, multiplied by 100.", [["cell", "ANATOMY", 25, 29], ["cells", "ANATOMY", 76, 81], ["cell", "CELL", 25, 29], ["cells", "CELL", 76, 81], ["the total RNA", "TREATMENT", 85, 98]]], ["This gave the equivalent number of cells that produced 100 ng of RNA and from this the RNA copy number per cell was inferred.Western blottingCells were lysed in Triton X-100 lysis buffer (1% [v/v] Triton X-100, 150 mM NaCl, 50 mM Tris-HCl pH 8.0 and 16 complete protease inhibitor cocktail [Roche]).", [["cells", "ANATOMY", 35, 40], ["cell", "ANATOMY", 107, 111], ["Cells", "ANATOMY", 141, 146], ["Triton X-100", "CHEMICAL", 161, 173], ["Triton X-100", "CHEMICAL", 197, 209], ["NaCl", "CHEMICAL", 218, 222], ["Tris-HCl", "CHEMICAL", 230, 238], ["NaCl", "CHEMICAL", 218, 222], ["Tris-HCl", "CHEMICAL", 230, 238], ["cells", "CELL", 35, 40], ["cell", "CELL", 107, 111], ["Cells", "CELL", 141, 146], ["Triton X-100", "SIMPLE_CHEMICAL", 161, 173], ["[v/v] Triton X-100", "SIMPLE_CHEMICAL", 191, 209], ["RNA", "RNA", 65, 68], ["Cells", "TEST", 141, 146], ["NaCl", "TEST", 218, 222], ["Tris", "TEST", 230, 234], ["HCl pH", "TEST", 235, 241], ["complete protease inhibitor cocktail", "TREATMENT", 253, 289]]], ["Protein concentrations were determined using the BCA method (Thermo Scientific) following the manufacturer's instructions.", [["Protein concentrations", "PROBLEM", 0, 22]]], ["Equal amounts of protein were mixed with reducing 36 Laemmli sample buffer (LSB), heated at 95uC for 5 min, separated by 15% SDS-PAGE and semi-dry transferred to a PVDF membrane (Immobilon-FL, Millipore).", [["PVDF membrane", "ANATOMY", 164, 177], ["PVDF", "CHEMICAL", 164, 168], ["membrane", "CELLULAR_COMPONENT", 169, 177], ["a PVDF membrane", "TREATMENT", 162, 177], ["amounts", "OBSERVATION_MODIFIER", 6, 13]]], ["Membranes were blocked in TBST (Tris-buffered saline pH 7.4 [TBS] with 0.05% [v/v] Tween 20) containing 5% (w/v) dried skimmed milk (Marvel) for 1 h and incubated with primary antibodies at 4uC overnight.", [["Membranes", "ANATOMY", 0, 9], ["milk", "ANATOMY", 127, 131], ["Tris", "CHEMICAL", 32, 36], ["Membranes", "ORGANISM_SUBSTANCE", 0, 9], ["Tris-buffered saline", "SIMPLE_CHEMICAL", 32, 52], ["[v/v] Tween 20", "SIMPLE_CHEMICAL", 77, 91], ["milk", "ORGANISM_SUBSTANCE", 127, 131], ["primary antibodies", "PROTEIN", 168, 186], ["TBST", "TEST", 26, 30], ["Tris", "TEST", 32, 36], ["buffered saline pH", "TREATMENT", 37, 55], ["TBS", "TEST", 61, 64], ["0.05% [v/v] Tween", "TREATMENT", 71, 88], ["w/v) dried skimmed milk (Marvel)", "TREATMENT", 108, 140], ["primary antibodies", "TREATMENT", 168, 186]]], ["For trypsin cleavage assays, samples were collected (as described below) and lysed directly in 16 reducing LSB then heated at 95uC for 5 min.", [["samples", "ANATOMY", 29, 36], ["trypsin", "GENE_OR_GENE_PRODUCT", 4, 11], ["trypsin", "PROTEIN", 4, 11], ["trypsin cleavage assays", "TEST", 4, 27]]], ["Equal volumes of cell lysates were loaded.Western blottingAntibodies used for protein detection were as follows: rabbit anti-IFITM3-NTD 1:500, rabbit anti-IFITM1-NTD 1:1000, mouse anti-HA 1:1000 and rabbit anti-VDAC 1:3000.", [["cell lysates", "ANATOMY", 17, 29], ["cell lysates", "ORGANISM_SUBSTANCE", 17, 29], ["rabbit", "ORGANISM", 113, 119], ["anti-IFITM3", "SIMPLE_CHEMICAL", 120, 131], ["rabbit", "ORGANISM", 143, 149], ["anti-IFITM1", "GENE_OR_GENE_PRODUCT", 150, 161], ["mouse", "ORGANISM", 174, 179], ["anti-HA", "GENE_OR_GENE_PRODUCT", 180, 187], ["rabbit", "ORGANISM", 199, 205], ["anti-IFITM3", "PROTEIN", 120, 131], ["NTD 1:500", "PROTEIN", 132, 141], ["anti-IFITM1", "PROTEIN", 150, 161], ["NTD 1:1000", "PROTEIN", 162, 172], ["mouse anti-HA 1:1000", "PROTEIN", 174, 194], ["rabbit anti-VDAC 1:3000", "PROTEIN", 199, 222], ["rabbit", "SPECIES", 113, 119], ["rabbit", "SPECIES", 143, 149], ["mouse", "SPECIES", 174, 179], ["rabbit", "SPECIES", 199, 205], ["rabbit", "SPECIES", 113, 119], ["rabbit", "SPECIES", 143, 149], ["mouse", "SPECIES", 174, 179], ["rabbit", "SPECIES", 199, 205], ["cell lysates", "PROBLEM", 17, 29], ["Western blottingAntibodies", "TEST", 42, 68], ["protein detection", "TEST", 78, 95], ["rabbit anti-IFITM3", "TREATMENT", 113, 131], ["NTD", "TEST", 132, 135], ["rabbit anti-IFITM1", "TREATMENT", 143, 161], ["mouse anti-HA", "TREATMENT", 174, 187], ["rabbit anti-VDAC", "TREATMENT", 199, 215], ["cell lysates", "OBSERVATION", 17, 29]]], ["The primary antibodies were detected using goat anti-rabbit IRDye 680 or goat anti-mouse IRDye 800 secondary antibodies, both at 1:10,000 (in 5% milk-TBST), then imaged and quantified using an Odyssey system (Li-COR).Western blottingTrypsin treatment IFITM1-HA expressing A549 cells, grown in 6635 mm well plates, were treated with 100 mg/ml trypsin (Sigma) for 5-30 min at 37uC.", [["A549 cells", "ANATOMY", 272, 282], ["IRDye 680", "SIMPLE_CHEMICAL", 60, 69], ["IRDye", "GENE_OR_GENE_PRODUCT", 89, 94], ["Trypsin", "GENE_OR_GENE_PRODUCT", 233, 240], ["IFITM1-HA", "GENE_OR_GENE_PRODUCT", 251, 260], ["A549 cells", "CELL", 272, 282], ["trypsin", "GENE_OR_GENE_PRODUCT", 342, 349], ["primary antibodies", "PROTEIN", 4, 22], ["goat anti-rabbit IRDye 680", "PROTEIN", 43, 69], ["goat anti-mouse IRDye 800 secondary antibodies", "PROTEIN", 73, 119], ["IFITM1-HA expressing A549 cells", "CELL_LINE", 251, 282], ["trypsin", "PROTEIN", 342, 349], ["goat", "SPECIES", 43, 47], ["anti-rabbit", "SPECIES", 48, 59], ["goat", "SPECIES", 73, 77], ["anti-mouse", "SPECIES", 78, 88], ["goat", "SPECIES", 43, 47], ["goat", "SPECIES", 73, 77], ["The primary antibodies", "TEST", 0, 22], ["goat anti-rabbit IRDye", "TREATMENT", 43, 65], ["goat anti-mouse IRDye", "TREATMENT", 73, 94], ["blottingTrypsin treatment", "TREATMENT", 225, 250], ["IFITM1", "TEST", 251, 257], ["HA expressing A549 cells", "PROBLEM", 258, 282], ["A549 cells", "OBSERVATION", 272, 282]]], ["Subsequently, the cells were transferred to microcentrifuge tubes on ice, the wells were rinsed with 1 mg/ml soybean trypsin inhibitor (SBTI) (Sigma) in PBS, and the rinse added to the microcentrifuge tubes.", [["cells", "ANATOMY", 18, 23], ["cells", "CELL", 18, 23], ["soybean trypsin inhibitor", "SIMPLE_CHEMICAL", 109, 134], ["SBTI", "SIMPLE_CHEMICAL", 136, 140], ["microcentrifuge tubes", "TREATMENT", 44, 65], ["ice", "TREATMENT", 69, 72], ["the wells", "TREATMENT", 74, 83], ["soybean trypsin inhibitor", "TREATMENT", 109, 134], ["PBS", "TREATMENT", 153, 156], ["the rinse", "TREATMENT", 162, 171], ["the microcentrifuge tubes", "TREATMENT", 181, 206], ["microcentrifuge tubes", "OBSERVATION", 185, 206]]], ["Untreated control cells, as well as cells treated with inactivated trypsin (1:1 volume ratio of SBTI to trypsin), were also collected.", [["cells", "ANATOMY", 18, 23], ["cells", "ANATOMY", 36, 41], ["cells", "CELL", 18, 23], ["cells", "CELL", 36, 41], ["trypsin", "GENE_OR_GENE_PRODUCT", 67, 74], ["trypsin", "GENE_OR_GENE_PRODUCT", 104, 111], ["trypsin", "PROTEIN", 67, 74], ["SBTI", "PROTEIN", 96, 100], ["trypsin", "PROTEIN", 104, 111], ["Untreated control cells", "PROBLEM", 0, 23], ["inactivated trypsin", "TREATMENT", 55, 74], ["SBTI to trypsin", "TREATMENT", 96, 111], ["control cells", "OBSERVATION", 10, 23]]], ["All samples were pelleted (5 min, 3000 RCF, 4uC) and washed with SBTI before direct lysis in LSB and western blotting, as described above.Flow cytometryCells in 35 mm dishes were treated with trypsin for 10 and 30 min or PBS for 30 min (as described above).", [["samples", "ANATOMY", 4, 11], ["Cells", "ANATOMY", 152, 157], ["SBTI", "CHEMICAL", 65, 69], ["Cells", "CELL", 152, 157], ["trypsin", "GENE_OR_GENE_PRODUCT", 192, 199], ["trypsin", "PROTEIN", 192, 199], ["SBTI", "TREATMENT", 65, 69], ["direct lysis in LSB", "TREATMENT", 77, 96], ["Flow cytometry", "TEST", 138, 152], ["trypsin", "TREATMENT", 192, 199], ["lysis", "OBSERVATION", 84, 89], ["LSB", "ANATOMY", 93, 96], ["35 mm", "OBSERVATION_MODIFIER", 161, 166]]], ["The cells were then fixed, quenched (as previously) and washed with PBS/BSA prior to labelling with rat anti-HA antibody in PBS/BSA for 1 h at RT.", [["cells", "ANATOMY", 4, 9], ["cells", "CELL", 4, 9], ["BSA", "SIMPLE_CHEMICAL", 72, 75], ["rat", "ORGANISM", 100, 103], ["BSA", "SIMPLE_CHEMICAL", 128, 131], ["rat anti-HA antibody", "PROTEIN", 100, 120], ["rat", "SPECIES", 100, 103], ["rat", "SPECIES", 100, 103], ["PBS/BSA", "TREATMENT", 68, 75], ["rat anti-HA antibody", "TREATMENT", 100, 120]]], ["The cells were then washed 36 with PBS/BSA and labelled with goat anti-rat Alexa-647 in PBS/BSA for 45 min.", [["cells", "ANATOMY", 4, 9], ["Alexa-647", "CHEMICAL", 75, 84], ["Alexa-647", "CHEMICAL", 75, 84], ["cells", "CELL", 4, 9], ["BSA", "SIMPLE_CHEMICAL", 39, 42], ["Alexa-647", "SIMPLE_CHEMICAL", 75, 84], ["BSA", "SIMPLE_CHEMICAL", 92, 95], ["goat anti-rat Alexa-647", "PROTEIN", 61, 84], ["goat", "SPECIES", 61, 65], ["goat", "SPECIES", 61, 65], ["PBS/BSA", "TREATMENT", 35, 42], ["goat anti-rat Alexa", "TREATMENT", 61, 80]]], ["Cells were washed 36 with PBS and subject to flow cytometry (LSR-II; BD Bioscience).", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["Cells", "TEST", 0, 5], ["PBS", "TEST", 26, 29], ["flow cytometry", "TEST", 45, 59], ["LSR", "TEST", 61, 64]]], ["Cells were gated on forward and side scatter and analysed for fluorescence labelling.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["fluorescence labelling", "TEST", 62, 84]]], ["The data were processed using FlowJo vX.0.7 software (Tree Star).", [["The data", "TEST", 0, 8]]], ["Antibodies were diluted as for immunofluorescence staining.Biotin labelling and pulldownHEK293T cells, grown in 10 cm dishes, were transfected with untagged IFITM1 or IFITM1-Vstop expressing plasmids using FuGENE6.", [["pulldownHEK293T cells", "ANATOMY", 80, 101], ["plasmids", "ANATOMY", 191, 199], ["Biotin", "CHEMICAL", 59, 65], ["Biotin", "SIMPLE_CHEMICAL", 59, 65], ["pulldownHEK293T cells", "CELL", 80, 101], ["IFITM1", "GENE_OR_GENE_PRODUCT", 157, 163], ["IFITM1", "GENE_OR_GENE_PRODUCT", 167, 173], ["Vstop", "GENE_OR_GENE_PRODUCT", 174, 179], ["FuGENE6", "GENE_OR_GENE_PRODUCT", 206, 213], ["pulldownHEK293T cells", "CELL_LINE", 80, 101], ["IFITM1", "PROTEIN", 157, 163], ["IFITM1", "PROTEIN", 167, 173], ["Vstop expressing plasmids", "DNA", 174, 199], ["FuGENE6", "DNA", 206, 213], ["Antibodies", "TEST", 0, 10], ["immunofluorescence staining", "PROBLEM", 31, 58], ["Biotin labelling and pulldownHEK293T cells", "TREATMENT", 59, 101], ["IFITM1", "TREATMENT", 167, 173], ["FuGENE6", "TREATMENT", 206, 213], ["pulldownHEK293T cells", "OBSERVATION", 80, 101], ["grown", "OBSERVATION_MODIFIER", 103, 108], ["10 cm", "OBSERVATION_MODIFIER", 112, 117]]], ["After 24 h, cells were detached with 5 mM EDTA and re-plated into 6635 mm well plates.", [["cells", "ANATOMY", 12, 17], ["EDTA", "CHEMICAL", 42, 46], ["cells", "CELL", 12, 17], ["EDTA", "SIMPLE_CHEMICAL", 42, 46], ["5 mM EDTA", "TREATMENT", 37, 46]]], ["After a further 24 h, cells were labelled with 1 mg/ml EZ-link Sulfo-NHS-SS-Biotin (Thermo Scientific) for 45 min at 37uC.", [["cells", "ANATOMY", 22, 27], ["EZ", "CHEMICAL", 55, 57], ["Sulfo-NHS-SS-Biotin", "CHEMICAL", 63, 82], ["EZ", "CHEMICAL", 55, 57], ["Biotin", "CHEMICAL", 76, 82], ["cells", "CELL", 22, 27], ["EZ", "SIMPLE_CHEMICAL", 55, 57], ["Sulfo-NHS-SS-Biotin", "SIMPLE_CHEMICAL", 63, 82], ["Biotin", "TREATMENT", 76, 82]]], ["The biotin label was washed off with TBS and the cells lysed with 100 ml Triton X-100 lysis buffer (as previously).", [["cells", "ANATOMY", 49, 54], ["biotin", "CHEMICAL", 4, 10], ["Triton X-100", "CHEMICAL", 73, 85], ["biotin", "CHEMICAL", 4, 10], ["Triton X-100", "CHEMICAL", 73, 85], ["biotin", "SIMPLE_CHEMICAL", 4, 10], ["cells", "CELL", 49, 54], ["Triton X-100", "SIMPLE_CHEMICAL", 73, 85], ["The biotin label", "TREATMENT", 0, 16], ["TBS", "TREATMENT", 37, 40], ["the cells", "TREATMENT", 45, 54]]], ["The whole cell lysate (70 ml) was added to a 25 ml NeutrAvidin agarose bead pellet (Thermo Scientific) and incubated for 3 h at 4uC on a rotor.", [["whole cell lysate", "ANATOMY", 4, 21], ["cell lysate", "ORGANISM_SUBSTANCE", 10, 21], ["The whole cell lysate", "TREATMENT", 0, 21], ["a 25 ml NeutrAvidin agarose bead pellet", "TREATMENT", 43, 82], ["a rotor", "TREATMENT", 135, 142]]], ["Beads were then pelleted and the unbound material collected.", [["Beads", "CELL", 0, 5], ["the unbound material", "TEST", 29, 49]]], ["The bead pellet was then washed with Triton X-100 lysis buffer, TBS and a TE buffer (10 mM Tris, 5 mM EDTA), prior to elution of proteins in 70 ml of 16 reducing LSB and heating at 95uC for 10 min.", [["Triton X-100", "CHEMICAL", 37, 49], ["LSB", "CHEMICAL", 162, 165], ["Tris", "CHEMICAL", 91, 95], ["EDTA", "CHEMICAL", 102, 106], ["Triton X-100", "SIMPLE_CHEMICAL", 37, 49], ["EDTA", "SIMPLE_CHEMICAL", 102, 106], ["LSB", "SIMPLE_CHEMICAL", 162, 165], ["The bead pellet", "TREATMENT", 0, 15], ["Triton X-100 lysis buffer", "TREATMENT", 37, 62], ["TBS", "TREATMENT", 64, 67], ["a TE buffer (10 mM Tris, 5 mM EDTA", "TREATMENT", 72, 106], ["proteins", "TREATMENT", 129, 137], ["bead pellet", "OBSERVATION", 4, 15]]], ["Eluate was collected and the elution procedure repeated.", [["the elution procedure", "TREATMENT", 25, 46]]], ["Equivalent volumes of whole cell lysate, unbound material and eluate from the NeutrAvidin beads were separated by 15% SDS-PAGE and western blotted as previously.", [["cell lysate", "ANATOMY", 28, 39], ["cell lysate", "ORGANISM_SUBSTANCE", 28, 39], ["whole cell lysate", "TREATMENT", 22, 39], ["unbound material", "PROBLEM", 41, 57], ["the NeutrAvidin beads", "TREATMENT", 74, 95], ["whole cell lysate", "OBSERVATION", 22, 39]]], ["Calreticulin was used as a loading control and detected with an anti-calreticulin antibody diluted 1:5000 in 1% BSA-TBST.Electron microscopyCells were fixed with 4% (w/v) FA in 0.1 M phosphate buffer pH7.4, infused with 2.3 M sucrose, supported in 12% (w/v) gelatin and frozen in liquid nitrogen.", [["Cells", "ANATOMY", 140, 145], ["Calreticulin", "CHEMICAL", 0, 12], ["FA", "CHEMICAL", 171, 173], ["phosphate", "CHEMICAL", 183, 192], ["sucrose", "CHEMICAL", 226, 233], ["Calreticulin", "CHEMICAL", 0, 12], ["phosphate", "CHEMICAL", 183, 192], ["sucrose", "CHEMICAL", 226, 233], ["nitrogen", "CHEMICAL", 287, 295], ["Calreticulin", "SIMPLE_CHEMICAL", 0, 12], ["BSA", "SIMPLE_CHEMICAL", 112, 115], ["Cells", "CELL", 140, 145], ["/v) FA", "SIMPLE_CHEMICAL", 167, 173], ["sucrose", "SIMPLE_CHEMICAL", 226, 233], ["v) gelatin", "SIMPLE_CHEMICAL", 255, 265], ["anti-calreticulin antibody", "PROTEIN", 64, 90], ["Calreticulin", "TREATMENT", 0, 12], ["a loading control", "TREATMENT", 25, 42], ["an anti-calreticulin antibody", "TEST", 61, 90], ["Electron microscopy", "TEST", 121, 140], ["Cells", "TEST", 140, 145], ["w/v) FA", "TREATMENT", 166, 173], ["phosphate buffer pH7.4", "TREATMENT", 183, 205], ["2.3 M sucrose", "TREATMENT", 220, 233], ["gelatin", "TREATMENT", 258, 265], ["frozen in liquid nitrogen", "TREATMENT", 270, 295]]], ["Ultrathin (70 nm) cryosections were cut at 2120uC and picked up in 1:1 2% sucrose:methylcellulose.", [["cryosections", "ANATOMY", 18, 30], ["sucrose", "CHEMICAL", 74, 81], ["methylcellulose", "CHEMICAL", 82, 97], ["sucrose", "CHEMICAL", 74, 81], ["methylcellulose", "CHEMICAL", 82, 97], ["sucrose", "SIMPLE_CHEMICAL", 74, 81], ["methylcellulose", "SIMPLE_CHEMICAL", 82, 97], ["Ultrathin (70 nm) cryosections", "TREATMENT", 0, 30], ["methylcellulose", "TREATMENT", 82, 97]]], ["Sections were labelled with primary antibody (mouse anti-HA 1:400), followed by rabbit anti-mouse intermediate antibody (DAKO) and protein A gold, as described [25, 26] .", [["mouse", "ORGANISM", 46, 51], ["anti-HA", "GENE_OR_GENE_PRODUCT", 52, 59], ["rabbit", "ORGANISM", 80, 86], ["anti-mouse intermediate antibody", "GENE_OR_GENE_PRODUCT", 87, 119], ["DAKO", "GENE_OR_GENE_PRODUCT", 121, 125], ["primary antibody", "PROTEIN", 28, 44], ["mouse anti-HA 1:400", "PROTEIN", 46, 65], ["rabbit anti-mouse intermediate antibody", "PROTEIN", 80, 119], ["DAKO", "PROTEIN", 121, 125], ["protein A", "PROTEIN", 131, 140], ["mouse", "SPECIES", 46, 51], ["rabbit", "SPECIES", 80, 86], ["anti-mouse", "SPECIES", 87, 97], ["mouse", "SPECIES", 46, 51], ["rabbit", "SPECIES", 80, 86], ["primary antibody (mouse anti-HA", "TEST", 28, 59]]], ["Images were obtained using a Tecnai T12 transmission electron microscope (FEI) and captured using a Morada CCD camera (Olympus-SIS).The human IFITM1 C-terminal domain resides extracellularlyTo investigate the cellular distributions of human (hu) IFITM1, 2 and 3 we used C-terminally HA-tagged proteins, stably expressed in A549 cells, and immunofluorescence microscopy.", [["cellular", "ANATOMY", 209, 217], ["A549 cells", "ANATOMY", 323, 333], ["C", "CHEMICAL", 270, 271], ["human", "ORGANISM", 136, 141], ["IFITM1", "GENE_OR_GENE_PRODUCT", 142, 148], ["cellular", "CELL", 209, 217], ["human", "ORGANISM", 235, 240], ["(hu) IFITM1", "GENE_OR_GENE_PRODUCT", 241, 252], ["2", "GENE_OR_GENE_PRODUCT", 254, 255], ["3", "GENE_OR_GENE_PRODUCT", 260, 261], ["A549 cells", "CELL", 323, 333], ["human IFITM1 C-terminal domain", "PROTEIN", 136, 166], ["human (hu) IFITM1, 2 and 3", "PROTEIN", 235, 261], ["C-terminally HA", "PROTEIN", 270, 285], ["tagged proteins", "PROTEIN", 286, 301], ["A549 cells", "CELL_LINE", 323, 333], ["human", "SPECIES", 136, 141], ["human", "SPECIES", 235, 240], ["human", "SPECIES", 136, 141], ["human", "SPECIES", 235, 240], ["Images", "TEST", 0, 6], ["a Morada CCD camera", "TREATMENT", 98, 117], ["IFITM1", "TEST", 246, 252], ["C-terminally HA-tagged proteins", "PROBLEM", 270, 301], ["immunofluorescence microscopy", "TEST", 339, 368], ["cellular distributions", "OBSERVATION", 209, 231], ["A549 cells", "OBSERVATION", 323, 333]]], ["When cells were permeabilised and labelled with anti-HA antibodies, all three IFITM proteins were detected, and each had a different cellular distribution.", [["cells", "ANATOMY", 5, 10], ["cellular", "ANATOMY", 133, 141], ["cells", "CELL", 5, 10], ["IFITM", "GENE_OR_GENE_PRODUCT", 78, 83], ["cellular", "CELL", 133, 141], ["anti-HA antibodies", "PROTEIN", 48, 66], ["IFITM proteins", "PROTEIN", 78, 92], ["anti-HA antibodies", "TEST", 48, 66], ["all three IFITM proteins", "TEST", 68, 92], ["different", "OBSERVATION_MODIFIER", 123, 132], ["cellular distribution", "OBSERVATION", 133, 154]]], ["IFITM1-HA was seen primarily at the plasma membrane (Fig. 2B) .", [["plasma membrane", "ANATOMY", 36, 51], ["IFITM1-HA", "GENE_OR_GENE_PRODUCT", 0, 9], ["plasma membrane", "CELLULAR_COMPONENT", 36, 51], ["IFITM1", "PROTEIN", 0, 6], ["HA", "PROTEIN", 7, 9], ["HA", "PROBLEM", 7, 9], ["plasma membrane", "ANATOMY", 36, 51]]], ["By contrast, IFITM2-HA and IFITM3-HA were seen mostly in intracellular compartments with distinct distributions.", [["intracellular compartments", "ANATOMY", 57, 83], ["IFITM2-HA", "GENE_OR_GENE_PRODUCT", 13, 22], ["IFITM3-HA", "GENE_OR_GENE_PRODUCT", 27, 36], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 57, 70], ["IFITM2", "PROTEIN", 13, 19], ["HA", "PROTEIN", 20, 22], ["IFITM3", "PROTEIN", 27, 33], ["HA", "PROTEIN", 34, 36], ["IFITM2", "TEST", 13, 19], ["HA", "PROBLEM", 20, 22], ["IFITM3-HA", "PROBLEM", 27, 36], ["intracellular", "ANATOMY_MODIFIER", 57, 70], ["compartments", "ANATOMY_MODIFIER", 71, 83], ["distinct distributions", "OBSERVATION", 89, 111]]], ["IFITM2-HA localised in a tight cluster of punctae close to the nucleus, while IFITM3-HA had a more dispersed, punctate distribution ( Fig. 2C and D) .The human IFITM1 C-terminal domain resides extracellularlyCells were also stained in the absence of detergent, thus maintaining the integrity of the plasma membrane.", [["punctae", "ANATOMY", 42, 49], ["nucleus", "ANATOMY", 63, 70], ["Cells", "ANATOMY", 208, 213], ["plasma membrane", "ANATOMY", 299, 314], ["C", "CHEMICAL", 167, 168], ["IFITM2-HA", "GENE_OR_GENE_PRODUCT", 0, 9], ["punctae", "CELLULAR_COMPONENT", 42, 49], ["nucleus", "CELLULAR_COMPONENT", 63, 70], ["IFITM3-HA", "GENE_OR_GENE_PRODUCT", 78, 87], ["human", "ORGANISM", 154, 159], ["IFITM1", "GENE_OR_GENE_PRODUCT", 160, 166], ["Cells", "CELL", 208, 213], ["plasma membrane", "CELLULAR_COMPONENT", 299, 314], ["IFITM2", "PROTEIN", 0, 6], ["HA", "PROTEIN", 7, 9], ["IFITM3", "PROTEIN", 78, 84], ["HA", "PROTEIN", 85, 87], ["human IFITM1 C-terminal domain", "PROTEIN", 154, 184], ["human", "SPECIES", 154, 159], ["human", "SPECIES", 154, 159], ["HA", "PROBLEM", 7, 9], ["detergent", "TREATMENT", 250, 259], ["tight", "OBSERVATION_MODIFIER", 25, 30], ["cluster", "OBSERVATION_MODIFIER", 31, 38], ["punctae", "OBSERVATION", 42, 49], ["nucleus", "ANATOMY", 63, 70], ["punctate", "OBSERVATION_MODIFIER", 110, 118], ["distribution", "OBSERVATION_MODIFIER", 119, 131], ["plasma membrane", "OBSERVATION", 299, 314]]], ["For IFITM1, anti-HA labelling was very similar on intact and detergentpermeabilised cells (compare Fig. 2F and Fig. 2B ).", [["cells", "ANATOMY", 84, 89], ["IFITM1", "GENE_OR_GENE_PRODUCT", 4, 10], ["anti-HA", "GENE_OR_GENE_PRODUCT", 12, 19], ["cells", "CELL", 84, 89], ["IFITM1", "PROTEIN", 4, 10], ["detergentpermeabilised cells", "CELL_LINE", 61, 89], ["IFITM1", "PROBLEM", 4, 10], ["anti-HA labelling", "TREATMENT", 12, 29]]], ["As a control for the integrity of the plasma membrane, cells were co-stained with an anti-tubulin antibody (Fig. S1 ).", [["plasma membrane", "ANATOMY", 38, 53], ["cells", "ANATOMY", 55, 60], ["plasma membrane", "CELLULAR_COMPONENT", 38, 53], ["cells", "CELL", 55, 60], ["anti-tubulin", "GENE_OR_GENE_PRODUCT", 85, 97], ["anti-tubulin antibody", "PROTEIN", 85, 106], ["S1", "PROTEIN", 113, 115], ["an anti-tubulin antibody", "TEST", 82, 106], ["plasma membrane", "ANATOMY", 38, 53]]], ["Detection of IFITM1-HA on non-permeabilised cells further demonstrated that the protein is located primarily at the cell surface in stable transfected A549 cells.", [["cells", "ANATOMY", 44, 49], ["cell surface", "ANATOMY", 116, 128], ["A549 cells", "ANATOMY", 151, 161], ["IFITM1-HA", "GENE_OR_GENE_PRODUCT", 13, 22], ["cells", "CELL", 44, 49], ["cell surface", "CELLULAR_COMPONENT", 116, 128], ["A549 cells", "CELL", 151, 161], ["IFITM1", "PROTEIN", 13, 19], ["HA", "PROTEIN", 20, 22], ["non-permeabilised cells", "CELL_LINE", 26, 49], ["A549 cells", "CELL_LINE", 151, 161], ["IFITM1", "TEST", 13, 19], ["HA on non-permeabilised cells", "PROBLEM", 20, 49], ["the protein", "TEST", 76, 87], ["cell surface", "OBSERVATION", 116, 128], ["stable", "OBSERVATION_MODIFIER", 132, 138], ["transfected A549 cells", "OBSERVATION", 139, 161]]], ["Furthermore, the C-terminal HA-tag is accessible on intact cells and therefore located on the extracellular surface of the plasma membrane.", [["cells", "ANATOMY", 59, 64], ["extracellular surface", "ANATOMY", 94, 115], ["plasma membrane", "ANATOMY", 123, 138], ["cells", "CELL", 59, 64], ["extracellular surface", "CELLULAR_COMPONENT", 94, 115], ["plasma membrane", "CELLULAR_COMPONENT", 123, 138], ["C-terminal HA-tag", "PROTEIN", 17, 34], ["the C-terminal HA-tag", "PROBLEM", 13, 34], ["tag", "OBSERVATION", 31, 34], ["intact cells", "OBSERVATION", 52, 64], ["extracellular", "ANATOMY_MODIFIER", 94, 107], ["surface", "ANATOMY_MODIFIER", 108, 115], ["plasma membrane", "OBSERVATION", 123, 138]]], ["Co-staining cells with fluorescent wheat germ agglutinin further confirmed this plasma membrane localisation (Fig. S2) .The human IFITM1 C-terminal domain resides extracellularlyNo anti-HA labelling was seen on intact IFITM2-HA expressing cells, in keeping with the notion that this protein is located on intracellular membranes (Fig. 2G) .", [["cells", "ANATOMY", 12, 17], ["plasma membrane", "ANATOMY", 80, 95], ["cells", "ANATOMY", 239, 244], ["intracellular membranes", "ANATOMY", 305, 328], ["C", "CHEMICAL", 137, 138], ["cells", "CELL", 12, 17], ["wheat germ agglutinin", "GENE_OR_GENE_PRODUCT", 35, 56], ["plasma membrane", "CELLULAR_COMPONENT", 80, 95], ["human", "ORGANISM", 124, 129], ["IFITM1", "GENE_OR_GENE_PRODUCT", 130, 136], ["anti-HA", "GENE_OR_GENE_PRODUCT", 181, 188], ["IFITM2", "GENE_OR_GENE_PRODUCT", 218, 224], ["cells", "CELL", 239, 244], ["intracellular membranes", "CELLULAR_COMPONENT", 305, 328], ["fluorescent wheat germ agglutinin", "PROTEIN", 23, 56], ["S2", "PROTEIN", 115, 117], ["human IFITM1 C-terminal domain", "PROTEIN", 124, 154], ["IFITM2", "PROTEIN", 218, 224], ["HA expressing cells", "CELL_TYPE", 225, 244], ["wheat", "SPECIES", 35, 40], ["human", "SPECIES", 124, 129], ["wheat", "SPECIES", 35, 40], ["human", "SPECIES", 124, 129], ["Co-staining cells", "PROBLEM", 0, 17], ["fluorescent wheat germ agglutinin", "TEST", 23, 56], ["this plasma membrane localisation", "PROBLEM", 75, 108], ["anti-HA labelling", "PROBLEM", 181, 198], ["this protein", "PROBLEM", 278, 290], ["anti-HA labelling", "OBSERVATION", 181, 198], ["intracellular membranes", "OBSERVATION", 305, 328]]], ["A similar result was seen for IFITM3-HA, although a low number of cells (,1%) did show some surface labelling with anti-HA antibodies ( Fig. 2H and Fig. S3 ).", [["cells", "ANATOMY", 66, 71], ["surface", "ANATOMY", 92, 99], ["IFITM3-HA", "GENE_OR_GENE_PRODUCT", 30, 39], ["cells", "CELL", 66, 71], ["IFITM3", "PROTEIN", 30, 36], ["anti-HA antibodies", "PROTEIN", 115, 133], ["IFITM3-HA", "PROBLEM", 30, 39], ["a low number of cells", "PROBLEM", 50, 71], ["some surface labelling", "PROBLEM", 87, 109], ["anti-HA antibodies", "TEST", 115, 133], ["low number", "OBSERVATION_MODIFIER", 52, 62], ["anti-HA antibodies", "OBSERVATION", 115, 133]]], ["This suggested that although the majority of IFITM3-HA is located on intracellular membranes (Fig. 2D) , in some cells IFITM3-HA is either mis-sorted and/or is expressed at the cell surface where the C-terminal HA epitope is accessible.IFITM N-terminal domains reside intracellularlyThe observation that the HA-tag of IFITM1 is accessible at the surface of intact cells prompted us to investigate the topology of the protein.", [["intracellular membranes", "ANATOMY", 69, 92], ["cells", "ANATOMY", 113, 118], ["cell surface", "ANATOMY", 177, 189], ["surface", "ANATOMY", 346, 353], ["cells", "ANATOMY", 364, 369], ["N", "CHEMICAL", 242, 243], ["IFITM3-HA", "GENE_OR_GENE_PRODUCT", 45, 54], ["intracellular membranes", "CELLULAR_COMPONENT", 69, 92], ["cells", "CELL", 113, 118], ["IFITM3-HA", "GENE_OR_GENE_PRODUCT", 119, 128], ["cell surface", "CELLULAR_COMPONENT", 177, 189], ["IFITM1", "GENE_OR_GENE_PRODUCT", 318, 324], ["surface", "CELLULAR_COMPONENT", 346, 353], ["cells", "CELL", 364, 369], ["IFITM3", "PROTEIN", 45, 51], ["HA", "PROTEIN", 52, 54], ["IFITM3", "PROTEIN", 119, 125], ["HA", "PROTEIN", 126, 128], ["C-terminal HA epitope", "PROTEIN", 200, 221], ["IFITM N-terminal domains", "PROTEIN", 236, 260], ["HA", "PROTEIN", 308, 310], ["IFITM1", "PROTEIN", 318, 324], ["intact cells", "CELL_TYPE", 357, 369], ["HA", "PROBLEM", 126, 128], ["the C-terminal HA epitope", "TREATMENT", 196, 221], ["the HA-tag of IFITM1", "PROBLEM", 304, 324], ["IFITM3", "OBSERVATION", 45, 51], ["intracellular membranes", "ANATOMY", 69, 92], ["cells IFITM3", "OBSERVATION", 113, 125], ["intact cells", "OBSERVATION", 357, 369]]], ["We used two commercially available antibodies against the hu IFITM1 and IFITM3 NTDs.", [["IFITM1", "GENE_OR_GENE_PRODUCT", 61, 67], ["IFITM3", "GENE_OR_GENE_PRODUCT", 72, 78], ["hu IFITM1", "PROTEIN", 58, 67], ["IFITM3 NTDs", "PROTEIN", 72, 83], ["antibodies", "TREATMENT", 35, 45], ["the hu IFITM1", "TREATMENT", 54, 67], ["IFITM3 NTDs", "PROBLEM", 72, 83], ["IFITM3 NTDs", "OBSERVATION", 72, 83]]], ["The IFITM1 NTD antibody (anti-IFITM1-NTD) was raised against a peptide encoding the first 35 amino acids of hu IFITM1.", [["amino acids", "CHEMICAL", 93, 104], ["amino acids", "CHEMICAL", 93, 104], ["IFITM1", "GENE_OR_GENE_PRODUCT", 4, 10], ["anti-IFITM1-NTD", "GENE_OR_GENE_PRODUCT", 25, 40], ["amino acids", "AMINO_ACID", 93, 104], ["IFITM1", "GENE_OR_GENE_PRODUCT", 111, 117], ["IFITM1 NTD antibody", "PROTEIN", 4, 23], ["IFITM1", "PROTEIN", 30, 36], ["NTD", "PROTEIN", 37, 40], ["hu IFITM1", "PROTEIN", 108, 117], ["The IFITM1 NTD antibody", "TEST", 0, 23], ["hu IFITM1", "TREATMENT", 108, 117]]], ["This domain has 69% and 75% amino acid identity with hu IFITM2 and IFITM3, respectively.", [["amino acid", "CHEMICAL", 28, 38], ["amino acid", "CHEMICAL", 28, 38], ["amino acid", "AMINO_ACID", 28, 38], ["IFITM2", "PROTEIN", 56, 62], ["IFITM3", "PROTEIN", 67, 73], ["This domain", "TEST", 0, 11], ["amino acid identity", "TEST", 28, 47], ["hu IFITM2", "TREATMENT", 53, 62], ["IFITM3", "PROBLEM", 67, 73], ["IFITM3", "OBSERVATION_MODIFIER", 67, 73]]], ["The IFITM3 NTD antibody (anti-IFITM3-NTD) was raised against a peptide with a sequence corresponding to the first 30 amino acids of hu IFITM3.", [["amino acids", "CHEMICAL", 117, 128], ["amino acids", "CHEMICAL", 117, 128], ["IFITM3", "GENE_OR_GENE_PRODUCT", 4, 10], ["anti-IFITM3-NTD", "GENE_OR_GENE_PRODUCT", 25, 40], ["amino acids", "AMINO_ACID", 117, 128], ["IFITM3", "GENE_OR_GENE_PRODUCT", 135, 141], ["IFITM3 NTD antibody", "PROTEIN", 4, 23], ["IFITM3", "PROTEIN", 30, 36], ["NTD", "PROTEIN", 37, 40], ["hu IFITM3", "PROTEIN", 132, 141], ["The IFITM3 NTD antibody", "TEST", 0, 23], ["anti-IFITM3", "TEST", 25, 36], ["a sequence", "TEST", 76, 86], ["the first 30 amino acids of hu IFITM3", "TREATMENT", 104, 141]]], ["Hu IFITM1 has an Nterminal 21 amino acid truncation compared to IFITM3, so contains only 9 amino acids overlapping with this domain.", [["amino acid", "CHEMICAL", 30, 40], ["amino acids", "CHEMICAL", 91, 102], ["amino acid", "CHEMICAL", 30, 40], ["amino acids", "CHEMICAL", 91, 102], ["Hu", "GENE_OR_GENE_PRODUCT", 0, 2], ["amino acid", "AMINO_ACID", 30, 40], ["IFITM3", "GENE_OR_GENE_PRODUCT", 64, 70], ["amino acids", "AMINO_ACID", 91, 102], ["Hu IFITM1", "PROTEIN", 0, 9], ["IFITM3", "PROTEIN", 64, 70], ["an Nterminal 21 amino acid truncation", "PROBLEM", 14, 51], ["IFITM3", "TEST", 64, 70], ["9 amino acids", "TREATMENT", 89, 102], ["amino acid truncation", "OBSERVATION", 30, 51]]], ["However, there is 90% amino acid identity between the first 30 amino acids of hu IFITM3 and IFITM2.IFITM N-terminal domains reside intracellularlyTo determine the specificity of the NTD antibodies, both were tested on samples from the HA-tagged IFITM1-3 expressing A549 cells by western blot analysis.", [["samples", "ANATOMY", 218, 225], ["A549 cells", "ANATOMY", 265, 275], ["amino acid", "CHEMICAL", 22, 32], ["amino acids", "CHEMICAL", 63, 74], ["amino acid", "CHEMICAL", 22, 32], ["amino acids", "CHEMICAL", 63, 74], ["N", "CHEMICAL", 105, 106], ["amino acid", "AMINO_ACID", 22, 32], ["amino acids", "AMINO_ACID", 63, 74], ["IFITM3", "GENE_OR_GENE_PRODUCT", 81, 87], ["IFITM2", "GENE_OR_GENE_PRODUCT", 92, 98], ["IFITM1-3", "GENE_OR_GENE_PRODUCT", 245, 253], ["A549 cells", "CELL", 265, 275], ["IFITM3", "PROTEIN", 81, 87], ["IFITM2", "PROTEIN", 92, 98], ["IFITM N-terminal domains", "PROTEIN", 99, 123], ["NTD antibodies", "PROTEIN", 182, 196], ["IFITM1", "PROTEIN", 245, 251], ["A549 cells", "CELL_LINE", 265, 275], ["90% amino acid identity", "PROBLEM", 18, 41], ["hu IFITM3", "TREATMENT", 78, 87], ["the NTD antibodies", "TEST", 178, 196], ["the HA", "TEST", 231, 237], ["tagged IFITM1", "TEST", 238, 251], ["blot analysis", "TEST", 287, 300], ["hu IFITM3", "OBSERVATION", 78, 87]]], ["Anti-IFITM1-NTD detected IFITM1-HA and IFITM3-HA, but not IFITM2-HA (Fig. 3A) .", [["Anti-IFITM1", "GENE_OR_GENE_PRODUCT", 0, 11], ["IFITM1-HA", "GENE_OR_GENE_PRODUCT", 25, 34], ["IFITM3-HA", "GENE_OR_GENE_PRODUCT", 39, 48], ["IFITM2-HA", "GENE_OR_GENE_PRODUCT", 58, 67], ["Anti-IFITM1", "PROTEIN", 0, 11], ["NTD", "PROTEIN", 12, 15], ["IFITM1", "PROTEIN", 25, 31], ["HA", "PROTEIN", 32, 34], ["IFITM3", "PROTEIN", 39, 45], ["HA", "PROTEIN", 46, 48], ["IFITM2", "PROTEIN", 58, 64], ["HA", "PROTEIN", 65, 67], ["Anti-IFITM1", "TEST", 0, 11], ["NTD", "PROBLEM", 12, 15], ["IFITM1", "TEST", 25, 31], ["HA", "PROBLEM", 32, 34], ["IFITM3", "PROBLEM", 39, 45], ["HA", "PROBLEM", 46, 48]]], ["Anti-IFITM3-NTD detected both IFITM3-HA and IFITM2-HA, but not IFITM1-HA (Fig. 3B ).", [["Anti-IFITM3", "GENE_OR_GENE_PRODUCT", 0, 11], ["IFITM3-HA", "GENE_OR_GENE_PRODUCT", 30, 39], ["IFITM2-HA", "GENE_OR_GENE_PRODUCT", 44, 53], ["IFITM1-HA", "GENE_OR_GENE_PRODUCT", 63, 72], ["Anti-IFITM3", "PROTEIN", 0, 11], ["NTD", "PROTEIN", 12, 15], ["IFITM3", "PROTEIN", 30, 36], ["HA", "PROTEIN", 37, 39], ["IFITM2", "PROTEIN", 44, 50], ["HA", "PROTEIN", 51, 53], ["IFITM1", "PROTEIN", 63, 69], ["HA", "PROTEIN", 70, 72], ["Anti-IFITM3", "TEST", 0, 11], ["NTD", "PROBLEM", 12, 15], ["IFITM3", "TEST", 30, 36], ["HA", "PROBLEM", 37, 39], ["IFITM2", "TEST", 44, 50], ["HA", "PROBLEM", 51, 53]]], ["No IFITM protein was detected in control A549 cells with either antibody by western blot.", [["A549 cells", "ANATOMY", 41, 51], ["IFITM", "GENE_OR_GENE_PRODUCT", 3, 8], ["A549 cells", "CELL", 41, 51], ["IFITM protein", "PROTEIN", 3, 16], ["A549 cells", "CELL_LINE", 41, 51], ["IFITM protein", "PROBLEM", 3, 16], ["A549 cells", "OBSERVATION", 41, 51]]], ["Multiple bands in the range of 12-17 kDa were seen with the NTD antibodies, but not the anti-HA, indicating possible post-translational modification of the proteins (see below).IFITM N-terminal domains reside intracellularlyWhen intact IFITM1, 2 or 3 cells were labelled with anti-IFITM1-NTD antibody, no staining was seen, suggesting intracellular NTDs (Fig. 4J , K and L).", [["3 cells", "ANATOMY", 249, 256], ["intracellular", "ANATOMY", 335, 348], ["N", "CHEMICAL", 183, 184], ["anti-HA", "GENE_OR_GENE_PRODUCT", 88, 95], ["IFITM1", "GENE_OR_GENE_PRODUCT", 236, 242], ["3 cells", "CELL", 249, 256], ["anti-IFITM1", "GENE_OR_GENE_PRODUCT", 276, 287], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 335, 348], ["NTD antibodies", "PROTEIN", 60, 74], ["anti-HA", "PROTEIN", 88, 95], ["IFITM N-terminal domains", "PROTEIN", 177, 201], ["IFITM1, 2 or 3 cells", "CELL_LINE", 236, 256], ["anti-IFITM1", "PROTEIN", 276, 287], ["NTD antibody", "PROTEIN", 288, 300], ["Multiple bands", "PROBLEM", 0, 14], ["the NTD antibodies", "TEST", 56, 74], ["the anti-HA", "PROBLEM", 84, 95], ["post-translational modification of the proteins", "PROBLEM", 117, 164], ["anti-IFITM1-NTD antibody", "TEST", 276, 300], ["staining", "PROBLEM", 305, 313], ["intracellular NTDs", "PROBLEM", 335, 353], ["bands", "OBSERVATION", 9, 14], ["intracellular NTDs", "OBSERVATION", 335, 353]]], ["Following detergent treatment, all three IFITM expressing lines were labelled (Fig. 4B, C and D) , though a weaker signal was seen for IFITM2, as expected from the western blot (Fig. 3A) .", [["lines", "CELL", 58, 63], ["D", "GENE_OR_GENE_PRODUCT", 94, 95], ["IFITM2", "GENE_OR_GENE_PRODUCT", 135, 141], ["IFITM expressing lines", "CELL_LINE", 41, 63], ["IFITM2", "PROTEIN", 135, 141], ["detergent treatment", "TREATMENT", 10, 29], ["all three IFITM expressing lines", "TREATMENT", 31, 63], ["Fig. 4B, C and D)", "TEST", 79, 96], ["a weaker signal", "PROBLEM", 106, 121], ["IFITM2", "PROBLEM", 135, 141]]], ["By immunofluorescence, the anti-IFITM3-NTD antibody gave a low signal in the untransfected A549 control and IFITM1-HA cells (Fig. 4E and D) , consistent with the low level of endogenous IFITM2 expression detected by qRT-PCR (Fig. S4) .", [["A549", "ANATOMY", 91, 95], ["IFITM1-HA cells", "ANATOMY", 108, 123], ["anti-IFITM3", "GENE_OR_GENE_PRODUCT", 27, 38], ["A549", "CELL", 91, 95], ["IFITM1-HA cells", "CELL", 108, 123], ["D", "CELL", 137, 138], ["IFITM2", "GENE_OR_GENE_PRODUCT", 186, 192], ["anti-IFITM3", "PROTEIN", 27, 38], ["NTD antibody", "PROTEIN", 39, 51], ["IFITM1-HA cells", "CELL_LINE", 108, 123], ["IFITM2", "PROTEIN", 186, 192], ["immunofluorescence", "TEST", 3, 21], ["the anti-IFITM3-NTD antibody", "TEST", 23, 51], ["a low signal", "PROBLEM", 57, 69], ["the untransfected A549 control", "TREATMENT", 73, 103], ["IFITM1", "TEST", 108, 114], ["endogenous IFITM2 expression", "PROBLEM", 175, 203], ["HA cells", "ANATOMY", 115, 123], ["consistent with", "UNCERTAINTY", 142, 157], ["endogenous IFITM2 expression", "OBSERVATION", 175, 203]]], ["However, the antibody clearly detected IFITM2-HA and IFITM3-HA ( Fig. 4G and H) .", [["IFITM2-HA", "GENE_OR_GENE_PRODUCT", 39, 48], ["IFITM3-HA", "GENE_OR_GENE_PRODUCT", 53, 62], ["IFITM2", "PROTEIN", 39, 45], ["HA", "PROTEIN", 46, 48], ["IFITM3", "PROTEIN", 53, 59], ["HA", "PROTEIN", 60, 62], ["Fig. 4G and H", "PROTEIN", 65, 78], ["the antibody", "TEST", 9, 21], ["IFITM2", "TEST", 39, 45], ["HA", "PROBLEM", 46, 48], ["IFITM3", "TEST", 53, 59]]], ["The observed cellular distributions, using the anti-NTD antibodies, agree with those seen using anti-HA antibodies (Fig. 2) , and the inaccessibility of the IFITM1-NTD to labelling on intact cells indicates the domain is on the cytoplasmic side of the plasma membrane.IFITM N-terminal domains reside intracellularlyThe IFITM1 C-terminal domain is accessible to extracellular proteases Immunofluorescence microscopy ( Fig. 2 and 4) suggested that the IFITM1 C-terminal HA-tag resides on the extracellular face of the plasma membrane, while the NTD is cytoplasmic.", [["cellular", "ANATOMY", 13, 21], ["cells", "ANATOMY", 191, 196], ["cytoplasmic", "ANATOMY", 228, 239], ["plasma membrane", "ANATOMY", 252, 267], ["extracellular", "ANATOMY", 361, 374], ["extracellular face", "ANATOMY", 490, 508], ["plasma membrane", "ANATOMY", 516, 531], ["cytoplasmic", "ANATOMY", 550, 561], ["N", "CHEMICAL", 274, 275], ["cellular", "CELL", 13, 21], ["IFITM1", "GENE_OR_GENE_PRODUCT", 157, 163], ["cells", "CELL", 191, 196], ["cytoplasmic", "ORGANISM_SUBSTANCE", 228, 239], ["plasma membrane", "CELLULAR_COMPONENT", 252, 267], ["IFITM1", "GENE_OR_GENE_PRODUCT", 319, 325], ["IFITM1", "GENE_OR_GENE_PRODUCT", 450, 456], ["extracellular face", "CELLULAR_COMPONENT", 490, 508], ["plasma membrane", "CELLULAR_COMPONENT", 516, 531], ["cytoplasmic", "ORGANISM_SUBSTANCE", 550, 561], ["NTD antibodies", "PROTEIN", 52, 66], ["anti-HA antibodies", "PROTEIN", 96, 114], ["Fig. 2", "PROTEIN", 116, 122], ["IFITM1", "PROTEIN", 157, 163], ["NTD", "PROTEIN", 164, 167], ["IFITM N-terminal domains", "PROTEIN", 268, 292], ["IFITM1 C-terminal domain", "PROTEIN", 319, 343], ["extracellular proteases", "PROTEIN", 361, 384], ["IFITM1 C-terminal HA-tag", "PROTEIN", 450, 474], ["NTD", "PROTEIN", 543, 546], ["The observed cellular distributions", "PROBLEM", 0, 35], ["the anti-NTD antibodies", "TREATMENT", 43, 66], ["anti-HA antibodies", "TREATMENT", 96, 114], ["the IFITM1", "TEST", 153, 163], ["The IFITM1 C-terminal domain", "PROBLEM", 315, 343], ["extracellular proteases", "TEST", 361, 384], ["Immunofluorescence microscopy", "TEST", 385, 414], ["the IFITM1 C-terminal HA-tag", "PROBLEM", 446, 474], ["cellular distributions", "OBSERVATION", 13, 35], ["intact cells", "OBSERVATION", 184, 196], ["plasma membrane", "ANATOMY", 252, 267], ["tag", "OBSERVATION", 471, 474], ["plasma membrane", "ANATOMY", 516, 531], ["cytoplasmic", "OBSERVATION", 550, 561]]], ["To further investigate this topology, we used protease cleavage assays.", [["protease", "PROTEIN", 46, 54], ["protease cleavage assays", "TREATMENT", 46, 70]]], ["Since IFITM1-HA is primarily localised to the plasma membrane we hypothesised that the CTD, and HA-tag, might be accessible to digestion by extracellular proteases.", [["plasma membrane", "ANATOMY", 46, 61], ["extracellular", "ANATOMY", 140, 153], ["IFITM1-HA", "GENE_OR_GENE_PRODUCT", 6, 15], ["plasma membrane", "CELLULAR_COMPONENT", 46, 61], ["CTD", "GENE_OR_GENE_PRODUCT", 87, 90], ["HA-tag", "GENE_OR_GENE_PRODUCT", 96, 102], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 140, 153], ["IFITM1", "PROTEIN", 6, 12], ["HA", "PROTEIN", 13, 15], ["CTD", "PROTEIN", 87, 90], ["HA", "PROTEIN", 96, 98], ["extracellular proteases", "PROTEIN", 140, 163], ["HA", "PROBLEM", 13, 15], ["the CTD", "PROBLEM", 83, 90], ["HA-tag", "PROBLEM", 96, 102], ["plasma membrane", "ANATOMY", 46, 61], ["CTD", "OBSERVATION", 87, 90], ["extracellular proteases", "OBSERVATION", 140, 163]]], ["Following analysis of the human IFITM1 CTD sequence with the ExPASy 'PeptideCutter' tool (http://web.expasy.org/peptide_cutter/) we chose to use trypsin, which was predicted to cleave at two positions close to the C-terminus of hu IFITM1 and thus expected to release the HA-tag (Fig. 5A) .IFITM N-terminal domains reside intracellularlyIFITM1-HA cells were incubated with trypsin for up to 30 min at 37uC.", [["intracellularlyIFITM1-HA cells", "ANATOMY", 321, 351], ["C", "CHEMICAL", 214, 215], ["N", "CHEMICAL", 295, 296], ["human", "ORGANISM", 26, 31], ["IFITM1", "GENE_OR_GENE_PRODUCT", 32, 38], ["trypsin", "GENE_OR_GENE_PRODUCT", 145, 152], ["hu IFITM1", "GENE_OR_GENE_PRODUCT", 228, 237], ["intracellularlyIFITM1", "GENE_OR_GENE_PRODUCT", 321, 342], ["trypsin", "GENE_OR_GENE_PRODUCT", 372, 379], ["human IFITM1 CTD sequence", "DNA", 26, 51], ["trypsin", "PROTEIN", 145, 152], ["C-terminus", "PROTEIN", 214, 224], ["hu IFITM1", "PROTEIN", 228, 237], ["HA-tag", "PROTEIN", 271, 277], ["Fig. 5A", "PROTEIN", 279, 286], ["IFITM N-terminal domains", "PROTEIN", 289, 313], ["intracellularlyIFITM1", "PROTEIN", 321, 342], ["HA cells", "CELL_LINE", 343, 351], ["trypsin", "PROTEIN", 372, 379], ["human", "SPECIES", 26, 31], ["human", "SPECIES", 26, 31], ["analysis", "TEST", 10, 18], ["the human IFITM1 CTD sequence", "TEST", 22, 51], ["trypsin", "TREATMENT", 145, 152], ["terminal domains", "PROBLEM", 297, 313], ["HA cells", "PROBLEM", 343, 351], ["trypsin", "TREATMENT", 372, 379]]], ["The trypsin was then inactivated by addition of excess soybean trypsin inhibitor (SBTI) and the cells analysed by western blot using antibodies against both the C-terminal HA-tag and the NTD.", [["cells", "ANATOMY", 96, 101], ["trypsin", "GENE_OR_GENE_PRODUCT", 4, 11], ["trypsin", "GENE_OR_GENE_PRODUCT", 63, 70], ["SBTI", "SIMPLE_CHEMICAL", 82, 86], ["cells", "CELL", 96, 101], ["trypsin", "PROTEIN", 4, 11], ["antibodies", "PROTEIN", 133, 143], ["C-terminal HA-tag", "PROTEIN", 161, 178], ["NTD", "PROTEIN", 187, 190], ["soybean", "SPECIES", 55, 62], ["The trypsin", "TREATMENT", 0, 11], ["excess soybean trypsin inhibitor", "TREATMENT", 48, 80], ["the cells", "TREATMENT", 92, 101], ["antibodies", "TREATMENT", 133, 143], ["the C-terminal HA", "TREATMENT", 157, 174], ["the NTD", "PROBLEM", 183, 190], ["NTD", "OBSERVATION", 187, 190]]], ["Analysis of samples from untreated cells with anti-IFITM1-NTD indicated two IFITM1 bands (Fig. 5Bi) , as previously seen (Fig. 3A) .", [["samples", "ANATOMY", 12, 19], ["cells", "ANATOMY", 35, 40], ["cells", "CELL", 35, 40], ["anti-IFITM1-NTD", "GENE_OR_GENE_PRODUCT", 46, 61], ["IFITM1", "GENE_OR_GENE_PRODUCT", 76, 82], ["anti-IFITM1", "PROTEIN", 46, 57], ["NTD", "PROTEIN", 58, 61], ["IFITM1 bands", "PROTEIN", 76, 88], ["Analysis of samples", "TEST", 0, 19], ["untreated cells", "PROBLEM", 25, 40], ["anti-IFITM1", "TEST", 46, 57], ["NTD", "TEST", 58, 61], ["two IFITM1 bands", "TEST", 72, 88]]], ["In samples from trypsin-treated cells the higher molecular weight band was rapidly lost, with a concomitant increase in the intensity of the lower band (Fig. 5Bi ).", [["samples", "ANATOMY", 3, 10], ["cells", "ANATOMY", 32, 37], ["trypsin", "GENE_OR_GENE_PRODUCT", 16, 23], ["cells", "CELL", 32, 37], ["trypsin-treated cells", "CELL_LINE", 16, 37], ["trypsin-treated cells", "TREATMENT", 16, 37], ["a concomitant increase", "PROBLEM", 94, 116], ["concomitant", "OBSERVATION_MODIFIER", 96, 107], ["increase", "OBSERVATION_MODIFIER", 108, 116], ["intensity", "OBSERVATION_MODIFIER", 124, 133], ["lower band", "OBSERVATION_MODIFIER", 141, 151]]], ["This suggested that the higher molecular weight band is IFITM1-HA (confirmed in an anti-HA and anti-IFITM1-NTD overlay analysis [ Fig. 5Biii]) , and that the lower band is a cleavage product that has lost the HA-tag.", [["IFITM1-HA", "GENE_OR_GENE_PRODUCT", 56, 65], ["IFITM1", "PROTEIN", 56, 62], ["HA", "PROTEIN", 63, 65], ["anti-IFITM1", "PROTEIN", 95, 106], ["HA-tag", "PROTEIN", 209, 215], ["the higher molecular weight band", "PROBLEM", 20, 52], ["HA", "PROBLEM", 63, 65], ["an anti-HA", "TREATMENT", 80, 90], ["anti-IFITM1-NTD overlay analysis", "TREATMENT", 95, 127], ["a cleavage product", "TREATMENT", 172, 190]]], ["We noted that about 8% (relative to untreated samples) of the HA-tagged protein was not digested by trypsin, even after long periods, suggesting that a small pool of IFITM1-HA protein was inaccessible to the protease (see below).IFITM N-terminal domains reside intracellularlyWe also analysed trypsin cleavage of the HA epitope by flow cytometry.", [["samples", "ANATOMY", 46, 53], ["N", "CHEMICAL", 235, 236], ["samples", "CANCER", 46, 53], ["HA", "GENE_OR_GENE_PRODUCT", 62, 64], ["trypsin", "GENE_OR_GENE_PRODUCT", 100, 107], ["IFITM1-HA", "GENE_OR_GENE_PRODUCT", 166, 175], ["trypsin", "GENE_OR_GENE_PRODUCT", 293, 300], ["HA-tagged protein", "PROTEIN", 62, 79], ["trypsin", "PROTEIN", 100, 107], ["IFITM1", "PROTEIN", 166, 172], ["HA protein", "PROTEIN", 173, 183], ["protease", "PROTEIN", 208, 216], ["IFITM N-terminal domains", "PROTEIN", 229, 253], ["trypsin", "PROTEIN", 293, 300], ["HA epitope", "PROTEIN", 317, 327], ["the HA", "PROBLEM", 58, 64], ["tagged protein", "TEST", 65, 79], ["a small pool of IFITM1", "PROBLEM", 150, 172], ["HA protein", "PROBLEM", 173, 183], ["the protease", "TREATMENT", 204, 216], ["trypsin cleavage", "TREATMENT", 293, 309], ["the HA epitope", "TREATMENT", 313, 327], ["flow cytometry", "TEST", 331, 345], ["small", "OBSERVATION_MODIFIER", 152, 157]]], ["Cells were treated with trypsin for 10 or 30 min and the trypsin inactivated with SBTI.", [["Cells", "ANATOMY", 0, 5], ["SBTI", "CHEMICAL", 82, 86], ["Cells", "CELL", 0, 5], ["trypsin", "GENE_OR_GENE_PRODUCT", 24, 31], ["trypsin", "GENE_OR_GENE_PRODUCT", 57, 64], ["SBTI", "SIMPLE_CHEMICAL", 82, 86], ["trypsin", "PROTEIN", 24, 31], ["trypsin", "PROTEIN", 57, 64], ["trypsin", "TREATMENT", 24, 31], ["the trypsin", "TREATMENT", 53, 64], ["SBTI", "PROBLEM", 82, 86]]], ["Cells were then fixed and labelled with an anti-HA antibody and detected with an Alexa-647 conjugated secondary antibody.", [["Cells", "ANATOMY", 0, 5], ["Alexa-647", "CHEMICAL", 81, 90], ["Alexa-647", "CHEMICAL", 81, 90], ["Cells", "CELL", 0, 5], ["Alexa-647", "SIMPLE_CHEMICAL", 81, 90], ["anti-HA antibody", "PROTEIN", 43, 59], ["Alexa-647 conjugated secondary antibody", "PROTEIN", 81, 120], ["Alexa-647", "SPECIES", 81, 90], ["Cells", "TEST", 0, 5], ["an anti-HA antibody", "TEST", 40, 59], ["an Alexa", "TEST", 78, 86]]], ["Untreated IFITM1-HA cells showed a high level of staining that was lost upon treatment with trypsin, as determined by a shift in the peak fluorescence intensity and decrease in mean fluorescence intensity (Fig. S5 ).Topology of untagged IFITM1To exclude the possibility that C-terminal tagging influences the topology of IFITM1, we made use of a lysine residue (K122) present in the CTD that, if the observed topology is correct, will be accessible to labelling with NHS-biotin (Fig. 6A) .", [["IFITM1-HA cells", "ANATOMY", 10, 25], ["lysine", "CHEMICAL", 346, 352], ["NHS-biotin", "CHEMICAL", 467, 477], ["C", "CHEMICAL", 275, 276], ["lysine", "CHEMICAL", 346, 352], ["NHS-biotin", "CHEMICAL", 467, 477], ["IFITM1-HA cells", "CELL", 10, 25], ["trypsin", "GENE_OR_GENE_PRODUCT", 92, 99], ["IFITM1To", "GENE_OR_GENE_PRODUCT", 237, 245], ["IFITM1", "GENE_OR_GENE_PRODUCT", 321, 327], ["NHS-biotin", "SIMPLE_CHEMICAL", 467, 477], ["IFITM1-HA cells", "CELL_LINE", 10, 25], ["trypsin", "PROTEIN", 92, 99], ["untagged IFITM1To", "PROTEIN", 228, 245], ["IFITM1", "PROTEIN", 321, 327], ["CTD", "PROTEIN", 383, 386], ["Untreated IFITM1-HA cells", "PROBLEM", 0, 25], ["a high level of staining", "PROBLEM", 33, 57], ["trypsin", "TREATMENT", 92, 99], ["the peak fluorescence intensity", "PROBLEM", 129, 160], ["mean fluorescence intensity", "PROBLEM", 177, 204], ["C-terminal tagging", "PROBLEM", 275, 293], ["a lysine residue", "TREATMENT", 344, 360], ["high level", "OBSERVATION_MODIFIER", 35, 45], ["decrease", "OBSERVATION_MODIFIER", 165, 173], ["mean fluorescence", "OBSERVATION", 177, 194]]], ["To investigate this hypothesis, HEK293T cells were transfected with an untagged IFITM1 expression plasmid and incubated with cell impermeable Sulfo-NHS-SS-Biotin for 45 min at 37uC.", [["HEK293T cells", "ANATOMY", 32, 45], ["cell", "ANATOMY", 125, 129], ["Sulfo-NHS-SS-Biotin", "CHEMICAL", 142, 161], ["HEK293T cells", "CELL", 32, 45], ["IFITM1", "GENE_OR_GENE_PRODUCT", 80, 86], ["cell", "CELL", 125, 129], ["Sulfo-NHS-SS-Biotin", "SIMPLE_CHEMICAL", 142, 161], ["HEK293T cells", "CELL_LINE", 32, 45], ["IFITM1 expression plasmid", "DNA", 80, 105], ["this hypothesis", "PROBLEM", 15, 30], ["HEK293T cells", "PROBLEM", 32, 45], ["an untagged IFITM1 expression plasmid", "TREATMENT", 68, 105], ["cell impermeable Sulfo", "TREATMENT", 125, 147], ["Biotin", "TREATMENT", 155, 161]]], ["While HEK293T cells appear to have a low level of IFITM1 mRNA (Fig. S4) , no protein was detected by western blot of mock transfected cells (Fig. 6Biii) .Topology of untagged IFITM1Following biotin labelling of untagged IFITM1, cell lysates were precipitated using NeutrAvidin beads and analysed by western blot.", [["HEK293T cells", "ANATOMY", 6, 19], ["cells", "ANATOMY", 134, 139], ["cell lysates", "ANATOMY", 228, 240], ["biotin", "CHEMICAL", 191, 197], ["biotin", "CHEMICAL", 191, 197], ["HEK293T cells", "CELL", 6, 19], ["IFITM1", "GENE_OR_GENE_PRODUCT", 50, 56], ["S4", "GENE_OR_GENE_PRODUCT", 68, 70], ["cells", "CELL", 134, 139], ["Fig. 6Biii", "CELL", 141, 151], ["biotin", "SIMPLE_CHEMICAL", 191, 197], ["IFITM1", "GENE_OR_GENE_PRODUCT", 220, 226], ["cell lysates", "ORGANISM_SUBSTANCE", 228, 240], ["HEK293T cells", "CELL_LINE", 6, 19], ["IFITM1 mRNA", "RNA", 50, 61], ["S4", "PROTEIN", 68, 70], ["mock transfected cells", "CELL_LINE", 117, 139], ["untagged IFITM1", "PROTEIN", 166, 181], ["untagged IFITM1", "PROTEIN", 211, 226], ["IFITM1 mRNA", "PROBLEM", 50, 61], ["protein", "PROBLEM", 77, 84], ["cell lysates", "TREATMENT", 228, 240], ["NeutrAvidin beads", "TREATMENT", 265, 282], ["low level", "OBSERVATION_MODIFIER", 37, 46], ["no", "UNCERTAINTY", 74, 76]]], ["IFITM1 labelled by biotin, and precipitated, is readily detected compared to unlabelled samples (Fig. 6B) .", [["samples", "ANATOMY", 88, 95], ["biotin", "CHEMICAL", 19, 25], ["biotin", "CHEMICAL", 19, 25], ["IFITM1", "GENE_OR_GENE_PRODUCT", 0, 6], ["biotin", "SIMPLE_CHEMICAL", 19, 25], ["IFITM1", "PROTEIN", 0, 6]]], ["The detection of IFITM1 in the biotin labelled, but unbound, fraction suggested that either the precipitation is not efficient, or only a proportion of IFITM1 has a CTD that is accessible to cell surface labelling.Topology of untagged IFITM1To control for the specificity of labelling, a plasmid encoding an IFITM1 protein with a stop codon after the V109 codon (referred to as IFITM1-Vstop) that removes K122 (Fig. 6A) , was transfected into HEK293T cells (Fig. 6C) .", [["cell surface", "ANATOMY", 191, 203], ["HEK293T cells", "ANATOMY", 443, 456], ["biotin", "CHEMICAL", 31, 37], ["IFITM1", "CHEMICAL", 152, 158], ["biotin", "CHEMICAL", 31, 37], ["IFITM1", "GENE_OR_GENE_PRODUCT", 17, 23], ["biotin", "SIMPLE_CHEMICAL", 31, 37], ["IFITM1", "GENE_OR_GENE_PRODUCT", 152, 158], ["cell", "CELL", 191, 195], ["IFITM1To", "GENE_OR_GENE_PRODUCT", 235, 243], ["IFITM1", "GENE_OR_GENE_PRODUCT", 308, 314], ["IFITM1-Vstop", "GENE_OR_GENE_PRODUCT", 378, 390], ["Fig. 6A", "GENE_OR_GENE_PRODUCT", 411, 418], ["HEK293T cells", "CELL", 443, 456], ["IFITM1", "PROTEIN", 17, 23], ["IFITM1", "PROTEIN", 152, 158], ["CTD", "PROTEIN", 165, 168], ["IFITM1To", "PROTEIN", 235, 243], ["plasmid", "DNA", 288, 295], ["IFITM1 protein", "PROTEIN", 308, 322], ["stop codon", "DNA", 330, 340], ["V109 codon", "DNA", 351, 361], ["IFITM1", "PROTEIN", 378, 384], ["Vstop", "DNA", 385, 390], ["K122", "DNA", 405, 409], ["HEK293T cells", "CELL_LINE", 443, 456], ["The detection", "TEST", 0, 13], ["IFITM1 in the biotin labelled", "PROBLEM", 17, 46], ["a CTD", "PROBLEM", 163, 168], ["untagged IFITM1To control", "TREATMENT", 226, 251], ["a plasmid encoding an IFITM1 protein", "TREATMENT", 286, 322], ["a stop codon", "TREATMENT", 328, 340], ["the V109 codon", "TREATMENT", 347, 361], ["CTD", "OBSERVATION", 165, 168]]], ["After cells expressing this protein were incubated with Sulfo-NHS-SS-Biotin, none of the IFITM1-Vstop was absorbed to the beads (Fig. 6D) . .", [["cells", "ANATOMY", 6, 11], ["Sulfo-NHS-SS-Biotin", "CHEMICAL", 56, 75], ["Biotin", "CHEMICAL", 69, 75], ["cells", "CELL", 6, 11], ["Sulfo-NHS-SS-Biotin", "SIMPLE_CHEMICAL", 56, 75], ["IFITM1-Vstop", "SIMPLE_CHEMICAL", 89, 101], ["IFITM1", "PROTEIN", 89, 95], ["Vstop", "PROTEIN", 96, 101], ["Sulfo", "TREATMENT", 56, 61], ["Biotin", "TREATMENT", 69, 75], ["the IFITM1-Vstop", "TREATMENT", 85, 101]]], ["Analysis of IFITM NTD antibodies.", [["IFITM", "GENE_OR_GENE_PRODUCT", 12, 17], ["IFITM NTD antibodies", "PROTEIN", 12, 32], ["Analysis", "TEST", 0, 8], ["IFITM NTD antibodies", "PROBLEM", 12, 32]]], ["Two commercially available antibodies targeting either the IFITM1-NTD or the IFITM3-NTD were screened by western blot to assess specificity using HA-tagged IFITM1-3 (M1, M2 and M3) cell lines along with control A549 cells.", [["IFITM1-3 (M1", "ANATOMY", 156, 168], ["M2", "ANATOMY", 170, 172], ["M3) cell lines", "ANATOMY", 177, 191], ["A549 cells", "ANATOMY", 211, 221], ["IFITM1-NTD", "GENE_OR_GENE_PRODUCT", 59, 69], ["IFITM3-NTD", "GENE_OR_GENE_PRODUCT", 77, 87], ["IFITM1-3", "CELL", 156, 164], ["M1", "CELL", 166, 168], ["M2", "CELL", 170, 172], ["M3) cell lines", "CELL", 177, 191], ["A549 cells", "CELL", 211, 221], ["IFITM1", "PROTEIN", 59, 65], ["NTD", "PROTEIN", 66, 69], ["IFITM3", "PROTEIN", 77, 83], ["NTD", "PROTEIN", 84, 87], ["HA-tagged IFITM1-3 (M1, M2 and M3) cell lines", "CELL_LINE", 146, 191], ["A549 cells", "CELL_LINE", 211, 221], ["the IFITM1", "TEST", 55, 65], ["specificity", "TEST", 128, 139], ["HA", "TEST", 146, 148], ["IFITM1", "TEST", 156, 162], ["cell lines", "TREATMENT", 181, 191], ["control A549 cells", "TREATMENT", 203, 221], ["cell lines", "OBSERVATION", 181, 191], ["A549 cells", "OBSERVATION", 211, 221]]], ["Proteins were also identified using the HA epitope.", [["HA epitope", "PROTEIN", 40, 50], ["Proteins", "TEST", 0, 8], ["the HA epitope", "TREATMENT", 36, 50]]], ["Blots were imaged on a Li-COR Odyssey system that uses far-red fluorophore conjugated secondary antibodies.", [["far-red fluorophore conjugated secondary antibodies", "PROTEIN", 55, 106], ["a Li-COR Odyssey system", "TREATMENT", 21, 44], ["red fluorophore conjugated", "TREATMENT", 59, 85]]], ["In the overlay image, red represents anti-IFITM-NTD labelling and green represents anti-HA labelling.", [["anti-IFITM", "SIMPLE_CHEMICAL", 37, 47], ["anti-HA", "GENE_OR_GENE_PRODUCT", 83, 90], ["anti-IFITM", "PROTEIN", 37, 47], ["NTD", "PROTEIN", 48, 51], ["the overlay image", "TEST", 3, 20], ["anti-IFITM", "TEST", 37, 47], ["NTD labelling", "PROBLEM", 48, 61], ["green", "OBSERVATION_MODIFIER", 66, 71], ["anti-HA labelling", "OBSERVATION", 83, 100]]], ["A) Anti-IFITM1-NTD detects IFITM1 and shows cross-reactivity with IFITM3.", [["Anti-IFITM1-NTD", "GENE_OR_GENE_PRODUCT", 3, 18], ["IFITM1", "GENE_OR_GENE_PRODUCT", 27, 33], ["IFITM3", "GENE_OR_GENE_PRODUCT", 66, 72], ["Anti-IFITM1", "PROTEIN", 3, 14], ["NTD", "PROTEIN", 15, 18], ["IFITM1", "PROTEIN", 27, 33], ["IFITM3", "PROTEIN", 66, 72], ["IFITM3", "PROBLEM", 66, 72]]], ["B) Anti-IFITM3-NTD detects IFITM3 and has cross-reactivity with IFITM2.", [["Anti-IFITM3-NTD", "GENE_OR_GENE_PRODUCT", 3, 18], ["IFITM3", "GENE_OR_GENE_PRODUCT", 27, 33], ["IFITM2", "GENE_OR_GENE_PRODUCT", 64, 70], ["Anti-IFITM3", "PROTEIN", 3, 14], ["NTD", "PROTEIN", 15, 18], ["IFITM3", "PROTEIN", 27, 33], ["IFITM2", "PROTEIN", 64, 70], ["IFITM3", "PROBLEM", 27, 33]]], ["VDAC was used as a loading control. doi:10.1371/journal.pone.0104341.g003 The IFITM1 CTD HA-tag resides on the outer leaflet of the plasma membraneTopology of untagged IFITM1To analyse hu IFITM1 in more detail, cryo-sections of IFITM1-HA cells were immuno-gold labelled for the HA-tag and examined by electron microscopy.", [["outer leaflet", "ANATOMY", 111, 124], ["plasma membrane", "ANATOMY", 132, 147], ["IFITM1-HA cells", "ANATOMY", 228, 243], ["doi:10.1371/journal.pone.0104341.g003", "CHEMICAL", 36, 73], ["VDAC", "GENE_OR_GENE_PRODUCT", 0, 4], ["IFITM1", "GENE_OR_GENE_PRODUCT", 78, 84], ["outer leaflet", "CELLULAR_COMPONENT", 111, 124], ["plasma membrane", "CELLULAR_COMPONENT", 132, 147], ["IFITM1To", "GENE_OR_GENE_PRODUCT", 168, 176], ["IFITM1-HA cells", "CELL", 228, 243], ["VDAC", "PROTEIN", 0, 4], ["IFITM1 CTD HA-tag", "DNA", 78, 95], ["untagged IFITM1To", "PROTEIN", 159, 176], ["hu IFITM1", "PROTEIN", 185, 194], ["IFITM1-HA cells", "CELL_LINE", 228, 243], ["HA-tag", "DNA", 278, 284], ["VDAC", "TREATMENT", 0, 4], ["a loading control", "TREATMENT", 17, 34], ["The IFITM1 CTD HA", "TEST", 74, 91], ["IFITM1", "TEST", 228, 234], ["HA cells", "PROBLEM", 235, 243], ["electron microscopy", "TEST", 301, 320], ["tag", "OBSERVATION", 92, 95], ["outer", "ANATOMY_MODIFIER", 111, 116], ["leaflet", "ANATOMY_MODIFIER", 117, 124], ["plasma membrane", "ANATOMY", 132, 147]]], ["As expected, labelling was seen predominantly at the plasma membrane ( Fig. 7A and B) .", [["plasma membrane", "ANATOMY", 53, 68], ["plasma membrane", "CELLULAR_COMPONENT", 53, 68], ["plasma membrane", "ANATOMY", 53, 68]]], ["Close examination indicated that the majority of gold particles resided on the extracellular face of the plasma membrane, consistent with the notion that the hu IFITM1 CTD is located extracellularly.", [["extracellular face", "ANATOMY", 79, 97], ["plasma membrane", "ANATOMY", 105, 120], ["extracellular face", "IMMATERIAL_ANATOMICAL_ENTITY", 79, 97], ["plasma membrane", "CELLULAR_COMPONENT", 105, 120], ["IFITM1", "GENE_OR_GENE_PRODUCT", 161, 167], ["hu IFITM1 CTD", "PROTEIN", 158, 171], ["Close examination", "TEST", 0, 17], ["gold particles", "PROBLEM", 49, 63], ["the hu IFITM1 CTD", "PROBLEM", 154, 171], ["gold particles", "OBSERVATION", 49, 63], ["extracellular", "ANATOMY_MODIFIER", 79, 92], ["face", "ANATOMY_MODIFIER", 93, 97], ["plasma membrane", "ANATOMY", 105, 120], ["consistent with", "UNCERTAINTY", 122, 137]]], ["Labelling was also seen in the Golgi apparatus and in multivesicular bodies (Fig. 7C and D) .", [["Golgi apparatus", "ANATOMY", 31, 46], ["multivesicular bodies", "ANATOMY", 54, 75], ["Golgi apparatus", "CELLULAR_COMPONENT", 31, 46], ["multivesicular bodies", "CELLULAR_COMPONENT", 54, 75], ["Golgi", "ANATOMY_MODIFIER", 31, 36], ["multivesicular", "ANATOMY_MODIFIER", 54, 68], ["bodies", "ANATOMY_MODIFIER", 69, 75]]], ["These intracellular pools presumably indicate IFITM1 trafficking in the biosynthetic and endocytic pathways.", [["intracellular", "ANATOMY", 6, 19], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 6, 19], ["IFITM1", "GENE_OR_GENE_PRODUCT", 46, 52], ["IFITM1", "PROTEIN", 46, 52], ["These intracellular pools", "PROBLEM", 0, 25], ["intracellular pools", "OBSERVATION", 6, 25], ["presumably indicate", "UNCERTAINTY", 26, 45], ["IFITM1 trafficking", "OBSERVATION", 46, 64], ["endocytic pathways", "OBSERVATION", 89, 107]]], ["This material would be inaccessible to extracellular proteases and labelling reagents, explaining the failure to completely digest IFITM1-HA with trypsin (Fig. 5B) and to fully label IFITM1 with biotin (Fig. 6B) .Conservation of the observed hu IFITM1 topology in hu IFITM2 and IFITM3Our results indicate that hu IFITM1 is located predominantly in the plasma membrane, making it highly amenable to the topological analysis described above.", [["extracellular", "ANATOMY", 39, 52], ["plasma membrane", "ANATOMY", 352, 367], ["biotin", "CHEMICAL", 195, 201], ["biotin", "CHEMICAL", 195, 201], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 39, 52], ["IFITM1-HA", "GENE_OR_GENE_PRODUCT", 131, 140], ["trypsin", "GENE_OR_GENE_PRODUCT", 146, 153], ["IFITM1", "GENE_OR_GENE_PRODUCT", 183, 189], ["biotin", "SIMPLE_CHEMICAL", 195, 201], ["hu IFITM1", "GENE_OR_GENE_PRODUCT", 310, 319], ["plasma membrane", "CELLULAR_COMPONENT", 352, 367], ["extracellular proteases", "PROTEIN", 39, 62], ["IFITM1", "PROTEIN", 131, 137], ["HA", "PROTEIN", 138, 140], ["trypsin", "PROTEIN", 146, 153], ["Fig. 5B", "PROTEIN", 155, 162], ["IFITM1", "PROTEIN", 183, 189], ["IFITM1", "PROTEIN", 245, 251], ["IFITM1", "PROTEIN", 313, 319], ["extracellular proteases", "TREATMENT", 39, 62], ["labelling reagents", "TREATMENT", 67, 85], ["the failure", "PROBLEM", 98, 109], ["biotin (Fig", "TREATMENT", 195, 206], ["hu IFITM1", "PROBLEM", 310, 319], ["the topological analysis", "TEST", 398, 422], ["plasma membrane", "ANATOMY", 352, 367]]], ["Conversely, we show that hu IFITM2-HA and IFITM3-HA are primarily intracellular and less accessible to these investigative methods.", [["intracellular", "ANATOMY", 66, 79], ["IFITM2-HA", "GENE_OR_GENE_PRODUCT", 28, 37], ["IFITM3-HA", "GENE_OR_GENE_PRODUCT", 42, 51], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 66, 79], ["IFITM2", "PROTEIN", 28, 34], ["HA", "PROTEIN", 35, 37], ["IFITM3", "PROTEIN", 42, 48], ["HA", "PROTEIN", 49, 51], ["HA", "PROBLEM", 35, 37], ["IFITM3-HA", "PROBLEM", 42, 51]]], ["Alternative approaches were therefore adopted to determine the location of the HAtagged CTD of hu IFITM2 or IFITM3.Conservation of the observed hu IFITM1 topology in hu IFITM2 and IFITM3An antibody-feeding approach was used in which live cells were cultured in medium containing anti-HA antibody for 3 h, prior to washing, fixation and visualisation by immunofluorescence microscopy.", [["cells", "ANATOMY", 238, 243], ["hu IFITM2", "GENE_OR_GENE_PRODUCT", 95, 104], ["hu IFITM2", "CELL", 166, 175], ["IFITM3An antibody", "GENE_OR_GENE_PRODUCT", 180, 197], ["cells", "CELL", 238, 243], ["HAtagged CTD", "PROTEIN", 79, 91], ["hu IFITM2", "PROTEIN", 95, 104], ["IFITM3", "PROTEIN", 108, 114], ["IFITM1", "PROTEIN", 147, 153], ["IFITM2", "PROTEIN", 169, 175], ["IFITM3An antibody", "PROTEIN", 180, 197], ["anti-HA antibody", "PROTEIN", 279, 295], ["Alternative approaches", "TREATMENT", 0, 22], ["hu IFITM2", "TREATMENT", 95, 104], ["IFITM3", "PROBLEM", 108, 114], ["the observed hu IFITM1 topology", "TREATMENT", 131, 162], ["hu IFITM2", "TREATMENT", 166, 175], ["IFITM3An antibody-feeding approach", "TREATMENT", 180, 214], ["anti-HA antibody", "TREATMENT", 279, 295], ["fixation", "TREATMENT", 323, 331], ["visualisation", "TEST", 336, 349], ["immunofluorescence microscopy", "TEST", 353, 382]]], ["As expected, control untransfected A549 cells, incubated with anti-HA antibodies, and IFITM3-HA cells that were not incubated with anti-HA antibodies, showed no labelling ( Fig. 8A and C) .", [["A549 cells", "ANATOMY", 35, 45], ["IFITM3-HA cells", "ANATOMY", 86, 101], ["A549 cells", "CELL", 35, 45], ["control untransfected A549 cells", "CELL_LINE", 13, 45], ["anti-HA antibodies", "PROTEIN", 62, 80], ["IFITM3", "PROTEIN", 86, 92], ["HA cells", "CELL_LINE", 93, 101], ["anti-HA antibodies", "PROTEIN", 131, 149], ["control untransfected A549 cells", "PROBLEM", 13, 45], ["anti-HA antibodies", "TEST", 62, 80], ["IFITM3-HA cells", "PROBLEM", 86, 101], ["anti-HA antibodies", "TEST", 131, 149], ["A549 cells", "OBSERVATION", 35, 45]]], ["IFITM1-HA expressing cells acted as a positive control and showed strong cell surface labelling (Fig. 8B) .", [["cells", "ANATOMY", 21, 26], ["cell surface", "ANATOMY", 73, 85], ["IFITM1", "GENE_OR_GENE_PRODUCT", 0, 6], ["cells", "CELL", 21, 26], ["cell", "CELL", 73, 77], ["IFITM1", "PROTEIN", 0, 6], ["HA expressing cells", "CELL_LINE", 7, 26], ["HA expressing cells", "PROBLEM", 7, 26], ["a positive control", "TREATMENT", 36, 54], ["strong cell surface labelling", "PROBLEM", 66, 95]]], ["By contrast, most IFITM2-HA and IFITM3-HA cells showed little, if any, labelling.", [["IFITM3-HA cells", "ANATOMY", 32, 47], ["IFITM2-HA", "GENE_OR_GENE_PRODUCT", 18, 27], ["IFITM3", "GENE_OR_GENE_PRODUCT", 32, 38], ["IFITM2", "PROTEIN", 18, 24], ["HA and IFITM3-HA cells", "CELL_LINE", 25, 47], ["IFITM2", "TEST", 18, 24], ["IFITM3-HA cells", "TEST", 32, 47], ["little", "OBSERVATION_MODIFIER", 55, 61]]], ["However, approximately 25% of IFITM3-HA cells and 10% of IFITM2-HA cells (calculated from 30 random fields of view at 40X magnification) showed intracellular, punctate labelling ( Fig. 8D and E) .", [["IFITM3-HA cells", "ANATOMY", 30, 45], ["IFITM2-HA cells", "ANATOMY", 57, 72], ["intracellular", "ANATOMY", 144, 157], ["IFITM3-HA cells", "CELL", 30, 45], ["IFITM2-HA cells", "CELL", 57, 72], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 144, 157], ["IFITM3", "PROTEIN", 30, 36], ["HA cells", "CELL_LINE", 37, 45], ["IFITM2-HA cells", "CELL_LINE", 57, 72], ["IFITM3-HA cells", "TEST", 30, 45], ["IFITM2", "TEST", 57, 63], ["HA cells", "PROBLEM", 64, 72], ["HA cells", "ANATOMY", 64, 72], ["punctate", "OBSERVATION_MODIFIER", 159, 167]]], ["Since the cells were labelled prior to fixation, this intracellular labelling suggested that, in some cells, the IFITM2-HA and IFITM3-HA proteins are trafficked to the cell surface where an externally exposed HA epitope could bind antibody, prior to internalisation into intracellular organelles.", [["cells", "ANATOMY", 10, 15], ["intracellular", "ANATOMY", 54, 67], ["cells", "ANATOMY", 102, 107], ["cell surface", "ANATOMY", 168, 180], ["intracellular organelles", "ANATOMY", 271, 295], ["cells", "CELL", 10, 15], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 54, 67], ["cells", "CELL", 102, 107], ["IFITM2-HA", "GENE_OR_GENE_PRODUCT", 113, 122], ["IFITM3-HA proteins", "GENE_OR_GENE_PRODUCT", 127, 145], ["cell surface", "CELLULAR_COMPONENT", 168, 180], ["intracellular organelles", "CELLULAR_COMPONENT", 271, 295], ["IFITM2", "PROTEIN", 113, 119], ["HA", "PROTEIN", 120, 122], ["IFITM3", "PROTEIN", 127, 133], ["HA proteins", "PROTEIN", 134, 145], ["HA epitope", "PROTEIN", 209, 219], ["fixation", "TREATMENT", 39, 47], ["this intracellular labelling", "TEST", 49, 77], ["the IFITM2", "TEST", 109, 119], ["HA", "PROBLEM", 120, 122], ["IFITM3-HA proteins", "TREATMENT", 127, 145], ["an externally exposed HA epitope", "PROBLEM", 187, 219]]], ["The lack of labelling in the majority of cells, which express the IFITM proteins, indicates the labelling is not due to non-specific fluid phase uptake of antibody.", [["cells", "ANATOMY", 41, 46], ["cells", "CELL", 41, 46], ["IFITM", "GENE_OR_GENE_PRODUCT", 66, 71], ["IFITM proteins", "PROTEIN", 66, 80], ["antibody", "PROTEIN", 155, 163], ["the IFITM proteins", "TEST", 62, 80], ["non-specific fluid phase uptake of antibody", "PROBLEM", 120, 163], ["labelling", "OBSERVATION", 12, 21], ["not due to", "UNCERTAINTY", 109, 119], ["non-specific", "OBSERVATION_MODIFIER", 120, 132], ["fluid phase", "OBSERVATION", 133, 144]]], ["B) IFITM1-HA cells were treated with exogenous trypsin for 5 to 30 mins at 37uC.", [["IFITM1-HA cells", "ANATOMY", 3, 18], ["IFITM1", "GENE_OR_GENE_PRODUCT", 3, 9], ["trypsin", "GENE_OR_GENE_PRODUCT", 47, 54], ["IFITM1-HA cells", "CELL_LINE", 3, 18], ["trypsin", "PROTEIN", 47, 54], ["HA cells", "PROBLEM", 10, 18], ["exogenous trypsin", "TREATMENT", 37, 54]]], ["The trypsin was inactivated with soybean trypsin inhibitor, the cells were lysed and the cellular proteins separated by SDS-PAGE.", [["cells", "ANATOMY", 64, 69], ["cellular", "ANATOMY", 89, 97], ["trypsin", "GENE_OR_GENE_PRODUCT", 4, 11], ["trypsin", "GENE_OR_GENE_PRODUCT", 41, 48], ["cells", "CELL", 64, 69], ["cellular", "CELL", 89, 97], ["trypsin", "PROTEIN", 4, 11], ["cellular proteins", "PROTEIN", 89, 106], ["soybean", "SPECIES", 33, 40], ["The trypsin", "TREATMENT", 0, 11], ["soybean trypsin inhibitor", "TREATMENT", 33, 58], ["the cells", "TREATMENT", 60, 69], ["the cellular proteins", "TEST", 85, 106]]], ["After transfer, proteins were identified with anti-IFITM1-NTD (i) and anti-HA (ii) antibodies.", [["anti-IFITM1-NTD", "GENE_OR_GENE_PRODUCT", 46, 61], ["anti-HA (ii) antibodies", "GENE_OR_GENE_PRODUCT", 70, 93], ["anti-IFITM1", "PROTEIN", 46, 57], ["NTD", "PROTEIN", 58, 61], ["anti-HA (ii) antibodies", "PROTEIN", 70, 93], ["proteins", "TEST", 16, 24], ["anti-IFITM1", "TEST", 46, 57], ["anti-HA (ii) antibodies", "TREATMENT", 70, 93]]], ["VDAC was used as a loading control (iii).", [["VDAC", "CHEMICAL", 0, 4], ["VDAC", "GENE_OR_GENE_PRODUCT", 0, 4], ["VDAC", "PROTEIN", 0, 4], ["VDAC", "TREATMENT", 0, 4], ["a loading control (iii)", "TREATMENT", 17, 40]]], ["Control samples were untreated (UN), or treated with SBTI-inactivated trypsin (IN).", [["samples", "ANATOMY", 8, 15], ["SBTI", "CHEMICAL", 53, 57], ["SBTI", "SIMPLE_CHEMICAL", 53, 57], ["trypsin", "GENE_OR_GENE_PRODUCT", 70, 77], ["IN", "GENE_OR_GENE_PRODUCT", 79, 81], ["SBTI", "PROTEIN", 53, 57], ["trypsin", "PROTEIN", 70, 77], ["IN", "PROTEIN", 79, 81], ["SBTI", "TREATMENT", 53, 57]]], ["In the overlay image, red represents anti-IFITM1-NTD labelling and green represents anti-HA labelling (iv). doi:10.1371/journal.pone.0104341.g005 fraction of A549 cells, the CTDs of both IFITM2-HA and IFITM3-HA proteins are, at least transiently, exposed on the cell surface.Conservation of the observed hu IFITM1 topology in hu IFITM2 and IFITM3Previous results have suggested that IFITM2 and 3 are localised to endosomes (Fig. 2, 4 and [6] ).", [["A549 cells", "ANATOMY", 158, 168], ["cell surface", "ANATOMY", 262, 274], ["endosomes", "ANATOMY", 413, 422], ["anti-IFITM1", "SIMPLE_CHEMICAL", 37, 48], ["anti-HA", "GENE_OR_GENE_PRODUCT", 84, 91], ["A549 cells", "CELL", 158, 168], ["IFITM2-HA", "GENE_OR_GENE_PRODUCT", 187, 196], ["IFITM3-HA proteins", "GENE_OR_GENE_PRODUCT", 201, 219], ["cell surface", "CELLULAR_COMPONENT", 262, 274], ["hu IFITM2", "GENE_OR_GENE_PRODUCT", 326, 335], ["IFITM2", "GENE_OR_GENE_PRODUCT", 383, 389], ["3", "GENE_OR_GENE_PRODUCT", 394, 395], ["endosomes", "CELLULAR_COMPONENT", 413, 422], ["anti-IFITM1", "PROTEIN", 37, 48], ["NTD", "PROTEIN", 49, 52], ["A549 cells", "CELL_LINE", 158, 168], ["IFITM2", "PROTEIN", 187, 193], ["HA", "PROTEIN", 194, 196], ["IFITM3", "PROTEIN", 201, 207], ["HA proteins", "PROTEIN", 208, 219], ["IFITM1", "PROTEIN", 307, 313], ["IFITM2 and 3", "PROTEIN", 383, 395], ["anti-IFITM1", "TEST", 37, 48], ["NTD labelling", "PROBLEM", 49, 62], ["anti-HA labelling", "TREATMENT", 84, 101], ["A549 cells", "PROBLEM", 158, 168], ["the CTDs", "TEST", 170, 178], ["IFITM2", "TEST", 187, 193], ["HA", "PROBLEM", 194, 196], ["IFITM3-HA proteins", "TEST", 201, 219], ["A549 cells", "OBSERVATION", 158, 168], ["cell surface", "OBSERVATION", 262, 274]]], ["The exposure of CTD HA-tags in the lumen of these organelles may result in their cleavage by endosomal/lysosomal proteases.", [["lumen", "ANATOMY", 35, 40], ["organelles", "ANATOMY", 50, 60], ["endosomal", "ANATOMY", 93, 102], ["lysosomal", "ANATOMY", 103, 112], ["lumen", "IMMATERIAL_ANATOMICAL_ENTITY", 35, 40], ["organelles", "CELLULAR_COMPONENT", 50, 60], ["endosomal", "CELLULAR_COMPONENT", 93, 102], ["CTD", "PROTEIN", 16, 19], ["endosomal/lysosomal proteases", "PROTEIN", 93, 122], ["CTD HA", "PROBLEM", 16, 22], ["CTD", "OBSERVATION", 16, 19], ["lumen", "ANATOMY_MODIFIER", 35, 40], ["lysosomal proteases", "OBSERVATION", 103, 122]]], ["This hypothesis is supported by western blots that showed low levels of HA-labelling for IFITM2 and 3 (Fig. 3) .", [["HA", "PROTEIN", 72, 74], ["IFITM2", "PROTEIN", 89, 95], ["western blots", "TEST", 32, 45], ["low levels of HA", "PROBLEM", 58, 74], ["IFITM2", "TEST", 89, 95]]], ["Moreover, when detected with anti-IFITM3-NTD, IFITM2-HA appears to have 3 bands in the range of 12-17 kDa, Figure 6 .", [["anti-IFITM3-NTD", "GENE_OR_GENE_PRODUCT", 29, 44], ["IFITM2-HA", "GENE_OR_GENE_PRODUCT", 46, 55], ["anti-IFITM3", "PROTEIN", 29, 40], ["NTD", "PROTEIN", 41, 44], ["IFITM2", "PROTEIN", 46, 52], ["HA", "PROTEIN", 53, 55], ["anti-IFITM3", "TEST", 29, 40], ["bands", "TEST", 74, 79]]], ["Biotin labelling and pulldown of untagged IFITM1.", [["Biotin", "CHEMICAL", 0, 6], ["Biotin", "SIMPLE_CHEMICAL", 0, 6], ["IFITM1", "GENE_OR_GENE_PRODUCT", 42, 48], ["IFITM1", "PROTEIN", 42, 48], ["Biotin labelling", "TREATMENT", 0, 16]]], ["Untagged, wild type IFITM1 or IFITM1-Vstop expression plasmids were transfected into HEK293T cells.", [["plasmids", "ANATOMY", 54, 62], ["HEK293T cells", "ANATOMY", 85, 98], ["IFITM1", "GENE_OR_GENE_PRODUCT", 20, 26], ["IFITM1-Vstop", "GENE_OR_GENE_PRODUCT", 30, 42], ["HEK293T cells", "CELL", 85, 98], ["wild type IFITM1 or IFITM1-Vstop expression plasmids", "DNA", 10, 62], ["HEK293T cells", "CELL_LINE", 85, 98], ["wild type IFITM1", "PROBLEM", 10, 26], ["IFITM1-Vstop expression plasmids", "TREATMENT", 30, 62]]], ["After two days the cells were labelled with cell impermeable Sulfo-NHS-SS-Biotin prior to incubation with NeutrAvidin agarose beads.", [["cells", "ANATOMY", 19, 24], ["cell", "ANATOMY", 44, 48], ["Sulfo-NHS-SS-Biotin", "CHEMICAL", 61, 80], ["cells", "CELL", 19, 24], ["cell", "CELL", 44, 48], ["Sulfo-NHS-SS-Biotin", "SIMPLE_CHEMICAL", 61, 80], ["NeutrAvidin agarose beads", "SIMPLE_CHEMICAL", 106, 131], ["cell impermeable Sulfo", "TREATMENT", 44, 66], ["SS-Biotin", "TREATMENT", 71, 80], ["NeutrAvidin agarose beads", "TREATMENT", 106, 131]]], ["A) Diagram to show the exposed CTD of IFITM1, with the targeted K122, or IFITM1-Vstop.", [["IFITM1", "GENE_OR_GENE_PRODUCT", 38, 44], ["IFITM1-Vstop", "GENE_OR_GENE_PRODUCT", 73, 85], ["CTD", "PROTEIN", 31, 34], ["IFITM1", "PROTEIN", 38, 44], ["K122", "PROTEIN", 64, 68], ["IFITM1", "PROTEIN", 73, 79], ["Vstop", "PROTEIN", 80, 85]]], ["B) Western blots probed with anti-IFITM1-NTD; WCL -whole cell lysates, UB -material that remained unbound by NeutrAvidin, PD1 and PD2 -two rounds of elution of protein from the NeutrAvidin beads.", [["cell lysates", "ANATOMY", 57, 69], ["NeutrAvidin", "CHEMICAL", 109, 120], ["NeutrAvidin", "CHEMICAL", 109, 120], ["anti-IFITM1-NTD", "GENE_OR_GENE_PRODUCT", 29, 44], ["WCL", "ORGANISM_SUBSTANCE", 46, 49], ["cell lysates", "ORGANISM_SUBSTANCE", 57, 69], ["UB -material", "CELL", 71, 83], ["NeutrAvidin", "SIMPLE_CHEMICAL", 109, 120], ["PD1", "GENE_OR_GENE_PRODUCT", 122, 125], ["PD2", "SIMPLE_CHEMICAL", 130, 133], ["anti-IFITM1", "PROTEIN", 29, 40], ["NTD", "PROTEIN", 41, 44], ["WCL", "PROTEIN", 46, 49], ["PD1", "PROTEIN", 122, 125], ["PD2", "PROTEIN", 130, 133], ["Western blots", "TEST", 3, 16], ["anti-IFITM1", "TEST", 29, 40], ["NTD", "PROBLEM", 41, 44], ["WCL", "TEST", 46, 49], ["whole cell lysates", "TEST", 51, 69], ["NeutrAvidin", "TREATMENT", 109, 120], ["PD2", "TEST", 130, 133], ["elution of protein", "TREATMENT", 149, 167], ["the NeutrAvidin beads", "TREATMENT", 173, 194]]], ["Gel i shows samples from cells labelled with biotin, gel ii shows unlabelled samples and gel iii shows samples from mock transfected HEK293T cells that were treated with Sulfo-NHS-SS-Biotin.", [["samples", "ANATOMY", 12, 19], ["cells", "ANATOMY", 25, 30], ["samples", "ANATOMY", 77, 84], ["samples", "ANATOMY", 103, 110], ["HEK293T cells", "ANATOMY", 133, 146], ["Sulfo-NHS-SS-Biotin", "CHEMICAL", 170, 189], ["biotin", "CHEMICAL", 45, 51], ["Biotin", "CHEMICAL", 183, 189], ["cells", "CELL", 25, 30], ["biotin", "SIMPLE_CHEMICAL", 45, 51], ["HEK293T cells", "CELL", 133, 146], ["Sulfo-NHS-SS-Biotin", "SIMPLE_CHEMICAL", 170, 189], ["HEK293T cells", "CELL_LINE", 133, 146], ["biotin, gel ii", "TEST", 45, 59], ["gel iii", "TEST", 89, 96], ["HEK293T cells", "TEST", 133, 146], ["Sulfo", "TREATMENT", 170, 175], ["Biotin", "TREATMENT", 183, 189], ["HEK293T cells", "OBSERVATION", 133, 146]]], ["NB.", [["NB", "ANATOMY", 0, 2], ["NB", "DISEASE", 0, 2], ["NB", "CANCER", 0, 2]]], ["The elution step detached some NeutrAvidin monomers from the beads.", [["NeutrAvidin", "CHEMICAL", 31, 42], ["NeutrAvidin", "CHEMICAL", 31, 42], ["NeutrAvidin", "SIMPLE_CHEMICAL", 31, 42], ["The elution step", "TREATMENT", 0, 16], ["some NeutrAvidin monomers", "TREATMENT", 26, 51], ["NeutrAvidin monomers", "OBSERVATION", 31, 51], ["beads", "OBSERVATION_MODIFIER", 61, 66]]], ["These run at approximately 14 KDa and are seen as background bands in the western blots (labelled 'NeutrAvidin').", [["background bands", "PROBLEM", 50, 66]]], ["Calreticulin was used as a loading control and negative control for pulldown specificity.", [["Calreticulin", "CHEMICAL", 0, 12], ["Calreticulin", "CHEMICAL", 0, 12], ["Calreticulin", "SIMPLE_CHEMICAL", 0, 12], ["Calreticulin", "TREATMENT", 0, 12], ["a loading control", "TREATMENT", 25, 42], ["pulldown specificity", "TEST", 68, 88]]], ["C) Western blot comparing the wild type IFITM1 (M1) with IFITM1-Vstop (Vstop), along with mock transfected HEK293T cells.", [["HEK293T cells", "ANATOMY", 107, 120], ["IFITM1", "GENE_OR_GENE_PRODUCT", 40, 46], ["IFITM1-Vstop", "GENE_OR_GENE_PRODUCT", 57, 69], ["HEK293T cells", "CELL", 107, 120], ["wild type IFITM1", "PROTEIN", 30, 46], ["M1", "PROTEIN", 48, 50], ["IFITM1", "PROTEIN", 57, 63], ["Vstop", "PROTEIN", 64, 69], ["Vstop", "PROTEIN", 71, 76], ["mock transfected HEK293T cells", "CELL_LINE", 90, 120], ["Western blot", "TEST", 3, 15], ["IFITM1", "TEST", 57, 63], ["mock transfected HEK293T cells", "TREATMENT", 90, 120], ["HEK293T cells", "OBSERVATION", 107, 120]]], ["D) Western blots probed with anti-IFITM1-NTD for whole cell lysates (i) material that remained unbound to NeutrAvidin (ii) and protein eluted from the NeutrAvidin beads (iii).", [["cell lysates", "ANATOMY", 55, 67], ["anti-IFITM1-NTD", "GENE_OR_GENE_PRODUCT", 29, 44], ["cell lysates", "CELL", 55, 67], ["anti-IFITM1", "PROTEIN", 29, 40], ["NTD", "PROTEIN", 41, 44], ["NeutrAvidin", "PROTEIN", 106, 117], ["anti-IFITM1", "TREATMENT", 29, 40], ["whole cell lysates", "TREATMENT", 49, 67], ["NeutrAvidin (ii)", "TREATMENT", 106, 122], ["protein", "TREATMENT", 127, 134], ["the NeutrAvidin beads", "TREATMENT", 147, 168]]], ["As previously, NeutrAvidin monomers were eluted, and have the same molecular weight at IFITM1-Vstop.", [["NeutrAvidin", "CHEMICAL", 15, 26], ["NeutrAvidin", "CHEMICAL", 15, 26], ["NeutrAvidin monomers", "SIMPLE_CHEMICAL", 15, 35], ["IFITM1", "PROTEIN", 87, 93], ["Vstop", "PROTEIN", 94, 99], ["NeutrAvidin monomers", "TREATMENT", 15, 35]]], ["This can be clearly seen in the pulldown blot due to the presence of a band in the unlabelled lane. doi:10.1371/journal.pone.0104341.g006Conservation of the observed hu IFITM1 topology in hu IFITM2 and IFITM3with the majority of the protein being of the lowest molecular weight, consistent with this protein having lost its HA-tag.", [["IFITM1", "PROTEIN", 169, 175], ["HA-tag", "PROTEIN", 324, 330], ["the pulldown blot", "TEST", 28, 45], ["a band in the unlabelled lane", "TREATMENT", 69, 98], ["hu IFITM2", "TREATMENT", 188, 197], ["this protein", "PROBLEM", 295, 307]]], ["A similar low molecular weight form was also seen for IFITM3-HA (Fig. 3) .Conservation of the observed hu IFITM1 topology in hu IFITM2 and IFITM3IFITM expressing A549 cells were co-stained with antibodies against the NTD and the HA-tag.", [["A549 cells", "ANATOMY", 162, 172], ["IFITM3-HA", "GENE_OR_GENE_PRODUCT", 54, 63], ["IFITM1", "GENE_OR_GENE_PRODUCT", 106, 112], ["hu IFITM2", "CELL", 125, 134], ["IFITM3IFITM", "GENE_OR_GENE_PRODUCT", 139, 150], ["A549 cells", "CELL", 162, 172], ["IFITM3", "PROTEIN", 54, 60], ["IFITM1", "PROTEIN", 106, 112], ["hu IFITM2", "CELL_LINE", 125, 134], ["IFITM3IFITM expressing A549 cells", "CELL_LINE", 139, 172], ["antibodies", "PROTEIN", 194, 204], ["NTD", "PROTEIN", 217, 220], ["HA-tag", "PROTEIN", 229, 235], ["hu IFITM2", "TEST", 125, 134], ["A549 cells", "TEST", 162, 172], ["antibodies", "TEST", 194, 204], ["the NTD", "PROBLEM", 213, 220], ["low molecular", "OBSERVATION_MODIFIER", 10, 23]]], ["As IFITM proteins are relatively short (less than 133 amino acids) co-staining for the NTD and CTD should give apparent co-localisation.", [["amino acids", "CHEMICAL", 54, 65], ["amino acids", "CHEMICAL", 54, 65], ["IFITM", "GENE_OR_GENE_PRODUCT", 3, 8], ["amino acids", "AMINO_ACID", 54, 65], ["IFITM proteins", "PROTEIN", 3, 17], ["NTD", "PROTEIN", 87, 90], ["CTD", "PROTEIN", 95, 98], ["IFITM proteins", "TEST", 3, 17], ["amino acids", "TEST", 54, 65], ["the NTD", "PROBLEM", 83, 90], ["CTD", "PROBLEM", 95, 98], ["relatively", "OBSERVATION_MODIFIER", 22, 32], ["short", "OBSERVATION_MODIFIER", 33, 38]]], ["IFITM1-HA expressing cells showed a high degree of overlap between the anti-IFITM1-NTD and anti-HA antibodies (Fig. S6A) .", [["cells", "ANATOMY", 21, 26], ["IFITM1", "GENE_OR_GENE_PRODUCT", 0, 6], ["cells", "CELL", 21, 26], ["anti-IFITM1-NTD", "GENE_OR_GENE_PRODUCT", 71, 86], ["anti-HA antibodies", "GENE_OR_GENE_PRODUCT", 91, 109], ["IFITM1", "PROTEIN", 0, 6], ["HA expressing cells", "CELL_LINE", 7, 26], ["anti-IFITM1", "PROTEIN", 71, 82], ["NTD", "PROTEIN", 83, 86], ["anti-HA antibodies", "PROTEIN", 91, 109], ["S6A", "PROTEIN", 116, 119], ["IFITM1", "TEST", 0, 6], ["HA expressing cells", "PROBLEM", 7, 26], ["a high degree of overlap", "PROBLEM", 34, 58], ["the anti-IFITM1", "TEST", 67, 82], ["anti-HA antibodies", "TREATMENT", 91, 109], ["high degree", "OBSERVATION_MODIFIER", 36, 47], ["NTD", "ANATOMY", 83, 86], ["anti-HA antibodies", "OBSERVATION", 91, 109]]], ["The overlap was seen across multiple images as demonstrated by Mander's correlation coefficients M1 and M2.", [["M2", "CELL_LINE", 104, 106], ["multiple images", "TEST", 28, 43]]], ["Furthermore, analysis of the areas of different pixel colours demonstrated that around 70% (61.8%) of pixels were detectable as yellow (Table S1) .Conservation of the observed hu IFITM1 topology in hu IFITM2 and IFITM3By contrast, on IFITM3-HA expressing cells, a lower level of colocalisation was seen with both NTD antibodies ( Fig. 9B and Fig. S6C ).", [["cells", "ANATOMY", 255, 260], ["IFITM1", "GENE_OR_GENE_PRODUCT", 179, 185], ["hu IFITM2", "GENE_OR_GENE_PRODUCT", 198, 207], ["IFITM3-HA", "GENE_OR_GENE_PRODUCT", 234, 243], ["cells", "CELL", 255, 260], ["IFITM1", "PROTEIN", 179, 185], ["IFITM3-HA expressing cells", "CELL_LINE", 234, 260], ["NTD antibodies", "PROTEIN", 313, 327], ["Fig. 9B", "PROTEIN", 330, 337], ["Fig. S6C", "PROTEIN", 342, 350], ["analysis", "TEST", 13, 21], ["different pixel colours", "TEST", 38, 61], ["pixels", "TEST", 102, 108], ["a lower level of colocalisation", "PROBLEM", 262, 293], ["NTD antibodies", "TEST", 313, 327], ["pixel colours", "OBSERVATION", 48, 61], ["yellow", "OBSERVATION_MODIFIER", 128, 134]]], ["Importantly, clear red punctae were visible, suggesting that in some organelles IFITM3 contains intact NTDs but lacks the CTD HA-tag.", [["red punctae", "ANATOMY", 19, 30], ["organelles", "ANATOMY", 69, 79], ["punctae", "ORGANISM_SUBSTANCE", 23, 30], ["organelles", "CELLULAR_COMPONENT", 69, 79], ["IFITM3", "PROTEIN", 80, 86], ["CTD HA-tag", "PROTEIN", 122, 132], ["clear red punctae", "PROBLEM", 13, 30], ["intact NTDs", "PROBLEM", 96, 107], ["clear", "OBSERVATION_MODIFIER", 13, 18], ["red punctae", "OBSERVATION", 19, 30], ["organelles IFITM3", "OBSERVATION", 69, 86], ["intact NTDs", "OBSERVATION", 96, 107]]], ["This conclusion is supported by the quantification of multiple images that demonstrate a lower Mander's M1 and M2, compared to IFITM1-HA, and show an excess of red pixels (55% [61.4%]) for IFITM3-HA expressing cells (Table 2, 3 and Table S1 ).Conservation of the observed hu IFITM1 topology in hu IFITM2 and IFITM3The anti-IFITM1-NTD antibody does not detect IFITM2-HA as well as IFITM1-HA and IFITM3-HA (Fig. 3) ; we therefore used the anti-IFITM3-NTD antibody for a similar investigation of IFITM2-HA (Fig. 9A) .", [["cells", "ANATOMY", 210, 215], ["IFITM1-HA", "GENE_OR_GENE_PRODUCT", 127, 136], ["IFITM3-HA", "GENE_OR_GENE_PRODUCT", 189, 198], ["cells", "CELL", 210, 215], ["anti-IFITM1", "GENE_OR_GENE_PRODUCT", 318, 329], ["IFITM2-HA", "GENE_OR_GENE_PRODUCT", 359, 368], ["IFITM1-HA", "GENE_OR_GENE_PRODUCT", 380, 389], ["IFITM3-HA", "GENE_OR_GENE_PRODUCT", 394, 403], ["anti-IFITM3", "GENE_OR_GENE_PRODUCT", 437, 448], ["IFITM2-HA", "GENE_OR_GENE_PRODUCT", 493, 502], ["M1", "PROTEIN", 104, 106], ["M2", "PROTEIN", 111, 113], ["IFITM1", "PROTEIN", 127, 133], ["IFITM3", "PROTEIN", 189, 195], ["HA expressing cells", "CELL_TYPE", 196, 215], ["IFITM1", "PROTEIN", 275, 281], ["IFITM2", "DNA", 297, 303], ["IFITM3", "CELL_LINE", 308, 314], ["anti-IFITM1", "PROTEIN", 318, 329], ["NTD antibody", "PROTEIN", 330, 342], ["IFITM2", "PROTEIN", 359, 365], ["HA", "PROTEIN", 366, 368], ["IFITM1", "PROTEIN", 380, 386], ["HA", "PROTEIN", 387, 389], ["IFITM3", "PROTEIN", 394, 400], ["HA", "PROTEIN", 401, 403], ["anti-IFITM3", "PROTEIN", 437, 448], ["NTD antibody", "PROTEIN", 449, 461], ["IFITM2", "PROTEIN", 493, 499], ["HA", "PROTEIN", 500, 502], ["multiple images", "TEST", 54, 69], ["IFITM1", "TEST", 127, 133], ["red pixels", "TEST", 160, 170], ["IFITM3", "TEST", 189, 195], ["The anti-IFITM1-NTD antibody", "TEST", 314, 342], ["IFITM2", "PROBLEM", 359, 365], ["HA", "PROBLEM", 366, 368], ["IFITM1", "TEST", 380, 386], ["HA", "PROBLEM", 387, 389], ["IFITM3", "TEST", 394, 400], ["the anti-IFITM3-NTD antibody", "TREATMENT", 433, 461], ["lower", "ANATOMY_MODIFIER", 89, 94], ["red pixels", "OBSERVATION", 160, 170], ["IFITM3", "OBSERVATION", 308, 314]]], ["When multiple images were quantified, the results for IFITM2-HA and IFITM3-HA expressing cells were largely equivalent, with 49% (61.1%) of pixels being red for IFITM2-HA cells, compared to 46% (60.9%) for IFITM3-HA cells ( Table 2 and 3 ).", [["cells", "ANATOMY", 89, 94], ["IFITM2-HA cells", "ANATOMY", 161, 176], ["IFITM3-HA cells", "ANATOMY", 206, 221], ["IFITM2-HA", "GENE_OR_GENE_PRODUCT", 54, 63], ["IFITM3-HA", "GENE_OR_GENE_PRODUCT", 68, 77], ["cells", "CELL", 89, 94], ["IFITM2", "PROTEIN", 54, 60], ["IFITM3-HA expressing cells", "CELL_LINE", 68, 94], ["IFITM2", "PROTEIN", 161, 167], ["HA cells", "CELL_LINE", 168, 176], ["IFITM3", "PROTEIN", 206, 212], ["HA cells", "CELL_LINE", 213, 221], ["multiple images", "TEST", 5, 20], ["IFITM2", "TEST", 54, 60], ["HA", "PROBLEM", 61, 63], ["IFITM3", "TEST", 68, 74], ["pixels", "TEST", 140, 146], ["IFITM2-HA cells", "TEST", 161, 176], ["IFITM3-HA cells", "TEST", 206, 221], ["HA cells", "ANATOMY", 168, 176]]], ["The observed excess of red pixels for both IFITM2-HA and IFITM3-HA indicates loss of the HA-tag, consistent with the western blots (Fig. 3) .", [["IFITM2-HA", "GENE_OR_GENE_PRODUCT", 43, 52], ["IFITM3-HA", "GENE_OR_GENE_PRODUCT", 57, 66], ["IFITM2", "PROTEIN", 43, 49], ["HA", "PROTEIN", 50, 52], ["IFITM3", "PROTEIN", 57, 63], ["HA", "PROTEIN", 64, 66], ["HA", "PROTEIN", 89, 91], ["red pixels", "TEST", 23, 33], ["HA", "PROBLEM", 50, 52], ["IFITM3", "PROBLEM", 57, 63], ["HA", "PROBLEM", 64, 66], ["loss of the HA-tag", "PROBLEM", 77, 95], ["red pixels", "OBSERVATION", 23, 33], ["loss", "OBSERVATION", 77, 81], ["consistent with", "UNCERTAINTY", 97, 112]]], ["Overall, the data suggest a topology in which the HA-tagged CTDs of IFITM2 and IFITM3 are exposed to the endosomal/lysosomal system.DiscussionThe membrane topology of the interferon-induced IFITM proteins has been controversial.", [["endosomal", "ANATOMY", 105, 114], ["lysosomal", "ANATOMY", 115, 124], ["membrane", "ANATOMY", 146, 154], ["HA", "GENE_OR_GENE_PRODUCT", 50, 52], ["IFITM2", "GENE_OR_GENE_PRODUCT", 68, 74], ["IFITM3", "GENE_OR_GENE_PRODUCT", 79, 85], ["endosomal", "CELLULAR_COMPONENT", 105, 114], ["lysosomal", "CELLULAR_COMPONENT", 115, 124], ["membrane", "CELLULAR_COMPONENT", 146, 154], ["interferon", "GENE_OR_GENE_PRODUCT", 171, 181], ["IFITM", "GENE_OR_GENE_PRODUCT", 190, 195], ["HA-tagged CTDs", "PROTEIN", 50, 64], ["IFITM2", "PROTEIN", 68, 74], ["IFITM3", "PROTEIN", 79, 85], ["interferon", "PROTEIN", 171, 181], ["IFITM proteins", "PROTEIN", 190, 204], ["the HA", "TEST", 46, 52], ["IFITM2", "TREATMENT", 68, 74], ["IFITM3", "PROBLEM", 79, 85], ["the interferon-induced IFITM proteins", "TREATMENT", 167, 204], ["lysosomal system", "ANATOMY", 115, 131]]], ["Initially it was suggested that both the NTD and CTD are located on the extracellular face of membranes and are connected by two transmembrane domains and the CIL domain (Fig. 1, model 1) [1, 15, 17, 18] .", [["extracellular face", "ANATOMY", 72, 90], ["membranes", "ANATOMY", 94, 103], ["transmembrane", "ANATOMY", 129, 142], ["CTD", "GENE_OR_GENE_PRODUCT", 49, 52], ["extracellular face", "CELLULAR_COMPONENT", 72, 90], ["membranes", "CELLULAR_COMPONENT", 94, 103], ["NTD", "PROTEIN", 41, 44], ["CTD", "PROTEIN", 49, 52], ["transmembrane domains", "PROTEIN", 129, 150], ["CIL domain", "PROTEIN", 159, 169], ["Fig. 1", "PROTEIN", 171, 177], ["the NTD and CTD", "PROBLEM", 37, 52], ["the CIL domain", "TEST", 155, 169], ["NTD", "OBSERVATION", 41, 44], ["CTD", "OBSERVATION", 49, 52]]], ["However subsequent studies, demonstrating post-translational modification of both the hu IFITM3 NTD and CIL domain by cytosolic enzymes, led to the proposal of a model that placed the NTD, CIL and CTD all within the cytoplasm (Fig. 1 model 2) [10, 19] .", [["cytosolic", "ANATOMY", 118, 127], ["cytoplasm", "ANATOMY", 216, 225], ["IFITM3", "GENE_OR_GENE_PRODUCT", 89, 95], ["CIL domain", "GENE_OR_GENE_PRODUCT", 104, 114], ["cytoplasm", "ORGANISM_SUBSTANCE", 216, 225], ["hu IFITM3 NTD", "PROTEIN", 86, 99], ["CIL domain", "PROTEIN", 104, 114], ["cytosolic enzymes", "PROTEIN", 118, 135], ["NTD", "PROTEIN", 184, 187], ["CIL", "PROTEIN", 189, 192], ["CTD", "PROTEIN", 197, 200], ["subsequent studies", "TEST", 8, 26], ["the hu IFITM3 NTD", "TREATMENT", 82, 99], ["CIL domain", "TEST", 104, 114], ["cytosolic enzymes", "TEST", 118, 135], ["a model", "TREATMENT", 160, 167], ["the NTD", "TREATMENT", 180, 187], ["CIL", "TREATMENT", 189, 192], ["CTD", "PROBLEM", 197, 200]]], ["The same topology was also suggested for mu IFITM1 [20] .DiscussionHere we present evidence that hu IFITM1, which localises primarily to the plasma membrane, has a topology with the NTD located in the cytoplasm and the CTD in the extracellular space ( Fig. 1, model 3) .", [["plasma membrane", "ANATOMY", 141, 156], ["cytoplasm", "ANATOMY", 201, 210], ["extracellular space", "ANATOMY", 230, 249], ["hu", "GENE_OR_GENE_PRODUCT", 97, 99], ["IFITM1", "GENE_OR_GENE_PRODUCT", 100, 106], ["plasma membrane", "CELLULAR_COMPONENT", 141, 156], ["cytoplasm", "ORGANISM_SUBSTANCE", 201, 210], ["extracellular space", "CELLULAR_COMPONENT", 230, 249], ["hu IFITM1", "PROTEIN", 97, 106], ["NTD", "PROTEIN", 182, 185], ["CTD", "PROTEIN", 219, 222], ["hu IFITM1", "PROBLEM", 97, 106], ["the NTD", "PROBLEM", 178, 185], ["plasma membrane", "ANATOMY", 141, 156], ["cytoplasm", "ANATOMY_MODIFIER", 201, 210], ["CTD", "OBSERVATION", 219, 222], ["extracellular space", "ANATOMY", 230, 249]]], ["Immunofluorescence microscopy showed that on non-permeabilised cells the NTD is not accessible to antibody labelling, whereas the CTD (through an HA-tag) is accessible.", [["cells", "ANATOMY", 63, 68], ["cells", "CELL", 63, 68], ["non-permeabilised cells", "CELL_TYPE", 45, 68], ["NTD", "PROTEIN", 73, 76], ["CTD", "PROTEIN", 130, 133], ["HA", "PROTEIN", 146, 148], ["Immunofluorescence microscopy", "TEST", 0, 29], ["non-permeabilised cells the NTD", "PROBLEM", 45, 76], ["antibody labelling", "TEST", 98, 116], ["the CTD", "PROBLEM", 126, 133], ["an HA-tag", "TREATMENT", 143, 152], ["not accessible", "UNCERTAINTY", 80, 94]]], ["In agreement, the majority of tagged IFITM1 was accessible to cleavage by exogenous trypsin.DiscussionOur results also suggested that the HA-tag itself did not induce the extracellular CTD topology since untagged IFITM1 could be biotinylated at K122 using a cell impermeable biotin-labelling reagent.", [["extracellular", "ANATOMY", 171, 184], ["cell", "ANATOMY", 258, 262], ["biotin", "CHEMICAL", 275, 281], ["biotin", "CHEMICAL", 275, 281], ["IFITM1", "GENE_OR_GENE_PRODUCT", 37, 43], ["trypsin", "GENE_OR_GENE_PRODUCT", 84, 91], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 171, 184], ["IFITM1", "GENE_OR_GENE_PRODUCT", 213, 219], ["K122", "SIMPLE_CHEMICAL", 245, 249], ["cell", "CELL", 258, 262], ["biotin", "SIMPLE_CHEMICAL", 275, 281], ["IFITM1", "PROTEIN", 37, 43], ["trypsin", "PROTEIN", 84, 91], ["extracellular CTD", "PROTEIN", 171, 188], ["IFITM1", "PROTEIN", 213, 219], ["K122", "PROTEIN", 245, 249], ["tagged IFITM1", "PROBLEM", 30, 43], ["the HA-tag", "PROBLEM", 134, 144], ["a cell impermeable biotin", "TREATMENT", 256, 281], ["labelling reagent", "TREATMENT", 282, 299], ["exogenous trypsin", "OBSERVATION", 74, 91]]], ["However, while a large proportion of untagged IFITM1 could be biotin labelled and absorbed to NeutrAvidin beads, some protein remained in the supernatant.", [["supernatant", "ANATOMY", 142, 153], ["biotin", "CHEMICAL", 62, 68], ["biotin", "CHEMICAL", 62, 68], ["NeutrAvidin", "CHEMICAL", 94, 105], ["IFITM1", "GENE_OR_GENE_PRODUCT", 46, 52], ["biotin", "SIMPLE_CHEMICAL", 62, 68], ["NeutrAvidin", "GENE_OR_GENE_PRODUCT", 94, 105], ["untagged IFITM1", "PROTEIN", 37, 52], ["untagged IFITM1", "PROBLEM", 37, 52], ["biotin labelled", "PROBLEM", 62, 77], ["NeutrAvidin beads", "TREATMENT", 94, 111], ["some protein", "PROBLEM", 113, 125], ["large", "OBSERVATION_MODIFIER", 17, 22]]], ["We propose that the unlabelled protein is that which resides in intracellular compartments such as the Golgi and multi-vesicular bodies, as seen by EM (Fig. 7) , and that there could also be accessibility issues at the plasma membrane due to the short length of the CTD.DiscussionAlthough not accessible on intact cells, the NTD of IFITM1 was accessible to labelling with antibodies following detergent treatment of cells and showed a very similar cellular distribution to that seen with CTD anti-HA labelling.", [["intracellular compartments", "ANATOMY", 64, 90], ["Golgi", "ANATOMY", 103, 108], ["multi-vesicular bodies", "ANATOMY", 113, 135], ["plasma membrane", "ANATOMY", 219, 234], ["cells", "ANATOMY", 314, 319], ["cells", "ANATOMY", 416, 421], ["cellular", "ANATOMY", 448, 456], ["intracellular compartments", "CELLULAR_COMPONENT", 64, 90], ["Golgi", "CELLULAR_COMPONENT", 103, 108], ["multi-vesicular bodies", "CELLULAR_COMPONENT", 113, 135], ["plasma membrane", "CELLULAR_COMPONENT", 219, 234], ["cells", "CELL", 314, 319], ["IFITM1", "GENE_OR_GENE_PRODUCT", 332, 338], ["cells", "CELL", 416, 421], ["cellular", "CELL", 448, 456], ["anti-HA", "GENE_OR_GENE_PRODUCT", 492, 499], ["unlabelled protein", "PROTEIN", 20, 38], ["CTD", "PROTEIN", 266, 269], ["NTD", "PROTEIN", 325, 328], ["IFITM1", "PROTEIN", 332, 338], ["antibodies", "PROTEIN", 372, 382], ["CTD", "PROTEIN", 488, 491], ["the unlabelled protein", "PROBLEM", 16, 38], ["accessibility issues at the plasma membrane", "PROBLEM", 191, 234], ["the CTD", "PROBLEM", 262, 269], ["antibodies", "TREATMENT", 372, 382], ["detergent treatment of cells", "TREATMENT", 393, 421], ["CTD anti-HA labelling", "TREATMENT", 488, 509], ["intracellular", "ANATOMY_MODIFIER", 64, 77], ["compartments", "ANATOMY_MODIFIER", 78, 90], ["multi-vesicular bodies", "ANATOMY", 113, 135], ["short length", "OBSERVATION_MODIFIER", 246, 258], ["CTD", "OBSERVATION", 266, 269], ["very", "OBSERVATION_MODIFIER", 435, 439], ["similar", "OBSERVATION_MODIFIER", 440, 447], ["cellular distribution", "OBSERVATION", 448, 469], ["anti-HA labelling", "OBSERVATION", 492, 509]]], ["The NTD contains two potential trypsin cleavage sites, but we saw no evidence of these sites being accessible to exogenous trypsin.", [["trypsin", "GENE_OR_GENE_PRODUCT", 31, 38], ["trypsin", "GENE_OR_GENE_PRODUCT", 123, 130], ["NTD", "PROTEIN", 4, 7], ["trypsin cleavage sites", "PROTEIN", 31, 53], ["trypsin", "PROTEIN", 123, 130], ["The NTD", "PROBLEM", 0, 7], ["two potential trypsin cleavage sites", "TREATMENT", 17, 53], ["these sites", "PROBLEM", 81, 92], ["two", "OBSERVATION_MODIFIER", 17, 20], ["potential", "OBSERVATION_MODIFIER", 21, 30], ["trypsin cleavage", "OBSERVATION", 31, 47], ["no evidence of", "UNCERTAINTY", 66, 80], ["exogenous trypsin", "OBSERVATION", 113, 130]]], ["Thus our results are consistent with a model recently proposed for murine and human IFITM3 indicating a cytoplasmic NTD and CIL domain, connected by an intramembrane hydrophobic domain (M1) that does not fully span the membrane, and a second transmembrane domain (M2) linking the CIL domain to an extracellular CTD [21, 22] .", [["cytoplasmic", "ANATOMY", 104, 115], ["intramembrane", "ANATOMY", 152, 165], ["membrane", "ANATOMY", 219, 227], ["transmembrane", "ANATOMY", 242, 255], ["extracellular", "ANATOMY", 297, 310], ["murine", "ORGANISM", 67, 73], ["human", "ORGANISM", 78, 83], ["IFITM3", "GENE_OR_GENE_PRODUCT", 84, 90], ["cytoplasmic", "ORGANISM_SUBSTANCE", 104, 115], ["membrane", "CELLULAR_COMPONENT", 219, 227], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 297, 310], ["murine and human IFITM3", "PROTEIN", 67, 90], ["cytoplasmic NTD", "PROTEIN", 104, 119], ["CIL domain", "PROTEIN", 124, 134], ["intramembrane hydrophobic domain", "PROTEIN", 152, 184], ["M1", "PROTEIN", 186, 188], ["transmembrane domain", "PROTEIN", 242, 262], ["M2", "PROTEIN", 264, 266], ["CIL domain", "PROTEIN", 280, 290], ["extracellular CTD", "PROTEIN", 297, 314], ["murine", "SPECIES", 67, 73], ["human", "SPECIES", 78, 83], ["human", "SPECIES", 78, 83], ["murine and human IFITM3", "TREATMENT", 67, 90], ["a cytoplasmic NTD", "TREATMENT", 102, 119], ["CIL domain", "TREATMENT", 124, 134], ["an intramembrane hydrophobic domain (M1", "TREATMENT", 149, 188], ["a second transmembrane domain (M2)", "TREATMENT", 233, 267], ["an extracellular CTD", "TEST", 294, 314], ["consistent with", "UNCERTAINTY", 21, 36], ["cytoplasmic NTD", "OBSERVATION", 104, 119], ["hydrophobic domain", "OBSERVATION", 166, 184]]], ["Our results with antibody labelling experiments indicate that hu IFITM2 and 3 are likely to have the same topology, suggesting this may be a common feature of human interferoninduced IFITM proteins, and mu IFITM3.", [["hu IFITM2", "GENE_OR_GENE_PRODUCT", 62, 71], ["3", "GENE_OR_GENE_PRODUCT", 76, 77], ["human", "ORGANISM", 159, 164], ["IFITM", "GENE_OR_GENE_PRODUCT", 183, 188], ["mu IFITM3", "GENE_OR_GENE_PRODUCT", 203, 212], ["hu IFITM2 and 3", "PROTEIN", 62, 77], ["human interferoninduced IFITM proteins", "PROTEIN", 159, 197], ["mu IFITM3", "PROTEIN", 203, 212], ["human", "SPECIES", 159, 164], ["human", "SPECIES", 159, 164], ["antibody labelling experiments", "TEST", 17, 47], ["human interferoninduced IFITM proteins", "TREATMENT", 159, 197]]], ["However, this model is not consistent with published data on mu IFITM1 [20] , in which palmitoylation of a CTD cysteine (mu IFITM1 C103) suggested a cytoplasmic location.", [["cytoplasmic", "ANATOMY", 149, 160], ["cysteine", "CHEMICAL", 111, 119], ["mu IFITM1 C103", "GENE_OR_GENE_PRODUCT", 121, 135], ["cytoplasmic", "ORGANISM_SUBSTANCE", 149, 160], ["CTD cysteine", "PROTEIN", 107, 119], ["mu IFITM1 C103", "PROTEIN", 121, 135], ["a CTD cysteine", "TEST", 105, 119], ["a cytoplasmic location", "PROBLEM", 147, 169], ["not consistent with", "UNCERTAINTY", 23, 42], ["cytoplasmic location", "OBSERVATION", 149, 169]]], ["This cysteine is not conserved in hu IFITM1, perhaps indicating why there is an apparent difference between hu and mu IFITM1 [20] .", [["cysteine", "CHEMICAL", 5, 13], ["cysteine", "AMINO_ACID", 5, 13], ["hu IFITM1", "GENE_OR_GENE_PRODUCT", 34, 43], ["hu IFITM1", "PROTEIN", 34, 43], ["perhaps indicating why", "UNCERTAINTY", 45, 67]]], ["Whether palmitoylation of mu IFITM1 or other non-human IFITM proteins influence protein topology and/ or its cellular distribution, as well as any possible effects on functional activities, remains to be examined.DiscussionThe model for mu IFITM3 [21] and proposed here for hu IFITMs has important implications.", [["cellular", "ANATOMY", 109, 117], ["mu IFITM1", "GENE_OR_GENE_PRODUCT", 26, 35], ["IFITM", "GENE_OR_GENE_PRODUCT", 55, 60], ["cellular", "CELL", 109, 117], ["mu IFITM1", "PROTEIN", 26, 35], ["non-human IFITM proteins", "PROTEIN", 45, 69], ["protein topology", "TEST", 80, 96]]], ["Many studies of the IFITM proteins have used tagged constructs.", [["IFITM", "GENE_OR_GENE_PRODUCT", 20, 25], ["IFITM proteins", "PROTEIN", 20, 34], ["Many studies", "TEST", 0, 12], ["the IFITM proteins", "TEST", 16, 34]]], ["If these tags are at the Cterminus they will reside in extracellular and lumenal spaces where they may be exposed to proteolytic conditions.", [["extracellular", "ANATOMY", 55, 68], ["lumenal spaces", "ANATOMY", 73, 87], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 55, 68], ["lumenal spaces", "CELLULAR_COMPONENT", 73, 87], ["these tags", "TEST", 3, 13], ["lumenal", "ANATOMY_MODIFIER", 73, 80]]], ["Indeed, our results suggest that, even under normal culture conditions, IFITM-HA expressing cells have cleavage products resulting from the loss of the HA-tag or residues from the CTD itself.", [["cells", "ANATOMY", 92, 97], ["IFITM-HA", "GENE_OR_GENE_PRODUCT", 72, 80], ["cells", "CELL", 92, 97], ["IFITM-HA expressing cells", "CELL_LINE", 72, 97], ["cleavage products", "PROTEIN", 103, 120], ["HA-tag", "PROTEIN", 152, 158], ["CTD", "PROTEIN", 180, 183], ["HA expressing cells", "PROBLEM", 78, 97], ["cleavage products", "PROBLEM", 103, 120], ["the loss of the HA", "PROBLEM", 136, 154]]], ["Western blots of A549 cells stably expressing IFITM1 show two bands when using the anti-IFITM1-NTD antibody.", [["A549 cells", "ANATOMY", 17, 27], ["A549 cells", "CELL", 17, 27], ["IFITM1", "GENE_OR_GENE_PRODUCT", 46, 52], ["anti-IFITM1", "GENE_OR_GENE_PRODUCT", 83, 94], ["A549 cells", "CELL_LINE", 17, 27], ["IFITM1", "PROTEIN", 46, 52], ["anti-IFITM1", "PROTEIN", 83, 94], ["NTD antibody", "PROTEIN", 95, 107], ["A549 cells", "TEST", 17, 27], ["two bands", "PROBLEM", 58, 67], ["the anti-IFITM1-NTD antibody", "TEST", 79, 107], ["A549 cells", "OBSERVATION", 17, 27]]], ["The higher molecular weight band is the HA-tagged form of the protein, while the lower weight band is a cleaved form of the protein that has lost the HA-tag, and possibly other residues from the CTD.", [["HA-tagged form", "PROTEIN", 40, 54], ["HA-tag", "PROTEIN", 150, 156], ["CTD", "PROTEIN", 195, 198], ["the protein", "TEST", 58, 69], ["the lower weight band", "TEST", 77, 98], ["the CTD", "PROBLEM", 191, 198], ["higher", "OBSERVATION_MODIFIER", 4, 10], ["CTD", "OBSERVATION", 195, 198]]], ["Since this band is seen in cells that were not treated with trypsin, we suggest that this Cterminal cleavage may occur in the endosomal system.", [["cells", "ANATOMY", 27, 32], ["endosomal system", "ANATOMY", 126, 142], ["cells", "CELL", 27, 32], ["trypsin", "GENE_OR_GENE_PRODUCT", 60, 67], ["Cterminal", "GENE_OR_GENE_PRODUCT", 90, 99], ["endosomal", "CELLULAR_COMPONENT", 126, 135], ["trypsin", "PROTEIN", 60, 67], ["trypsin", "TREATMENT", 60, 67], ["this Cterminal cleavage", "TREATMENT", 85, 108]]], ["This conclusion is supported by the observation that in A549 cells expressing HA-tagged IFITM2 or 3, intracellular organelles can be seen that contain IFITM2 or 3 with intact NTD epitopes but lacking the CTD HA-tag (Fig. 9) .DiscussionThe potential for loss of the CTD or C-terminal tags will affect the interpretation of cell localisation studies that rely on CTD epitopes.", [["A549 cells", "ANATOMY", 56, 66], ["intracellular organelles", "ANATOMY", 101, 125], ["cell", "ANATOMY", 322, 326], ["C", "CHEMICAL", 272, 273], ["A549 cells", "CELL", 56, 66], ["HA-tagged IFITM2", "GENE_OR_GENE_PRODUCT", 78, 94], ["3", "GENE_OR_GENE_PRODUCT", 98, 99], ["intracellular organelles", "CELLULAR_COMPONENT", 101, 125], ["IFITM2", "GENE_OR_GENE_PRODUCT", 151, 157], ["3", "GENE_OR_GENE_PRODUCT", 161, 162], ["CTD", "GENE_OR_GENE_PRODUCT", 265, 268], ["cell", "CELL", 322, 326], ["A549 cells", "CELL_LINE", 56, 66], ["HA", "PROTEIN", 78, 80], ["IFITM2", "PROTEIN", 88, 94], ["IFITM2", "PROTEIN", 151, 157], ["NTD epitopes", "PROTEIN", 175, 187], ["CTD HA-tag", "PROTEIN", 204, 214], ["CTD", "PROTEIN", 265, 268], ["C-terminal tags", "PROTEIN", 272, 287], ["CTD epitopes", "PROTEIN", 361, 373], ["HA", "PROBLEM", 78, 80], ["intact NTD epitopes", "PROBLEM", 168, 187], ["the CTD", "PROBLEM", 261, 268], ["C-terminal tags", "PROBLEM", 272, 287], ["cell localisation studies", "TEST", 322, 347], ["CTD epitopes", "TEST", 361, 373]]], ["IFITM3 has been localised to endosomal compartments that co-label with markers for early and late endosomes (transferrin, CD63, Rab proteins, LAMP1, LAMP2 and Lyso-Tracker Red (as a marker for acidic compartments) [4, 9, 12, 27, 28] ), but IFITM2 has proved harder to localise.", [["endosomal compartments", "ANATOMY", 29, 51], ["late endosomes", "ANATOMY", 93, 107], ["acidic compartments", "ANATOMY", 193, 212], ["IFITM3", "CHEMICAL", 0, 6], ["IFITM3", "GENE_OR_GENE_PRODUCT", 0, 6], ["endosomal compartments", "CELLULAR_COMPONENT", 29, 51], ["late endosomes", "CELLULAR_COMPONENT", 93, 107], ["transferrin", "GENE_OR_GENE_PRODUCT", 109, 120], ["CD63", "GENE_OR_GENE_PRODUCT", 122, 126], ["Rab", "GENE_OR_GENE_PRODUCT", 128, 131], ["LAMP1", "GENE_OR_GENE_PRODUCT", 142, 147], ["LAMP2", "GENE_OR_GENE_PRODUCT", 149, 154], ["Lyso-Tracker Red", "GENE_OR_GENE_PRODUCT", 159, 175], ["IFITM2", "GENE_OR_GENE_PRODUCT", 240, 246], ["IFITM3", "PROTEIN", 0, 6], ["early and late endosomes", "PROTEIN", 83, 107], ["transferrin", "PROTEIN", 109, 120], ["CD63", "PROTEIN", 122, 126], ["Rab proteins", "PROTEIN", 128, 140], ["LAMP1", "PROTEIN", 142, 147], ["LAMP2", "PROTEIN", 149, 154], ["Lyso", "PROTEIN", 159, 163], ["Tracker Red", "PROTEIN", 164, 175], ["IFITM2", "PROTEIN", 240, 246], ["IFITM3", "PROBLEM", 0, 6], ["transferrin", "TEST", 109, 120], ["CD63", "TEST", 122, 126], ["Rab proteins", "TEST", 128, 140], ["LAMP1", "TEST", 142, 147], ["LAMP2", "TEST", 149, 154], ["Lyso", "TEST", 159, 163]]], ["Reliance on CTD epitope tags to determine the cellular distribution of the protein may not reveal the full cellular content of protein, and functionally important pools may be overlooked.DiscussionThe relevance of the proposed topology to IFITM protein function is unclear at this stage.", [["cellular", "ANATOMY", 46, 54], ["cellular", "ANATOMY", 107, 115], ["cellular", "CELL", 46, 54], ["cellular", "CELL", 107, 115], ["IFITM", "GENE_OR_GENE_PRODUCT", 239, 244], ["IFITM", "PROTEIN", 239, 244], ["CTD epitope tags", "TREATMENT", 12, 28], ["the protein", "TEST", 71, 82], ["cellular content", "OBSERVATION", 107, 123]]], ["To date, published work has found that functionally important residues are located within the NTD [27] and the conserved CD225 domain [19, 29] , comprising the membrane interacting domains and the CIL loop, as well as the second membrane domain that is proposed to interact with VAPA [12] .", [["membrane", "ANATOMY", 160, 168], ["membrane", "ANATOMY", 229, 237], ["membrane", "CELLULAR_COMPONENT", 160, 168], ["membrane", "CELLULAR_COMPONENT", 229, 237], ["NTD [27]", "PROTEIN", 94, 102], ["CD225 domain", "PROTEIN", 121, 133], ["membrane interacting domains", "PROTEIN", 160, 188], ["CIL loop", "PROTEIN", 197, 205], ["membrane domain", "PROTEIN", 229, 244], ["VAPA", "PROTEIN", 279, 283], ["the CIL loop", "TREATMENT", 193, 205], ["CIL loop", "OBSERVATION", 197, 205]]], ["Our data suggest the first membrane domain enters into, but does not span, the lipid bilayers, perhaps allowing the protein to induce membrane curvature.", [["membrane domain", "ANATOMY", 27, 42], ["lipid bilayers", "ANATOMY", 79, 93], ["membrane", "ANATOMY", 134, 142], ["membrane", "CELLULAR_COMPONENT", 27, 35], ["lipid bilayers", "CELLULAR_COMPONENT", 79, 93], ["membrane", "CELLULAR_COMPONENT", 134, 142], ["membrane domain", "PROTEIN", 27, 42], ["Our data", "TEST", 0, 8], ["lipid bilayers", "OBSERVATION", 79, 93], ["membrane curvature", "OBSERVATION", 134, 152]]], ["Image analysis of anti-IFITM3-NTD antibody and anti-HA antibody co-labelling.", [["anti-IFITM3", "GENE_OR_GENE_PRODUCT", 18, 29], ["anti-IFITM3", "PROTEIN", 18, 29], ["NTD antibody", "PROTEIN", 30, 42], ["anti-HA antibody", "PROTEIN", 47, 63], ["Image analysis", "TEST", 0, 14], ["anti-IFITM3", "TEST", 18, 29], ["NTD antibody", "TEST", 30, 42], ["anti-HA antibody co-labelling", "TEST", 47, 76]]], ["Co-localisation analysis of multiple images, for each cell line, from two independent experiments.", [["cell line", "ANATOMY", 54, 63], ["cell line", "CELL", 54, 63], ["cell line", "CELL_LINE", 54, 63], ["Co-localisation analysis", "TEST", 0, 24], ["multiple images", "TEST", 28, 43], ["each cell line", "TREATMENT", 49, 63], ["cell line", "OBSERVATION", 54, 63]]], ["Pearson's R-value represents the correlation in intensity between the red (anti-IFITM3-NTD) and green (HA) channels.", [["IFITM3-NTD", "GENE_OR_GENE_PRODUCT", 80, 90], ["green (HA)", "GENE_OR_GENE_PRODUCT", 96, 106], ["IFITM3", "PROTEIN", 80, 86], ["NTD", "PROTEIN", 87, 90], ["green (HA) channels", "PROTEIN", 96, 115], ["Pearson's R-value", "TEST", 0, 17], ["the red (anti-IFITM3", "TREATMENT", 66, 86], ["green (HA) channels", "PROBLEM", 96, 115]]], ["Mander's correlation coefficients, M1 and M2, represent the overlap of red, in pixels that are green, and the overlap of green, in pixels that are red, respectively.", [["M1", "PROTEIN", 35, 37], ["M2", "PROTEIN", 42, 44], ["the overlap of red, in pixels", "PROBLEM", 56, 85], ["M2", "ANATOMY", 42, 44], ["red", "OBSERVATION", 71, 74], ["green", "OBSERVATION_MODIFIER", 95, 100], ["green", "OBSERVATION_MODIFIER", 121, 126], ["red", "OBSERVATION_MODIFIER", 147, 150]]], ["Error given is of the standard deviation. doi:10.1371/journal.pone.0104341.t002 extracellular CTD may allow IFITM proteins to interact with key membrane components that are inaccessible on the cytoplasmic face of the membrane.DiscussionIn conclusion, our data, together with those recently published for mu and hu IFITM3, provide a compelling case for hu IFITM proteins having an intracellular NTD and CIL domain, and an extracellular CTD.", [["extracellular", "ANATOMY", 80, 93], ["membrane components", "ANATOMY", 144, 163], ["cytoplasmic face", "ANATOMY", 193, 209], ["membrane", "ANATOMY", 217, 225], ["intracellular", "ANATOMY", 380, 393], ["extracellular", "ANATOMY", 421, 434], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 80, 93], ["IFITM proteins", "GENE_OR_GENE_PRODUCT", 108, 122], ["membrane components", "CELLULAR_COMPONENT", 144, 163], ["cytoplasmic", "ORGANISM_SUBSTANCE", 193, 204], ["membrane", "CELLULAR_COMPONENT", 217, 225], ["hu IFITM3", "GENE_OR_GENE_PRODUCT", 311, 320], ["hu IFITM", "GENE_OR_GENE_PRODUCT", 352, 360], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 380, 393], ["extracellular CTD", "CELLULAR_COMPONENT", 421, 438], ["doi:10.1371/journal.pone.0104341.t002 extracellular CTD", "PROTEIN", 42, 97], ["IFITM proteins", "PROTEIN", 108, 122], ["hu IFITM3", "PROTEIN", 311, 320], ["hu IFITM proteins", "PROTEIN", 352, 369], ["intracellular NTD", "PROTEIN", 380, 397], ["CIL domain", "PROTEIN", 402, 412], ["extracellular CTD", "PROTEIN", 421, 438], ["the standard deviation", "PROBLEM", 18, 40], ["extracellular CTD", "PROBLEM", 80, 97], ["IFITM proteins", "PROBLEM", 108, 122], ["key membrane components", "TREATMENT", 140, 163], ["hu IFITM proteins", "TREATMENT", 352, 369], ["an intracellular NTD", "TREATMENT", 377, 397], ["CIL domain", "TREATMENT", 402, 412], ["an extracellular CTD", "TREATMENT", 418, 438], ["standard deviation", "OBSERVATION", 22, 40], ["CTD", "OBSERVATION", 94, 97], ["cytoplasmic", "ANATOMY_MODIFIER", 193, 204], ["face", "ANATOMY_MODIFIER", 205, 209], ["membrane", "ANATOMY_MODIFIER", 217, 225], ["CTD", "OBSERVATION", 435, 438]]], ["Whether all vertebrate IFITM proteins conform to the same organisation and, if not, the functional implications of other topologies, remain to be established.", [["IFITM", "GENE_OR_GENE_PRODUCT", 23, 28], ["vertebrate IFITM proteins", "PROTEIN", 12, 37], ["all vertebrate IFITM proteins", "PROBLEM", 8, 37]]], ["Figure S1 Tubulin co-staining on intact and permeabilised IFITM cell lines.", [["IFITM cell lines", "ANATOMY", 58, 74], ["Tubulin", "GENE_OR_GENE_PRODUCT", 10, 17], ["IFITM cell lines", "CELL", 58, 74], ["permeabilised IFITM cell lines", "CELL_LINE", 44, 74], ["Figure S1 Tubulin co-staining", "PROBLEM", 0, 29], ["Tubulin co-staining", "OBSERVATION", 10, 29], ["intact", "OBSERVATION_MODIFIER", 33, 39], ["cell lines", "OBSERVATION", 64, 74]]], ["C-terminal domain HA-tagged IFITM1-3 and A549 cell lines were co-stained intact, or following permeabilisation, with an anti-HA antibody and an anti-tubulin antibody.", [["IFITM1-3", "ANATOMY", 28, 36], ["A549 cell lines", "ANATOMY", 41, 56], ["C", "CHEMICAL", 0, 1], ["IFITM1-3", "GENE_OR_GENE_PRODUCT", 28, 36], ["A549 cell lines", "CELL", 41, 56], ["anti-tubulin", "GENE_OR_GENE_PRODUCT", 144, 156], ["C-terminal domain HA-tagged IFITM1-3", "DNA", 0, 36], ["A549 cell lines", "CELL_LINE", 41, 56], ["anti-HA antibody", "PROTEIN", 120, 136], ["anti-tubulin antibody", "PROTEIN", 144, 165], ["C", "TEST", 0, 1], ["terminal domain HA", "PROBLEM", 2, 20], ["tagged IFITM1", "TEST", 21, 34], ["A549 cell lines", "TREATMENT", 41, 56], ["permeabilisation", "TEST", 94, 110], ["an anti-HA antibody", "TEST", 117, 136], ["an anti-tubulin antibody", "TEST", 141, 165], ["terminal", "ANATOMY_MODIFIER", 2, 10], ["A549 cell lines", "OBSERVATION", 41, 56]]], ["These antibodies were detected with Alexa-488 (green) and Alexa-594 (red), respectively.", [["Alexa-488", "CHEMICAL", 36, 45], ["Alexa-594", "CHEMICAL", 58, 67], ["Alexa-488", "SIMPLE_CHEMICAL", 36, 45], ["green)", "SIMPLE_CHEMICAL", 47, 53], ["Alexa-594", "SIMPLE_CHEMICAL", 58, 67], ["antibodies", "PROTEIN", 6, 16], ["Alexa-594", "SPECIES", 58, 67], ["These antibodies", "TEST", 0, 16], ["Alexa", "TEST", 36, 41], ["Alexa", "TEST", 58, 63]]], ["A) Permeabilised IFITM-HA cells show positive labelling for all IFITM proteins and tubulin.", [["IFITM-HA cells", "ANATOMY", 17, 31], ["IFITM-HA cells", "CELL", 17, 31], ["IFITM proteins", "GENE_OR_GENE_PRODUCT", 64, 78], ["tubulin", "GENE_OR_GENE_PRODUCT", 83, 90], ["Permeabilised IFITM-HA cells", "CELL_LINE", 3, 31], ["IFITM proteins", "PROTEIN", 64, 78], ["tubulin", "PROTEIN", 83, 90], ["A) Permeabilised IFITM-HA cells", "TEST", 0, 31], ["positive labelling", "PROBLEM", 37, 55], ["positive labelling", "OBSERVATION", 37, 55]]], ["B) Intact IFITM-HA cells show no labelling for tubulin, indicating that the plasma membrane has remained intact and the antibody does not have access to the cytoplasm.", [["IFITM-HA cells", "ANATOMY", 10, 24], ["plasma membrane", "ANATOMY", 76, 91], ["cytoplasm", "ANATOMY", 157, 166], ["tubulin", "GENE_OR_GENE_PRODUCT", 47, 54], ["plasma membrane", "CELLULAR_COMPONENT", 76, 91], ["cytoplasm", "ORGANISM_SUBSTANCE", 157, 166], ["Intact IFITM-HA cells", "CELL_LINE", 3, 24], ["tubulin", "PROTEIN", 47, 54], ["Intact IFITM-HA cells", "TEST", 3, 24], ["tubulin", "PROBLEM", 47, 54], ["the plasma membrane", "PROBLEM", 72, 91], ["the antibody", "TEST", 116, 128], ["intact", "OBSERVATION", 105, 111], ["cytoplasm", "OBSERVATION", 157, 166]]], ["As previously, IFITM1-HA can be labelled on intact cells, IFITM2-HA has no labelling and only a minority of IFITM3-HA expressing cells shows plasma membrane labelling.", [["cells", "ANATOMY", 51, 56], ["cells", "ANATOMY", 129, 134], ["plasma membrane", "ANATOMY", 141, 156], ["IFITM1-HA", "GENE_OR_GENE_PRODUCT", 15, 24], ["cells", "CELL", 51, 56], ["IFITM2-HA", "GENE_OR_GENE_PRODUCT", 58, 67], ["IFITM3-HA", "GENE_OR_GENE_PRODUCT", 108, 117], ["cells", "CELL", 129, 134], ["plasma membrane", "CELLULAR_COMPONENT", 141, 156], ["IFITM1", "PROTEIN", 15, 21], ["HA", "PROTEIN", 22, 24], ["IFITM2", "PROTEIN", 58, 64], ["HA", "PROTEIN", 65, 67], ["IFITM3-HA expressing cells", "CELL_LINE", 108, 134], ["IFITM2", "TEST", 58, 64], ["IFITM3", "TEST", 108, 114], ["plasma membrane labelling", "PROBLEM", 141, 166], ["plasma membrane labelling", "OBSERVATION", 141, 166]]], ["Nuclei were labelled with Hoechst.", [["Nuclei", "ANATOMY", 0, 6], ["Hoechst", "CHEMICAL", 26, 33], ["Nuclei", "ORGANISM_SUBSTANCE", 0, 6], ["Hoechst", "SIMPLE_CHEMICAL", 26, 33]]], ["All images are maximum projections of 0.25 mm optical sections taken through the depth of the cells on a confocal microscope.", [["sections", "ANATOMY", 54, 62], ["cells", "ANATOMY", 94, 99], ["cells", "CELL", 94, 99], ["All images", "TEST", 0, 10], ["a confocal microscope", "TEST", 103, 124]]], ["All images were taken using the same microscope settings and the levels adjusted uniformly.", [["All images", "TEST", 0, 10], ["the same microscope settings", "TEST", 28, 56]]], ["Scale bars represent 15 mm.", [["15 mm", "OBSERVATION_MODIFIER", 21, 26]]], ["Table S1 Image analysis of anti-IFITM1-NTD antibody and anti-HA antibody co-labelling.", [["anti-IFITM1-NTD", "GENE_OR_GENE_PRODUCT", 27, 42], ["anti-IFITM1", "PROTEIN", 27, 38], ["NTD antibody", "PROTEIN", 39, 51], ["anti-HA antibody", "PROTEIN", 56, 72], ["Table S1 Image analysis", "TEST", 0, 23], ["anti-IFITM1", "TEST", 27, 38], ["NTD antibody", "TEST", 39, 51], ["anti-HA antibody", "TEST", 56, 72]]], ["Co-localisation analysis of multiple images, for each cell line, from three independent experiments.", [["cell line", "ANATOMY", 54, 63], ["cell line", "CELL", 54, 63], ["Co-localisation analysis", "TEST", 0, 24], ["multiple images", "TEST", 28, 43], ["each cell line", "TREATMENT", 49, 63], ["cell line", "OBSERVATION", 54, 63]]], ["Pearson's R-value represents the correlation in intensity between the red (anti-IFITM1-NTD) and green (HA) channels.", [["IFITM1-NTD", "GENE_OR_GENE_PRODUCT", 80, 90], ["green (HA)", "GENE_OR_GENE_PRODUCT", 96, 106], ["IFITM1", "PROTEIN", 80, 86], ["NTD", "PROTEIN", 87, 90], ["green (HA) channels", "PROTEIN", 96, 115], ["Pearson's R-value", "TEST", 0, 17], ["the red (anti-IFITM1", "TREATMENT", 66, 86], ["green (HA) channels", "PROBLEM", 96, 115]]], ["Mander's correlation coefficients, M1 and M2, represent the overlap of red, in pixels that are green, and the overlap of green, in pixels that are red, respectively.", [["M1", "PROTEIN", 35, 37], ["M2", "PROTEIN", 42, 44], ["the overlap of red, in pixels", "PROBLEM", 56, 85], ["M2", "ANATOMY", 42, 44], ["red", "OBSERVATION", 71, 74], ["green", "OBSERVATION_MODIFIER", 95, 100], ["green", "OBSERVATION_MODIFIER", 121, 126], ["red", "OBSERVATION_MODIFIER", 147, 150]]], ["Relative areas of each colour were calculated as described in materials and methods.", [["areas", "OBSERVATION_MODIFIER", 9, 14]]], ["Error given is of the standard deviation.", [["the standard deviation", "PROBLEM", 18, 40], ["standard deviation", "OBSERVATION", 22, 40]]], ["Image analysis of anti-IFITM3-NTD antibody and anti-HA antibody co-labelling.", [["anti-IFITM3", "GENE_OR_GENE_PRODUCT", 18, 29], ["anti-IFITM3", "PROTEIN", 18, 29], ["NTD antibody", "PROTEIN", 30, 42], ["anti-HA antibody", "PROTEIN", 47, 63], ["Image analysis", "TEST", 0, 14], ["anti-IFITM3", "TEST", 18, 29], ["NTD antibody", "TEST", 30, 42], ["anti-HA antibody co-labelling", "TEST", 47, 76]]], ["Relative areas of each colour were calculated as described in materials and methods.", [["areas", "OBSERVATION_MODIFIER", 9, 14]]], ["Red represents anti-IFITM3-NTD labelling, green represents anti-HA labelling and yellow represents overlap of the two stains.", [["anti-IFITM3", "GENE_OR_GENE_PRODUCT", 15, 26], ["anti-HA", "GENE_OR_GENE_PRODUCT", 59, 66], ["anti-IFITM3", "PROTEIN", 15, 26], ["NTD", "PROTEIN", 27, 30], ["anti-IFITM3", "TEST", 15, 26], ["NTD labelling", "PROBLEM", 27, 40], ["anti-HA labelling", "PROBLEM", 59, 76], ["anti-HA labelling", "OBSERVATION", 59, 76], ["yellow", "OBSERVATION_MODIFIER", 81, 87]]], ["Error given is of the standard deviation. doi:10.1371/journal.pone.0104341.t003", [["doi:10.1371/journal.pone.0104341.t003", "CHEMICAL", 42, 79], ["the standard deviation", "PROBLEM", 18, 40], ["standard deviation", "OBSERVATION", 22, 40]]]]}